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Objectives: To determine effective and efficient monitoring criteria for ocular hypertension 
[raised intraocular pressure (IOP)] through (i) identification and validation of glaucoma risk 
prediction models; and (ii) development of models to determine optimal 
surveillance pathways.
Design: A discrete event simulation economic modelling evaluation. Data from systematic 
reviews of risk prediction models and agreement between tonometers, secondary analyses 
of existing datasets (to validate identified risk models and determine optimal monitoring 
criteria) and public preferences were used to structure and populate the economic model.
Setting: Primary and secondary care.
Participants: Adults with ocular hypertension (IOP > 21mmHg) and the public 
(surveillance preferences).
Interventions: We compared five pathways: two based on National Institute for Health and 
Clinical Excellence (NICE) guidelines with monitoring interval and treatment depending on 
initial risk stratification, ‘NICE intensive’ (4-monthly to annual monitoring) and ‘NICE 
conservative’ (6-monthly to biennial monitoring); two pathways, differing in location 
(hospital and community), with monitoring biennially and treatment initiated for a ≥ 6% 
5-year glaucoma risk; and a ‘treat all’ pathway involving treatment with a prostaglandin 
analogue if IOP > 21 mmHg and IOP measured annually in the community.
Main outcome measures: Glaucoma cases detected; tonometer agreement; public 
preferences; costs; willingness to pay and quality-adjusted life-years (QALYs).
Results: The best available glaucoma risk prediction model estimated the 5-year risk 
based on age and ocular predictors (IOP, central corneal thickness, optic nerve damage iv Abstract
and index of visual field status). Taking the average of two IOP readings, by tonometry, true 
change was detected at two years. Sizeable measurement variability was noted between 
tonometers. There was a general public preference for monitoring; good communication 
and understanding of the process predicted service value. ‘Treat all’ was the least costly 
and ‘NICE intensive’ the most costly pathway.  Biennial monitoring reduced the number of 
cases of glaucoma conversion compared with a ‘treat all’ pathway and provided more 
QALYs, but the incremental cost-effectiveness ratio (ICER) was considerably more than 
£30,000. The ‘NICE intensive’ pathway also avoided glaucoma conversion, but NICE-based 
pathways were either dominated (more costly and less effective) by biennial hospital 
monitoring or had a ICERs > £30,000.  Results were not sensitive to the risk threshold for 
initiating surveillance but were sensitive to the risk threshold for initiating treatment, NHS 
costs and treatment adherence. 
Limitations: Optimal monitoring intervals were based on IOP data. There were insufficient 
data to determine the optimal frequency of measurement of the visual field or optic nerve 
head for identification of glaucoma. The economic modelling took a 20-year time horizon 
which may be insufficient to capture long-term benefits. Sensitivity analyses may not fully 
capture the uncertainty surrounding parameter estimates.
Conclusions: For confirmed ocular hypertension, findings suggest that there is no clear 
benefit from intensive monitoring. Consideration of the patient experience is important.  
A cohort study is recommended to provide data to refine the glaucoma risk prediction 
model, determine the optimum type and frequency of serial glaucoma tests and estimate 
costs and patient preferences for monitoring and treatment. 
Funding: The National Institute for Health Research Health Technology 
Assessment Programme.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Executive summary
Background
Glaucoma is a chronic progressive optic neuropathy leading to impaired vision and blindness 
if inadequately treated. Open-angle glaucoma is the most common form. A raised intraocular 
pressure (IOP) is the only modifiable risk factor. Ocular hypertension (OHT) is defined as IOP 
> 21 mmHg and the absence of clinical signs of glaucoma.
Around 1 million people in the UK have OHT with most identified during a routine ‘sight’ test; 
diagnosis is typically confirmed in secondary care. Treatment (daily eye drops) may be indicated 
to reduce IOP. Surveillance should identify those who would benefit from treatment, and should 
be affordable and acceptable to patients.
Clinical management establishes that OHT is truly present. Once confirmed, monitoring includes 
measuring IOP by tonometry and tests to detect glaucoma [visual field by standard automated 
perimetry (SAP) and evaluation of structural changes in the optic nerve]. Outcomes from all 
three parameters inform whether or not treatment is necessary. Long-term surveillance requires 
interpretation of serial tests and, for those requiring treatment, the responsiveness of IOP to 
treatment. In choosing the monitoring frequency, a strategy that separates ‘true’ long-term 
change (signal) from short-term variation and measurement error ‘noise’ is required.
Guidelines were published by the National Institute for Health and Clinical Excellence (NICE) in 
2009, but few data were available to guide best monitoring practice.
Aim
To determine effective and efficient monitoring criteria for OHT.
Objectives
1.  To identify and validate the most relevant tool(s) for predicting risk of developing glaucoma.
2.  To determine optimal monitoring criteria. (Which tests? How often?).
3.  To determine public preferences for a service, taking into account health outcomes and 
patient experiences.
4.  To undertake an economic evaluation of different surveillance pathways, considering costs, 
clinical outcomes, quality-adjusted life-years (QALYs) and willingness to pay (WTP).
5.  To determine risk thresholds for initiating surveillance.
6.  To make recommendations for research.
Methods
The study comprised three interlinked substudies, described in Figure 1.xii Executive summary
A: risk prediction models (objectives 1 and 6)
This involved (1) systematic review of prediction models estimating risk of progression to 
glaucoma and (2) external validation of the most robust using individual patient data from four 
populations: Moorfields Eye Hospital, London, and Rotterdam Eye Hospital, the Netherlands 
[randomised controlled trials (RCTs)], and Dunfermline and Nottingham [UK observational 
cohorts (hospital- and community-based, respectively)]. The 5-year risk was calculated using 
the prediction equation and the patients’ observed or imputed value of the predictors. The 
discriminatory ability of the model was assessed using Harrell’s c-index. Model calibration was 
assessed using calibration plots and calibration slopes.
B: optimal monitoring criteria (objectives 2 and 6)
This involved (1) evidence synthesis of the measurement agreement between alternative 
tonometers and the reference standard, Goldmann applanation tonometry (GAT), and (2) 
statistical modelling of the variability of IOP and visual field indices over time:
1.  A systematic search was undertaken. Meta-analyses of the mean differences and the standard 
deviation of the differences were undertaken for the agreement between each tonometer 
and GAT. Summary 95% limits of agreement were generated. Data on study characteristics, 
recordability, acceptability, practicality and reliability were summarised.
2.  Secondary analysis of data from the placebo arm of the London trial, conducted in the mid-
1990s to evaluate medical treatment for OHT, was used to estimate:
i.  average true long-term change of the whole group
Individual patient data analysis
Trial data sets (Moorfields, London, UK; 
Rotterdam, the Netherlands)
Existing economic evaluations of
alternative surveillance regimes for OHT:
systematic review
Optimal monitoring frequency of
IOP and VFs
Alternative surveillance pathways
Baseline IOP and VF
and change in IOP and VF
over time
Cost and effectiveness estimates
from literature
Monetary
benefits
IOP agreement
between tonometers
Individual risk profiles
Advisory panel and focus group
Development of attributes
for the survey
Survey
(discrete choice experiment)
Population preferences for monitoring
Economic modelling:
comparison of 5 surveillance pathways for OHT
OUTCOME
Cost–benefit, cost–utility and cost–consequences of alternative OHT suveillance regimes
Substudy A:
risk prediction
Substudy B:
monitoring frequency
Substudy C:
economic evaluation
Estimation of signal-to-noise ratio of IOP;
exploration of visual field (VF) parameters
Agreement between tonometers:
systematic review
Identification of best risk prediction tool:
systematic review
Individual patient data analysis
Trial data sets (Moorfields, London, UK; 
Rotterdam, the Netherlands)
UK observational cohorts (Nottingham, UK;
Dunfermline, UK)
Independent validation of risk prediction tool
FIGURE 1  Overview of the project.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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ii.  short-term variability: combination of analytic variability and biological fluctuation 
around a stable average – the ‘noise’
iii.  long-term variability: variation in long-term true change between individuals – the 
‘signal’.
The variability was estimated using a direct method and a linear random-effects model. Three 
imputation methods were employed for missing data. The effect of age and observer was analysed 
by fitting a separate model for each covariate in the London data set. The models were externally 
validated using patient-level data from the Rotterdam trial conducted between 1997 and 2008.
C: health economic evaluation (objectives 3–6)
This involved two components:
1.  A discrete choice experiment (DCE) to investigate the relative importance of attributes of a 
monitoring service to the public. Attributes and levels were identified by an advisory panel 
and a focus group. Attributes included a description of health outcomes (‘10-year risk of 
developing glaucoma, severe glaucoma and visual impairment’ and ‘unwanted effects of 
treatment’), patient experience (‘communication/understanding’ and ‘location’) and a cost 
attribute (price proxy) to provide a composite monetary measure of utility (WTP). Each 
DCE question involved a choice between two monitoring programmes (differing in the levels 
of the attributes) and a no-monitoring alternative. A Bayesian experimental design was used 
to determine choices, using information from a pilot (n = 184). Data were collected using a 
web-based survey (n = 814). The conditional logit model was used to analyse aggregate data 
and subgroup analyses by age.
2.  A discrete event simulation model to assess the relative efficiency of monitoring strategies for 
those with OHT, estimated by cost-effectiveness, cost–utility and cost–benefit analyses (using 
monetary values generated from the DCE). Pathways were informed by NICE guidelines, 
by the literature and in consultation with clinical experts, service users and the DCE. The 
model was populated with parameter estimates informed by components of earlier objectives 
and the literature. Sensitivity analyses, for the cost–utility analysis, explored the effect of 
monitoring or treating higher risk only, reducing the unit cost of the prostaglandin analogue 
by 50% and reducing NHS costs. A scenario analysis was conducted to determine the effects 
of varying estimates of adherence to medication, IOP measurement precision, accuracy of 
glaucoma detection and rate of progression to glaucoma.
Results
A: risk prediction models
Three models were identified, derived using data from two large multicentre RCTs, the Ocular 
Hypertension Treatment Study (OHTS) and the European Glaucoma Prevention Study (EGPS), 
evaluating ocular hypotensive medication. The OHTS-EGPS means model, the most robust, 
estimates the 5-year risk based on age, IOP, central corneal thickness (CCT), vertical cup-to-disc 
(C/D) ratio and pattern standard deviation (PSD); all variables are routinely collected in clinical 
practice. The model uses the mean values of the right and left eyes of an individual to calculate 
eye-specific predictors.
The discriminatory ability was good in the four populations tested, with c-indexes between 
0.69 and 0.83; however, in calibration analyses, the OHTS-EGPS means model generally 
overestimated the risk of glaucoma, although for the Rotterdam cohort the calibration slope was 
close to 1 (1.09, 95% confidence interval 0.72 to 1.46), the ideal value when there is complete 
agreement between predicted and observed risks.xiv Executive summary
This OHTS-EGPS model was developed using selected trial populations and may not include all 
important predictors. Both trial and observational validation cohorts were highly selected and 
none satisfactorily covered the full spectrum of risk. Furthermore, missing data for the predictors 
was considerable in all cohorts and definitions of glaucoma were not standardised. Despite these 
limitations, the model is useful in conjunction with clinical assessment.
B: optimal monitoring criteria
Systematic review and meta-analysis of tonometers
A total of 102 comparative studies assessed the agreement of at least one tonometer with GAT 
(HAAG-STREIT, Koeniz, Switzerland). Comparators were dynamic contour tonometer, non-
contact tonometer (NCT) (Canon USA, Inc., Lake Success, NY, USA; Keeler Ltd, Windsor, UK; 
NIDEK Co. Ltd, Gamagori, Japan; Reichert Ophthalmic Instruments, Buffalo, NY, USA; Topcon 
Corporation, Tokyo, Japan), Ocular response analyser® (ORA) (Reichert Inc., Depew, NY, USA), 
Ocuton S® (EPSa Elektronik & Präzisionsbav, Saalfeld, Germany), Perkins® (Kowa HA-2, Kowa, 
Japan), rebound tonometer, TonoPen® (Mentor O&O Inc., Santa Barbara, CA; Reichert Inc., 
Depew, NY, USA)  and transpalpebral tonometer. Studies were generally poorly reported. The 
agreement in IOP (95% limits) varied across tonometers, from 0.2 mmHg (–3.8 to 4.3 mmHg) for 
NCT to 2.7 mmHg (–4.1 to 9.6 mmHg) for Ocuton S. Sizeable inter- and intraobserver variability 
was observed for all tonometers, including GAT, casting doubt on the validity of GAT as the 
default standard.
Optimal frequency of monitoring intraocular pressure and tests to 
detect glaucoma
Statistical modelling was performed on ocular measures from the London placebo group 
{n = 153; mean IOP 24.4 mmHg [standard deviation (SD) 3.5 mmHg], 14 4-monthly visits}. 
Validation was performed using the Rotterdam placebo data [n = 132, mean IOP 25.7 mmHg 
(SD 2.5 mmHg), 21 visits biannually].
A linear random-effects model, using the last value carried forward to impute missing data, was 
the best fit to IOP data. The average change in IOP over time for the whole group was < 1 mmHg 
in 3 years, although a ≥ 5 mmHg change occurred in 25% of participants. For most individuals 
any true change in underlying IOP (‘signal’) was smaller than the estimated ‘noise’. Observed 
changes, using a single measure of IOP at each time point, of ≤ 3 mmHg can be explained as 
‘noise’. Assuming independence of repeated measures, the mean of two baseline IOP readings 
increased the signal-to-noise ratio such that true change in IOP of 2 mmHg could be detected 
at 2 years. With three baseline measures averaged, true change could be detectable between 1 
and 2 years.
For lower baseline IOP (< 26 mmHg) the model suggested that a true change in IOP would be 
unlikely within 3 years. The model may have underestimated the small proportion of individuals 
with a large change in IOP; this was adjusted for in the economic model. Mean deviation (MD) 
data, a visual field index measured by SAP, were available only in the London data set. MD 
fluctuated, increasing and decreasing, with minimal signal detected over 4 years.
Because of limited patient data on sequential measures of visual fields, the determination of 
optimal monitoring frequency was based on IOP variability.
C: health economic evaluation
Discrete choice experiment
There was a general public preference for monitoring of individuals with OHT. Individuals were 
willing to pay £28 per year for a service, everything else being equal. Coefficients representing © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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each attribute, other than hospital location, were significant predictors of preferences at the 1% 
level. Specifically, marginal valuations of the risk of glaucoma and sight loss over 10 years were 
statistically significant in the expected direction but small. Side effects of treatment reduced the 
value of any service, with more disbenefits as side effects increased. Good communication with 
the health professional and understanding of the testing process were important predictors of 
the value of alternative services. Preferences varied according to age, with those aged > 50 years 
being less concerned with the risk of sight loss (compared with those aged < 50 years), but 
more concerned about treatment side effects and the importance of good communication and 
understanding of the process.
Economic modelling evaluation
Five pathways were compared. Two were based on NICE guidelines with monitoring interval 
depending on initial risk stratification: ‘NICE intensive’ – 4-monthly to annual monitoring – 
and ‘NICE conservative’ – 6-monthly to biennial monitoring – with treatment according to 
baseline risk stratification by age, IOP and CCT; two further pathways, differing in location 
[‘surveillance for ocular hypertension (SOH) hospital’ and ‘SOH primary care’], included 
monitoring biennially with treatment initiated for a ≥ 6% 5-year glaucoma risk. The pathways 
included repeated IOP measurements, within 4 months, following treatment initiation or change. 
A ‘treat all’ pathway involved treatment if IOP was > 21 mmHg, measurement of IOP annually 
in community optometry and referral to secondary care if treatment response was inadequate 
(< 15% IOP reduction). 
‘Treat all’ was the least costly pathway and ‘NICE intensive’ the most costly pathway. The ‘SOH 
hospital’ pathway reduced the number of cases of conversion to glaucoma compared with 
the ‘treat all’ pathway and provided more QALYs but the incremental cost per extra QALY 
(incremental cost-effectiveness ratio; ICER) was considerably more than £30,000. The ‘NICE 
intensive’ pathway also avoided conversion to glaucoma, but NICE-based pathways were 
dominated (more costly and less effective) by the ‘SOH hospital’ pathway. In the cost–benefit 
analysis, compared with ‘no monitoring’ the ‘SOH hospital’ pathway was the only pathway to 
show net benefit.
Results were sensitive to the risk threshold for initiating treatment, NHS costs and treatment 
adherence. If treatment was initiated when the 5-year risk of developing glaucoma was > 10% 
(e.g. a 60-year-old with an IOP of 27 mmHg, CCT of 560 µm, vertical cup-to-disc (VCD) ratio of 
0.4 and a PSD of 1.4 dB has a 10.3% risk in at least one eye), an ‘SOH hospital’ pathway was less 
costly and more effective than a ‘treat all’ pathway. The SOH pathways had ICERs of < £30,000 
compared with the ‘treat all’ pathway when service cost for repeat IOP measurement, in response 
to treatment change, was < £60. Differences in treatment adherence between the ‘treat all’ and 
SOH pathways of approximately 40% or higher led to the SOH pathways having ICERs of 
≤ £30,000. NICE-based pathways were more costly and either were dominated or had ICERs well 
above £30,000 per QALY.
In the cost–utility analysis, surveillance was not compared with a ‘no monitoring’ alternative as 
this was not an acceptable option given current NHS policy. A ‘treat all’ pathway was included 
based on emerging findings from the literature. The acceptability to users and health-care 
professionals of a ‘treat all’ pathway was not explored. The modelling took a 20-year time horizon, 
which may be insufficient to capture longer-term benefits. Sensitivity analyses conducted may 
not fully capture the uncertainty surrounding parameter estimates. Although patient views were 
consulted when developing the DCE, the results were based on public preferences, which may 
differ from those of patients.xvi Executive summary
Conclusions
Implications for health care
The best available prediction model (OHTS-EGPS means model) estimates the 5-year risk 
of glaucoma based on age and the ocular predictors IOP, CCT, VCD ratio and PSD. An IOP 
measurement algorithm using the average of repeat measurements at one visit reduces noise. Our 
findings support the clinical importance of establishing a true baseline IOP prior to initiating 
monitoring or treatment. IOP measurement using the NCT or hand held applanation tonometer 
appears to give the closest agreement with GAT with > 75% of measurements within 3 mmHg. 
However, findings suggest that GAT may not be the most appropriate reference standard. The 
same type of tonometer should be used to compare IOP measurements in an individual.
Our findings, based on a small sample, suggest biennial IOP monitoring for untreated or stable 
treated OHT. The optimal frequency of clinical testing (perimetry or optic nerve evaluation) 
to detect glaucoma remains uncertain. The economic evaluation suggests no clear benefit 
in intensive monitoring to detect glaucoma; any service reconfigurations should consider 
patient experiences, ensuring adequate time to explain the purpose of monitoring and avoid 
treatment side effects. If the NHS costs for repeat visits to monitor IOP response to treatment are 
minimised, biennial hospital-based monitoring appears optimal. The economic model may not 
have fully captured data uncertainties or the opportunity cost of resource use. The feasibility of 
community care pathways should be explored.
Recommendations for research
  ■ A prospective cohort study including a representative sample of newly diagnosed OHT 
to update the risk prediction model and evaluate the optimal interval of serial glaucoma 
tests; standardisation of a measure of perimetry or optic nerve analysis with consensus on 
glaucoma conversion criteria; a comparison of alternative tonometers; costs and patient 
preferences for surveillance and treatment; and an updated economic model.
  ■ Further development of tonometers to meet the needs of patients and the NHS.
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Chapter 1 
Background
Description of the health problem (glaucoma)
Glaucoma is a chronic progressive optic neuropathy leading to impaired vision and blindness 
if left untreated. The underlying pathophysiology is an accelerated loss of retinal ganglion cells 
compared with the normal ageing process, leading to a characteristic pattern of retinal nerve 
fibre layer (RNFL) atrophy, optic nerve head changes and loss of peripheral visual function. 
Open-angle glaucoma (OAG) is the most common form of glaucoma, affecting about 2% of the 
population aged > 40 years in the UK.1 In the UK, glaucoma is second to age-related macular 
degeneration as a main cause of blindness.2,3
Open-angle glaucoma is diagnosed primarily by detecting the structural, that is glaucomatous, 
optic neuropathy (characteristic changes of the optic nerve head, the optic disc) and functional 
loss based on a corresponding visual field defect. The drainage pathway, the anterior chamber 
angle, appears open and normal. Early diagnosis is difficult as there is an overlap between 
normal appearance and glaucomatous changes in terms of both optic disc changes and visual 
field loss. A repeatable visual field defect consistent with structural damage of the optic nerve 
determines whether or not OAG is truly present. Having a raised intraocular pressure (IOP) 
is the most important risk factor for developing glaucoma and is the only one that is treatable. 
OAG is treated by interventions to lower the IOP. These include a variety of topical ocular 
hypotensive medications (eye drops), laser trabeculoplasty or glaucoma drainage surgery or a 
combination of these.
Ocular hypertension as a risk factor for open-angle glaucoma
Risk factors for developing OAG include raised IOP, greater age, non-white ethnicity (those of 
black ethnicity being a higher risk group), having a first-degree relative with OAG, myopia and 
diabetes.4 Ocular hypertension (OHT) is generally defined as an IOP of > 21 mmHg [2 standard 
deviations (SDs) above the population mean IOP] in the absence of clinical signs of glaucoma 
(optic nerve damage or visual field loss consistent with glaucoma). The risk of developing OAG, 
and of worsening of existing disease, increases with increasing IOP,5–7 and those presenting with 
advanced glaucoma at diagnosis have higher IOPs.8,9 The population prevalence estimates for 
OHT range from 4.5% to 9.4% for those aged > 40 years,10 with prevalence increasing with age.10,11
The effectiveness of treatment for OHT has been evaluated in two large trials of medical 
treatment [the Ocular Hypertension Treatment Study (OHTS)12,13 and the European Glaucoma 
Prevention Study (EGPS)].14
Combining the findings from these studies and data from eight smaller trials, a Cochrane 
systematic review and meta-analysis by Vass and colleagues,15 evaluating different topical 
ocular hypotensive medications against placebo or no treatment, showed that lowering the 
IOP for individuals with OHT was effective, with about a 40% reduction in the incidence of 
glaucomatous visual field defects with treatment at 5 years [odds ratio 0.62; 95% confidence 
interval (CI) 0.5 to 0.8].2 Background
Baseline factors predicting the development of OAG for those with OHT have been identified. 
These are described in detail in Chapter 4. Because of the risk of developing glaucoma, patients 
with OHT, either treated or untreated, are monitored in terms of IOP, visual function as 
measured by a visual field test, usually standard automated perimetry (SAP), and an assessment 
of the structural damage of the optic nerve and the RNFL.
The uncertainty lies in ascertaining, when OHT exists, how many measures are required to 
define the baseline IOP, and at what level of IOP should monitoring to detect early glaucoma be 
recommended. In addition, there is uncertainty whether monitoring should vary according to 
baseline risk factors for the development of OAG.
Impact of the health problem
Significance for patients
An effective monitoring service for people with OHT has the potential to directly benefit those 
with OHT in terms of identifying the need for treatment and thus reducing the risk of sight loss 
due to glaucoma. However, this has to be balanced against the inconvenience of attending for 
monitoring and any potential harms of monitoring. Although it is important to treat early disease 
to reduce the costs and disability associated with OAG, only a minority of those with OHT 
develop OAG, and not all of these are at risk of visual impairment in their lifetime. The challenge 
is therefore to identify the groups most at risk of developing significant OAG, and to determine 
effective and efficient monitoring criteria to identify those individuals who are most likely to 
benefit from treatment.
Significance for the NHS
Around 1 million people in the UK have OHT, assuming an estimate of the prevalence of OHT 
of 5%10 applied to the UK population aged > 40 years.16 Guidelines for the management of OHT 
and OAG in England, Wales and Northern Ireland were published by the National Institute for 
Health and Clinical Excellence (NICE) in 2009.1 The guideline review was based on an economic 
modelling evaluation supported by evidence from systematic reviews when available. However, 
it was acknowledged that there was little evidence to guide monitoring possibilities for patients 
with OHT and glaucoma.
The potential benefits to the NHS of evidence-based guidelines for monitoring people with 
OHT include:
  ■ reducing inappropriate referrals and retaining capacity in hospital services for 
higher-risk patients
  ■ ensuring that all people who meet the criteria have access to surveillance services
  ■ managing capacity in the hospital eye service by monitoring people in the community if the 
latter is an effective and cost-effective pathway
  ■ increasing patient choice and accessibility so that resources are used appropriately
  ■ better value for money.17
Current service provision
In the UK, the majority of people are identified as having OHT during a ‘sight’ test, usually to 
obtain glasses, at a community-based optometrist. People aged ≥ 60 years and those ≥ 40 years 
with a self-reported family history of glaucoma or considered to be at risk of glaucoma by an © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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ophthalmologist qualify for a free ‘sight test’ under the General Ophthalmic Services in England, 
Wales and Northern Ireland. The UK College of Optometrists guidelines for examining a patient 
with glaucoma or at risk of glaucoma suggest that an eye examination should normally include an 
assessment of the optic nerve head and tonometry (measurement of IOP). The guidelines advise 
that, when IOP is high or borderline, arrangements should be made for the test to be repeated. A 
central visual field assessment using perimetry with threshold control may also be included at the 
discretion of the optometrist and practitioners should consider repeating visual field assessment 
to obtain a meaningful result.18
In Scotland, since April 2006, everyone is eligible for a free ‘sight’ test, which includes a 
comprehensive eye examination appropriate to need. An eye examination is recommended 
annually for those with OHT.
There is considerable debate about the role and optimal organisation of a monitoring service 
for those with OHT and thus at risk of glaucoma. The NICE guidelines1 aimed to include 
recommendations on the most appropriate service models for monitoring OHT where evidence 
of effectiveness is available. OHT is defined in the guidelines as consistently or recurrently 
elevated IOP > 21 mmHg [measured with slit lamp-mounted Goldmann applanation tonometry 
(GAT) on more than one occasion] in the absence of optic nerve damage or corresponding visual 
field defect. The guidelines recommend that optometrists who have been trained to work in the 
field of glaucoma should refer people with OHT or suspected glaucoma, based on optic nerve 
damage or repeatable visual field defect, or both, to a consultant ophthalmologist-led service for 
definitive diagnosis and formulation of a management plan.
The guidelines provide recommendations for monitoring people with OHT and treatment 
recommendations according to risk (see Chapter 8 for a more detailed description). Briefly, the 
recommendations include monitoring IOP by GAT and monitoring of clinical status change 
[visual fields by automated perimetry (suprathreshold perimetry is acceptable)]. Van Herick’s 
peripheral anterior chamber depth assessment and stereoscopic slit lamp biomicroscopic 
examination of the optic nerve head are also recommended. Where GAT is not practical, the 
guidelines suggest Perkins hand-held tonometry as an acceptable alternative.1
In Scotland, the NICE guidelines are advisory. The Centre for Change and Innovation for NHS 
Scotland has developed patient pathways for ophthalmology designed to facilitate optimal patient 
care. Close collaboration between primary and secondary care is encouraged with the aim of 
optimising the expertise available in the community, particularly between optometry, general 
practitioners (GPs) and the hospital eye service. Currently there is no documented patient 
pathway for the management of OHT or suspect glaucoma.19 Optometrists in Scotland, under 
the National Health Service (General Ophthalmic Services) (Scotland) Amendment Regulations 
2010,20 monitor people with OHT (IOP ≥ 21 mmHg as determined by GAT) annually and follow 
the NICE guidance as to when to refer to the hospital eye service.
Current service cost
The annual additional cost of implementing the NICE guidelines for monitoring people with 
OHT or suspect glaucoma in England, Wales and Northern Ireland has been estimated as £11M, 
with potential cost savings of moving hospital-based monitoring to the community of around 
£7.5M. Future NHS savings, resulting from fewer people losing their vision because of improved 
treatment and monitoring of those with OHT, are estimated at £0.6M per year for England.214 Background
Variation in services
Clinical guidelines for the management of OHT and suspect glaucoma have been developed 
for other countries; these are consistent with the NICE guidelines in terms of the tests required, 
but recommendations for the frequency of monitoring according to risk are based on expert 
consensus opinion.22–24
Uncertainties regarding best practice for managing 
ocular hypertension
Measurement of intraocular pressure
Although the NICE guidelines advocate that IOP should be measured with contact tonometry by 
ophthalmologists (GAT is the most widely used), if surveillance is to be considered in primary 
care, tonometers that do not touch the cornea may be more applicable. In addition, a thick or 
thin cornea can lead to measurement error in tonometry, including GAT.25–27 New tonometers 
are available that account for the biomedical properties and thickness of the cornea. In addition, 
non-invasive self-measurement devices are available and may be highly appropriate and relevant 
as monitoring devices. The measurement performance of the alternative tonometers has not been 
systematically compared.
Defining individual risk of developing glaucoma and treatment policy
Although it is important to treat early disease to reduce the costs and disability associated with 
OAG, only a minority of those with OHT develop OAG and of these not all are at risk of visual 
impairment in their lifetime. The challenge is therefore to identify the groups most at risk of 
developing significant OAG, and to determine effective and efficient monitoring criteria to 
identify those individuals who are most likely to benefit from treatment.
The decision problem to be addressed is whether to treat all with OHT defined as an IOP 
> 21 mmHg, withhold treatment until a patient shows signs of early glaucoma or to target 
treatment only to those with OHT at a higher risk of developing glaucoma. Risk prediction 
algorithms are useful tools for risk assessment for conversion from OHT to OAG. The 
applicability of published risk prediction models needs to be evaluated in a UK context, and the 
cost-effectiveness of monitoring according to risk thresholds would inform policy decisions on 
managing OHT.
Frequency of testing (intraocular pressure measurement, perimetry and 
optic nerve assessment)
The aims of monitoring people with OHT is (1) initially to establish that OHT is truly present 
and not ‘noise’ in the IOP measurement; (2) to decide the long-term variability of the monitoring 
tests among individuals, commonly referred to as the ‘signal’ for monitoring purposes, to 
establish whether or not prophylactic treatment to reduce IOP is advisable; (3) to measure 
changes in the level of IOP in response to treatment; and (4) to detect those individuals 
progressing to glaucoma in a timely manner. There is currently insufficient evidence to guide 
clinicians with respect to the optimal intertest spacing and frequency of testing necessary to 
identify clinically significant changes in IOP or the optimal frequency and spacing of testing 
required to detect clinically significant changes in the visual field or optic nerve over a relevant 
time period, which could be up to 5 years.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Service provision
There is uncertainty regarding the best model for service provision in terms of the best location 
for a monitoring service, either in primary care or in a specialist-led secondary-care service.
Cost-effectiveness of alternative surveillance strategies for 
ocular hypertension
Across Europe the annual direct costs associated with managing OHT and glaucoma were 
estimated in 2003 as €455 per person for OHT, increasing to €595 for early glaucoma and 
rising to €969 for end-stage disease.28 These estimates are, however, very imprecise as they are 
based on retrospectively collected patient data from only 194 patient records collected across 
four countries, including three centres in the UK. Costs increase with increasing disease stage, 
with the main cost driver of the total direct health-care cost of glaucoma care being the cost of 
glaucoma medications. In the USA, a cost–utility analysis, taking a societal perspective and using 
the OHTS data, found that treatment for individuals with an IOP ≥ 24 mmHg and a ≥ 2% annual 
risk of developing glaucoma treatment would be cost-effective if society were willing to pay 
$50,000 for an additional quality-adjusted life-year (QALY).29
A recent economic modelling evaluation of monitoring pathways for OHT by van Gestel and 
colleagues30,31 suggested that a pathway of treating all with an IOP > 21 mmHg was cost-effective 
in a Dutch context and concluded that direct treatment of OHT is associated with health gains 
and cost savings compared with monitoring until conversion to glaucoma.
This study aims to determine the optimum frequency of monitoring individuals identified as 
being at risk of glaucoma because of OHT and to determine the extent to which this varies 
according to an individual’s risk characteristics. Several methodological approaches were used 
across three interlinked substudies: expert and consumer opinions; population preferences; 
systematic reviews; individual patient data (IPD) analysis; and decision-analytic modelling 
comparing alternative surveillance regimes taking into account the NHS costs and the health and 
wider benefits, as well as public preferences for the process of care, health and other outcomes.
This study was commissioned prior to the publication of the NICE guidelines. The remit of this 
study does not include an evaluation of the training required for health-care professionals or 
the optimal location of testing, although the survey of the general public and the subsequent 
incorporation of these findings within the economic model evaluate preferences for alternative 
models of care.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Chapter 2 
Aim and objectives
Aim
The overall aim was to determine effective and efficient monitoring criteria for individuals with 
OHT taking into account the NHS costs and the health and wider benefits, as well as public 
preferences for the process of care, health and other outcomes.
Objectives
The objectives were to:
1.  identify and validate the most relevant prediction tool(s) for predicting the risk of developing 
OAG in individuals with OHT (see Chapter 4)
2.  determine optimal monitoring criteria (which tests, frequency of monitoring) 
(see Chapters 5 and 6)
3.  determine public preferences for a service, taking into account health outcomes and patient 
experience factors (see Chapter 7)
4.  undertake an economic evaluation of different surveillance pathways, considering costs, 
clinical outcomes, QALYs and willingness to pay (WTP) (see Chapter 8)
5.  determine risk thresholds for initiating surveillance (see Chapter 8)
6.  make recommendations for surveillance regimes for OHT and
7.  identify future research needs (see Chapters 4–8).
The study involves three linked substudies (A, B and C), which are illustrated in Figure 1. 
Priorities for future research are identified from the outputs of each substudy.
A: risk prediction
Chapter 4 describes (1) the systematic identification and critical appraisal of risk prediction 
models for the progression of OHT to OAG and (2) a comparison of the performance of the 
models using IPD from four identified cohorts [randomised controlled trials (RCTs) and 
observational cohorts] of individuals with raised IOP. A schematic diagram showing the outputs 
of substudy A is given in Figure 2.
B: monitoring criteria
To determine effective monitoring criteria to identify those individuals who will most 
benefit from treatment as well as to identify those who may not need treatment or follow-up 
we undertook (1) a systematic review to determine the level of agreement between IOP 
measurement devices (tonometers) (reported in Chapter 5) and (2) a statistical modelling 
evaluation using IPD from identified RCTs to estimate values that would inform the optimal 
frequency for monitoring according to IOP for individuals with OHT. An exploratory analysis 
of the variability in visual field indices, namely mean deviation (MD) and pattern standard 
deviation (PSD), is also reported. A schematic diagram showing the outputs of substudy B is 
given in Figure 3. The findings are reported in Chapter 6.8 Aim and objectives
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FIGURE 1  Overview of the study process.
FIGURE 2  Schematic diagram showing the outputs of substudy A. VF, visual field.
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C: economic modelling evaluation of alternative surveillance regimes
The economic modelling evaluation includes three related components:
1.  determining the surveillance pathways for the economic model (see Chapters 7 and 8)
2.  a systematic review of economic evaluations of surveillance regimes for OHT (see Chapter 8)
3.  an individual sampling economic model (a discrete event simulation) of the alternative 
surveillance pathways, using the results of the systematic reviews and primary data sets, 
to determine the effectiveness, cost-effectiveness, cost–utility and cost–benefit of differing 
surveillance regimes for people with OHT (see Chapters 7 and 8).
A schematic diagram showing the outputs of substudy C is given in Figure 4.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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FIGURE 3  Schematic diagram showing the outputs of substudy B.
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Chapter 3 
Materials
Overview of searching for the evidence
Electronic searches were conducted to identify reports of published, unpublished and ongoing 
studies. The search strategies were designed to be highly sensitive, including appropriate subject 
heading and text word terms that reflect both the clinical content and the type of study required 
for each component of the research project. This involved:
  ■ identification of studies that report on risk prediction tools (see Chapter 4)
  ■ identification of studies that report on the reliability of the selected IOP measurement 
techniques (see Chapter 5)
  ■ identification of economic evaluations of surveillance programmes for OHT (see Chapter 8)
  ■ focused searches to identify parameter values for the economic model (see Chapter 8).
Full details of databases searched and the search strategies used are given in Appendix 1.
Description of individual patient data sets
Before the start of the project we consulted the literature, approached the investigators of the 
OHT treatment trials and searched for any available existing IPD sets of OHT in primary or 
secondary care in the UK. Data sets needed to be accessible in terms of electronic storage of the 
data and agreement from the data holders to collaborate.
The following four data sets met these criteria and provided non-identifiable IPD. The data sets 
include data from two RCTs (Moorfields Eye Hospital, London, UK, and Rotterdam Eye Hospital, 
the Netherlands) and data from two observational cohorts – one hospital based (Dunfermline, 
UK) and one based on a community optometry-led monitoring scheme (Nottingham, UK). The 
four data sets were used for the validation of the best risk prediction tool (see Chapter 4) and 
the two RCT data sets provided data to determine the optimal frequency for measuring IOP and 
visual fields to identify true change (see Chapter 6).
A summary of the available data in these data sets is provided in Table 1. Overviews of the 
pathways for inclusion of participants in the analyses are provided in Figures 5–8. Specific details 
of each data set are provided in the following text.
Data from randomised controlled trials
Moorfields Eye Hospital
The Moorfields Eye Hospital data set comprises data from a RCT of medical treatment with 
betaxolol eye drops (FDC International Ltd, Fareham, UK) or placebo in OHT.32 In the original 
study 356 patients with OHT were randomised during the period 1992–6.
Eligible participants for the trial included those:
  ■ aged > 35 years with an IOP, by GAT, between 22 mmHg and 35 mmHg and12 Materials
  ■ with no significant ocular or neurological pathology that would affect visual field 
performance and
  ■ with visual acuity of 6/12 or better and
  ■ with normal visual fields on Humphrey SAP defined as a mean Advanced Glaucoma 
Intervention Study (AGIS)33 score on two baseline fields of 0.
There were criteria violations: three participants had an IOP > 35 mmHg on the day of treatment 
commencement (36, 37 and 40 mmHg) and there were two participants aged < 35 years. Data 
from these participants were included in the analysis.
Participants were followed up every 4 months with Humphrey SAP, IOP measurement and optic 
nerve imaging in the study eye for a minimum of 2 years. Treatment status was noted at each 
visit. Conversion to glaucoma was based on predefined criteria (Box 1). Any participants reaching 
the conversion end point had IOP lowered by a topical ocular hypotensive other than betaxolol.
For the purpose of the secondary analysis of the trial data set for this study, the variables required 
were not available for 56 of the 356 trial participants and thus 300 participants are included in 
the analysis. The Moorfields Eye Hospital data set provides valuable RCT data and, additionally, 
post-trial surveillance with repeated measures of visual field using SAP. A flow diagram to 
illustrate the selection of patients to be included in the analysis for the Moorfields cohort is 
provided in Figure 5.
TABLE 1  Individual patient data sets for analysis
Source Patient group Study design
Median length of 
follow-up (years)
Moorfields Eye Hospital, 
London, UK
356 participants with OHT randomised; 
300 with available data for this study
RCT of treatment with betaxolol 0.5% eye 
drops or placebo
9.3
Rotterdam Eye Hospital,  
Rotterdam, the Netherlands
412 participants with OHT randomised; 
396 with available data for this study 
RCT of treatment with betaxolol 0.25% 
eye drops, timolol 0.5% eye drops (FDC 
International Ltd, Fareham, UK) or placebo
8.2
Queen Margaret Hospital, 
Dunfermline, UK
304 people with OHT 
188 with available data for analysis
Registry with hospital-based monitoring 2.7
Queens Medical Centre, 
Nottingham, UK
185 people with OHT 
159 with available data for analysis
Registry with community-based monitoring 4.3
Conversion was defined as the change from an initial AGIS score of 0 to an AGIS score of ≥ 1 on three 
consecutive reliable visual fields, with at least one of the locations consistently below the threshold for normality. 
Criteria defining a reliable field were < 25% fixation losses, < 30% false-negative errors and < 30% false-positive 
errors. The study protocol dictated that, if a patient developed a visual field defect, the test was repeated within 
1 month, and if the same defect was then reproduced on a reliable second field then a third test was performed 
3–4 months after that. Conversion was confirmed if the field defect was present on the three consecutive tests.
BOX 1  Moorfields Eye Hospital trial criteria for conversion to glaucoma© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Rotterdam Eye Hospital
The Rotterdam Eye Hospital data set comprises data from a placebo-controlled, double-masked, 
prospective, three-arm RCT (placebo, timolol 0.5% twice a day, betaxolol 0.25% twice a day) 
that was completed on 31 August 2008. This study randomised 412 participants with OHT 
between November 1997 and March 2001, including both eyes, with raised IOP ≥ 22 mmHg and 
≤ 32 mmHg by GAT, and normal visual fields on Humphrey automated perimetry. Participants 
were deemed eligible if they were of white ethnic origin and had a best corrected Snellen visual 
acuity of at least 20/40. Participants with any significant coexisting ocular or systemic disease or 
any use of ocular hypotensives in the preceding 3 months were excluded. The follow-up entailed 
6-monthly IOP measurement, visual field analysis and imaging of the optic disc using automated 
technology.34 Conversion to glaucoma was based on predefined criteria (Box 2).
For the secondary analysis of the data for the purpose of this study, participants who had used 
eye drops for at least 6 months or who had not had baseline visual field testing on at least three 
occasions were not included in the data set. A total of 16 participants were excluded on this basis 
and thus data on 396 participants were potentially available for analysis from the study start date 
in November 1997.
On 31 August 2008, the end date for the study, data on 393 participants were available for 
analysis: two participants did not have follow-up data and were excluded and on reviewing the 
Conversion to glaucoma was defined as a reproducible defect in the visual field (SAP) of either one individual 
point below the 0.5% probability level, or two clustered points below the 1% probability level, or three clustered 
points below the 2% probability level, or four clustered points below the 5% probability level on either the total 
deviation or the pattern deviation probability plot.
BOX 2  Rotterdam Eye Hospital trial criteria for conversion to glaucoma
FIGURE 5  Flow diagram of patients from the Moorfields cohort included in the analyses.
356 patients randomised
300 patients in data set
298 patients analysed
56 patients excluded
as unable
to verify IOP data
1 patient without
follow-up
1 patient with OAG
at baseline
254 patients
without OAG
44 patients
developed OAG14 Materials
baseline visual field data one participant was deemed to have early glaucomatous visual field 
defect at baseline and was excluded from the risk prediction analysis (see Chapter 4). A flow 
diagram to illustrate the selection of patients to be included in the analysis for the Rotterdam 
cohort is provided in Figure 6.
Data from observational data sets
Dunfermline
The Dunfermline data set was collated on an electronic patient record of all referrals with 
confirmed OHT from the year 2000 up until the end of December 2010. A flow diagram to 
illustrate the selection of patients to be included in the analysis for the Dunfermline cohort is 
provided in Figure 7.
412 patients randomised
396 patients in data set
393 patients analysed
(if patient status was active and no
conversion to OAG, then the exit date
was taken to be the trial end date of
31 August 2008)
16 patients excluded
(withdrew from the RCT
within 6 months of 
randomisation)
2 patients without
follow-up
1 patient with OAG
at baseline
365 patients
without OAG
28 patients
developed OAG
FIGURE 6  Flow diagram of patients from the Rotterdam cohort included in the analyses.
FIGURE 7  Flow diagram of patients from the Dunfermline cohort included in the analyses.
304 patients recorded
188 patients analysed
(if not discharged or converted and the
date of enrolment was < 1 year,
then exit date was the date the data set was
frozen for analysis, which was 4 May 2010)
16 patients without
follow-up (5 discharged)
100 patients excluded
(not ocular hypertensives)
160 patients
without OAG
28 patients
developed OAG© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Absolute features common to all deemed low risk:
  ■ no field loss
  ■ IOP < 23 mmHg at discharge
  ■ stable disc appearances.
Relative features:
1.  negative family history of glaucoma
2.  not on drugs (such as steroids) that may induce glaucoma.
BOX 3  Dunfermline criteria for discharge from the scheme
Conversion was based on the development of a repeatable visual field defect and/or a significant change in 
optic disc morphology. A visual field defect was defined as a reproducible defect in SAP of either one individual 
point below the 0.5% probability level, or two clustered points below the 1% probability level, or three clustered 
points below the 2% probability level, or four clustered points below the 5% probability level on either the total 
deviation or the pattern deviation probability plot. At least two sets of fields were required to deem conversion.
BOX 4  Dunfermline definition of conversion to glaucoma
The Dunfermline guidelines for the management of their ocular hypertensive patients 
recommend that low-risk cases (see Box 3 for definition) are discharged after two visits (at 
1 year); those who develop glaucoma (Box 4) and those deemed as being at high risk of 
developing glaucoma remain under review.
Visual field data using Humphrey SAP were available for both eyes of all patients (except those 
unable to complete the test).
Nottingham
The Nottingham data set includes data from a cohort of 185 patients with OHT followed in a 
community scheme run by locally trained optometrists. The scheme started in 2003 and we 
included those who had at least 1 year of follow-up at the time of ascertaining the data set for this 
study in January 2010. Of the 185 patients recorded, 26 did not have follow-up data. Thus, data 
on 159 participants were analysed. Measurements on both eyes were available. A flow diagram 
to illustrate the selection of patients to be included in the analysis for the Nottingham cohort is 
shown in Figure 8.
Patients were eligible to enter the scheme if they were being followed up for OHT in hospital-
based clinics and had normal visual fields and normal optic discs and an IOP recorded as 
> 21 mmHg on at least one occasion. Patients had to be able to undergo reliable visual field testing 
and have a visual acuity better than 6/12, and patients with both treated (single drop only) and 
untreated OHT were eligible. At baseline a visual field test was performed (24-2 SITA Fast) and 
stereoscopic optic disc imaging was performed as a baseline assessment of optic disc appearance/
morphology. The community optometrists were provided with stereo viewers and stereo 
photographs of the patients’ optic disc appearance at entry for comparison throughout follow-up. 
In addition, the referral guidelines to the community-based service indicated what cut-off of IOP 
should prompt referral back to the hospital eye service. Patients were reviewed once a year by 
visual field tests, GAT and clinical disc examination. Treatment state was recorded at each visit. 
Patients were referred back to the hospital eye service if the optometrist undertaking the annual 
assessment judged the optic disc appearance to have changed (comparing it with the baseline 16 Materials
appearance) or noted a visual field defect on visual field testing or if the patient was unable to 
undergo reliable visual field testing or the IOP had become elevated above the cut-off indicated 
in the referral template. All patients were referred back to the hospital eye service at 6 years for 
assessment by a consultant ophthalmologist. Patients were then returned to the community-
based service to continue their annual follow-up.
Criteria for discharge from the monitoring scheme and the definition for conversion to glaucoma 
are described in Boxes 5 and 6.
FIGURE 8  Flow diagram of patients from the Nottingham cohort included in the analyses.
Generally patients were discharged if they had untreated IOP consistently < 21 mmHg and a normal visual field 
and optic discs.
BOX 5  Nottingham criteria for discharge
Conversion was based on the development of a repeatable visual field defect and/or a significant change in 
optic disc morphology. This was initially detected by the optometrist on their annual review and confirmed with 
a repeat visual field on return to the hospital eye service for consultant assessment.
BOX 6  Nottingham definition of conversion to glaucoma
185 patients recorded
159 patients analysed
(if not discharged or converted and the
date of enrolment was < 1 year,
then exit date was the date the data set was
frozen for analysis, which was 4 May 2010)
24 patients discharged but without
discharge date (2 of these self-discharged.
The others either did not attend for
follow-up or were lost to follow-up)
2 patients without follow-up but
not discharged
154 patients
without OAG
5 patients
developed OAG© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Chapter 4 
Risk prediction tools for development of 
open-angle glaucoma
Introduction
The aetiology of OAG is not well understood, and elevated IOP, a well-known risk factor for the 
development of OAG, cannot be prevented. However, IOP can be lowered by medication, laser 
or surgery. Treatment decisions such as initiation and extent of therapy rely on many factors 
including the patient’s risk of developing OAG and life expectancy. Risk factors for conversion 
from OHT to OAG have been investigated in several longitudinal population-based35–39 and 
randomised40–44 studies. Although both increased age and elevated IOP have been consistently 
shown to be important factors,45 patients with IOP in the normal range (10–21 mmHg) can 
develop glaucoma. Consequently, multifactorial risk prediction models have been developed in 
an attempt to quantify the risk of developing the disease.
Validated risk calculators have become a useful tool in risk assessment for coronary heart disease 
(CHD)46,47 and parallels have been drawn between CHD and glaucoma; both are chronic diseases 
with known modifiable risk factors.48,49 Ideally, internal and external validation of a prediction 
model should be performed. For internal validation of performance, only patients from the 
model’s derivation set are used by applying bootstrapping, cross-validation or split-sampling 
techniques.50 However, prediction models often do not generalise beyond the population 
used in model derivation, and so it is widely accepted that a prediction model should not be 
applied in clinical practice before it has been validated in at least one other population and 
preferably by different investigators.51,52 Studies with long-term follow-up of OHT patients with 
varying characteristics can be used to assess transferability and generalisability of an OAG 
prediction model.
Aims
1.  To identify prediction models for development of OAG that include IOP as a predictor.
2.  To critically appraise the construction and validation of the models.
3.  To compare the performance of the models in four existing data sets.
Methods
Search strategy
Sensitive electronic searches were conducted to identify reports on the development and 
validation of risk prediction models for patients with OHT. Databases were searched from 1987 
until January 2011 with no language restriction. Conference proceedings were not included. The 
following bibliographic databases were searched: MEDLINE, MEDLINE-In Process & Other 
Non-Indexed Citations, EMBASE, Science Citation Index and BIOSIS. In addition, full-text 
searches of key journals from 2004 onwards were undertaken for relevant published and in-press 
publications, including American Journal of Ophthalmology, Archives of Ophthalmology, British 18 Risk prediction tools for development of open-angle glaucoma
Journal of Ophthalmology, Eye, Graefe’s Archive for Clinical and Experimental Ophthalmology, 
Investigative Ophthalmology and Visual Science, Journal of Glaucoma and Ophthalmology.
Additional searches were undertaken in the Health Technology Assessment (HTA) database 
and the Database of Abstracts of Reviews of Effects (DARE) for relevant evidence synthesis 
reports. An internet search using Copernic Agent was also undertaken and included key 
professional organisations.
Full details of the search strategies used are provided in Appendix 1.
Four authors independently reviewed all titles and abstracts to identify studies that should 
be read in full to determine their eligibility for inclusion. The reference lists of all included 
studies were also scanned for additional reports. Disagreements were discussed and resolved 
by consensus.
Study selection
Prospective studies and studies in which patients were retrospectively identified but prospectively 
followed up were included if:
  ■ only patients with OHT were recruited or they could be identified from the rest of the study 
cohort and models were fitted separately for them
  ■ they were conducted post 1987, when reliable computerised perimetry became the standard 
of care
  ■ a prediction equation for the development of OAG could be obtained
  ■ the reported model included at least two variables, one of which was IOP
  ■ the performance of the model was reported in any data set (derivation or validation) 
of longitudinal follow-up of a cohort initially free of OAG irrespective of the length of 
follow-up.
Population
Adults with OHT (defined as elevated IOP but no evidence of glaucomatous optic nerve damage 
or visual field loss) aged ≥ 18 years.53
Quality assessment
The quality of included studies was assessed using a checklist that included assessment of the 
definition of OAG, the method of measurement of candidate predictors and how continuous 
predictors were used in the models. Categorising a continuous predictor can lead to loss of 
information, but sometimes it may be necessary to categorise in order to assess the variation of 
risk across the range of values of a predictor. Such categorisation should be prespecified and not 
data driven. The definition of OAG was acceptable if the diagnosis was made using visual field 
testing with automated perimetry and optic nerve head examination. The acceptable method of 
visual field measurement was automated white-on-white perimetry. GAT, the clinical reference 
standard for IOP measurement, was the only acceptable method of IOP measurement. We 
also considered the number of conversions per variable in the multivariate analysis because 
estimates may not be accurate or precise if there are few conversions per predictor. We assessed 
this criterion based on the rule of thumb that logistic and Cox models should be used with a 
minimum of 10 outcome events per predictor variable.54,55
Data extraction
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  ■ demographic and clinical characteristics of the derivation and/or validation population such 
as age, gender, race and eye-specific measures – IOP, central corneal thickness (CCT), PSD 
and vertical cup-to-disc (VCD) ratio
  ■ features of the model development process such as method of analysis and variable selection
  ■ coefficients or hazard ratios (HRs) of predictors and prediction equations
  ■ measures of model performance (c-index, calibration chi-squared text and calibration slope).
Statistical analysis
Data synthesis
Meta-analysis of each predictor was not performed because the effects of other predictors in 
a multivariate model are not accounted for and so this would be misleading. Each model was 
reviewed and summarised separately.
Model validation
Baseline data from the four cohorts described in Chapter 3 were used to validate each included 
prediction model. However, for the Rotterdam cohort, with the exception of VCD ratio 
measurements, which were taken 2–3 years after randomisation, we used ocular measurements 
taken at the first follow-up visit (usually 1 month after randomisation) because of learning 
curve errors in the visual fields taken at baseline. Because the vertical VCD ratio is used in the 
assessment of OAG, if the time interval between measurement of the vertical VCD ratio and 
conversion to OAG was < 12 months, the measurements were not used and were considered 
missing. Sensitivity analysis was performed to assess the effect of using a time interval of 
< 24 months. The four data sets were analysed individually to enable assessment of the 
transferability of models between different geographical locations and settings.
The missing data mechanism was investigated in each cohort. To make the best use of the 
available data and to avoid bias, missing values were imputed using multivariate imputation by 
chained equations.56 By replacing missing values with plausible values based on the distribution 
of the observed data, 10 imputed data sets were created based on the predictors and outcome 
variables (Nelson–Aalen estimator for time to glaucoma and the censoring indicator). To avoid 
excluding a completely missing predictor from the risk estimation, we imputed the average value 
from a similar data set. Visual inspection of the distribution of imputed values was used to assess 
comparability with the observed data. For comparison with analyses based on imputed data, 
complete case analyses were also performed.
Ideally, model validation should be performed using an untreated population but this approach 
would have more than halved the sample size of some cohorts. Thus, we performed Cox 
regression analysis with and without stratification by treatment on each imputed data set. 
Estimates of the coefficient of each predictor were averaged across the 10 data sets to obtain a 
single estimate. Standard errors were computed based on Rubin’s rules,57 which take into account 
the between- and within-imputation components of variation in the parameter estimates.
The 5-year risk of developing glaucoma for each patient was calculated using each included 
prediction equation and the patient’s observed or imputed value of the predictors. The predicted 
5-year risk of glaucoma was grouped into three categories, low (< 6%), intermediate (6–13%) and 
high (> 13%), as defined by the OHTS.13 Five-year Kaplan–Meier failure curves for each cohort 
were plotted according to this risk classification and log-rank tests performed to assess equality of 
the survivor function across groups (note that each plot and the associated log-rank test depicts a 
single imputed data set as an example).
The predictive ability of a model is frequently assessed in terms of discrimination and 
calibration.58 The ability of the model to discriminate between patients who did or did not 20 Risk prediction tools for development of open-angle glaucoma
develop OAG was assessed using Harrell’s c-index. This measure is similar to the area under 
the receiver characteristic operating curve and is more appropriate for survival analysis.59 A 
c-index of 1.0 indicates perfect discrimination (e.g. predicted risks for those with OAG are all 
greater than for those without OAG, with perfect separation of both groups) whereas a c-index 
of 0.5 indicates random discrimination. Approximate 95% CIs were computed for the c-index by 
applying Rubin’s rules to jackknife standard errors obtained for the c-indexes of the 10 imputed 
data sets. Where the upper limit of the 95% CI exceeded 1.0 the value was truncated at 1.0.
Calibration refers to the agreement between predicted and observed risk. Model overfitting 
(where predictions in the model are more certain than justified because of the play of chance 
in the derivation data set) can be identified by assessing model calibration in independent 
validation data sets. Patients were divided into quintiles according to their predicted risk. Within 
each quintile, the average predicted risk was compared with the corresponding Kaplan–Meier 
estimate of the observed risk. Calibration plots were used to illustrate the fit of the models; for 
a perfectly calibrated model, all points will lie on the 45° line. Additionally, we used the slope of 
the prognostic index (linear predictor), known as the calibration slope, to quantify calibration. 
The slope of the prognostic index is the regression coefficient β in a Cox regression model 
with the prognostic index as the only covariate. The calibration slope should ideally be 1 when 
predicted risks agree completely with observed risks,60 which will be the case if the effects of 
predictors in the validation data set are on average similar to those in the development data set 
(note that, although the tests and summary statistics are based on appropriate analyses of all 10 
imputed data sets, the plot depicts a single imputed data set and thus may not directly depict 
the final results). Because pretreatment values of the baseline predictors were known in the 
trial-based cohorts, we produced calibration plots for treated and untreated patients separately 
to assess the extent to which calibration of the model was affected by treatment. Calibration and 
Kaplan–Meier plots were based on one of the imputed data sets for each cohort. All analyses were 
performed using Stata 11.1 (StataCorp LP, College Station, TX, USA).
Results
Systematic review
Study selection
The titles and abstracts of 565 articles were screened to identify eligible studies. Full-text papers 
of 54 of these were retrieved for more detailed evaluation of eligibility (Figure 9). Forty-nine 
papers were excluded and the reasons are provided in Appendix 2. Of the five included papers, 
four were based on the results of two RCTs, the OHTS61 and the EGPS.14,41 These provided three 
models for which prediction equations were available (full and reduced OHTS models42,62,63 and 
the pooled OHTS-EGPS means model64,65). The fifth paper reported the independent validation 
study of the OHTS model in the Diagnostic Innovations in Glaucoma Study (DIGS) cohort.63
Assessment of study quality
Both the OHTS and EGPS were large prospective studies that included patients with OHT aged 
≥ 30 years who had no evidence of glaucomatous damage at baseline. The OHTS randomised 
1636 individuals, with an IOP between 24 mmHg and 32 mmHg in one eye and between 
21 mmHg and 32 mmHg in the other eye, to treatment or observation. The EGPS randomised 
1081 individuals with IOP ≥ 22 mmHg in at least one eye to treatment or placebo. The inclusion 
and exclusion criteria used in the DIGS cohort were very similar to those used by the OHTS. For 
a patient to be included, his or her baseline IOP had to be ≥ 24 mmHg in one eye and ≥ 21 mmHg 
in the other eye, on at least two occasions.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
21   Health Technology Assessment 2012; Vol. 16: No. 29 DOI: 10.3310/hta16290
In the OHTS, all visual fields were assessed using full-threshold white-on-white Humphrey 
program 30-2 perimetry, whereas in the EGPS this was used for 79.6% of the participants and 
Octopus 32-2 visual fields for the rest. Visual field assessment was based on three consecutive 
abnormal and reliable tests with defect in the same location and index. In the DIGS, visual field 
examination was performed with SAP. At baseline, SAP testing was performed using the program 
24-2 full-threshold strategy, but during follow-up, SAP testing was performed using either the 
full-threshold or the Swedish Interactive Threshold Algorithm strategy.63 Using different visual 
field programs based on different algorithms is not ideal, but in a clinical context of determining 
whether or not glaucoma has developed it is acceptable. In the OHTS, optic discs were assessed 
using two consecutive sets of photographs judged to have a clinically significant change, whereas 
the EGPS used a set of photographs judged to have changed by at least two of three masked 
readers. In both studies, detection of OAG was by a masked end-point committee and was based 
on reproducible visual field abnormalities or optic disc deterioration. In the DIGS, structural 
damage to the optic disc at baseline was based on assessment of simultaneous stereoscopic 
optic disc photographs by two masked readers; conversion from OHT to OAG was based on the 
development of a reproducible visual field defect or glaucomatous change in the appearance of 
the optic disc in at least one eye. The original protocols of the OHTS and EGPS did not include 
CCT and measurements were taken later, 2–3 years after randomisation of the last patient 
enrolled in the studies. All patients in the DIGS had CCT measurements taken during follow-up.
Cox regression analysis was used to obtain all of the prediction models and all continuous 
predictors were modelled without categorisation. The OHTS identified candidate variables during 
the planning phase of the study. For the pooled OHTS-EGPS model, variables in univariate 
models in the OHTS or the EGPS with p < 0.10 were the candidate variables. Statistically 
significant variables in the pooled univariate analyses were included in the pooled multivariate 
analyses. Measures of model performance in the development set were not reported for the 
OHTS models.
Assessment of a patient’s risk requires the baseline hazard/survivor function in addition to the 
prognostic index. In the validation of the OHTS models, the baseline survivor function was 
approximated by the average survival probability at 5 years obtained from the Kaplan–Meier 
estimates because the function was not published by the OHTS.63 The OHTS reduced model was 
published in a brief report,62 and the same population and analyses described for the full model 
applies. The methodological quality of the two studies42,64 that fully described the development 
of the OHTS full model and the OHTS-EGPS means model, respectively, and the validation 
FIGURE 9  Flow chart of the study selection process.
54 full-text papers assessed
for eligibility
565 titles and abstracts
identified
49 full-text papers excluded:
   • Not risk prediction model
      development or validation, n = 18
   • Not only ocular hypertensives, n = 18
   • Retrospective, n = 2
   • Conducted before 1987, n = 2
   • No prediction equation, n = 7
   • No IOP in model, n = 1
   • Model performance not assessed, n = 1
5 studies included
511 titles excluded22 Risk prediction tools for development of open-angle glaucoma
study in the DIGS cohort63 is summarised in Table 2. Unlike the OHTS models, the OHTS-EGPS 
model has not been independently validated. The model derived from the observation group of 
the OHTS was validated in the EGPS placebo group, but the pooled OHTS-EGPS model derived 
from both populations was not externally validated.
Prediction models
In univariate analyses of the OHTS or pooled OHTS and EGPS data, statistically significant 
predictors for development of OAG were age, IOP, CCT, VCD ratio, horizontal cup-to-disc 
(C/D) ratio, PSD, history of heart disease, gender, race and diabetes mellitus. In both OHTS 
and EGPS, history of diabetes and heart disease were self-reported and not clinically verified. 
Table 3 summarises the models including the reduced OHTS model and validation of the full and 
reduced OHTS models in the DIGS cohort. The factors common to all models in multivariate 
analyses were IOP, age and CCT.
Ocular Hypertension Treatment Study prediction model
The OHTS multivariate Cox regression analysis used the means of both eyes for eye-specific 
variables and identified six factors that were significantly associated with the risk of conversion 
from OHT to OAG: age, IOP, CCT, VCD ratio, PSD and diabetes mellitus.42 Horizontal C/D 
ratio was also significantly associated with glaucoma development in multivariate analysis but, 
because of its high correlation with the VCD ratio, only the VCD ratio was included in the final 
multivariate model. Also, the VCD ratio had slightly better predictive ability. Analyses were 
performed using only the untreated group as well as the combined treated and untreated groups. 
Similar results were obtained and only the model based on the entire sample was reported.
Changes in PSD and VCD ratio may be indicative of early OAG damage and their inclusion in 
the model may result in an overestimation of risk. Thus, to avoid inclusion of variables used in 
the definition of the disease, another model, the reduced OHTS model, was developed.62 HRs 
from the multivariate Cox models with and without PSD and VCD ratio were found to be similar 
and in the reduced model all factors remained statistically significant.
Using 252 eyes from 126 untreated OHT patients retrospectively selected from DIGS, a 
prospective longitudinal study, Medeiros and colleagues63 validated the OHTS prediction model. 
TABLE 2  Summary of methodological quality
Quality item OHTS42 OHTS-EGPS64 DIGS63
1.  Was the sample of patients representative (i.e. consecutively or randomly sampled)? Yes Yes Yes
2.  Were groups of interest included?  Yes Yes Yes
3.  Was the definition of OAG appropriate? Yes Yes Yes
4.  Was the method of measurement of visual field parameters acceptable?  Yes Yes Yes
5.  Was the method of measurement of IOP acceptable?  Yes Yes Yes
6.  Was the duration of follow-up adequate (at least 5 years)?  Yes Yes Yes
7.  Was the number of conversions adequate for the number of predictors in the model? Yes Yes NA
8.  Did the model include IOP as well as other known risk factors? Yes Yes NA
9.  Was categorisation of continuous variables prespecified and rationalised to avoid data-dependent 
analysis? 
NA NA NA
10. Was the model validated in a data set different to the derivation data set (a, b or c)? Yes No NA
(a)  A different sample, source and investigator (this provides best evidence) Yes
(b)  A different sample from a different source
(c)  A different sample but from the same source as the data used to derive it
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Fifteen (12%) of the 126 patients received treatment during follow-up, and for these patients only 
the pretreatment period was evaluated. To derive the OHTS prediction equation, the average 
survival probability at 5 years was approximated using the Kaplan–Meier estimates because the 
baseline survivorship function was not included in the published OHTS results. For the full 
OHTS model (containing all six predictor variables), the risk estimate for glaucoma development 
in 5 years was calculated as:
Risk estimate = 1 – 0.906exp(PI)  [Model 1]
where 0.906 is the average survival probability at 5 years and
PI = ∑β () −
=
Xx ii i
i
k
1
 = ln(1.25) × (AGEDECADE – 5.54) + ln(1.11) × (IOP – 24.9)  
+ ln (1.82) × (T_CCT + 14.3625) + ln(1.25) × (T_PSD – 9.5)  
+ ln(1.32) × (T_VCD – 3.9) + ln(0.35) × (DIABETES – 0.121)  [Equation 1]
where βi is the regression coefficient in the Cox proportional hazards model for the ith predictor 
and is the log HR, Xi is an individual’s value for one of the k predictors and xi to xk are the mean 
values from the OHTS cohort for the k predictors. Four of the five predictors were transformed 
as follows:
AGEDECADE = AGE/10  [Equation 2]
T_CCT = –1 × CCT/40  [Equation 3]
T_VCD = VCD/0.1  [Equation 4]
T_PSD = PSD/0.2  [Equation 5]
TABLE 3  Multivariate HRs and performance measures for the risk prediction models
Characteristic
Full OHTS model 
(development set)
Full OHTS model 
(DIGS validation 
set)
Reduced 
OHTS model 
(development set)
Reduced OHTS 
model (DIGS 
validation set)
OHTS-EGPS model 
(development set)
n/N a 125/1618 31/126 125/1618 31/126 154/1123
Baseline predictor, HR 
(95% CI)
Age (decade) 1.25 (1.04 to 1.49) 1.49 (1.06 to 2.11) 1.29 (1.09 to 1.53) 1.56 (1.13 to 2.16) 1.26 (1.06 to 1.50)
IOP (mmHg) 1.11 (1.03 to 1.17) 1.17 (1.05 to 1.30) 1.10 (1.04 to 1.17) 1.16 (1.04 to 1.29) 1.09 (1.03 to 1.17)
CCT (per 40 µm thinner) 1.82 (1.51 to 2.19) 1.92 (1.25 to 2.96) 1.92 (1.60 to 2.30) 2.10 (1.39 to 3.18) 2.04 (1.70 to 2.45)
History of diabetes 
mellitus
0.35 (0.15 to 0.78) 1.13 (0.40 to 3.18) 0.38 (0.17 to 0.86) 1.28 (0.47 to 3.46) Excluded
VCD ratio (per 0.1 larger) 1.32 (1.20 to 1.45) 1.10 (0.85 to 1.44) Excluded Excluded 1.19 (1.09 to 1.31)
PSD (per 0.2 dB greater) 1.25 (1.06 to 1.48) 1.15 (0.95 to 1.39) Excluded Excluded 1.13 (1.04 to 1.24)
Performance measure
c-index NR 0.68 NR 0.73 0.74 (0.70 to 0.78)
Calibration χ2 NR NE NR NE 7.05
Calibration slope NR 0.826 (SE 0.195) NR 1.086 (SE 0.255) NE
NE, not estimated; NR, not reported; SE, standard error of the calibration slope.
a  n is the number of OAG cases and N is the total number of patients. It was not always apparent whether these were the numbers analysed in 
multivariate Cox regression analysis though there was no report of imputation for missing values. CCT measurements were only available for 
119 cases and 1279 non-cases in OHTS. The numbers shown for the OHTS-EGPS model were the numbers analysed.24 Risk prediction tools for development of open-angle glaucoma
The ‘DIABETES’ variable takes the value 1 if the patient has a history of diabetes mellitus and 
0 otherwise. VCD is the vertical C/D ratio. A risk scoring system based on this model was 
also developed.
For the reduced model, excluding the VCD ratio and PSD, the risk estimate was calculated as:
Risk estimate = 1 – 0.906exp(PI)  [Model 2]
where
PI = ∑β () −
=
Xx ii i
i
k
1
 = ln(1.29) × (AGEDECADE – 5.54) + ln(1.10) × (IOP – 24.9)  
+ ln (1.92) × (T_CCT + 14.3625) + ln(0.38)  
× (DIABETES – 0.121)  [Equation 6]
The full model containing the VCD ratio and PSD performed similarly to the reduced 
model that excluded these variables. In updated univariate and multivariate analyses of the 
OHTS model, the protective effect of a history of diabetes mellitus was no longer statistically 
significant.66 The authors suggest that the difference from the 2002 article was a reflection of more 
complete ascertainment of diabetes mellitus. Also, individuals with diabetic retinopathy were 
excluded from the OHTS and so the patients in the study may not be representative of patients 
with diabetes.
Ocular Hypertension Treatment Study-European Glaucoma 
Prevention Study prediction model
A prediction model was developed from the OHTS observation group and validated in the 
EGPS placebo group.64 Unlike the OHTS, the EGPS included patients with pigment dispersion 
syndrome or pseudoexfoliation syndrome (PEX), conditions that may lead to secondary OAG. 
However, the 19 patients with either condition were excluded from the analyses. In both the 
OHTS and the EGPS, interactions were not detected between predictors.64 The final model 
was derived from both groups combined. The OHTS-EGPS model estimates the 5-year risk of 
developing glaucoma based on age, IOP, CCT, VCD ratio and PSD. This model uses the means of 
the right and left eyes of each participant to calculate eye-specific predictors. Similar results were 
obtained when the pooled analysis was performed with and without the EGPS participants with 
only one eye eligible for the study and so they were all included in the analyses.
The OHTS and EGPS groups further assessed whether the accuracy and clinical application of 
the OHTS-EGPS model based on the means of the right and left eyes, the ‘means model’, are 
equal, superior or inferior to those of prediction models that include eye-specific information.65 
These models include the ‘means plus asymmetry’ model, which includes age and the means of 
the right and left eyes as well as the absolute difference between eyes for eye-specific variables, 
and the ‘worse’ eye model, which includes age and values from the eye at higher risk for 
developing OAG. The ‘worse’ eye was selected using the OHTS-EGPS means model, which was 
developed from the same sample as the ‘worse’ eye model, thus introducing statistical circularity 
and increasing the predictive accuracy of the ‘worse’ eye model. The prediction model that uses 
the means of both eyes for eye-specific variables was reported as the simplest to use and the most 
robust to measurement variability and error.65 Using the same transformation as in the OHTS 
model for age, CCT, PSD and VCD, the risk estimate for glaucoma development in 5 years was 
calculated as:
Risk estimate = 1 – 0.91831exp(PI)  [Model 3]© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
25   Health Technology Assessment 2012; Vol. 16: No. 29 DOI: 10.3310/hta16290
where
PI = ∑β () −
=
Xx ii i
i
k
1
 = 0.23260 × (AGEDECADE – 5.64301) + 0.09025 × (IOP – 24.1386)  
+ 0.71503 × (T_CCT + 14.3349) + 0.12376 × (T_PSD – 9.76001)  
+ 0.17689 × (T_VCD – 3.60828)  [Equation 7]
A calculator to estimate the 5-year risk of developing OAG, based on the pooled OHTS–EGPS 
means model, is available online at http://ohts.wustl.edu/risk/calculator.html. The calculator 
truncates predictor values at the bounds of the values recorded for each predictor in the OHTS-
EGPS cohort (see Table 8 for the lower and upper limit values of each predictor). To simplify risk 
assessment, a points-based system was also developed by the OHTS-EGPS group.
Model validation
Because the inclusion of a history of diabetes mellitus as a predictor in the OHTS models (model 
1 and model 2) was no longer valid and the models have been superseded by the OHTS-EGPS 
model (model 3), only model 3 was validated using the four cohorts. The OHTS-EGPS prediction 
model used the average values of eye-specific predictors and so when values were available for 
both eyes we adopted the same approach in our validation. Only patients with an exit date, that 
is a conversion date, discharge date, date of death or at least one follow-up date, were included 
in the analyses. For those considered as active in the Rotterdam cohort but without a known 
follow-up date, the trial end date of 31 August 2008 was taken to be their exit date. Patients in the 
Dunfermline cohort who were not due for their first follow-up were assigned the date that the 
data sets were frozen for analyses (4 May 2010). Analyses were based on 393, 298, 188 and 159 
patients for the Rotterdam, Moorfields, Dunfermline and Nottingham cohorts, respectively, as 
described in Chapter 3.
Missing predictors
All cohorts provided complete data on age. IOP was missing for a few patients, especially for 
those recently enrolled in the Dunfermline cohort. The frequency of missing data for each 
predictor in each cohort is shown in Table 4. The proportion of missing values for CCT was high 
in all cohorts (between 22.6% and 100%). CCT was sporadically collected for both the Moorfields 
and Dunfermline cohorts. However, in the Dunfermline cohort, CCT was not recorded in the 
electronic patient record system. To retrieve this information would have required manual 
retrieval of all case notes, an immense task with possibly very little yield. Therefore, we imputed 
the average value, 556 µm, from the Nottingham cohort to allow for calculation of each 
patient’s risk.
For the Rotterdam cohort, VCD ratio was measured from November 2000 onwards only and 
CCT from September 2003 onwards. Patients who dropped out or were excluded prior to these 
dates did not have either a VCD ratio (32.8%) or a CCT measurement (22.6%). For two patients, 
the time interval between measurement of VCD ratio and conversion to OAG was < 1 year 
and so their measurements were regarded as missing. Of the 393 patients in the cohort, there 
were 64 patients (16%) with at least two missing predictors and in all 64 patients both CCT 
and VCD ratio were missing. For the Moorfields cohort, there were 87 patients (29.2%) with 
multiple missing predictors, of whom both CCT and PSD were missing in 74. In more than half 
of the Moorfields cohort, PSD was missing because corrected PSD (CPSD) was recorded more 
frequently, with this being missing in only 24 (8.1%) patients. In contrast to the Rotterdam and 
Moorfields cohorts, the Dunfermline and Nottingham cohorts included very few patients with 
multiple missing predictors – 14 (7.4%) and eight (5.0%), respectively.26 Risk prediction tools for development of open-angle glaucoma
Validation sample
The median follow-up times of our observational cohorts (2.7 years for Dunfermline and 
4.3 years for Nottingham) were much shorter than those of our trial-based cohorts (8.2 years for 
Rotterdam and 9.3 years for Moorfields). The median follow-up time was 4.8 years and 6.6 years 
for the EGPS and the OHTS, respectively. The Kaplan–Meier estimate of the 5-year cumulative 
probability of developing OAG was 9.3% in the OHTS observation group and 16.8% in the EGPS 
placebo group. These values were 4.0% (95% CI 2.3% to 6.9%) for Rotterdam, 11.3% (95% CI 
7.8% to 16.4%) for Moorfields, 23.7% (95% CI 14.1% to 39.9%) for Dunfermline and 5.1% (95% 
CI 2.0% to 12.7%) for Nottingham. The baseline characteristics of the four cohorts were generally 
similar to those of the OHTS-EGPS cohort, although patients in our observational cohorts were 
on average older than those in the randomised cohorts (Table 5). On average, patients in the 
Moorfields cohort had a lower CCT than those in the OHTS-EGPS, Rotterdam or Nottingham 
cohorts. Average PSD in the group that converted to OAG and the group that did not were lower 
in the Rotterdam cohort than in the corresponding groups in other cohorts.
In univariate analysis, a history of cardiovascular disease was associated with OAG in the OHTS, 
the EGPS and the pooled OHTS-EGPS. This information was not recorded for the Rotterdam 
and Moorfields cohorts. Only a few of the Dunfermline cohort had a history of heart disease 
(10/188, 5.3%), and 5.0% of those who did not convert to OAG had heart disease, compared with 
7.1% of those who converted. In the OHTS-EGPS, 7.8% of those who did not convert to OAG 
had heart disease, compared with 11.5% of those who converted. The proportions of patients for 
whom predictor values were outside the bounds of the OHTS-EGPS cohort is shown in Table 6. 
In 22.1% (66/298) of the Moorfields cohort, IOP was < 20 mmHg, and 12.0% (17/142) of the 
Dunfermline cohort had a PSD value > 3.
Model performance
Examination of the distribution of imputed values showed similarity with observed values and 
the imputed data were used to compute predicted risks. Using one of the 10 imputed data sets, 
an example of the distribution of predicted risks for those who developed and those who did not 
develop OAG is shown in Figure 10. Stratified (treated vs untreated) and unstratified analyses 
gave similar results, and so only the unstratified analysis is reported. Figures 11–14 show the 
Kaplan–Meier curves for the risk of conversion from OHT to glaucoma by risk group from the 
same imputed data sets used for Figure 10. Based on analysis of all 10 imputed data sets for the 
trial-based cohorts, there was a statistically significant difference in survival across risk groups. 
Multivariate HRs (and 95% CIs) for the risk factors and the performance measures of the model 
applied to each cohort using imputed data and complete cases are shown in Tables 7 and 8, 
respectively. For the Rotterdam and Dunfermline cohorts, there was little or no difference in 
model performance using multiple imputed data instead of complete case analyses. The converse 
TABLE 4  Frequency of missing data for the five predictors in each cohort
Characteristic Rotterdam, n (%) Moorfields, n (%) Dunfermline, n (%) Nottingham, n (%)
na 393 298 188 159
Complete cases 238 (60.6) 78 (26.2) 135 (71.8) 112 (70.4)
Age  0 0 0 0
IOP  2 (0.5) 0 12 (6.4) 2 (1.3)
CCT 89 (22.6) 143 (48.0) 188 (100) 37 (23.3)
VCD ratio 129 (32.8) 13 (4.4) 17 (9.0) 10 (6.3)
PSD  1 (0.3) 155 (52.0) 46 (24.5) 10 (6.3)
a  n is the number of completed cases from imputed data and is the number of patients analysed.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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was the case for the Moorfields and Nottingham cohorts. Data were complete for only 78 patients 
(26%) in the Moorfields cohort.
The c-indexes were between 0.69 and 0.83; the Rotterdam cohort had the best discriminatory 
ability (0.83, 95% CI 0.75 to 0.91), whereas the Moorfields cohort yielded the lowest c-index 
(0.69, 95% CI 0.59 to 0.78). Figures 15–22 illustrate calibration of the model in the four cohorts 
based on the same imputed data sets as in Figures 10–14. For the Rotterdam and Moorfields 
cohorts, the calibration plots are shown separately for the treated, untreated and combined data 
to highlight differences in calibration that may exist as a result of the effect of IOP-lowering 
treatment. The effect of treatment on calibration is not clear from Figures 15, 16, 18 and 19, 
although calibration appears to be better in the treated groups. However, these plots should be 
viewed cautiously because they were based on small study sizes and few conversions to OAG, 
and they depict only a single imputation, which may be atypical. The calibration slopes presented 
in Table 7 were computed based on the 10 imputed data sets. There was little variation in the 
estimated calibration slope between imputations for all data sets except the Moorfields cohort, 
and this may be owing to sensitivity to missing data. For the Rotterdam cohort, the calibration 
slope was close to 1 (1.09, 95% CI 0.72 to 1.46), the ideal value when there is complete agreement 
between predicted and observed risks, although the example calibration plot presented in 
Figure 17, based on a single imputation, shows an atypical relationship. The calibration slopes 
were 0.59 (95% CI 0.19 to 0.99), 0.21 (95% CI –0.33 to 0.74) and 0.24 (95% CI –0.17 to 0.65) for 
the Moorfields, Dunfermline and Nottingham cohorts, respectively. Values of the calibration 
slope that are < 1 represent overfitting, suggesting that, on average, the effects of the predictors 
were smaller in these cohorts than in the OHTS-EGPS cohort.
Sensitivity analysis
Vertical cup-to-disc ratio was missing in > 30% of the Rotterdam cohort because the 
measurements were not taken at baseline. The time interval between VCD ratio measurement 
TABLE 6  Percentage of values in each cohort outside the range of predictor values in the OHTS-EGPS cohort
Rotterdam Moorfields Dunfermline Nottingham
N n (%) N n (%) N n (%) N n (%)
Age (years) 393 298 188 159
< 30 2 (0.5) 2 (0.7) 0 0
> 80 2 (0.5) 4 (1.3) 10 (5.3) 3 (1.9)
IOP (mmHg) 391 298 176 157
< 20 3 (0.8) 66 (22.1) 11 (6.3) 33 (21.0)
> 32 3 (0.8) 3 (1.0) 5 (2.8) 0
CCT (µm) 304 155 0 122
< 475 0  1 (0.6) NA 2 (1.6)
> 658 2 (0.7) 0 NA 2 (1.6)
VCD ratio (by contour) 264 285 171 149
< 0 0 0 0 0
> 0.8 2 (0.8) 3 (1.1) 1 (0.6) 0
PSD (dB) 392 143 142 149
< 0.5 0 1 (0.7) 0 0
> 3 3 (0.8) 10 (7.0) 17 (12.0) 6 (4.0)
NA, not available.
N is the number of non-missing values for the predictor; n is the number of values less than the lower bound value of the predictor or greater 
than the upper bound value of the predictor in the OHTS-EGPS cohort.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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FIGURE 10  Illustrative distribution of predicted 5-year risk in those who developed OAG and those who did not develop 
OAG during the follow-up period in each of the cohorts for the first imputed data set.
FIGURE 11  Rotterdam cohort: illustrative Kaplan–Meier curve for the risk of conversion from OHT to glaucoma by risk 
category for the first imputed data set. Log-rank test: p < 0.001. The number at risk in each risk category – low (< 6%), 
intermediate (6–13%) and high (> 13%) – is shown at 2-yearly intervals. The numbers who converted to OAG during 
each time interval are shown in parentheses.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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FIGURE 12  Moorfields cohort: illustrative Kaplan–Meier curve for the risk of conversion from OHT to glaucoma by risk 
category for the first imputed data set. Log-rank test: p = 0.001. The number at risk in each risk category – low (< 6%), 
intermediate (6–13%) and high (> 13%) – is shown at 2-yearly intervals. The numbers who converted to OAG during 
each time interval are shown in parentheses.
FIGURE 13  Dunfermline cohort: illustrative Kaplan–Meier curve for the risk of conversion from OHT to glaucoma by 
risk category for the first imputed data set. Log-rank test: p = 0.6. The number at risk in each risk category – low (< 6%), 
intermediate (6–13%) and high (> 13%) – is shown at 2-yearly intervals. The numbers who converted to OAG during 
each time interval are shown in parentheses.
FIGURE 14  Nottingham cohort: illustrative Kaplan–Meier curve for the risk of conversion from OHT to glaucoma by risk 
category for the first imputed data set. Log-rank test: p = 0.08. The number at risk in each risk category – low (< 6%), 
intermediate (6–13%) and high (> 13%) – is shown at 2-yearly intervals. The numbers who converted to OAG during 
each time interval are shown in parentheses.
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FIGURE 15  Example calibration plot for the Rotterdam cohort for the first imputed data set: untreated group. For each 
quintile, the average observed risk is plotted with its 95% CI against the predicted 5-year risk of developing OAG. The 
dotted straight line through the origin represents perfect calibration. The histogram above the horizontal axis represents 
the distribution of predicted risks.
FIGURE 16  Example calibration plot for the Rotterdam cohort for the first imputed data set: treated group. For each 
quintile, the average observed risk is plotted with its 95% CI against the predicted 5-year risk of developing OAG. The 
dotted straight line through the origin represents perfect calibration. The histogram above the horizontal axis represents 
the distribution of predicted risks.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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FIGURE 17  Example calibration plot for the Rotterdam cohort for the first imputed data set: all participants. For each 
quintile, the average observed risk is plotted with its 95% CI against the predicted 5-year risk of developing OAG. The 
dotted straight line through the origin represents perfect calibration. The histogram above the horizontal axis represents 
the distribution of predicted risks.
FIGURE 18  Example calibration plot for the Moorfields cohort for the first imputed data set: untreated group. For each 
quintile, the average observed risk is plotted with its 95% CI against the predicted 5-year risk of developing OAG. The 
dotted straight line through the origin represents perfect calibration. The histogram above the horizontal axis represents 
the distribution of predicted risks.34 Risk prediction tools for development of open-angle glaucoma
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FIGURE 20  Example calibration plot for the Moorfields cohort for the first imputed data set: all participants. For each 
quintile, the average observed risk is plotted with its 95% CI against the predicted 5-year risk of developing OAG. The 
dotted straight line through the origin represents perfect calibration. The histogram above the horizontal axis represents 
the distribution of predicted risks.
FIGURE 19  Example calibration plot for the Moorfields cohort for the first imputed data set: treated group. For each 
quintile, the average observed risk is plotted with its 95% CI against the predicted 5-year risk of developing OAG. The 
dotted straight line through the origin represents perfect calibration. The histogram above the horizontal axis represents 
the distribution of predicted risks.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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FIGURE 21  Example calibration plot for the Dunfermline cohort for the first imputed data set: all participants. For each 
quintile, the average observed risk is plotted with its 95% CI against the predicted 5-year risk of developing OAG. The 
dotted straight line through the origin represents perfect calibration. The histogram above the horizontal axis represents 
the distribution of predicted risks.
FIGURE 22  Example calibration plot for the Nottingham cohort for the first imputed data set: all participants. For each 
quintile, the average observed risk is plotted with its 95% CI against the predicted 5-year risk of developing OAG. The 
dotted straight line through the origin represents perfect calibration. The histogram above the horizontal axis represents 
the distribution of predicted risks.
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and conversion to OAG was < 24 months for five patients in the Rotterdam cohort. Sensitivity 
analysis using imputed values for these patients did not affect performance of the model (c-index: 
0.83, 95% CI 0.75 to 0.91; calibration slope: 1.06, 95% CI 0.64 to 1.47).
Discussion
Systematic review
Several studies have identified potential risk factors for OAG, but there are few risk prediction 
tools that predict an individual’s likelihood of developing the disease over a specified period 
of time (e.g. 5 years). We found only three models with published prediction equations. These 
models were derived using either the OHTS or the combined OHTS and EGPS populations. The 
OHTS-EGPS collaboration produced a model, the ‘means’ model, which was the most robust, 
and it is the model referred to as the OHTS-EGPS model. Unlike the OHTS model, this OHTS-
EGPS model has not been validated in a different population by independent investigators. The 
OHTS and OHTS-EGPS models demonstrated good discriminatory ability (c-indexes between 
0.68 and 0.74),63,64 similar to those of the Bach model for lung cancer (0.69, 95% CI 0.66 to 0.72),67 
the EuroScore model for identifying patients with prolonged intensive care unit stay (0.71, 
95% CI 0.70 to 0.72),68 the Framingham model for CHD (between 0.69 and 0.83 in six different 
cohorts)69 and better than that of the Gail model for invasive breast cancer (0.58, 95% CI 0.56 
to 0.60).70 All of the variables included in the models are or can be routinely collected in clinical 
practice. A simple calculator based on the OHTS-EGPS model is available online and can be 
freely downloaded, enabling quick and easy estimation of the 5-year risk of a patient with OHT 
developing OAG in at least one eye. A points-based system is also provided.
Intraocular pressure and central corneal thickness
Intraocular pressure and age are important and well-established risk factors, but CCT was a 
major predictor for the development of OAG over 5 years. For the OHTS-EGPS model, there was 
an increase in risk per 40-µm decrease in corneal thickness (HR 2.04, 95% CI 1.70 to 2.45). The 
log-HR standardised according to the SD of the measurements of each predictor in the OHTS-
EGPS cohort provides a measure of the contribution of each predictor in the model; CCT was the 
most important predictor. It is unclear to what extent lower CCT is responsible for the increased 
risk of OAG and previous studies have shown that CCT tends to decrease with increasing age.71,72 
It is also well known that corneal thickness influences the measurement of IOP because GAT 
has an inherent measurement error because of CCT variations; IOP is overestimated in thicker 
corneas and underestimated in thinner ones.73–75 Nevertheless, there is no consensus on the 
clinical significance of the effect of CCT on IOP measurements.76 No correlation was found 
between CCT and IOP (or any of the other predictors) in either the OHTS or the EGPS. This 
may be owing to exclusion of patients with normal or very low IOPs and also those with very 
high IOPs.77 In the Early Manifest Glaucoma Trial, CCT was identified as a significant predictive 
factor for glaucoma progression in patients with higher baseline IOP but not in those with lower 
baseline IOP.78 Racial differences in CCT have been reported in several population studies, with 
individuals of African ancestry having thinner corneas, on average, than Caucasians, Hispanics 
or Asians.79–85 It has been suggested that black race may not be an independent risk factor 
because black patients tend to have higher IOP, thinner corneas and higher C/D ratios than 
other patients with OHT and are therefore generally at a higher risk than white patients.86 In 
the OHTS and OHTS-EGPS, when either VCD ratio or CCT was included in the multivariate 
model, race was no longer statistically significant.42,64 CCT has also been shown to be a highly 
heritable trait.87–89 Because thinner CCT has also been found to predict progression of visual 
loss in patients with OAG, it is plausible that a biological link exists between aspects of the 
cornea that regulate its thickness and the physical and structural properties of tissues involved in 
glaucoma pathogenesis.76© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Choice of one eye, two eyes or worse eye
Glaucoma can affect either eye or both eyes but it is often asymmetrical, occurring first in one 
eye only. The prediction models use the mean of the measurements taken from both eyes for all 
of the eye-specific predictors. Analysis based on a single eye per individual or on the average of 
both eyes is convenient but may be suboptimal because of intereye differences. Using a single 
eye could introduce bias if, for example, data on both eyes are available in some individuals, with 
one eye randomly selected for analysis, but in other individuals are available for only one eye 
and so are included by default.90 With respect to IOP, 21% (105/500) of the EGPS participants 
randomised to the placebo group and included in the OHTS-EGPS analyses had only one eligible 
eye. Only the data from the included eye were used.64 Nevertheless, unpublished data from the 
EGPS showed that conversion to OAG was almost the same in the group of patients with both 
eyes included as in those with only one eye included in the trial.91 When both eyes are available, 
an alternative approach is to use the ‘worse’ eye, the eye at higher risk of developing OAG; 
however, this can be problematic when a single variable cannot be used to identify the ‘worse’ 
eye. Identification of the worse eye in the OHTS-EGPS ‘worse’ eye model was based on IOP, 
CCT, VCD ratio and PSD. Selection of the ‘worse’ eye was challenging because the eyes of many 
participants had nearly identical risk estimates at baseline.65 Using the means of right and left 
eyes enables the inclusion of relevant data from both eyes of each patient, but potentially at the 
expense of predictive accuracy. Nevertheless, the performance of the OHTS-EGPS prediction 
model based on the means of right and left eyes for eye-specific variables was compatible with 
prediction models that included additional information on baseline differences between eyes.65
Limitations of the prediction models
The models are limited because they do not include other major risk factors such as race 
and family history of glaucoma. Race was not associated with the risk of developing OAG in 
univariate or multivariate analyses of the OHTS or the pooled OHTS-EGPS data. All of the 439 
patients from the EGPS included in the pooled data were Caucasians, and the lack of association 
may be owing to limited power in the OHTS and the combined data set. In the OHTS, data 
on family history of glaucoma (parent or sibling) were collected by patient recall, without 
verification, and so may be subject to recall bias. This information was not collected in the EGPS. 
A positive family history of glaucoma was not significantly associated with an increased risk of 
OAG in the OHTS analyses. Conversely, the Barbados Eye Studies found more than a twofold 
increase in risk (relative risk 2.4, 95% CI 1.3 to 4.6) after adjustment for age, gender, IOP, and 
IOP and blood pressure treatment.38 Other ocular conditions, such as PEX36,37,41,92 and optic disc 
haemorrhage,78,91,93 have been found to be predictive for the development of OAG. The OHTS 
excluded individuals with PEX and pigment dispersion whereas the EGPS included only 19 
individuals with these conditions and they were excluded from the pooled analyses.
Another limitation of the models is the use of only baseline measurements of predictors – except 
for CCT, which was measured later during follow-up – without accounting for fluctuations and 
changes over time in any of the predictors, especially IOP. IOP fluctuation has been suggested as 
an independent risk factor for glaucomatous optic nerve damage, but reports are conflicting.94 
In the EGPS, the area under the curve of IOP, a ‘time-dependent’ evaluation of IOP, taking into 
account the IOP behaviour for each 6-month period, was associated with the development of 
OAG yet IOP fluctuation during follow-up was not.91 Medeiros and colleagues95 found that long-
term IOP fluctuations were not a significant risk factor for glaucoma development in untreated 
patients with OHT observed over time, but higher mean IOP levels were consistently associated 
with increased likelihood of developing glaucoma. Similarly, in the Malmö Ocular Hypertension 
Study, IOP fluctuations were not an independent risk factor for the incidence of glaucomatous 
visual field loss in patients with OHT, and higher IOP fluctuation was found in eyes with 
higher IOP levels.9638 Risk prediction tools for development of open-angle glaucoma
Model validation
We assessed the external validity of the OHTS-EGPS model by investigating its discriminatory 
ability and calibration in four different populations. In the Rotterdam, Moorfields and 
Nottingham cohorts, the model reliably stratified patients into the three risk categories (low, 
intermediate and high), but the model performed best in the Rotterdam cohort. The ability of 
the model to distinguish between patients with OHT who developed OAG and those who did 
not was good in all four cohorts, with c-indexes ranging between 0.69 and 0.83. A c-index of 
0.83 indicates that, in approximately 83% of the cases, the model allocated a higher predicted 
probability to an individual who converted than to one who did not.
In the model calibration analyses, the OHTS-EGPS model generally overestimated the risk 
of OAG in all cohorts. In the Moorfields and Dunfermline cohorts, there were fewer patients 
in the low-risk group than in the intermediate- and high-risk groups. In contrast, patients in 
the Rotterdam cohort were almost equally distributed among the three risk groups. Because 
of differences in case mix, a prediction model is likely to be more appropriate in a population 
similar to the one used to derive the model.97 For instance, a risk model derived from a more 
heterogeneous case mix provided better calibration in risk assessment across the spectrum of 
acute coronary syndromes than another model derived using a clinical trial population, although 
both models showed similar discriminatory ability.98
Predictor effects
The HRs obtained when the OHTS-EGPS model was fitted to our cohorts were similar to those 
obtained in the development cohort, although they were not always statistically significant. 
Our cohorts were much smaller than the OHTS-EGPS cohort. CCT was the only statistically 
significant predictor in the Moorfields cohort (HR 2.76, 95% CI 1.44 to 5.26), but was not 
significant in the Rotterdam cohort (HR 1.31, 95% CI 0.79 to 2.17). This may be because average 
CCT was lower in the Moorfields cohort than in the other cohorts. Seventeen patients (12%) in 
the Dunfermline cohort had an average PSD value > 3, the upper limit allowed in the OHTS-
EGPS model, and the HR was 1.06 (95% CI 0.96 to 1.16) per 0.2-dB increase in PSD. A large 
PSD could be a sign of early optic nerve damage and unconfirmed glaucoma but can also reflect 
an unreliable field, for example because of incorrect patient positioning when undertaking the 
perimetry. In the observational cohorts patients are likely to have had only one baseline visual 
field examination, unlike the trial cohorts for which data from at least two reliable baseline visual 
fields would have been required.
Generalisability
The trial-based cohorts were a highly selected population. The OHTS and EGPS excluded 
pregnant or nursing women, those with best corrected visual acuity worse than 20/40 in either 
eye, a history of previous intraocular surgery, life-threatening or debilitating disease, secondary 
causes of elevated IOP, systemic or ocular conditions capable of causing visual field loss or optic 
disc abnormalities, patients with diabetes who had evidence of diabetic retinopathy and those on 
medication. In addition, in the OHTS, patients with pigment dispersion or exfoliation syndrome 
were excluded. Most of these criteria were applied in the selection of the Rotterdam and 
Moorfields cohorts (see Chapter 3). The OHTS and DIGS used similar patient selection criteria 
and the calibration slope (1.086) of the OHTS model in the DIGS cohort was similar to that of 
the OHTS-EGPS model in the Rotterdam cohort. In both cases, the values were not statistically 
different from 1, the ideal value. Selection criteria were more flexible in the two observational 
cohorts, yet both cohorts may not be representative of the general OHT population. Low-risk 
cases in the Dunfermline hospital-based registry were discharged after two visits (at 1 year), and 
in the Nottingham community-based registry they were discharged if they had untreated IOP 
consistently < 21 mmHg as well as normal visual fields and optic discs. Patients in the Nottingham 
scheme suspected of conversion or with IOP above recommended predefined guidelines (see © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Chapter 3) were referred back to secondary care. If the secondary-care clinician confirmed 
conversion, the patient was treated and retained in the secondary-care system. However, if no 
conversion was judged to have occurred, the patient was returned to the community scheme for 
annual review. The Dunfermline and the Nottingham data sets represent routinely collected data 
in clinical practice. A risk prediction tool is potentially most valuable in this context and used as 
an aid to define criteria for monitoring and treatment guidelines for the management of OHT. 
Because the discriminatory ability of the model was generally good, the model can be adjusted or 
recalibrated to correct for model optimism; calibration errors can be eliminated without affecting 
the discriminatory ability of the model. However, given the limitations of our data, we did not 
attempt to recalibrate the model to correct for the overestimation of risk.
Variable and outcome definition
Differences in the methods used for data collection or in the definitions of the predictors or the 
outcome variable can affect model performance.97 Variability of IOP measurements is a well-
known phenomenon, and in both the OHTS and the EGPS between two and nine measurements 
of IOP were taken in each eye to obtain a stable estimate of baseline IOP. The variability of IOP 
measurements in the same eye between consecutive visits has been shown to be moderate and is 
greater than the variability of IOP measurements between right and left eyes at the same visit.99 
IOP of ≥ 22 mmHg and < 35 mmHg on two or more occasions measured within a 2-week period 
was the entry criterion for the Moorfields cohort.32 Yet 22% of the Moorfields cohort had an IOP 
of < 20 mmHg at baseline, a likely reflection of the regression to the mean. One IOP measurement 
was recorded in each eye, which is typically the case in clinical practice.
In the OHTS and the EGPS, CCT was measured using ultrasonic pachymeters and an average 
of five measurements per eye was carried out; this was also the case in the Nottingham scheme. 
Intereye difference in CCT tends to be small but, to ensure data quality and reproducibility, 
in the OHTS, repeat measurements were made when the intereye difference was ≥ 40 µm.71 In 
clinical practice, only one CCT measurement, based on an average of five readings at one visit, 
is undertaken.
Pattern standard deviation is an objective index of severity of visual field loss. However, the 
evaluation of the VCD ratio (especially in clinical practice) is subjective and is expected to have a 
large intra- and interobserver variability.
For risk estimation, the online calculator requires three IOP measurements per eye taken 
using GAT, three CCT measurements per eye using an ultrasound pachymeter and two PSD 
measurements per eye using any of the following: Humphrey full threshold 30-2 or 24-2; SITA 
standard 30-2 or 24-2; or loss variance from Octopus 32-2. Only one measurement of each of 
these variables was recorded per eye in our cohorts, except for the visual field parameter (PSD), 
for which at least two baseline visual fields were required.
Events and conversion criteria
With the exception of Dunfermline, there were few incident cases of OAG and the rate of 
conversion varied between cohorts. Substantial variation in the incidence of OAG was also 
observed between clinics in the OHTS (3.7–42.9%) and the EGPS (0–25%). The variation was 
attributed to differences in characteristics of the participants enrolled at the various clinics as 
well as the small number of participants in some clinics.64 The rate of conversion from OHT to 
OAG may also depend on the conversion criteria used. Glaucoma is diagnosed on the basis of 
a characteristic pattern of damage to the optic nerve with a corresponding and reproducible 
visual field defect. The conversion criteria used in the observational cohorts were not as rigid 
and well defined as those used in the trial-based cohorts; conversion was generally based on 
the development of a visual field defect. This is likely to be a better reflection of clinical practice 40 Risk prediction tools for development of open-angle glaucoma
than the criteria and processes adopted in the trials, but is unlikely to be consistent across the 
validation data sets as there is no ‘gold’ standard case definition of early glaucoma. The OHTS 
and EGPS also had a mixed population comprising newly diagnosed and existing patients with 
OHT attending clinics. Including the latter group could have introduced bias because those 
with OHT who converted to OAG before recruitment started were excluded from the study, and 
those who did not convert may be less likely to convert than the whole population with OHT.
Limitations of the model validation
One of the limitations of this study was the inclusion of treated patients in all cohorts, 
although the only predictor affected by treatment is IOP. This may be important for those 
who were untreated at the time of recruitment into the study, but is less important for those 
who were already on treatment when entered into the study cohort, as may be the case with 
the observational (Dunfermline and Nottingham) cohorts. Although the OHTS-EGPS model 
was developed to estimate the risk for a patient left untreated for 5 years, the HRs were similar 
to those of the OHTS model based on treated and untreated patients. This OHTS model was 
validated in an untreated population and similar HRs were obtained for the predictors.63
A second limitation was the number of patients and OAG cases in some cohorts. In the UK, 
patients considered to have a moderate or high risk are often kept in secondary care whereas 
those deemed to be very low risk are discharged (i.e. no follow-up). This may explain the higher 
incidence of OAG in the Dunfermline cohort (28/188, 14.9%) than in the other cohorts, and 
the very low incidence in the Nottingham cohort (5/159, 3.1%) compared with the DIGS cohort 
(31/126, 24.6%),63 although it exceeds that of the Visual Impairment Project (66/2415, 2.7%).37 
Some patients in the Nottingham cohort received treatment for OHT prior to entry into the 
scheme, and this could account for the low incidence of OAG, as well as the strict entry criterion 
(see Chapter 3, Data from observational data sets). Thus, the Dunfermline (secondary care) and 
Nottingham (community care) cohorts may be unrepresentative of the wider OHT population.
A third limitation was the large proportion of missing values for some predictors in some 
cohorts. CCT was missing in > 20% of patients in each cohort (100% in the Dunfermline cohort), 
and was more likely to be missing in those who were enrolled earlier or dropped out/discharged 
early in the study. The OHTS was the first study to prospectively document that a lower CCT 
measurement predicts the development of OAG and recommended its measurement in the 
clinical evaluation of patients with OHT.42 CCT measurements were not included originally in 
the protocols of OHTS and EGPS, and 184 patients without CCT measurements were excluded 
from their analyses. The Moorfields study commenced in 1992, at a time when CCT was not 
measured routinely, and CCT data were collected during follow-up. It is possible that only those 
at higher risk of developing glaucoma had a CCT measurement.
A fourth limitation was the enrolment of only Caucasians in the Rotterdam and Dunfermline 
cohorts, and the fact that race was not documented in the Nottingham cohort (it is likely that 
there were few non-Caucasians because black patients were considered to be at higher risk of 
OAG and so were unlikely to be referred to the scheme). Although race was not a predictor in 
the OHTS-EGPS model, the OHTS population was racially diverse, and approximately 25% of 
patients enrolled in the study were African Americans. Because there is evidence to suggest that 
blacks and whites differ with respect to several risk factors for OAG,100 the poor calibration in 
some cohorts may be partly because of racial differences.
A risk prediction model cannot replace clinical decision-making but is a tool that can facilitate 
more objective assessment and management of patients. It has been shown that ophthalmologists 
underestimated the risk of glaucoma in patients with OHT compared with the risk obtained 
using a risk calculator.101 Furthermore, the use of a risk calculator changed treatment 
recommendations made by glaucoma specialists.102© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Conclusions
To guide therapeutic intervention and for the prevention of OAG there is a need for accurate and 
reliable risk assessment for conversion from OHT to OAG. The applicability of a multivariate 
risk prediction model beyond the setting in which it was developed is essential to its adoption 
and acceptability in clinical practice. We identified and validated a risk prediction model 
that can be used for objective risk assessment in the management of patients with OHT (the 
OHTS-EGPS model). Despite the limitations of our cohorts, the OHTS-EGPS model generally 
discriminated well in estimating the 5-year risk of conversion to OAG but was not well calibrated 
in all populations. It could provide more accurate risk assessment in conjunction with clinical 
assessment, but its usefulness in different settings and populations other than trial populations 
remains uncertain. Validation in a population-based setting is important because of its relevance 
to daily clinical practice. Therefore, further validation, especially in non-Caucasians, and 
recalibration in relevant patient subgroups is needed. Prediction models tend to evolve over 
time as the role and impact of existing risk factors become more apparent, or new candidate 
predictors are identified. The model has not been revised since its original publication and future 
research may seek to update the model to reflect such new knowledge and potentially improve 
predictive ability.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Chapter 5 
Agreement and reliability of 
candidate tonometers for measuring 
intraocular pressure
Introduction
Background
Raised IOP is the most important risk factor for glaucoma and is the only one that is treatable. 
The instrument used to measure IOP is called a tonometer. The desirable attributes for a 
tonometer for use in a monitoring programme are accuracy, precision, acceptability to patients 
and ease of use. GAT, a contact tonometer, is currently the tonometer most widely used by 
ophthalmologists and is accepted as the current clinical standard. However, GAT has several 
limitations (see below for further information), and because of the skills required for its 
interpretation it is not ideal for the monitoring setting. In this setting, tonometers that do not 
touch the cornea (non-contact) and the use of which does not require extensive training would 
be both preferable and more practical. In recent years, a variety of new tonometers for estimating 
IOP have emerged with potential advantages, including being easy to deliver, non-contact, 
automated and self-administered, and compensating for, or not being influenced by, corneal 
thickness and other properties of the cornea.25,26
Description of technologies
Tonometers can be categorised as contact and non-contact tonometers depending on whether or 
not they involve direct corneal contact. In most cases, measurement of IOP using a tonometer 
should be carried out by a health-care professional. However, as described below, some 
tonometers [Ocuton S® (EPSa Elektronik & Präzisionsbav, Saalfeld, Germany) and transpalpebral 
tonometers] have been specifically designed for self-measurement.27
Contact tonometers
This term refers to tonometers that have direct contact with the cornea.
Goldmann applanation tonometer
The GAT, a contact tonometer, is currently the instrument most commonly used by 
ophthalmologists to estimate the IOP. It is a slit lamp-mounted device. However, there are 
some limitations associated with GAT, including the influence of corneal thickness and corneal 
biomechanical properties, the potential for transmitting infections or causing corneal abrasion 
and its relative difficulty of use. The GAT calibration assumes that the cornea has a central 
thickness of between 530 and 560 µm and IOP is likely to be an under- or overestimated when 
using GAT in people with thinner or thicker corneas, respectively.103 The operating manual 
recommends three measurements, but this is often not undertaken in clinical practice.
Dynamic contour tonometer
The dynamic contour tonometer (DCT) is a slit lamp-mounted, contact, digital, non-applanation 
tonometer and is operated in a fashion similar to GAT. It is commercially available as the 
PASCAL® DCT (SMT Swiss Microtechnology, Port, Switzerland). Corneal anaesthesia is required 44 Agreement and reliability of candidate tonometers for measuring intraocular pressure
and there is no need for fluorescein. As corneal thickness is an important factor influencing the 
IOP measurement, the PASCAL DCT minimises the effect of the architecture of the cornea by 
using a built-in ‘sensor tip’ with solid-state ‘pressure sensor’, which matches corneal curvature. 
The concave contour surface approximates the corneal shape when the pressures on both sides 
of it are equal, with minimum distortion, and directs all forces acting within the cornea to the 
pressure sensor surface, providing an IOP measure. The pressure in the eye is detected 100 times 
per second and presented as the diastolic IOP (mmHg) in the LCD (liquid crystal display) screen 
together with the ocular pulse amplitude (OPA) and a quality score, ‘Q’. OPA is the difference 
between the systolic and diastolic IOP. The quality score of the data and results can be interpreted 
as follows: ‘Q1’ is optimum; ‘Q2’ and ‘Q3’ are acceptable; and ‘Q4’ and ‘Q5’ are poor and indicate 
that the measurement should be repeated. The PASCAL DCT self-calibrates at the beginning of 
every measurement although a performance test can also be performed.104 A measurement takes 
about 5 seconds to achieve. Good cooperation is necessary to maintain a steady eye and head 
position, which are required during the measurement.
Ocuton S
The Ocuton S is a self-measurement tonometer that calculates and displays the IOP value 
automatically through direct contact of the measuring prism with the cornea. The use of topical 
anaesthetic is required.105
The Perkins applanation tonometer
The Perkins applanation tonometer is a hand-held device but otherwise uses the same principles 
as GAT and requires topical anaesthesia and fluorescein instillation. All hand-held applanation 
tonometers were included under this heading.
Rebound tonometer
The rebound tonometer (RT) is a simple portable device, commercially available as the Icare® 
tonometer (Tiolat, Helsinki, Finland). Although it is a contact tonometer, topical anaesthetic 
drops are not required and the tonometer has a disposable tip to minimise the risk of cross-
infection. The device processes the rebound movement of a rod probe resulting from its 
interaction with the eye; there is a shorter duration of impact as the IOP increases. The rebound 
is influenced by corneal thickness, and for this reason measurement of IOP by this tonometer is 
prone to measurement error as a result of corneal properties.106,107 Like GAT, it is calibrated for 
a typical CCT value. Six measurements are recommended to provide accurate results, and the 
average of six IOP measurements is displayed on the LCD.108 Regular calibration is required.
TonoPen
The TonoPen® (Mentor O&O Inc., Santa Barbara, CA, USA; Reichert Inc., Depew, NY, USA) is 
a hand-held, self-contained portable tonometer that determines IOP by making contact with the 
cornea (central contact is recommended) through a probe tip, causing applanation/indentation of 
a small area. The tip contains a transducer that measures the applied force on the cornea. Topical 
anaesthetic eye drops are used. After four valid readings are obtained, the averaged measurement 
will appear on the LCD screen. Up to 10 measurements can be performed according to the 
manufacturer recommendations. It is recommended that calibration is performed daily before 
instrument use, when indicated by the LCD screen or whenever batteries are replaced.
Non-contact tonometers
This term refers to tonometers that do not have direct contact with the cornea.
Non-contact tonometer
The air-puff tonometer uses a rapid air pulse to applanate (flatten) the cornea, thus working 
on the same basic principle as the Goldmann tonometer. The force of the air stream increases © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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linearly over milliseconds, progressively flattening a known area of the cornea. The moment 
of applanation is determined by an optical sensor and the air pulse is then interrupted. The 
advantages of the non-contact tonometer (NCT) include speed, the fact that there is no need 
for topical anaesthesia, and thus a low risk of corneal abrasion (hence its use requires minimal 
training), and, because there is no direct contact with the eye, any infection issues are avoided. 
IOP measurement by NCT is affected by the corneal thickness. There are several models 
available in the market; calibration and the number of recommended measurements may vary 
accordingly. Some models seek to correct the measurement for the CCT. Some patients find the 
air puff uncomfortable.
Ocular response analyser
The Ocular response analyser® (ORA) (Reichert Inc., Depew, NY, USA) utilises air-puff 
technology and an electro-optical system to record two applanation measurements of IOP, one 
while the cornea is moving inward and the other as the cornea returns. Because of its viscoelastic 
property, the cornea resists the dynamic air puff, delaying the inward and outward applanation 
process and resulting in two different pressure values; the average of these two IOP values 
provides a repeatable, Goldmann-correlated IOP measurement (IOPG). The difference between 
these two IOP readings is corneal hysteresis (CH), a new measurement related to corneal tissue 
properties that is a result of viscous damping in the corneal tissue.109 The CH measurement 
provides a basis for two additional new parameters: corneal-compensated intraocular pressure 
(IOPCC) and corneal resistance factor.110,111 The IOPCC is an IOP measurement that is less affected 
by the corneal properties. Four good-quality readings per eye are recommended.112
Transpalpebral tonometer
This type of tonometry includes devices that measure IOP through the eyelid avoiding direct 
corneal contact. Topical anaesthesia is not required. The Diaton® tonometer (BiCOM Inc., Long 
Beach, NY, USA; previously commercialised as TGDc-01, Ryazan State Instrument-Making 
Enterprise, Ryazan, Russia) is a hand-held, pen-like portable device applying this principle. The 
pressure phosphene tonometer (PPT; Proview® Eye Pressure Monitor, Bausch & Lomb Inc., 
Rochester, NY, USA) has been developed as a self-measurement tonometer. The PPT is a spring 
compression device calibrated in mmHg that consists of a probe with a flat applicator of the same 
diameter (3.06 mm) as the area applanated by the GAT. This instrument delivers a phosphene 
spot when pressure is applied through the closed eyelid in the superior nasal portion of the eye, a 
self-perceptible visual phenomenon. The threshold pressure for creating a phosphene spot is the 
estimated IOP.113
Aim and objectives
Aim
  ■ To compare the agreement, recordability, practicality, acceptability and reliability of the 
tonometers used in clinical practice using GAT as the reference tonometer.
Primary objectives
  ■ To compare the agreement of IOP readings of one or more tonometers in adults with the 
readings of GAT as the reference tonometer.
  ■ To explore the factors affecting the agreement between tonometers including CCT, IOP level, 
previous corneal refractory surgery, type of examiner and use of disposable tonometer heads.
Secondary objectives
  ■ To report the recordability (proportion of measurements that are recordable) of the 
alternative tonometers.46 Agreement and reliability of candidate tonometers for measuring intraocular pressure
  ■ To report the practicality of the alternative tonometers from the ‘doer’ (examiner) point of 
view and their acceptability from the ‘user’ perspective.
  ■ To compare the reliability when reported of the comparator tonometers with that of GAT, 
including intra/interobserver reliability.
Methods
Inclusion and exclusion criteria
Types of study
Direct comparative studies that assessed the agreement of one or more tonometers with the 
reference standard tonometer (GAT) in the same group of people were included. Non-English-
language studies and conference abstracts were excluded.
Types of participant
Adults aged > 16 years, including those with a diagnosis of OHT or glaucoma, representative 
of the general population, were included. When the age range was not reported, confirmation 
from the authors was sought. If no response was received and a mean age and SD or median 
age and interquartile range (IQR) were provided, a formula was applied (mean – 3SD ≥ 16 or 
median – IQR/1.35  × 3 ≥ 16) to assess inclusion. This was carried out to prevent exclusion purely 
on the failure to report the age range of the participants when it was very unlikely that any of 
the participants were under 16 based on data on the age distribution. Participants with corneal 
abnormalities were excluded (corneal pathology, including keratoconus, bullous keratopathy or 
post-corneal grafts).
Types of technology
Reference tonometer
The reference tonometer was the GAT.
Comparator tonometers
All tonometers that could be conceivably used in a monitoring context were eligible for 
inclusion. Studies that evaluated the agreement of manometry114 (invasive procedure) were not 
eligible. Tonometers that were primarily used as a research device (such as ocular blood flow115 
– recommended for research only) or were unsuitable/unavailable in a clinical setting were not 
eligible. If a study compared both an eligible and a non-eligible tonometer with GAT the study 
was included.
Types of examiner
Tonometry performed by any type of examiner including optometrists, ophthalmologists, nurses, 
technicians and patients was included.
Primary outcome
The primary outcome was the agreement [mean difference and limits of agreement (LoA)] 
between a tonometer and the reference standard.
Secondary outcomes
  ■ Interobserver reliability for two observations taken by different observers with the 
same tonometer.
  ■ Intraobserver reliability for two observations taken by the same observer with the 
same tonometer.
  ■ Practicality for ‘doers’ using the technologies.
  ■ Acceptability of the tonometers to users and providers.
  ■ Proportion of participants with a recordable IOP (recordability).© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Search strategy
Sensitive electronic searches were conducted to identify reports of published and ongoing 
studies on the reliability and agreement of tonometers. Databases were searched from 1987 
until February 2010 and searches were restricted to articles published in English. Conference 
proceedings were not included. Studies prior to 1987 were not considered because of technology 
changes. The following bibliographic databases were searched: MEDLINE, MEDLINE-In 
Process & Other Non-Indexed Citations, EMBASE, Science Citation Index, BIOSIS and the 
Cochrane Central Register of Controlled Trials. The websites of key journals were screened 
for additional relevant or in-press publications, including American Journal of Ophthalmology, 
Archives of Ophthalmology, British Journal of Ophthalmology, Eye, Graefe’s Archive for Clinical 
and Experimental Ophthalmology, Investigative Ophthalmology and Visual Science, Journal of 
Glaucoma and Ophthalmology.
Additional searches were undertaken in current research registers, including ClinicalTrials.gov, 
Current Controlled Trials and World Health Organization International Clinical Trials Registry 
Platform, and in the HTA database, DARE and the Cochrane Database of Systematic Reviews 
(CDSR) for relevant evidence synthesis reports. An internet search using Copernic Agent was 
also undertaken and included key professional organisations and manufacturers of tonometers.
Full details of the search strategies used are provided in Appendix 1.
Data extraction strategy
Two reviewers (AA, AA-B, KMc, ABP or JB) independently screened the titles and abstracts 
(if available) of all reports identified by the electronic searches. Full-text copies of all studies 
deemed to be potentially relevant were obtained and independently assessed for inclusion by two 
reviewers (AA, AA-B, KMc, ABP or JB) using a screening tool developed for this review. Authors 
were contacted by email (if provided in the manuscript) when only age range data were missing. 
Any disagreements were resolved by consensus or arbitration by a third party (AA-B, JB).
A data extraction form was developed and piloted. Two reviewers (AA, ABP, JC or AE) 
independently extracted data on study design, participant characteristics, type of tonometer 
used and outcome data. We conducted a 20% check of all extracted data (ABP). When outcome 
data were provided per eye (right/left) and overall (average measurement per participant) for 
each comparison, right eye data were used. If studies compared different versions of the same 
technology in the same study only data on the most recent tonometer version were included. 
IOPCC data were used for ORA. When an individual study provided data from two different 
groups (e.g. normal/glaucoma), the study with the bigger sample size was included in the 
analysis. If the sample size was the same in both groups, data from the group with the higher IOP 
measured by GAT were included. When measurements were performed during different sessions 
(days apart), data from the first session were used. If the measurements were taken and results 
reported at different time points during the same day, a measurement time likely to occur in 
practice (e.g. 10am) was used. When measurements taken before and after surgery were available, 
preoperative results were included in the main analysis.
When raw outcome data were provided, mean values and SDs per tonometer were calculated. 
When outcome data were not provided, and if authors’ details (email address) were available, they 
were asked for the mean difference or the SD of the difference between GAT and the comparator 
tonometer. When mean differences were not reported, they were calculated from the reported 
data (e.g. GAT and comparator means) by reading the values from a published Bland–Altman 
plot. When a difference of opinion existed, a third party was consulted (JC).48 Agreement and reliability of candidate tonometers for measuring intraocular pressure
Quality assessment strategy
Two reviewers (AA, AA-B, ABP or JB) independently assessed the quality of all included studies 
using a modified checklist adapted from Whiting and colleagues116 and Craig and colleagues.117 
Each item was graded as ‘yes’, ‘no’, or ‘unclear’. The quality assessment of diagnostic accuracy 
studies (QUADAS) tool116 is a recently developed quality assessment tool for use in systematic 
reviews of diagnostic accuracy studies; however, for this review it was adapted to make it 
applicable to assessing the quality of reliability and agreement studies. We conducted a 20% check 
of quality assessment (ABP, JC). Discrepancies were resolved by discussion or arbitration. We 
classified studies as low quality if they did not meet one or more of the quality criteria.
Data analysis
General approach
The primary outcome, agreement, was assessed by calculating summary LoA.118 Secondary 
outcomes were tabulated with no quantitative analysis conducted. The 95% LoA interval 
was calculated for each candidate tonometer from pooled estimates of the mean difference 
(systematic difference) between a tonometer and the reference standard and of the corresponding 
variability of agreement (random error). Pooled estimates of mean difference and random 
error were calculated using the DerSimonian and Laird random-effects method.119 Measures 
of agreement variability were based on reported (or derived) SDs of within-participant 
differences. Imputation of within-participant correlation coefficients to allow calculation of the 
SD of differences was employed, if required, when a correlation estimate was available from 
other studies of the same type of tonometer. The imputed value was the arithmetic mean of 
available correlation estimates when more than one study estimate was available. Sensitivity 
analyses included a fixed-effect analysis and/or imputation of correlations using the minimum 
correlation coefficient reported from the studies comparing the same tonometer. Additionally, 
an approximate 95% prediction interval was calculated for both parameters using the estimated 
τ-value (±1.96τ) from the random-effects analysis to quantify the impact of between-study 
heterogeneity on the systematic difference and the random error. The prediction interval provides 
a range of values that could plausibly be observed if a new study was undertaken, based on the 
observed between-study heterogeneity. Finally, the proportion of studies within 2 and 3 mmHg 
of GAT was estimated from the pooled difference and SD using the cumulative distribution 
function for the standard normal deviates for values within ±2/3 mmHg.
Additional sensitivity analyses
Further sensitivity analyses looked at the impact of excluding studies that used suboptimal 
methods according to our quality assessment tool (i.e. studies in which at least one of the 
requirements is clearly not met), excluding studies that reported data clustered within persons 
(i.e. studies in which some or all of the participants contributed data on more than one eye but in 
which data for one eye only was unavailable) and using the standardised mean difference (SMD) 
metric, that is, mean difference divided by pooled SD, to address variation in the number of 
measurements (systematic difference only). An additional analysis was conducted to correct for 
the underestimated variation in studies with repeated measurements by using reported estimates 
of within-participant variation to adjust the results of such studies to reflect the variation if only a 
single measurement had been taken.120
Clinical factor analyses
Heterogeneity between the study estimates in the meta-analyses was explored by visual 
inspection of forest plots and calculation of I2 statistics. Possible reasons for heterogeneity were 
explored through prespecified clinical factor analyses. Where possible, studies were categorised 
according to CCT, previous corneal refractory surgery, type of examiner and IOP level, with 
corresponding meta-analyses being conducted. For some studies, data relating to a subset of the © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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main cohort were used for the factor analyses if sufficient data were given for the subset but not 
the full cohort. For the IOP analyses, studies in which the estimated proportion of the sample 
with OHT (i.e. > 21 mmHg) was > 33% were compared with studies in which this proportion was 
estimated to be < 33%. The proportion was estimated using the mean and SD for GAT, assuming 
a normal distribution (studies in which this was not reported were excluded from the subgroup 
analysis). A similar approach was taken for the CCT analysis with one of the two subgroups being 
defined as studies in which 33% of patients in the sample had CCT of < 555 µm (i.e. patients with 
the highest risk of glaucoma conversion). It was not possible to carry out analyses on the use of 
disposable tonometer heads as none of the included studies reported such data.
A clinical factor analysis was conducted to compare studies with no previous refractive surgery 
in their sample with studies that had postoperative subsamples. Another analysis compared 
studies in which the comparator examiner(s) were known to be solely ophthalmologists with 
studies in which the comparator examiner(s) were all known to be non-ophthalmologists. 
For self-tonometers, studies in which patients were the sole examiner type were included as 
a third category in this subgroup analysis. Because of the observed level of heterogeneity, a 
further clinical factor analysis investigated the impact of manufacturers in studies in which 
multiple manufacturers produced the same type of tonometer. Formal comparison between 
factor subgroups was not conducted because of the high level of heterogeneity in the main 
analyses. When individual studies reported on the impact of the clinical factors considered in 
the analyses the results of the individual studies were summarised in narrative form without any 
statistical analysis.
Data abstraction
When the mean difference was not reported, it was derived from the reported mean GAT and 
mean comparator IOP values. Authors were contacted for clarification if a discrepancy existed 
between reported mean difference and mean GAT/comparator scores (other than owing to 
rounding). The study was excluded from the meta-analysis if it was not possible to obtain a 
satisfactory value for the mean difference. Where IPD were published in the included study 
report, the IPD were used to calculate all necessary statistics.
The reported mean difference and SD of the differences were ‘validated’ by assessing the 
consistency between various reported statistics, where available (i.e. reported SD, 95% LoAs, 
95% CIs, paired t-tests and Pearson correlation coefficients). In cases in which LoAs were not 
explicitly reported, the limits were derived if an appropriate Bland–Altman121 plot had been 
presented. However, LoAs were considered valid only if the mid-point corresponded with a 
validated measure of the mean difference. If there were any discrepancies between any of the 
reported statistics relating to the SD, then the value that was most prevalent was used. If a value 
for the SD was explicitly reported, then it was assumed that the reported value was correct and 
this was used in the meta-analysis. If this process still failed to be conclusive, then the authors 
were contacted for clarification. However, if no satisfactory SD was reported (or satisfactory 
statistics from which it could be derived), then mean correlation imputation (previously 
described) was used.
Intraobserver repeatability coefficients (RCs) were used as the measure of within-subject variance 
to adjust the meta-analysis for repeated measurements with the same tonometer, as proposed by 
Bland and Altman.120 Reported within-subject SDs were converted into RC, where appropriate. If 
a measure of within-subject variation was not reported, it was imputed using the highest reported 
value (i.e. the most conservative) from other studies within the same tonometer comparison. 
Adjustments for repeatability were made for GAT and also for the comparator tonometer (if there 
was at least one study for the tonometer) reported repeatability statistics.50 Agreement and reliability of candidate tonometers for measuring intraocular pressure
Data were validated and prepared using Microsoft Excel (Microsoft Corporation, Redmond, WA, 
USA) and SPSS version 18 (IBM Corporation, NY, USA). Meta-analyses were carried out using 
the metan command in Stata version 11.
Results
This section is broken down into three main parts: an overview of included studies, a summary 
of agreement across tonometers and, finally, results per candidate tonometer including quality 
assessment of included studies, the meta-analysis of agreement and results for the other outcomes 
(recordability, acceptability, practicality and reliability).
Overview
The study selection process is summarised in Figure 23. In total, 642 reports were identified 
from the electronic searches as being possibly relevant. The full text of 189 reports was obtained 
for assessment: 143 from the electronic searches and an additional 46 from reference lists of the 
selected studies. Finally, 102 reports met the inclusion criteria, including six RCTs.122–127
Characteristics of included and excluded studies
Details of the characteristics of the included studies are provided in Appendix 3. A total of 102 
studies reporting 130 comparisons involving 11,582 participants (15,525 eyes) were included. 
The earliest studies took place in 1988128 and the latest in 2010.129,130 Fifteen studies took place 
in the USA,111,124,127,131–142 nine in Italy,143–151 nine in the UK,110,128,129,152–157 seven in Germany,158–164 
six in each of Australia,165–170 China (excluding Taiwan)171–176 and Japan,107,130,177–180 five in 
each of Belgium122,181–184 and Switzerland,104,185–188 four in Spain,189–192 three in each of Saudi 
Arabia,193–195 India,196–198 Portugal106,199,200 and Greece201–203 and two in Taiwan,125,204 Israel,205,206 
the Netherlands,207,208 Sweden209,210 and Turkey.211,212 One study took place in each of Austria,126 
Brazil,213 France,123 Ireland,214 New Zealand,215 Norway216 and Denmark.217 One additional study 
was reported as a multicentre study, taking place in Italy and Spain.218
After contacting authors to clarify the age of study participants, eight authors from nine 
studies135,140,141,148,189,190,192,201,212 confirmed eligibility for inclusion. One study included only 
participants who were aged ≥ 50 years but did not give the age range.166
Seventy-three studies (72%) provided information on gender of the participants, with 3337 
women and 2900 men. Fourteen studies provided data on participants’ race. Almost all studies 
reported the diagnosis; populations varied: healthy volunteers,158 those diagnosed with OHT155 or 
glaucoma196 or a mixed population.131
Included studies compared the reference standard tonometer GAT (Haag Streit, Koeniz, 
Switzerland) with eight different types of tonometer: DCT (PASCAL); RT (Icare); TonoPen; 
Medtronic Solan, Jacksonville, FL, USA (incorporating Xomed); or Intermedics Intraocular Inc., 
Pasadena, CA, USA]; Ocuton S; Perkins (Kowa HA-2, Kowa, Japan), NCT (Canon USA Inc., 
Lake Success, NY, USA; Keeler Ltd., Windsor, UK; NIDEK Co. Ltd., Gamagori, Japan; Reichert 
Ophthalmic Instruments, Buffalo, NY, USA; or Topcon Corporation, Tokyo, Japan); ORA; 
transpalpebral tonometer, including the PPT (Proview Eye Pressure Monitor) and the TGDc-01, 
also known as the Diaton tonometer.
All but three104,179,187 of the included studies reported sufficient data (or data were provided by the 
authors when contacted) to be included in the agreement meta-analysis. A total of 27, 20, 17 and 
37 studies provided data on recordability, acceptability, practicality and reliability, respectively.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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The 87 reports that were excluded at the full-text assessment stage as they failed to meet 
one or more of the inclusion criteria in terms of study participants, study design, candidate 
tonometers and reference standard are listed in Appendix 2. The tonometers that were not 
included because they were not commercially available and/or were not suitable for clinical 
practice were the applanation resonance tonometer,219 ocular blood flow instrument,115 Schiotz 
tonometer,220 SmartLens (Ophthalmic Development Company, Zurich, Switzerland) tonometer221 
and pneumotonometer.222
Summary of agreement across tonometers
Agreement of tonometers with Goldmann applanation tonometer
In total, 99 studies (125 paired comparisons) provided enough data on agreement to be included 
in the meta-analysis. Comparison across tonometers is difficult given the indirect nature of the 
analysis. A summary of the main analyses for all candidate tonometers is provided in Tables 9 and 
10. Full results of all of the meta-analyses for the candidate tonometers are given in Appendix 4. 
The percentage of results that would be within 2 mmHg based on the main analysis mean 
difference and random error (assuming a normal distribution) is also presented. Based on the 
analysed studies the expected difference did appear to vary across tonometers, with NCT and 
Tonopen having the smallest estimated difference and Ocuton S the largest. There was substantial 
uncertainty for most of the tonometers. In terms of the estimated random error, results varied, 
with Perkins having marginally (over NCT) the smallest expected random error and Ocuton S 
the largest. For all tonometers, the 95% LoA stretched from at least 3 mmHg less to 3 units higher 
FIGURE 23  Flow diagram of the selection process.
642 titles/abstract screened
499 reports excluded:
      • 6 conferences abstracts
      • 6 background/discussion
      • 487 clear from abstract/title that inclusion
         criteria were not met
189 reports selected for full-text assessment
      • 143 from abstract screening
      • 46 from reference list of included studies
87 reports excluded:
      • 45 aged < 16 years or uncertain
      • 17 no eligible tonometer
      • 9 comparison of disposable prism
      • 5 no reference standard
      • 4 inclusion of participants with corneal 
  disease/surgery
      • 2 correspondence
      • 1 contact lenses wearer
      • 1 eye filled with silicone
      • 1 non-human population
      • 1 unclear inclusion/exclusion criteria
      • 1 same study sample as an included study 
102 reports included individual studies
      • 99 sufficient data for meta-analysis
      • 3 insufficient data for meta-analysis
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with Ocuton S and transpalpebral with the widest intervals. With regard to the percentage of 
measurements that were within 2 mmHg of the GAT value, for most tonometers this value was 
approximately 50%; Ocuton S at 33% had the lowest value and NCT and Perkins with 66% and 
59%, respectively, had the highest. Corresponding values for the percentage within 3 mmHg of 
the GAT value were 48%, 85% and 79%, respectively, for Ocuton S, NCT and Perkins. 
Prediction intervals
Substantial heterogeneity was observed in estimates between studies for most tonometers. The 
95% prediction intervals for the mean difference and random error are shown in Table 10. The 
values illustrate the impact of the heterogeneity between individual study estimates of the mean 
difference: –4.0 to 9.4 mmHg for Ocuton S, whereas for NCT the range of values was only from 
–1.4 to 1.9 mmHg. For most tonometers except NCT and Perkins, a difference of > 2mmHg bar 
was observed. Similarly, the random error 95% prediction intervals illustrate the difference in the 
level of variability between studies.
Results by tonometer
Dynamic contour tonometer
Quality assessment
Thirty-four studies representing 3726 participants (4933 eyes) compared DCT with GAT. 
Figure 24 summarises the quality assessment for these studies. All 34 studies (100%) specified the 
TABLE 9  Pooled estimates and summary 95% LoAs of IOP (mmHg unless otherwise stated) 
Comparator No. of Studies
Mean 
differencea 95% CI
Random 
errorb 95% CI 95% LoA
% within 
2/3 mmHg
DCT 32 1.8 1.4 to 2.2 2.4 2.1 to 2.6 –2.9 to 6.5 48/67
NCT 26 0.2 –0.1 to 0.6 2.1 1.8 to 2.3 –3.8 to 4.3 66/85
Ocuton S 3 2.7 –1.2 to 6.6 3.5 2.4 to 4.6 –4.1 to 9.6 33/48
ORA 12 1.5 0.9 to 2.2 2.8 2.5 to 3.1 –3.9 to 7.0 46/65
Perkins 4 –1.2 –2.8 to 0.4 2.1 1.3 to 2.8 –5.2 to 2.8 59/79
RT 14 0.9 0.4 to 1.4 2.6 2.1 to 3.2 –4.3 to 6.1 52/72
TonoPen 14 –0.2 –1.0 to 0.5 3.1 2.5 to 3.7 –6.2 to 5.8 48/67
Transpalpebral 20 –0.5 –1.3 to 0.3 3.3 2.8 to 3.7 –6.9 to 5.9 46/64
a  Mean difference is mean comparator value minus mean GAT value.
b  Random error is the estimated SD of the differences.
TABLE 10  Pooled estimates with 95% prediction intervals of IOP (mmHg unless otherwise stated)
Comparator No. of Studies Mean differencea
95% prediction 
interval Random errorb
95% prediction 
interval
DCT 32 1.8 –0.4 to 4.0 2.4 1.1 to 3.6
NCT 26 0.2 –1.4 to 1.9 2.1 0.8 to 3.3
Ocuton S 3 2.7 –4.0 to 9.4 3.5 1.7 to 5.3
ORA 12 1.5 –0.6 to 3.7 2.8 1.6 to 4.0
Perkins 4 –1.2 –4.4 to 2.0 2.1 0.6 to 3.6
RT 14 0.9 –0.9 to 2.7 2.6 0.6 to 4.7
TonoPen 14 –0.2 –3.0 to 2.5 3.1 0.9 to 5.3
Transpalpebral 20 –0.5 –3.8 to 2.8 3.3 1.2 to 5.4
a  Mean difference is mean comparator value minus mean GAT value.
b  Random error is the estimated SD of the differences.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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selection criteria. In nine studies (26%), cases were selected consecutively. A total of 21 studies 
(62%) reported individual measures taken within 1 hour. In 24 studies (71%) the same clinical 
data were available for interpretation as would be in clinical practice. In total, 12 studies (35%) 
reported whether the examiner(s) were masked to the results. In 13 studies (38%), the tonometers 
were reported as calibrated. Almost all of the studies (31; 91%) included all participants 
approached in the analysis or stated a reason why not. Only three studies144,148,218 met all of the 
quality criteria.
Agreement between dynamic contour tonometer and Goldmann 
applanation tonometer
Thirty-two studies provided sufficient data to include in the meta-analysis. The full results of 
the agreement analyses of DCT and GAT are given in Appendix 4. Under the main analysis, the 
pooled mean difference was 1.8 mmHg (95% CI 1.4 mmHg to 2.2 mmHg) with a corresponding 
random error of 2.4 mmHg (95% CI 2.1 mmHg to 2.6 mmHg). For both analyses there was 
evidence of a large amount of heterogeneity, with very large I2 values (97% and 95%, respectively), 
and this can be seen in Figures 25 and 26, in which the forest plots are presented. Based on the 
main analysis the expected mean difference is 1.8 mmHg (95% LoA –2.9 mmHg to 6.5 mmHg).
Recordability
Six studies134,142,161,189,192,210 provided information on the recordability of the DCT. The data are 
shown in Appendix 5. Individual studies varied in size from 63 to 211 observations. Recordability 
was high varying from 93% to 100% across the studies.
Acceptability and practicality
Eight studies123,132,143,144,163,184,210,215 reported on the acceptability and/or practicality of the DCT. 
The data are shown in Appendix 6. For the five studies reporting acceptability, comments were 
favourable for DCT, and in one study,215 which measured preference, a substantial proportion (36; 
34%) expressed a preference for DCT over GAT, with 55 (52%) having no preference. Only three 
studies reported on practicality, with all three reporting difficulty with its use: the tonometer was 
‘not easy to use’123 and ‘entailed a learning curve’144 or extra measurements were needed.210
Reliability
Ten studies104,123,129,142,150,155,159,181,210,218 reported on either inter- and/or intraobserver reliability of 
DCT. The data are shown in Appendix 7. A variety of reliability measures [LoA, coefficient of 
variance (CoV), concordance correlation coefficient (CCC), intracluster correlation (ICC) and 
RC] and types of observers (student, ‘experienced’ ophthalmologist, optometrist and technician) 
FIGURE 24  Dynamic contour tonometer: summary of quality assessment.
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were used, with variable numbers of measurements taken (two or three up to six). Substantial 
(± 3 mmHg or more) interobserver variation was observed in the 95% LoA for two of the studies 
with the same lead author,129,155 with a narrower interval for one study (± 2 mmHg).142
Non-contact tonometer
Twenty-eight studies enrolling 2222 participants (2868 eyes) compared NCT with GAT. Figure 27 
summarises the quality assessment for these studies.
Quality assessment
Selection criteria were specified in 24 studies (86%). In only nine studies (32%) were cases 
consecutive. A total of 19 studies (68%) reported individual measures taken within 1 hour. In 
18 studies (67%), the same clinical data were available for interpretation as would be in clinical 
practice. In total, 15 studies (54%) reported whether or not the examiner(s) were masked to 
the results. In nine studies (30%) the tonometers used were calibrated. All bar one study (96%) 
included all participants approached in the analysis, or stated a reason why not. Only one 
comparison156 met all quality criteria specified.
FIGURE 25  Meta-analysis of mean difference between DCT and GAT (main analysis – random effects).
DCT study % weight
Papastergiou 2008
201 3.19
Lanza 2008
143 3.25
Johannesson 2008
210 3.25
Herdener 2008
159 3.26
Eichenbaum 2007
132 3.29
Salvetat 2007
144 3.21
Medeiros 2007
134 3.28
Pepose 2007
135 3.08
Martinez-de-la-Casa 2006
189 3.24
Barleon 2006
161 3.26
Ku 2006
215 3.24
Kotecha 2005
155 3.19
Pache 2005
163 3.17
Doyle 2005
123 2.73
Duba 2004
186 3.08
Milla 2009
192 2.81
Ceruti 2009
148 3.32
Realini 2009
141 3.25
Detorakis 2010
203 1.36
Morita 2010
130 3.26
Halkiadakis 2009
202 3.20
Vandewalle 2009
184 3.09
Fogagnolo 2010
218 3.31
Sullivan-Mee 2009
142 3.22
Pelit 2009
151 3.27
Vasconcelos De Moraes 2009
213 2.77
Roszkowska 2009
150 3.23
Kotecha 2010
129 3.23
Oncel 2009
212 3.16
Punjabi 2006
131
171
3.32
Liu 2006 3.33
Pourjavan 2007
181 3.12
Overall 100.00
Mean difference 
(95% CI)
0.20 (−0.30 to 0.70)
2.10 (1.70 to 2.50)
1.18 (0.79 to 1.57)
0.79 (0.41 to 1.17)
−0.10 (−0.41 to 0.21)
3.20 (2.73 to 3.67)
0.39 (0.06 to 0.72)
3.30 (2.65 to 3.95)
4.40 (3.98 to 4.82)
0.40 (0.02 to 0.78)
1.95 (1.54 to 2.36)
0.70 (0.21 to 1.19)
1.06 (0.54 to 1.58)
0.06 (−0.96 to 1.08)
1.90 (1.26 to 2.54)
5.43 (4.49 to 6.37)
2.61 (2.38 to 2.84)
1.60 (1.20 to 2.00)
4.75 (2.18 to 7.32)
−0.20 (−0.58 to 0.18)
2.10 (1.62 to 2.58)
3.10 (2.46 to 3.74)
2.39 (2.11 to 2.67)
2.60 (2.15 to 3.05)
2.47 (2.12 to 2.82)
1.16 (0.18 to 2.14)
2.00 (1.57 to 2.43)
2.36 (1.93 to 2.79)
1.60 (1.07 to 2.13)
1.70 (1.47 to 1.93)
1.11 (0.88 to 1.34)
1.20 (0.60 to 1.80)
1.80 (1.41 to 2.19)
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FIGURE 26  Meta-analysis of random error between DCT and GAT (main analysis – random effects).
DCT study % weight
Papastergiou 2008
201 3.20
Lanza 2008
143 3.28
Johannesson 2008
210 3.29
Herdener 2008
159 3.30
Eichenbaum 2007
132 3.35
Salvetat 2007
144 3.22
Medeiros 2007
134 3.34
Pepose 2007
155 3.04
Martinez-de-la-Casa 2006
189 3.27
Barleon 2006
161 3.30
Ku 2006
215 3.28
Kotecha 2005
155 3.20
Pache 2005
163 3.17
Doyle 2005
123 2.57
Duba 2004
186 3.04
Milla 2009
192 2.68
Ceruti 2009
148 3.40
Realini 2009
141 3.28
Detorakis 2010
203 1.08
Morita 2010
130 3.30
Halkiadakis 2009
202 3.22
Vandewalle 2009
184 3.05
Fogagnolo 2010
218 3.37
Sullivan-Mee 2009
142 3.24
Pelit 2009
151 3.32
Vasconcelos de Moraes 2009
213 2.62
Roszkowska 2009
150 3.26
Kotecha 2010
129 3.26
Oncel 2009
212 3.16
Punjabi 2006
131
171
3.40
Liu 2006 3.40
Pourjavan 2007
181 3.09
Overall 100.00
Random error 
(95% CI)
1.72 (1.37 to 2.07)
2.24 (1.95 to 2.53)
2.46 (2.18 to 2.74)
1.37 (1.10 to 1.64)
2.58 (2.36 to 2.60)
2.40 (2.07 to 2.73)
2.25 (2.01 to 2.49)
2.68 (2.22 to 3.14)
2.60 (2.30 to 2.90)
2.75 (2.48 to 3.02)
2.15 (1.86 to 2.44)
2.86 (2.51 to 3.21)
2.67 (2.30 to 3.04)
2.60 (1.88 to 3.32)
2.04 (1.59 to 2.49)
4.76 (4.10 to 5.42)
2.04 (1.88 to 2.20)
2.00 (1.71 to 2.29)
6.42 (4.60 to 8.24)
1.07 (0.80 to 1.34)
2.43 (2.09 to 2.77)
3.11 (2.66 to 3.56)
2.63 (2.44 to 2.82)
2.51 (2.20 to 2.83)
2.08 (1.83 to 2.33)
3.17 (2.48 to 3.87)
1.82 (1.52 to 2.12)
2.17 (1.87 to 2.47)
2.11 (1.73 to 2.49)
2.69 (2.52 to 2.86)
0.89 (0.73 to 1.05)
2.20 (1.78 to 2.62)
2.38 (2.15 to 2.60)
–8.24 0 8.24
FIGURE 27  Non-contact tonometer: summary of quality assessment.
0% 20% 40% 60% 80% 100%
Participant selection described
Consecutive case selection
Repeated measures within 1 hour
Routine clinical data available for
interpretation
Examiners masked to results
Tonometers calibrated
All participants accounted for
Yes
No
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Agreement between non-contact tonometer and Goldmann 
applanation tonometer
Twenty-six studies provide sufficient data to be included in the meta-analysis. The full results of 
the agreement analyses of NCT and GAT are given in Appendix 4. Under the main analysis, the 
pooled mean difference was 0.2 mmHg (95% CI –0.1 mmHg to 0.6 mmHg) with a corresponding 
random error of 2.1 mmHg (95% CI 1.8 mmHg to 2.3 mmHg). For both analyses, there was 
evidence of a large amount of heterogeneity with very large I2 values (95% for both), and this can 
be seen in Figures 28 and 29, in which the forest plots are presented. Based on the main analysis, 
the expected mean difference is 0.2 mmHg (95% LoA –3.8 mmHg to 4.3 mmHg).
Recordability
Four studies147,156,182,194 provided information on the recordability of NCT tonometers. The 
data are shown in Appendix 5. Individual studies varied in size from 45 to 100 observations. 
Recordability was very high (96–100%) for all bar one study (76%).147
Acceptability and practicality
Three studies156,173,194 reported on the acceptability and practicality of NCT tonometers. The data 
are shown in Appendix 6. In one study,173 ‘approximately 50%’ of participants appeared to prefer 
NCT 2000 to Pulsair 2000 or GAT. In another study,194 11% of participants expressed anxiety 
about the NCT Pulsair EasyEye, necessitating a 5-minute period between measurements to allow 
patients to ‘calm down’. Two studies173,194 found NCT tonometers to be faster than GAT, with NCT 
2000 favoured over Pulsair 2000 for ease of use and speed. One study156 found Pulsair 2000 (mean 
of 2 minutes) to be faster than GAT and Ao MkII (both with a mean time of 3 minutes).
NCT study % weight
Papastergiou 2008
201 0.00 (−0.55 to 0.55) 3.76
AlMubrad 2008
193 0.30 (−0.04 to 0.64) 4.02
Ogbuehi 2008
194 0.10 (−0.27 to 0.47) 3.99
Lafaut 2007
122 2.31 (1.69 to 2.93) 3.66
Garcia Resua 2005
191 3.21 (2.67 to 3.75) 3.78
Lam 2004
175 0.10 (−0.74 to 0.94) 3.30
Naruse 2004
178 −1.60 (−2.05 to −1.15) 3.90
Jorge 2003
199 0.09 (−0.89 to 1.07) 3.08
Jorge 2002
200 0.12 (−0.25 to 0.49) 3.99
Garzozi 2001
206 0.13 (−0.03 to 0.29) 4.16
Popovich 1997
139 −0.30 (−0.52 to −0.08) 4.12
Cho 1997
173 0.20 (−0.39 to 0.79) 3.71
Mackie 1996
156 1.04 (0.29 to 1.79) 3.46
Van de Velde 1995
182 0.43 (0.07 to 0.79) 4.00
Boles Carenini 1992
147 −0.50 (−0.89 to −0.11) 3.97
Chauhan 1988
128 −1.36 (−1.72 to −1.00) 4.01
Regine 2006
149 1.37 (0.93 to 1.81) 3.91
Murase 2009
180 0.60 (0.20 to 1.00) 3.96
Ogbuehi 2006
195 0.20 (−0.18 to 0.58) 3.98
Cheng 2005
176 0.46 (0.18 to 0.74) 4.08
Pelit 2009
151 1.39 (0.93 to 1.85) 3.89
Oncel 2009
212 −0.10 (−0.59 to 0.39) 3.84
Gupta 2006
196 −0.93 (−1.46 to −0.40) 3.79
Ko 2005
204 1.00 (0.55 to 1.45) 3.89
Tonnu 2005
75 −0.70 (−1.18 to −0.22) 3.86
Hansen 1995
–3.75 3.75 0
217 −0.92 (−1.38 to −0.46) 3.88
Overall 0.24 (−0.09 to 0.58) 100.00
Mean difference 
(95% CI)
FIGURE 28  Meta-analysis of mean difference between NCT and GAT (main analysis – random effects).© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Reliability
Nine studies122,149,152,156,175,193–195,217 reported a reliability measure. The data are shown in Appendix 7. 
None reported on interobserver reliability. A variety of reliability measures [including CoV, LoA, 
mean (SD), RC and variance of the difference between the middle reading and the average of 
the first and last readings (Varmid)] and types of observers (ophthalmologist and optometrist) 
was used with variable numbers of measurements taken (three to four). Three studies reported 
substantial 95% LoA for intraobserver reliability and one a substantial RC value.152,193,195,217
Ocuton S
Three studies enrolling 173 participants (258 eyes) compared Ocuton S with GAT. Figure 30 
summarises the quality assessment for these studies.
Quality assessment
In all three studies (100%) the selection criteria were specified, the same clinical data were 
available for interpretation as would be in clinical practice and all participants approached in the 
analysis were included or a reason was stated why not. On the other hand, none of the studies 
reported calibration of the tonometers used. Only the study by Sacu and colleagues126 reported 
selection of the cases consecutively and reported individual measures taken within 1 hour. In the 
studies by Marchini and colleagues146 and Wells170 the examiner(s) were masked to the results. 
None of the studies met all criteria specified.
Agreement between Ocuton S and Goldmann applanation tonometer
All three studies126,146,170 provided sufficient data to be included in the meta-analysis. The full 
results of the agreement analyses of Ocuton S and GAT are given in Appendix 4. Under the main 
FIGURE 29  Meta-analysis of random error between NCT and GAT (main analysis – random effects).
–4.13 4.13 0
NCT study
Random error 
(95% CI) % weight
Papastergiou 2008
201 1.92 (1.53 to 2.31) 3.77
AlMubrad 2008
193 1.40 (1.16 to 1.64) 4.00
Ogbuehi 2008
194 1.60 (1.34 to 1.86) 3.97
Lafaut 2007
122 2.80 (2.36 to 3.24) 3.69
Garcia Resua 2005
191 2.09 (1.71 to 2.47) 3.79
Lam 2004
175 2.40 (1.80 to 3.00) 3.37
Naruse 2004
178 1.37 (1.05 to 1.69) 3.90
Jorge 2003
199 3.30 (2.61 to 3.99) 3.17
Jorge 2002
200 1.11 (0.85 to 1.37) 3.97
Garzozi 2001
206 1.02 (0.90 to 1.13) 4.11
Popovich 1997
139 2.30 (2.14 to 2.46) 4.08
Cho 1997
173 1.40 (0.99 to 1.81) 3.73
Mackie 1996
156 3.60 (3.07 to 4.13) 3.51
Van de Velde 1995
182 1.83 (1.58 to 2.08) 3.98
Boles Carenini 1992
147 1.65 (1.37 to 1.93) 3.95
Chauhan 1988
128 1.83 (1.58 to 2.08) 3.99
Regine 2006
149 2.24 (1.93 to 2.55) 3.90
Murase 2009
180 1.70 (1.42 to 1.98) 3.94
Ogbuehi 2006
195 1.50 (1.23 to 1.77) 3.96
Cheng 2005
176 1.56 (1.36 to 1.76) 4.05
Pelit 2009
151 2.72 (2.40 to 3.04) 3.88
Oncel 2009
212 1.94 (1.60 to 2.29) 3.85
Gupta 2006
196 3.10 (2.72 to 3.48) 3.80
Ko 2005
204 3.02 (2.70 to 3.35) 3.89
Tonnu 2005
75 2.52 (2.18 to 2.86) 3.86
Hansen 1995
217 2.52 (2.19 to 2.85) 3.88
Overall 2.07 (1.82 to 2.32) 100.0058 Agreement and reliability of candidate tonometers for measuring intraocular pressure
analysis the pooled mean difference was 2.7 mmHg (95% CI –1.2 mmHg to 6.6 mmHg) with a 
corresponding random error of 3.5 mmHg (95% CI 2.4 mmHg to 4.6 mmHg). For both analyses, 
there was evidence of a large amount of heterogeneity with very large I2 values (96% and 88%, 
respectively), and this can be seen in Figures 31 and 32, in which the forest plots are presented. 
Based on the main analysis the expected mean difference is 2.7 mmHg (95% LoA –4.1 mmHg 
to 9.6 mmHg).
Recordability
Two studies126,170 provided information on the recordability of Ocuton S. The data are shown 
in Appendix 5. Individual studies varied in size from 68 to 85 observations. Recordability was 
reasonably high in both studies (82% and 94%).
Acceptability and practicality
Only one study146 reported on the acceptability and practicality of Ocuton S. The data are shown 
in Appendix 6. Of the 80 participants, 62 (78%) reported no issue, 14 (18%) reported a foreign 
body sensation and four (5%) complained of burning. Examiners were taught how to use the 
tonometer by carrying out at least three practice examinations each.
Reliability
Two studies146,170 reported on intraobserver and interobserver reliability for Ocuton S. The data 
are shown in Appendix 7, with the kappa statistic given for two observers (both intra- and inter-
reliability) in one study and a very large RC of 9.2 mmHg reported in the second study.
Ocular response analyser
Quality assessment
Twelve studies enrolling 867 participants (1147 eyes) compared ORA with GAT. Figure 33 
summarises the quality assessment for these studies.
All 12 studies (100%) specified the selection criteria and included all participants approached 
in the analysis or stated a reason why not. None of the studies selected cases consecutively; it 
was unclear in most of the cases (92%). Half of the studies (50%) reported details on individual 
measures were taken within 1 hour. In nine studies (75%) the same clinical data were available 
for interpretation as would be in clinical practice. Five studies (42%) reported whether the 
examiner(s) were masked to the results. Only two studies (17%) reported calibration of the 
tonometers. No studies met all of the specified criteria.
FIGURE 30  Ocuton S: summary of quality assessment.
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Agreement between ocular response analyser and Goldmann 
applanation tonometer
Twelve studies110,111,129,130,135,136,142,174,183,184,212,214 provide sufficient data to include in the meta-
analysis. The full results of the agreement analyses of ORA and GAT are given in Appendix 4. 
Under the main analysis, the pooled mean difference was 1.5 mmHg (95% CI 0.9 mmHg to 
2.2 mmHg), with a corresponding random error of 2.8 mmHg (95% CI 2.5 mmHg to 3.1 mmHg). 
For both analyses, there was evidence of a large amount of heterogeneity with very large I2 values 
(93% and 89%), and this can be seen in Figures 34 and 35, in which the forest plots are presented. 
Based on the main analysis the expected mean difference is 1.5 mmHg (95% LoA –3.9 mmHg 
to 7.0 mmHg).
Recordability
Two studies142,185 reported on recordability with 62 of 63 and 49 of 50 participants (98%) having a 
valid measurement.
Ocuton S study
Mean difference 
(95% CI) % weight
Sacu 2004
126 2.40 (1.39 to 3.41) 33.27
Marchini 2002
146 6.30 (5.29 to 7.31) 33.27
Wells 2003
–7.31 7.31 0
170 −0.46 (−1.33 to 0.41) 33.46
Overall 2.74 (−1.16 to 6.64) 100.00
FIGURE 31  Meta-analysis of mean difference between Ocuton S and GAT (main analysis – random effects).
FIGURE 32  Meta-analysis of random error between Ocuton S and GAT (main analysis – random effects).
–4.85 4.85 0
Ocuton S study
Random error 
(95% CI) % weight
Sacu 2004
126 4.13 (3.41 to 4.85) 32.93
Marchini 2002
146 2.30 (1.59 to 3.01) 32.96
Wells 2003
170 3.98 (3.36 to 4.60) 34.11
Overall 3.48 (2.36 to 4.59) 100.00
FIGURE 33  Ocular response analyser: summary of quality assessment.
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Acceptability and practicality
One study184 reported on acceptability and none reported on practicality. Discomfort was 
reported to be higher for ORA than for RT and DCT.
Reliability
Five studies110,129,142,183,185 reported a reliability measure. The data are shown in Appendix 7. Two 
studies129,142 reported on interobserver reliability, showing substantial LoA ± 3 or 4 mmHg. A 
variety of reliability measures (CCC, CoV, LoA, mean difference and RC) and types of observers 
(ophthalmologist and optometrist) was used with variable numbers of measurements taken 
(three up to eight).193,195 One study142 reported a substantial 95% LoA for intraobserver reliability.
Perkins
Four studies132,166,191,200 enrolling 433 participants (506 eyes) compared Perkins with GAT. 
Figure 36 summarises the quality assessment for these studies.
Quality assessment
All four studies132,166,191,200 (100%) specified the selection criteria and included all participants 
assessed in the analysis or stated a reason why not. Three132,191,200 of the four studies (75%) 
FIGURE 34  Meta-analysis of mean difference between ORA and GAT (main analysis – random effects).
–4.45 4.45 0
ORA study
Mean difference 
(95% CI) % weight
Kirwan 2008
214 0.70 (0.08 to 1.32) 8.37
Kynigopoulos 2008
185 1.68 (0.95 to 2.41) 8.13
Lam 2007
174 0.24 (−0.19 to 0.67) 8.71
Pepose 2007
135 1.60 (0.88 to 2.32) 8.16
Kotecha 2006
110 1.68 (1.18 to 2.18) 8.61
Medeiros 2006
111 −0.07 (−0.51 to 0.37) 8.70
Morita 2010
130 0.40 (−0.16 to 0.96) 8.49
Vandewalle 2009
184 3.60 (2.75 to 4.45) 7.84
Sullivan-Mee 2009
142 3.00 (2.40 to 3.60) 8.42
Ehongo 2009
183 2.50 (1.60 to 3.40) 7.73
Kotecha 2010
129 2.43 (1.89 to 2.97) 8.53
Oncel 2009
212 1.00 (0.34 to 1.66) 8.30
Overall 1.54 (0.88 to 2.19) 100.00
FIGURE 35  Meta-analysis of random error between ORA and GAT (main analysis – random effects).
–4.78 4.78 0
ORA study
Random error 
(95% CI) % weight
Kirwan 2008
214 3.01 (2.57 to 3.45) 8.39
Kynigopoulos 2008
185 2.62 (2.10 to 3.14) 7.89
Lam 2007
174 2.46 (2.16 to 2.76) 9.15
Pepose 2007
135 2.98 (2.47 to 3.49) 7.96
Kotecha 2006
110 3.04 (2.69 to 3.39) 8.91
Medeiros 2006
111 2.77 (2.46 to 3.08) 9.12
Morita 2010
130 1.56 (1.17 to 1.96) 8.65
Vandewalle 2009
184 4.18 (3.58 to 4.78) 7.34
Sullivan-Mee 2009
142 3.35 (2.93 to 3.77) 8.49
Ehongo 2009
183 2.20 (1.57 to 2.84) 7.13
Kotecha 2010
129 2.75 (2.37 to 3.13) 8.74
Oncel 2009
212 2.60 (2.13 to 3.06) 8.24
Overall 2.78 (2.46 to 3.10) 100.00© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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reported individual measures taken within 1 hour, and three studies132,166,200 (75%) reported 
calibration of the tonometers. In two studies (50%)132,166 participants were selected consecutively 
and the same clinical data were available for interpretation as would be in clinical practice. The 
examiner(s) were masked to the results in two studies (50%).166,200 None of the studies met all of 
the specified criteria.
Agreement between Perkins and Goldmann applanation tonometer
Four132,166,191,200 studies provide sufficient data to include in the meta-analysis. The full results of 
the agreement analyses of Perkins and GAT are given in Appendix 4. Under the main analysis, the 
pooled mean difference was –1.2 mmHg (95% CI –2.8 mmHg to 0.4 mmHg) with a corresponding 
random error of 2.1 mmHg (95% CI 1.3 mmHg to 2.8 mmHg). For both analyses, there was 
evidence of a large amount of heterogeneity, with large I2 values (99% and 97%), and this can be 
seen in Figures 37 and 38, in which the forest plots are presented. This finding is driven by one 
study166 that had both a much larger mean difference and a much larger random error than the 
other three studies (see Appendices 3 and 4 for more information on this study). Based on the 
main analysis the expected mean difference is –1.2 mmHg (95% LoA –5.2 mmHg to 2.8 mmHg).
Recordability
No studies reported on the recordability of the Perkins tonometer.
Acceptability and practicality
Two studies132,166 reported on the acceptability of the Perkins tonometer, one166 of which also 
reported on its practicality. Perkins was faster to use than GAT (96 vs 120 seconds). The data are 
shown in Appendix 6. No difficulties were observed but it was noted that the patients were ‘not 
new to the practice’ in one study.132
Reliability
None of the studies reported on the reliability of the Perkins tonometer.
Rebound tomometer
Fourteen studies106,107,145,154,160,165,167,184,189,190,207,209–211 representing 1239 participants (1792 eyes) 
compared RT with GAT. Figure 39 summarises the quality assessment for these studies.
FIGURE 36  Perkins tonometer: summary of quality assessment.
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Quality assessment
Nearly all of the studies106,107,145,160,165,167,184,189,190,207,209–211 (13, 93%) specified the selection 
criteria. In five studies145,165,189,190,209 (36%), cases were selected consecutively. In eight 
studies106,145,154,165,190,209–211 (57%), individual measures taken within 1 hour were reported and 
the same clinical data were available for interpretation as would be in clinical practice. Ten 
studies106,107,145,154,165,167,184,207,209,211 (71%) reported whether or not the examiner(s) were masked to 
the results. In seven studies106,107,145,165,207,209,211 (50%), the tonometers used were calibrated. Almost 
all studies106,107,145,154,165,167,184,189,190,207,209-211 (13, 93%) included all participants approached in the 
analysis or stated a reason why not. Only two studies145,165 met all of the specified criteria.
Perkins study
Mean difference 
(95% CI) % weight
Eichenbaum 2007
132 0.00 (−0.22 to 0.22) 25.32
Garcia Resua 2005
191 −0.42 (−0.85 to 0.01) 24.99
Jorge 2002
200 0.34 (−0.03 to 0.71) 25.10
Jackson 1995
166 −4.80 (−5.40 to −4.20) 24.58
Overall −1.20 (−2.83 to 0.44) 100.00
−5.4 0 5.4
FIGURE 37  Meta-analysis of mean difference between Perkins and GAT (main analysis – random effects).
FIGURE 38  Meta-analysis of random error between Perkins and GAT (main analysis – random effects).
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FIGURE 39  Rebound tonometer: summary of quality assessment.
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Agreement between rebound tonometer and Goldmann 
applanation tonometer
Fourteen studies106,107,145,154,160,165,167,184,189,190,207,209–211 provided sufficient data to be included in the 
meta-analysis. The full results of the agreement analyses of RT and GAT are given in Appendix 4. 
Under the main analysis, the pooled mean difference was 0.9 mmHg (95% CI 0.4 mmHg to 
1.4 mmHg), with a corresponding random error of 2.6 mmHg (95% CI 2.1 mmHg to 3.2 mmHg). 
For both analyses, there was evidence of a large amount of heterogeneity, with very large I2 values 
(94% and 98%), and this can be seen in Figures 40 and 41, in which the forest plots are presented. 
Based on the main analysis the expected mean difference is 0.9 mmHg (95% LoA –4.3 mmHg to 
6.1 mmHg).
Recordability
Four studies167,189,190,210 provided information on the recordability of RT. The data are shown in 
Appendix 5. Individual studies varied in size from 36 to 146 observations. Recordability was very 
low in one study (18; 50%)190 or 100% in the others.
FIGURE 40  Meta-analysis of mean difference between RT and GAT (main analysis – random effects).
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FIGURE 41  Meta-analysis of random error between RT and GAT (main analysis – random effects).
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Acceptability and practicality
Seven studies160,167,184,207,209–211 reported on acceptability and/or practicality for RT. The data are 
shown in Appendix 6. Of the four studies167,184,207,209 reporting acceptability, comments were 
favourable for RT, with one study167 that measured preference showing a large proportion 
(28; 74%) in favour of RT over GAT (2; 5%), with 18 (21%) showing no preference. Six 
studies160,167,207,209–211 reported on practicality, with three reporting its use as ‘easy’, two noting that 
additional measurements were required and one that there was no need for anaesthesia and that 
it used disposable tips.
Reliability
Four studies154,165,190,210 reported on either inter- and/or intraobserver reliability for RT. The 
data are shown in Appendix 7. A variety of reliability measures (correlation coefficient, CoV, 
LoA, ‘intrasubject variation coefficient’ and RC) and types of observers (student, ‘experienced’ 
ophthalmologist and optometrist) was used with variable numbers of measurements taken (two 
up to six). Only one study190 reported the interobserver correlation coefficient, which was 0.82 
for a small number of eyes (n = 12). Substantial intraobserver variation was observed in the LoA 
measures for one study,154 with a substantial RC for two studies.165,210
TonoPen
Fifteen studies75,107,138,140,144,153,157,166,169,188,191,197,206,207,216 enrolling 1413 participants (1950 eyes) 
compared TonoPen with GAT. Figure 42 summarises the quality assessment for these studies.
Quality assessment
All but one study75,107,138,140,144,157,166,169,188,191,197,206,207,216 (93%) specified the selection criteria. In six 
studies144,153,157,166,206,216 (40%), cases were selected consecutively. Nine studies75,138,140,144,157,169,188,191,216 
(60%) reported individual measures taken within 1 hour and 10 studies75,138,140,144,166,169,188,206,207,216 
(61%) that the same clinical data were available for interpretation as would be in clinical practice. 
Nine studies107,140,144,153,157,166,169,207,216 (60%) reported whether or not the examiner(s) were masked 
to the results. In eight studies75,107,140,144,153,157,166,169 (53%), the tonometers used were calibrated. 
Almost all studies107,138,140,144,153,157,166,188,191,197,206,207,216 (13, 87%) included all participants approached 
in the analysis or stated a reason why not. The Salvetat144 study met all of the specified criteria.
FIGURE 42  TonoPen: summary of quality assessment.
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Meta-analysis of agreement between TonoPen and Goldmann 
applanation tonometer
Fourteen studies76,138,140,144,153,157,166,169,188,191,197,206,207,216 provided sufficient data to be included in 
the meta-analysis. The full results of the agreement analyses of TonoPen and GAT are given 
in Appendix 4. Under the main analysis, the pooled mean difference was –0.2 mmHg (95% CI 
–1.0 mmHg to 0.5 mmHg), with a corresponding random error of 3.1 mmHg (95% CI 2.5 mmHg 
to 3.7 mmHg). For both analyses, there was evidence of a large amount of heterogeneity, with 
very large I2 values (97% and 98%), and this can be seen in Figures 43 and 44, in which the forest 
plots are presented. One study166 had a much larger mean difference than the other studies, as was 
the case for the Perkins mean difference for this study. Based on the main analysis the expected 
mean difference is –0.2 mmHg (95% LoA –6.2 mmHg to 5.8 mmHg).
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FIGURE 43  Meta-analysis of mean difference between TonoPen and GAT (main analysis – random effects).
FIGURE 44  Meta-analysis of random error between TonoPen and GAT (main analysis – random effects).
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Recordability
Three studies197,207,216 provided information on the recordability of the TonoPen tonometer. The 
data are shown in Appendix 5. Individual studies varied in size from 103 to 208 observations. 
Recordability was high in all three: 90–100%.
Acceptability and practicality
Four studies144,166,197,207 reported on acceptability and practicality for TonoPen. The data are shown 
in Appendix 6. All four reported favourably on acceptability, with one study,197 which measured 
preference, showing a large proportion (64; 32%) preferring TonoPen over GAT (30 ; 15%), and 
100 (49%) having no preference. Two studies144,207 reported that TonoPen was ‘easy to use’ and 
two studies166,197 reported the time to undertake measurement. Bandyopadhyay and colleagues197 
reported a mean (SD) of 54 (18) seconds for TonoPen compared with 15 (4) seconds for GAT, 
wherease Jackson and colleagues166 reported means of 50 and 120 seconds for TonoPen and 
GAT, respectively.
Reliability
Three studies152,153,169 reported a reliability measure. The data are shown in Appendix 7. Only 
intraobserver data were reported. A variety of measures were reported (CoV, ICC, mean 
difference, LoA and RC). One study169 reported a mean difference of 0.7 (95% LoA –3.3 to 3.6) 
for TonoPen compared with 0.74 (95% LoA –2.3 to 3.7) for GAT. Tonnu and colleagures152 
reported an RC of 4.3 mmHg and 2.2 mmHg for TonoPen and GAT, respectively. The third 
study153 stated that the CoV was < 5% for 97/99 eyes whereas 2/99 eyes had a CoV between 5% 
and 10%.
Transpalpebral tonometer
Twenty studies124,125,127,133,136–138,158,162,164,168,172,176–178,191,198,205,207,208 enrolling 1509 participants (2091 
eyes) compared transpalpebral tonometer with GAT.
Quality assessment
Figure 45 summarises the quality assessment for these studies. A total of 19 studies124,125,127,133,136–138, 
158,164,168,172,176–178,191,198,205,207,208 (95%) specified the selection criteria and in six studies124,125,172,176,178,205 
(30%) cases were selected consecutively. In total, 10 studies124,127,137,138,168,176,178,191,198,208 (50%) 
reported individual measures taken within 1 hour. In 12 studies (60%) the same clinical data were 
available for interpretation as would be available in clinical practice124,127,133,137,138,158,162,168,172,177,205,207 
and it was reported that the examiner(s) were masked to the results.124,125,158,162,168,172,176–178,205,207,208 
In seven studies125,127,172,177,178,205,208 (35%) the tonometers used were calibrated. Almost all 
FIGURE 45  Transpalpebral tonometer: summary of quality assessment.
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studies124,127,133,136–138,158,164,168,172,176–178,191,198,205,207,208 (18, 90%) included all participants approached in 
the analysis or stated a reason why not. No studies met all of the specified criteria.
Meta-analysis of agreement between transpalpebral tonometers and 
Goldmann applanation tonometer
Twenty studies124,125,127,133,136–138,158,162,164,168,172,176–178,191,198,205,207,208 provide sufficient data to be 
included in the meta-analysis. The full results of the agreement analyses of transpalpebral 
and GAT are given in Appendix 4. Under the main analysis the pooled mean difference was 
–0.5 mmHg (95% CI –1.3 mmHg to 0.3 mmHg) with a corresponding random error of 3.3 mmHg 
(95% CI 2.8 mmHg to 3.7 mmHg). For both analyses, there was evidence of a large amount of 
heterogeneity, with very large I2 values (98% and 97%), and this can be seen in Figures 46 and 47, 
in which the forest plots are presented. Based on the main analysis, the expected mean difference 
is –0.5 mmHg (95% LoA –6.9 mmHg to 5.9 mmHg).
Recordability
Nine studies124,127,137,138,168,174,176,177,198 reported on recordability, with all but one study137 
(recordability of 76%) having very high recordability percentages (91–97%). Seven 
studies127,137,168,172,176,177,198 reported the reason, i.e. why participants could not see the phosphene. 
The data are shown in Appendix 5.
Acceptability and practicality
Eight studies125,133,136–138,172,205,207 reported on acceptability and/or practicality. Approaches varied 
between studies although the data were generally favourable. Two studies133,136 reported on 
practicality from a clinical perspective, with one criticising the subjectivity of patient perception 
of the phosphene. One study207 suggested that the tonometer was ‘easy to use’. The data are shown 
in Appendix 6.
FIGURE 46  Meta-analysis of mean difference between transpalpebral tonometer and GAT (main analysis –  
random effects).
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Reliability
Eight studies124,127,136,137,158,168,172,177 reported a reliability measure. The data are shown in Appendix 7. 
One study reported on interoberver reliability.158 A variety of reliability measures (correlation 
coefficient, CoV, LoA, mean difference and RC) and types of observers (ophthalmologist, patient 
and technician) was used with variable numbers of measurements taken (3 up to 15). Two 
studies137,168 reported a wide 95% LoA for intraobserver reliability and one study158 reported 
a very wide 95% LoA for interobserver reliability. One study127 had an RC of 5.1 mmHg and 
another of 4.2 mmHg.168
Discussion
Overview
This review was conducted to systematically evaluate the properties of a range of IOP 
measurement devices (tonometers) and their suitability to replace the current reference standard 
(i.e. GAT) for surveillance of patients with OHT in a primary-care setting. We identified 102 
studies comparing eight candidate tonometer types against GAT. Studies included a variety of 
individuals, both patients and healthy subjects and patients with treated and untreated OHT 
and glaucoma. Poor reporting limited the assessment of the quality of the included studies. 
Most studies did not provide sufficient details to assess all of the criteria. In particular, many 
studies did not state whether or not cases were consecutive, whether or not the tonometers 
were calibrated, if examiners were masked to results and the time period within which repeated 
measurements were taken. Despite comprehensive guidance being available on how to undertake 
measurement of IOP in clinical studies,223 a substantial proportion of studies appear to adopt 
suboptimal practice, or at least reporting of such aspects.
FIGURE 47  Meta-analysis of random error between transpalpebral tonometer and GAT (main analysis –  
random effects).
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Agreement
The results of this study suggest that, compared with GAT, NCT was the tonometer with the most 
agreement for measuring IOP. Almost two-thirds of measurements with NCT were estimated to 
be within 2 mmHg of the GAT value and > 80% were within 3 mmHg. Next best was the Perkins 
tonometer (59% and 79% of measurements, respectively), which was not surprising because 
it is also an applanation tonometer based on the Goldmann principle. Perkins has the same 
advantages and limitations as GAT, the only substantial difference being that Perkins is a portable 
instrument. Other tonometers had about half or less of measurement differences within 2 mmHg 
or about two-thirds within 3 mmHg. Ocuton S appeared to have the lowest agreement with GAT, 
with only a third of measurements within 2 mmHg and half within 3 mmHg.
Recordability
Recordability was reported for all tonometer categories except for Perkins. Disappointingly, 
many studies did not explicitly state the number of participants in whom a measurement was 
attempted, as opposed to the number in whom a measurement was successfully taken. In general, 
reported recordability was moderate to very high, with most studies reporting values of ≥ 90%. 
For one RT study of only 36 participants, recordability was low, at 50%. For NCT, Ocuton S and 
transpalpebral tonometer, values in the range of 70–90% were observed in a single study, which 
could be considered problematic if representative of a monitoring scenario.
Acceptability and practicality
Acceptability data were available for all eight tonometers. Because of the variable nature of 
reporting it is difficult to provide a precise summary. Overall, the data suggest that the candidate 
tonometers were as acceptable to patients as GAT, if not more so. Marchini and colleagues146 
reported short-term side effects (foreign body sensation or burning) associated with Ocuton S 
in a sizeable number of participants. Ogbuehi and AlMubrad194 reported some anxiety about the 
procedure, with time breaks of 5 minutes used between measurements. Patient preferences were 
stated for DCT, TonoPen, RT and NCT over GAT in four studies that assessed this.167,173,197,215
Reliability
Some reliability data were reported for all except the Perkins tonometer; however, data were 
available for both inter- and intraobserver reliability for only five of the eight tonometers. The 
number of measurements used to determine reliability varied across studies, as did the statistical 
measure used. Greater consistency of reporting would be an aid. Either LoA or RC should, in 
our opinion, always be reported. Nevertheless, there was a clear suggestion of sizeable inter- and 
intraobserver variability for all seven tonometers for which data were available. It is worth noting 
that GAT reliability, although often lower than the candidate tonometer values, was also usually 
sizeable. This would to some extent explain the scale of heterogeneity observed in the agreement 
meta-analyses, although the use of repeated measurements for both GAT and the candidate 
tonometer should have lessened the impact.
Clinical issues
Tonometers that could potentially be used to measure IOP in a monitoring setting were eligible 
for this review. They are based on different principles, and were categorised as contact and non-
contact. Another possible classification would be those that are automated compared with those 
that require investigator judgement. A subgroup of technologies has been designed to enable 
users to measure their own IOP.
Although GAT is the device currently used in secondary care, and recommended by NICE to 
diagnose and monitor OHT, it is relatively complex to use, and is influenced by the investigator’s 
experience.1 There are other potential limitations of GAT. Applanation tonometry is based on 70 Agreement and reliability of candidate tonometers for measuring intraocular pressure
the Imbert–Fick law, which states that the force to applanate (flatten) the anterior corneal surface 
is equal to the true IOP multiplied by the applanated area at the posterior corneal surface.224 
However, although the applanated area of the anterior surface of the cornea is constant the 
CCT and the rigidity and resistance to a deforming force vary among individuals. Previous 
corneal refractive surgery for myopia can lead to measurement errors with GAT by thinning 
and fattening the cornea and changing its rigidity. The tear film can also affect IOP readings 
with GAT. The surface tension of the tear film attracts the prism to the cornea, and may cancel 
the force needed to flatten the cornea. The precise effect of the tear film on IOP readings is not 
fully understood.25 GAT implicitly assumes a CCT value in its calculation. Some of the candidate 
tonometers (e.g. ORA and DCT) purport to compensate for the patient’s CCT and other corneal 
properties. Finally, GAT has been shown to underestimate IOP compared with manometry.114 
Together, the above issues seem to have led, at least in some studies, to GAT measurements 
having substantial imprecision, which in turn will have contributed to the substantial random 
error observed between candidate tonometers and GAT measurements. Reliability data for GAT 
support this understanding, as noted above.
Two independent experts suggested that a difference of ≥ 2 mmHg would be clinically relevant 
and might influence the clinical management of patients with OHT. To help in the interpretation 
of the variability results we explored the proportion of measurements with a difference of 
≤ 2 mmHg or 3 mmHg. Others may view a larger difference as acceptable.90
Methodological issues
We chose to include only studies that compared a candidate tonometer against GAT, which 
we used as a reference standard. In principle, this should have provided some consistency 
across comparisons, although the results perhaps suggest that this standard, although widely 
accepted, is somewhat variable in implementation. Implicitly, any contrast between studies is an 
indirect comparison and suffers from the limitations of such approaches, such that the observed 
difference may reflect at least to some degree the differences between the studies (e.g. population 
and observers) that contribute to each comparison. As a result, comparisons between candidate 
tonometers should be made cautiously.
Although LoA studies are very common, methods for the meta-analysis of such studies have 
been proposed only fairly recently.118 The approach outlined here was to generate a summary 
or ‘pooled’ LoA. The mean difference and random error (SD) of individual studies were pooled 
and 95% LoA generated from pooled estimates. This provides a summary of the evidence 
across multiple studies that assess the same comparison. Our approach, following that of the 
original LoA approach for primary studies225 and the meta-analysis approach of Williamson and 
colleagues,118 assumes an underlying normal distribution for the differences to generate the LoA. 
This is often at least approximately true for the differences and may still be a reasonable approach 
even when the assumption is violated in individual studies.120
An important finding of the review was the large-scale heterogeneity between the results of 
individual studies that assess the same comparison. This was unlike the original example in 
which this methodology was used.117 Sensitivity analyses and subgroup analyses were undertaken 
to seek to identify sources of heterogeneity although with little light generated. The scale of the 
heterogeneity can perhaps be most clearly seen in the prediction intervals, which illustrate a 
plausible range of values for the mean difference and random error of individual studies for each 
comparison. For only one of the eight tonometers (NCT) the prediction intervals did not include 
a difference of ≥ 2 mmHg. Between-study heterogeneity, which reflected differences in study 
population and methodology, was clearly substantial. Nevertheless, in the absence of clarity of 
factors that contribute to the IOP measurement the prediction intervals show the uncertainty and 
the scale of difference that is plausible if a new study were to be carried out.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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There were a number of limitations in the reporting of individual studies that limited the extent 
to which we could accurately represent the evidence. A number of studies included more than 
one eye per participant, which resulted in clustering of intraindividual data.90 Where possible, we 
used only one eye per participant, but we chose not to exclude the study if this was not possible. 
The scale of the clustering effect is uncertain, but our sensitivity analyses, which included only 
studies with one eye per participant, did not suggest a substantial impact on the estimate of 
the random error. Four studies did not even provide sufficient information to estimate the 
mean difference and the within-person difference for all the tonometers, even when allowing 
imputation of the correlation coefficient. A number of reports did not report any measure 
of variability for within-person differences and it was necessary to impute a correlation. The 
sensitivity analyses showed that the results were not unduly influenced by this assumption.
Another limitation for conducting a systematic review was that studies used varying numbers 
of observations both for the candidate tonometer and for the reference standard. In some cases 
it was not clear how many measurements had been taken because of ambiguous reporting. We 
sought to address the impact of variation in the number of measurements in two ways. First, 
we used the SMD as the effect size given that, in theory, such variability could be addressed this 
way. Second, where an estimate of the within-person SD was known, we used this value to adjust 
the variance to match the situation with a single observation of both the candidate tonometer 
and GAT. If this value was not reported for a particular study but it was reported for another 
within the same comparison, then the value from the other study was used. Although this did 
change the estimate of the random error, the magnitude of the change was not large and it did not 
suggest that it was the primary cause of observed inconsistency in estimates.
Clinical factor analyses
Prespecified analyses looked at the impact of IOP, CCT, refractive surgery and examiner type on 
the LoA. Because of the magnitude of observed heterogeneity, an additional subgroup analysis 
investigating the impact of manufacturer and excluding low-quality studies was undertaken. All 
of the subgroup analyses reflect the limitations in the reported data, although less markedly so 
for manufacturer, which was generally well reported. Overall, the analyses were inconclusive. The 
scale of heterogeneity made any subgroup analysis susceptible to spurious differences when only 
a small number of studies were in a group. In a few studies there were suggestions that IOP was 
an influencing factor in the observed differences, although this was not a universal finding and 
appeared to vary by tonometer. Refractive surgery appears to impact on the difference for the 
transpalpebral tonometer. There was no clear pattern regarding examiner and manufacturer. It 
was not possible to undertake a subgroup analysis of CCT even on the basis of a crude dichotomy 
of the group for any of the studies. The exclusion of (based on reporting) lower-quality studies 
similarly did not provide clarity in this regard, although this perhaps reflects the substantial 
amount of non-reporting of key information in the studies. Ideally, IPD would have been 
available to form subgroups, for example according to IOP and CCT. This would allow more 
informative investigation of the influence of these factors at a review level.
Further research
There is a need for a reporting standard tailored for method comparison studies of tonometers 
building on recent work in this area.226 Reporting is inconsistent, and basic let alone desirable 
data are often not presented. The quality assessment highlighted a lack of reporting of key 
study characteristics and the fact that the issues of clustering of eyes with participants and the 
number of observations used is regularly ignored. Furthermore, an in-depth study of factors that 
could influence the pressure measurements is needed for the reference standard and candidate 
tonometers. This could either be a large primary study or potentially take the form of an IPD 
meta-analysis.118 Given the level of heterogeneity, it may be the case that a systematic review of 
LoA studies requires very focused study inclusion criteria akin to those recently proposed for 72 Agreement and reliability of candidate tonometers for measuring intraocular pressure
diagnostic test accuracy.227 Further studies evaluating the agreement of the Perkins and Ocuton S 
tonometers would also be beneficial given that only a small number of studies have been carried 
out. Finally, further evaluation of the role of GAT as the default tonometer in clinical practice 
is warranted.
Conclusions
A variety of tonometers are used to evaluate IOP, and GAT is the current reference standard. 
The NCT or Perkins tonometer appears preferable if the aim is to achieve as close to a GAT 
measurement as possible. However, the findings cast doubt on the validity of GAT as the default 
standard. Consistent use of the same tonometer during clinical follow-up is arguably almost as 
important as the choice of tonometer.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Chapter 6 
Optimal frequency of monitoring of 
intraocular pressure and visual fields
Introduction
Clinical management of individuals with OHT is based on the measurement and interpretation 
of initial IOP levels as well as monitoring to detect the onset of OAG, hereafter referred to as 
glaucoma. The initial monitoring is to establish whether or not treatment is required to lower the 
IOP and, subsequently, monitoring is to establish the response to treatment.
It is widely accepted that, in addition to IOP measurement, monitoring to detect glaucoma 
should include a measure of the visual field, commonly by SAP, and an evaluation of structural 
changes in the optic nerve and RNFL to detect the tissue loss that is characteristic of glaucoma.
When any quantity (such as an individual’s IOP) is measured over time, the observed value can 
be thought of as a product of the true underlying value and its variability. This variability is the 
result of genuine short-term fluctuations such as biological variability and also the inherent 
imprecision in the method of measurement. Additionally, over time, the true IOP level may 
change, and it is this change in the underlying level of IOP that a monitoring programme is 
seeking to detect. The short-term variation (noise) in the IOP measurement can mask the ‘true’ 
IOP level and thereby inhibit detection of a change in IOP. The long-term change will vary 
between individuals and this can be described as long-term between-individual variability. 
The majority of individuals being monitored may present with a chronic ‘stable’ condition, and 
therefore the signal can be thought as the divergence of a few individuals from the population 
average. The same principles apply to monitoring of the visual fields to detect glaucoma, in which 
the variability of visual field indices can be described. To determine the optimal frequency of 
monitoring it is necessary to quantify both short- and long-term variability in measurement of 
the test parameter for individuals in the target population.228
The signal-to-noise ratio is a useful indicator of the magnitude of long-term variability in 
relation to the noise. A high signal-to-noise ratio means that the changes observed are likely to 
be larger than the noise and hence represent a true change, whereas a low ratio indicates that the 
change observed is likely to be caused mainly by the noise. Clinical decisions need to be based 
on a true change (high signal-to-noise ratio) instead of being driven by spurious short-term 
changes (noise).
In choosing the monitoring frequency, there is a trade-off between predominantly measuring 
noise and the early detection of those at increased risk (signal). Previous work in other chronic 
conditions suggests that, in the short term, the signal can be relatively weak in comparison 
with the noise.228,229 In the context of monitoring subjects with OHT, decisions on long-term 
management based on short-term measurement could lead to over- or undertreatment of OHT. 
Hence, quantifying the noise and the signal levels present will help inform the optimal frequency 
for monitoring.74 Optimal frequency of monitoring of intraocular pressure and visual fields
Choosing monitoring tests and criteria
When choosing monitoring tests and criteria four factors should be considered:228
1.  Clinical validity: the monitoring pathway (including test types and frequency of testing) 
should be either a measure of the clinically relevant outcome or a good predictor of the 
clinically relevant outcome.
2.  Responsiveness: the test should change promptly in response to changes in the underlying 
value (e.g. after therapy).
3.  Signal-to-noise ratio: the test should differentiate clinically important changes over time 
from background measurement variability (short-term biological fluctuations and technical 
measurement error).
4.  Practicality: ideally the test should be non-invasive, cheap and simple to perform; test results 
should be immediately available and suitable for patient self-monitoring.
Although, in terms of clinical validity, measuring the visual field (by SAP) is the widely accepted 
test to detect the clinical outcome of glaucoma, IOP is also valid as it is the measure on which 
treatment decisions are made. In relation to responsiveness, clinical trials have shown that it is 
possible to detect a rapid reduction in IOP levels after treatment.32 In addition, IOP is a measure 
for which it is possible to determine its monitoring characteristics (signal and noise), although 
these have not been determined previously. Finally, in terms of practicality, both IOP and visual 
fields are generally measured during the same session, making them equally practical.
There is currently insufficient evidence to guide clinicians with respect to the optimal frequency 
of monitoring necessary to identify clinically significant changes in IOP or the optimal frequency 
and spacing of testing required to detect clinically significant changes in the visual field over a 
relevant time period, which could be up to 5 years.
The aim of the study was to quantify the signal-to-noise ratio of IOP and visual field measures 
(MD and PSD), thereby informing a monitoring pathway. Data from two randomised placebo-
controlled trials were used to estimate the short-term variability (noise) and long-term true 
change and variability (signal).
Objectives
The objectives were to:
1.  determine the optimal monitoring criteria (tests, frequency of monitoring, and determinants 
of progression to glaucoma) by:
i.  estimating the ‘noise’ in IOP and visual field measurements (measurement error and 
biological variation)
ii.  estimating the ‘signal’ in IOP and visual field measurements (change over time plus 
long-term variability)
iii.  identifying the optimal number of measurements required to quantify the true IOP
iv.  estimating the signal-to-noise ratio in IOP and visual field measurements given different 
risk of OAG
2.  provide estimates to inform the economic modelling evaluation of the impact of different 
plausible surveillance regimes for monitoring OHT (see Chapter 8)
3.  identify future research needs.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Methods
Our methods involved the secondary analysis of data from randomised placebo-controlled trials 
involving participants with OHT with repeated monitoring over a long-term follow-up. These 
trials should provide suitable data for quantifying the signal-to-noise ratio of IOP and visual 
fields. The placebo group consists of a homogeneous group having long-term follow-up. This 
highly controlled group can then be used to estimate how IOP changes over time, estimate the 
‘noise’ and determine the impact that the small number of individuals with rapid IOP changes 
has over the population (variation component of the ‘signal’). The basis of this analysis relies on 
estimating the within-person variability, the between-person variability and the natural trend 
of IOP as well as the variability of other clinically relevant measures of glaucoma (visual field 
variables MD and PSD) within specified periods. These estimates are determined by fitting 
statistical models to IOP measurements over time for a group of individuals. Two statistical 
models were used to obtain these estimates: (1) a direct method and (2) a linear random-effects 
model, both of which are discussed in Modelling variability. A more detailed description of 
possible models of IOP or visual field parameter changes over time, taking into account both 
measurement change and long-term true change, is provided in Appendix 8.
Data sets used in the analysis
Data from two RCTs carried out at Moorfields Eye Hospital, London, and Rotterdam Eye 
Hospital, the Netherlands, were used for the analyses; a description of the data sets is provided 
in Chapter 3.
Moorfields data set
The Moorfields cohort included data from participants randomised between 1992 and 1996. The 
following variables were available for each participant and used in this analysis:
1.  Baseline characteristics: participant identifier (ID), observer (clinician measuring the IOP), 
age, gender, date after randomisation, eye (under study), IOP, MD, PSD and medication.
2.  Conversion to glaucoma: eye and visit date of conversion to glaucoma.
3.  Repeated measures at each 4-monthly visit (1–14): visit date (recoded as days from baseline 
visit), IOP, MD, PSD and medication.
Rotterdam data set
The Rotterdam cohort included data on participants randomised between 1997 and 2001. The 
following variables were available for each participant and used in this analysis:
1.  Baseline characteristics: participant ID, date after randomisation, IOP and medication.
2.  Conversion to glaucoma: repeated measures at each 6-monthly visit (0–16).
3.  Visit number, IOP and medication: as the number of days between visits (or dates) was not 
recorded, this was estimated by determining the total number of days from baseline to final 
follow-up for each participant divided by the total number of visits. This defined the average 
days between visits per participant, which was used for the analysis.
Both data sets included data on both eyes. In the Moorfields data set, one eye per patient was 
selected for analysis; this was based on the eye that was chosen in the original study (indicated 
in the data set). In the Rotterdam data set, one eye per participant was selected randomly 
for analysis. In both data sets, only IOP measurements obtained with GAT were included in 
the analysis. The analyses use information from the placebo group only, which was formed 
by participants who had been allocated to receive either placebo or no medication within 
the trial period. Participants in the placebo group who were put on treatment during the 76 Optimal frequency of monitoring of intraocular pressure and visual fields
study period (crossovers) were treated as censored and contributed information only during 
the non-medicated period with their data treated as missing for the rest of the study (see 
Imputation assumptions).
Modelling variability
As the data arose from placebo-controlled RCTs, the apparent change in IOP and visual field 
measurements over time can be thought of as made up of three components:
1.  the long-term (true) change in IOP and visual field measures of the whole group
2.  short-term variability, that is, a combination of analytic variability and a week-to-week 
biological fluctuation around a stable average
3.  long-term variability, that is, a variation in long-term true change between individuals 
(as would be seen with the theoretical average of a large number of measurements 
per individual).
All three components were modelled using two different methods: (1) a direct method and (2) a 
linear random-effects model. For monitoring purposes, the short-term variability is equal to the 
‘noise’ in the measurement whereas the combination of the average true long-term change and 
the long-term variability are equal to the ‘signal’.
Direct method
The average change of the group can be estimated from the group average at each time point. 
Therefore, a direct method for estimating the long-term variability uses the variance of the 
differences between the baseline value and each subsequent time point i. Taking IOP as an 
example, this can be calculated as:
∑(IOPtime i – IOPbaseline)2  [Equation 8]
The time i corresponds to the different follow-up times at which data were recorded – 4-monthly 
for the Moorfields RCT and 6-monthly for the Rotterdam RCT – with a maximum of 10 years’ 
follow-up for either trial. The baseline IOP was taken as the first visit measurement for the 
Moorfields data set and the second visit for the Rotterdam data set, to reduce the potential 
noise created by the initial response to therapy as well as any potential ‘regression to the mean’ 
effect. The variability of change is used as a proxy for variation from the true mean at different 
time points. Therefore, using linear extrapolation on the variation of change it is possible to 
estimate short-term variation in IOP (noise), which would be proportional to the variance at 
time point 0.228 The long-term variability at different time points (signal) can be estimated by 
subtracting the short-term variability from the variability of the change.
The direct estimation method was used to explore the variability of IOP and visual field variables, 
specifically MD and PSD.
Linear random-effects model
In addition, the three variability components of IOP were estimated using a linear random-effects 
model. The main assumption of this model is that the IOP (or some transformation of IOP) for 
each individual can be adequately described as having a linear change (increase/decrease) over 
time; importantly, it allows this rate of change to vary between individuals. This model can be 
written as:
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for each individual, where α is the baseline level (in the transformed IOP scale) and β is the 
change in IOP for every day that passes from the first measurement (days0 = number of days since 
first visit). The observed IOP will have a measurement error (ε) and this model can be extended 
to the whole population using a linear random-effects model on all relevant parameters so that 
for an individual j at a given time i:
Transf I0P ij ( )=α j +βj × days0 ( )+εij   [Equation 10]
α j N a,σ  α
2 ( ),βj N b,σ  β
2 ( ),εij N 0,σ  W
2 ( )
where ~N(x,y) refers to a normal distribution with a mean x and a variance y. From this model, 
the average true long-term change is equal to the mean of β = b; the short-term variability 
or ‘noise’ is equal to the variance of the ε = σ2
w, whereas the long-term variability is equal to 
the variance of the βs = σ2
β. The two main assumptions in this model are the linearity of the 
association and the normality in the distributions of α, β and ε. To satisfy these assumptions, 
the raw IOP data were transformed, using a Box–Cox or power transformation to normalise 
the complete set of IOP measurements, at each time point and over all the assessment 
points combined.
Descriptive statistics were used to identify both the degree of normality of the IOP data as well as 
the presence of possible outliers. Shapiro–Wilk normality tests were carried out to further test the 
assumption of normality at each assessment point. Allowing for multiple tests adjustment, a 10% 
significance level was chosen, below which normality was rejected.
Variability of estimates to baseline intraocular pressure and 
other covariates
Bland–Altman plots were used to investigate the relationship between variability and mean IOP 
values. First, the mean versus SD was plotted for each subject to check for differences in variance 
based on an overall mean (as the measures for IOP seemed to be very stable over time for the 
majority). Second, the mean of the baseline and first visit measurements was plotted against the 
difference between baseline and first visit to check for differences in variance based on initial 
IOP measure.
Estimates of the variability components were obtained after stratification by IOP baseline level 
(threshold at 26 mmHg) to explore potential differences. Relevant covariates were included as 
part of the linear random-effects model to determine potential association with IOP.
Imputation assumptions
Missing data make the accurate estimation of a change in a measurement variable and the 
quantification of the variability problematic. Additionally, the number of visits per participant 
in both trial data sets was variable, with right-sided censoring at high values of IOP. The high 
IOP values are the most informative with regards to monitoring IOP. Imputation methods are 
therefore needed to incorporate these right-censored values into the analysis.
The analyses were conducted under different imputation assumptions for the missing times 
between visits, and for the missing IOPs. For the missing times between visits, imputed values 
were obtained for the independent variable, time, using a regression imputation method. In this 
method, each imputed value is predicted from the regression of the observed values at the time 
the value is missing on all observed data at each previous time point.
For missing IOP values, three approaches were assessed: non-imputation (missing at random), 
median imputation and last value carried forward (LVCF). Under the first approach, the analyses 78 Optimal frequency of monitoring of intraocular pressure and visual fields
were carried out without any imputation of missing data. For the second approach, the median 
value was imputed when IOP values were missing. Briefly, if IOPij is the missing IOP value for 
patient i at visit j, then the difference between the averages of all observed values for patient i and 
all observed values at visit j is added to each observed value at visit j. This generates a set of values 
whose median will be the imputed IOPij. The median imputation method has the characteristic of 
returning values close to the individual’s mean. This was not the obvious pattern for individuals 
with a tendency to reach very high IOP values and thus leaving the placebo group. To eliminate 
this effect, the imputed values for individuals with last observed values higher than their mean 
were excluded from the analysis. Fourteen per cent of the placebo group were in this situation. 
The linear random-effects model was fitted to the remaining data.
The third imputation approach applied to missing IOP data was the LVCF. In this approach the 
last observed value is used to replace all subsequent missing data, that is, visits for which no IOP 
measurement was available. If there was an observed measurement available before and after a 
missing measurement, the average of these IOP values (before and after) was imputed for the 
missing value.
Based on the different imputation assumptions, three different versions of the data sets were 
created for the transformed IOP data: (1) non-imputed IOP data, (2) median imputation data 
with points regressing to the mean removed and (3) LVCF imputed data.
Model validation
Estimates obtained using the above methods allow modelling of the number of patients whose 
‘true’ IOP level exceeds predefined threshold(s). The average change in IOP per year and the 
estimated within-person variability at different times (e.g. 1, 2 and 5 years) allow us to estimate 
the proportion whose true value would, and would not, have drifted beyond a specific level. The 
signal-to-noise ratio can also be computed at different time points to identify the time point 
at which the signal of the measurement is greater than the noise or measurement error. These 
models were used to simulate the proportions of individuals with a given predicted change at 
different time points, which were compared against the observed change from baseline IOP for 
both data sets (Moorfields and Rotterdam). Graphical methods were used to explore divergence 
from normality on the slopes and noise estimates as was the Shapiro–Wilk normality test.
External validation
Having estimated the parameters using the Moorfields data set, the Rotterdam data set was 
used for external validation of these models. For the Rotterdam data, the eyes were selected 
for inclusion randomly. For values of IOP entered as a range, the mid-point in the range was 
used. After running descriptive statistics for IOP, the extreme values found were replaced with 
the maximum IOP observation for the particular patient, excluding the outlier. Up to 16 visits 
within the trial period were considered for this analysis. The same imputation methods and 
Box–Cox transformation as for the Moorfields data were used. The validation process consisted 
of predicting the transformed Rotterdam IOP values using each estimated Moorfields model. The 
proportion of times that the observed value fell in the estimation interval given by:
PTTit ± 1.96 × sqrt(Var(PTTit)), where Var(PTTit) = σTT
2 + β2t2 + σw
2  [Equation 11]
was calculated, where PTT is the predicted transformed Rotterdam IOP, TT represents the 
transformed IOP and σ2
TT is equivalent to σ2
α in Equation 10. High values indicate greater 
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Results
Description of included data
Moorfields data set
The placebo group in the Moorfields data set includes data on 153 participants (61% male) with 
a mean (SD) age of 58.8 (10.9) years and an age range of 29–90 years. The majority were of white 
ethnicity (76%). The mean (SD) baseline IOP was 24.5 (3.5) mmHg with a range of 16–36 mmHg.
A total of 14 approximately 4-monthly visits in the period 1992–8 were included in this analysis. 
As the visit number (i.e. follow-up) increased, the number of participants with data steadily 
decreased. This ranged from 4.6% missing values at visit 2 to 63.4% missing values at visit 14. The 
mean IOP measurement over time for the placebo group is shown in Figure 48. A slight reduction 
can be observed over time, contrary to initial expectations.
Figure 49 shows the distribution of IOP at each of the 14 visits. The normality test results are also 
shown and normality was rejected at four time points (visits 4, 5, 6 and 9). A single outlier was 
identified (IOP = 48 mmHg, visit 4). This outlier was not included in further analyses.
Figure 50 shows the IOP measurements after the data were transformed (Box–Cox 
transformation with λ = 0.26) and corresponding normality test results. Normality was rejected 
for only one visit (visit 2, p = 0.002) suggesting that the transformation resulted in data that were 
more suitable for methods (such as the linear random-effects model) that assumed normality.
Handling of missing data
Intraocular pressure
The change in IOP from baseline at each visit (visits 2–14) was calculated for the raw and 
imputed data sets. Graphs of the mean and variance of the change in IOP from baseline as 
a function of time are shown in Appendix 8. Bland–Altman plots (Figure 51) show that the 
variability decreases with high mean IOP. This could be owing to censoring of those with 
higher IOP.
A total of 50 out of the 153 patients in the data set had crossed over from placebo to treatment, 
representing 33% of this group. Once a patient crossed over to treatment, his or her measured 
IOP was not included in the analysis. In these patients, the data points after crossover were 
replaced using LVCF. A single case presented several crossovers during the trial period, starting 
as a placebo case. This patient was included in the analysis and a sensitivity analysis run later 
to investigate the effect of the presence of this patient on the estimated parameters, with their 
inclusion having no significant impact. Stratification of the placebo group by baseline IOP 
resulted in 59 (39%) patients with IOP higher than the risk value (26 mmHg), of whom 30 (51%) 
were included among the crossover group mentioned above.
FIGURE 48  Mean IOP values over follow-up period (Moorfields data – placebo group only).
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Visual fields
For visual fields, the proportion of missing MD measurements ranged from 10% at baseline 
to 60% at visit 14, whereas PSD was not recorded for every patient at all time points. The PSD 
variable was measured at baseline in 75 (49%) patients. The mean (SD) MD at baseline was –0.39 
(1.52). The mean and variance of MD change scores as functions of time show that up to visit 11 
the mean and variance of change had an increasing trend (figure not shown). As for PSD, this 
was a highly skewed variable at baseline. Its mean (SD) is given by 2.20 (1.05 dB), with a median 
(range) of 1.98 (0.08–7.82 dB) and a skewness value of 2.85.
Rotterdam data set
The Rotterdam placebo data set includes data on 132 participants (51% male). The age range was 
24–81 years, with a mean (SD) of 56.1 (11.0) years. Only those of white ethnicity were eligible 
to participate in the RCT. The mean (SD) baseline IOP was 25.7 (2.5) mmHg with a range of 
18–35 mmHg.
A total of 23 visits were available; however, the second visit was taken as the baseline visit to 
account for regression to the mean, leaving only 21 visits for the initial analysis. The percentage 
FIGURE 49  Intraocular pressure measurements over time (Moorfields placebo group – original IOP data).
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of missing data at each visit, illustrated in Appendix 9, increased over time, as expected, with a 
peak at visit 10 of 38%, and then a slow increase from 25% to 36% between visits 10 and 15, to be 
followed by a sharp increase to a final 85%. We used data up to visit 15.
The IOP values in the placebo group from baseline (equivalent to visit 2 in the original data set) 
show a steady increase up to visit 7 and then a decline in mean IOP (Figure 52). Bland–Altman 
plots showed no association between variability and mean IOP level (Figure 53).
Short-term and long-term intraocular pressure variability
For both estimation methods (direct method and linear random-effects model), three analyses 
making different assumptions about the missing data were carried out. All six analyses used the 
transformed IOP as the dependent variable and time as the independent variable. The chosen 
Box–Cox transformation implied that the true baseline IOP at time i was given by:
IOPi = (0.26 × TTi + 1)3.84  [Equation 12]
FIGURE 50  Intraocular pressure measurements over time (Moorfields placebo group – transformed incomplete 
IOP data).
Visit
number  
Normality
test 
0.150 0.356 0.129 0.097 0.026 0.316 0.062 0.013 0.184 0.393 0.213 0.065 0.388 0.002
1
3.5
4.0
4.5
5.0
5.5
6.0
234567891 01 11 21 31 4
1234567891 01 11 21 31 4
Visit number
T
r
a
n
s
f
o
r
m
e
d
 
I
O
P
 
(
m
m
H
g
)82 Optimal frequency of monitoring of intraocular pressure and visual fields
0
.
0
4
.
5
5
.
0
M
e
a
n
 
t
r
a
n
s
f
o
r
m
e
d
 
I
O
P
5
.
5
S
D
 
o
f
 
t
r
a
n
s
f
o
r
m
e
d
 
I
O
P
0
.
1
0
.
2
0
.
3
0
.
4
0
.
5
(
a
)
(
b
)
–
1
.
5
4
.
5
5
.
0
M
e
a
n
5
.
5
D
i
f
f
e
r
e
n
c
e
–
1
.
0
–
0
.
5
0
.
0
M
e
a
n
 
S
D
±
1
 
S
D
±
1
.
9
6
 
S
D
M
e
a
n
d
i
f
f
e
r
e
n
c
e
±
1
 
S
D
±
1
.
9
6
 
S
D
0
.
5
F
I
G
U
R
E
 
5
1
 
B
l
a
n
d
–
A
l
t
m
a
n
 
p
l
o
t
s
 
u
s
i
n
g
 
t
r
a
n
s
f
o
r
m
e
d
 
M
o
o
r
fi
e
l
d
s
 
I
O
P
 
d
a
t
a
:
 
(
a
)
 
m
e
a
n
 
v
s
 
S
D
 
o
f
 
t
r
a
n
s
f
o
r
m
e
d
 
I
O
P
 
p
e
r
 
s
u
b
j
e
c
t
;
 
(
b
)
 
m
e
a
n
 
v
s
 
d
i
f
f
e
r
e
n
c
e
 
o
f
 
t
r
a
n
s
f
o
r
m
e
d
 
I
O
P
 
a
t
 
b
a
s
e
l
i
n
e
 
a
n
d
 
v
i
s
i
t
 
1
.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
83   Health Technology Assessment 2012; Vol. 16: No. 29 DOI: 10.3310/hta16290
where TTi is equivalent to the transformed IOP at time point i (or α in our notation in 
Modelling variability).
From an exploratory analysis of the data it became apparent that estimates from the direct 
method would be less stable than those obtained using the linear random-effects model. Such 
estimates would also have been difficult to incorporate into an economic model, and therefore 
the following results focus on the linear random-effects model. For completeness, the estimates 
obtained using the direct method are reported in Appendix 9. Table 11 reports the estimates 
for the linear random-effects model under three missing data assumptions. Under these 
assumptions, missing data were imputed using either LVCF or the median imputation method 
or there was no imputation (i.e. missing at random assumption). The last scenario is included for 
completeness of presentation as it allows us to observe the effect of the sample size increment in 
the variances compared with the previous two models.
There is a difference in the estimates of the noise and the variance of the random slope (signal) 
in these three models. The LVCF model was chosen out of the three for further validation and 
reporting as it has the smallest estimate of the noise (0.036) with the highest estimate of the 
variance for the random slope (3.6 × 10–8). High variability in the random slope means that 
individuals have a greater chance of showing a divergence from the overall population whereas 
a small noise would also mean that any change has a greater chance to be real (as opposed to 
random error). Therefore, this model should give the most conservative estimates for monitoring 
purposes (monitor more often). All three models estimate the average change over time to be 
close to 0 (–7.0 × 10–6 for model 1). This is equivalent to a decrease in IOP of approximately 
0.08 mmHg in a 3-year interval (baseline of 25 mmHg to 24.92 mmHg at 3 years).
Signal-to-noise ratio
Table 12 presents the signal-to-noise ratio (σβ
2t2/σw
2) at 3 and 6 months, and 1, 2 and 3 years 
obtained under the models for IOP in the placebo group. According to these ratios, the LVCF 
linear random-effects model estimates a greater signal than noise after 3 years. To explore the 
impact of having multiple measurements of IOP at a single visit and using the average as an 
estimate for the true IOP, we generated the equivalent signal-to-noise ratios based on the average 
IOP of two and three observations (this assumes conditional independence between the IOP 
measures of an individual in one visit). These values are presented in Table 12 and show that, for 
the average of two measures, the signal-to-noise ratio would reach a value of 1 within 2 years, 
while for the average of three measures the signal-to-noise ratio reaches a value of 1 between 1 
and 2 years from baseline.
True- and false-positives
We explored the impact of the noise in the observed IOP measurement given a defined threshold 
of IOP (26 mmHg) for different baseline levels (21, 25 and 28 mmHg). The calculation of true and 
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TABLE 11  Linear random-effects model outputs for transformed IOP (Moorfields placebo group)
Baseline distribution of TTi 
Distribution of the random 
slope β Correlation of TTi and β Noise estimate σw
2
Assumption 1: using LVCF to impute missing data
N(4.96,0.104) N(–7.0 × 10–6,3.6 × 10–8) 0.07 0.036
Assumption 2: using the incomplete median imputed data
N(4.94,0.107) N(–1.6 × 10–5,1.0 × 10–8) 0.21 0.039
Assumption 3: using incomplete (non-imputed) data
N(4.97,0.106) N(–3.6 × 10–5,2.3 × 10–8) 0.15 0.048
TTi is the transformed IOP following Box–Cox transformation at time i.
N(x,y) represents a normal distribution with mean of x and variance of y.
TABLE 12  Signal-to-noise ratio estimates at several time points – based on the linear random-effects model estimation
Model 3 months 6 months 1 year 2 years 3 years
Placebo group
LVCF 0.0 0.0 0.1 0.5 1.2
(Incomplete) median imputation 0.0 0.0 0.0 0.1 0.3
Transformed not imputed IOP 0.0 0.0 0.1 0.3 0.6
Several measures at a single time point a
LVCF – average of two 
observations
0.0 0.1 0.3 1.1 2.4
LVCF – average of three 
observations
0.0 0.1 0.4 1.6 3.6
a  Equivalent to multiplying the signal-to-noise ratio by the number of measures.
false-positives indicates that measuring IOP in shorter than 1-year periods results in identifying 
only noise. However, for the purposes of clinical management it is more relevant to explore the 
potential changes as defined by the model, that is, the expected change in IOP (both true and 
observed) for an average individual in the population and for one having an extreme change in 
IOP. Table 13 presents these IOP values for different baseline levels.
Based on the results obtained from the LVCF linear random-effects model (see Table 11), 
we can estimate the number of observed IOP measures that differ from their true IOP by 
≥ 2 mmHg and explore how different measurement regimes, using the mean of two, three, four 
or five measures (assuming independence), improve on these percentages. These estimates are 
presented in Table 14.
For comparison, linear random-effects models were fitted over the treatment group using 
the transformed not imputed data. Model 1T in Table 15 was obtained by regression of the 
transformed IOP on time. In this case, the distribution of the random slope was similar to the 
one obtained with model 1 in the placebo group. The mean of the baseline transformed IOP was 
slightly lower but its variance was much larger than the one estimated by any of the three models 
in the placebo group. The same was true for the noise estimate.86 Optimal frequency of monitoring of intraocular pressure and visual fields
TABLE 13  Examples of median and extreme monitoring IOP scenarios given baseline IOP of 21, 25 and 28 mmHg using 
the LVCF model
IOP (mmHg)
Baseline 4 months 1 year 2 years 3 years 4 years
Median β (–1.1 × 10–5)
True 21.0 21.0 21.0 20.9 20.9 20.9
Observed 22.4 19.3 21.7 19.5 20.0 24.7
True 25.0 25.0 25.0 24.9 24.9 24.8
Observed 25.2 27.6 23.9 26.3 25.3 25.7
True 28.0 28.0 28.0 27.9 27.9 27.8
Observed 27.7 27.4 31.3 27.4 28.2 27.8
Extreme β (6.1 × 104)
True 21.0 21.7 23.2 25.5 28.0 30.6
Observed 22.9 21.1 22.2 25.2 25.6 31.3
True 25.0 25.8 27.5 30.1 32.9 35.9
Observed 30.2 25.8 30.4 28.9 28.8 34.9
True 28.0 28.9 30.7 33.5 36.6 39.8
Observed 25.0a 27.3 29.5 37.1 36.3 37.7
a  Low value randomly obtained showing that error in measurement could be either above or below the true IOP level.
TABLE 14  Percentage of patients with differences between real and observed IOP ≥ 2 mmHg
Initial IOP 
(mmHg)
Missing data 
assumption
Number of measuresa
1 2 3 4 5
21.0 LVCF 28.3 11.4 6.3 3.2 1.7
Pseudo 28.9 14.1 6.4 4.2 2.4
No imputation 31.9 18.1 10.6 4.6 2.5
25.0 LVCF 34.7 16.8 9.7 5.7 2.9
Pseudo 35.3 19 9.8 6.2 4.4
No imputation 37.2 25 14.8 7.4 4.3
28.0 LVCF 38.4 20.1 11.8 8.7 4.5
Pseudo 39.1 22 12.7 8.5 6.8
No imputation 41.7 29.7 17.7 10.7 6.9
a  For two, three, four and five measures the comparison is between the mean of all observed measures and the ‘real’ IOP.
TABLE 15  Linear random-effects model outputs for transformed IOP (Moorfields – treatment group)
Baseline distribution of TTi 
Distribution of the  
random slope β Correlation of TTi and β Noise estimate σw
2
Model 1T: using incomplete (non-imputed) data and leaving out covariates
N(4.71,0.160) N(–7.3 × 10–5,3.2 × 10–8) –0.46 0.058
TTi is the transformed IOP following Box–Cox transformation at time i.
N(x,y) represents a normal distribution with mean of x and variance of y.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Validation of intraocular pressure models
Internal validation – Moorfields data
The purpose of these models is to predict the optimal monitoring frequency, particularly for 
inclusion into the economic model. For this reason it is necessary to explore the accuracy of these 
models on the prediction of change at a population level. To do this, we simulated the percentage 
of patients with a given predicted change from baseline at different time points using data from 
the LVCF model and compared these proportions against the observed change from baseline IOP 
for the Moorfields data set (placebo group only). These are presented in Tables 16 and 17 and 
show that the model underestimates large changes in IOP (≥ 5mmHg) for all time points.
The histograms in Figure 54 present the empirical (histogram) and estimated (dotted 
line) distributions of the residuals and slopes obtained from the (LVCF) transformed IOP 
Moorfields data. They show that the normality assumption is adequate for the residuals, but 
the corresponding slopes-estimated model underestimates the proportion of extreme values 
observed. Appendix 9 gives a table comparing the cumulative distributions from the model 
(normal distribution) and the empirical distribution for the slopes.
Converting these estimates to the original IOP scale (Figure 55a) shows that the noise term for a 
single measure is likely to be in the region of 0.6–1.4 mmHg (normal range). Therefore, assuming 
two measurements (e.g. baseline and follow-up) with additive errors and taking the upper level 
of the normal range for the error (1.4 mmHg), a difference of 3 mmHg between two readings can 
be due only to noise (no real change). Figure 55b presents a histogram of a series of simulated 
differences between two values with no real change (difference owing to noise only). The 
probability of having a difference of ≤ 3 mmHg is 73% (dotted lines in figure).
External validation – Rotterdam data
The distribution of the placebo IOP data from the Rotterdam data set after applying the same 
Box–Cox transformation as for the Moorfields data set (λ = 0.26 for all visits) resulted in a normal 
distribution in 12 out of the 16 visits. Normality was rejected at visits 1 (p = 0.002), 2 (p = 0.003), 
4 (p = 0.004) and 13 (p = 0.004).
TABLE 16  Moorfields observed data – percentage of patients with a given change from baseline (IOPt – IOP0)
Time from baseline 0–1 mmHg 1–2 mmHg 2–3 mmHg 3–4 mmHg 4–5 mmHg ≥ 5 mmHg
4 months 13.7 26 18.5 18.5 11.0 12.3
1 year 10.3 20.6 20.6 16.9 15.4 16.2
2 years 8.9 26.8 17.9 15.2 13.4 17.9
3 years 6.1 20.4 21.4 16.3 11.2 24.5
TABLE 17  Simulated data – percentage of patients with a given change from baseline (IOPt – IOP0)
Time from baseline 0–1 mmHg 1–2 mmHg 2–3 mmHg 3–4 mmHg 4–5 mmHg ≥ 5 mmHg
4 months 28.1 24.6 18.6 13.9 7.1 7.7
1 year 26.3 25.4 19.3 12.5 7.6 8.9
2 years 26.2 23.7 17.5 11.0 10.2 11.4
3 years 21.8 21.7 17.3 15.5 8.9 15.188 Optimal frequency of monitoring of intraocular pressure and visual fields
For each model (i.e. LVCF, reduced median imputation, no imputed data), 98% of the time the 
observed TTit in the Rotterdam file fell within the 95% CI defined by Equation 11. This would 
suggest that, in terms of predictive ability, the model would accurately predict the observed 
variability in the Rotterdam data.
As with the internal validation with the Moorfields data set, we calculated the proportions of 
observed change from baseline IOP for selected differences. These are presented in Table 18. 
Reassuringly, these percentages appear to be similar to those obtained in the observed Moorfields 
data set and suggest that the variance is similar across populations. As for the Moorfields data, 
the model consistently underestimates the proportion of individuals with large observed changes.
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Impact of baseline intraocular pressure and covariates
Impact of baseline intraocular pressure
We explored the variability of estimates according to different IOP baseline levels. Two separate 
models were obtained based on IOP levels at baseline. A low IOP level group was defined as 
those individuals with observed baseline IOP < 26 mmHg whereas a high IOP level was defined 
as ≥ 26 mmHg. All estimates were obtained using a linear random-effects model and LVCF as 
the imputation method. Table 19 shows that the estimates are very similar for both groups with 
a smaller noise estimate in the high IOP level. The impact of this is that the signal-to-noise ratio 
reaches a value of 1 earlier in the high IOP level group (Table 20).
As with the model for the full data, we explored whether the assumption of normality on the 
errors and the slopes was appropriate. The histograms in Figure 56 present the empirical and 
estimated distributions of the slopes for the two strata (IOP < 26 mmHg and IOP ≥ 26 mmHg) 
obtained from the (LVCF) transformed IOP Moorfields data. They show that the corresponding 
slopes estimated by the model underestimate the proportion of extreme values observed (heavier 
tails), as was observed in the full model.
TABLE 18  Rotterdam observed data – percentage of patients with a given change from baseline (IOPt – IOP0)
0–1 mmHg 1–2 mmHg 2–3 mmHg 3–4 mmHg 4–5 mmHg ≥ 5 mmHg
6 months 14.0 27.1 26.4 10.1 7.0 15.5
1 year 8.5 27.4 19.7 20.5 13.7 10.3
2 years 9.7 31.0 15.9 14.2 10.6 8.0
3 years 8.7 17.5 23.3 10.7 14.6 18.4
TABLE 19  Linear random-effects model outputs for transformed IOP, stratified by IOP at baseline (Rotterdam 
placebo group)
Baseline distribution of TTi 
Distribution of the random 
slope β Correlation of TTi and β Noise estimate σw
2
Model 1a: low IOP (baseline IOP < 26 mmHg, LVCF imputation)
N(4.83,0.076) N(–1.0 × 10–6,2.34 × 10–8) 0.07 0.037
Model 1b: high IOP (baseline IOP ≥ 26 mmHg, LVCF imputation)
N(5.28,0.075) N(–1.9 × 10–5,5.29 × 10–8) 0.07 0.032
Model 1: using LVCF full sample 
N(4.96,0.104) N(–7.0 × 10–6,3.6 × 10–8) 0.07 0.036
TTi is the transformed IOP following Box–Cox transformation at time i.
N(x,y) represents a normal distribution with mean of x and variance of y.
TABLE 20  Signal-to-noise ratio estimates, stratified by IOP at baseline (Rotterdam placebo group)
Model 3 months 6 months 1 year 2 years 3 years
IOPbaseline < 26 mmHg 0.0 0.0 0.1 0.3 0.8
IOPbaseline ≥ 26 mmHg 0.0 0.1 0.2 0.9 2.0
Full sample 0.0 0.0 0.1 0.5 1.290 Optimal frequency of monitoring of intraocular pressure and visual fields
The histograms in Figure 57 present the empirical and estimated distributions of the residuals for 
the two strata (IOP < 26 mmHg and IOP ≥ 26 mmHg) obtained from the (LVCF) transformed IOP 
Moorfields data. They show that the assumption of normality appears adequate.
Impact of important covariates
The covariates age and observer are regarded clinically as potential modifiers of IOP 
measurement. The effect of these clinically significant covariates was analysed by fitting a separate 
model for each covariate. None of these covariates was statistically significant for the models 
fitted over the placebo group. In the treatment group, the coefficient for age was not significantly 
different from 0, whereas investigator had a significant effect (Table 21). Also, this model returned 
a smaller estimated variability [i.e. Var(TTi), Var(β) and σw
2 decreased].
Models for the visual field parameters: mean deviation and pattern 
standard deviation
Because of limitations in the available data, the variability of MD was explored only by fitting a 
model using the direct method. The variability of PSD could not be explored as only baseline data 
were available. The direct method returned an estimated mean (SD) for MD at baseline of –0.39 
(1.52) with a noise estimate of σw
2 = 1.15. This method gives an estimate of the mean and variance 
of change at every visit. On three occasions the estimate of this variance was negative (Table 22). 
This is owing to the additive formula for estimating such variance and the lack of linearity of this 
variance over time (R2 of the regression of variance of change on time = 0.24).
Discussion
Recent research has highlighted how the variability of the measures used for monitoring chronic 
conditions impacts on the usefulness of these measures.230–232 This research suggests that, in 
most cases, measurements are carried out too frequently and that most of the change identified 
is owing to biological (day-to-day) variability and inherent measurement error and therefore 
not a real change in the health status of the individual. Clinical decisions such as changes to 
medication titration based on such measurements are potentially detrimental to a patient’s health. 
Quantifying this variability is therefore a necessary step for optimal monitoring.232
FIGURE 56  Histograms for the empirical and estimated distributions of slopes based on the Moorfields’ (LVCF) 
transformed IOP data for two strata: (a) IOPbaseline ≥ 26 mmHg; (b) IOPbaseline < 26 mmHg.
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FIGURE 57  Histograms for the empirical and estimated distributions of residuals based on the Moorfields’ (LVCF) 
transformed IOP data for two strata: (a) IOPbaseline ≥ 26 mmHg; (b) IOPbaseline < 26 mmHg.
TABLE 21  Estimates of effect of covariates (treatment group)
Baseline distribution of TTi 
Distribution of the random 
slope β Correlation of TTi and β Noise estimate σw
2
Model 2T: using incomplete (non-imputed) data and including investigator as a covariate
N(4.77,0.149) N(–8.9 × 10–5,2.6 × 10–8) –0.30 0.053
For investigator: only one statistically significant comparison was observed: investigator Garway-Heath (reference category) vs investigator Tan 
(coefficient = 0.15, standard error = 0.05, p = 0.004).
TTi is the transformed IOP following Box–Cox transformation at time i.
N(x,y) represents a normal distribution with mean of x and variance of y.
TABLE 22  Direct method outputs for MD
Characteristic
Visit number, t a
2 3 4 5 6 7 8 9 10 11 12 13 14
Mean change 0.01 0.03 0.10 0.07 0.11 –0.01 0.01 0.10 0.10 0.09 0.12 –0.19 –0.11
Variance of change –0.11 –0.13 –0.24 1.71 0.30 0.40 0.57 1.41 0.49 0.78 0.67 1.70 0.77
Months 4 8 12 16 20 24 28 32 36 40 44 48 52
Signal-to-noise 
ratio 
–0.1 –0.1 –0.2 1.5 0.3 0.4 0.5 1.2 0.4 0.7 0.6 1.5 0.7
Baseline: mean = –0.39, variance = 1.52, noise = 1.2.
a  Visit frequency every 4 months.
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For individuals with high risk of developing glaucoma, there are several factors that are 
monitored with regularity, including IOP, visual function measured by visual fields and structural 
changes in the RNFL and the optic nerve. The monitoring frequency should be determined by 
the outcome that has greatest bearing on treatment decisions, which in this context is monitoring 
the visual fields and the optic nerve and RNFL to detect early progression to glaucoma. However, 
quantifying changes in visual fields and the RNFL/optic nerve is characteristically difficult, with 
no unified single measure for either. In the present study it was not possible to make conclusions 
about the long-term variability for the visual field variables PSD and MD. For PSD it would 
be necessary to identify the subjects with this measurement at follow-up; these data were not 
available in the data sets used. Neither data set had repeated measures of the RNFL or optic nerve 
head that were available for this analysis.
Thus, the focus of this chapter has been almost entirely on IOP and on estimating the ‘noise’ 
(biological variability and measurement error) and the signal (variability and change beyond 
the noise) in IOP measurement. This chapter presents estimates for the signal and noise of 
IOP measurement based on data from the placebo arm of the Moorfields RCT32 evaluating 
the effectiveness of a treatment for OHT. These data have the advantage that individuals were 
followed over a long period with no treatment and therefore IOP variability is not affected 
by medication changes. The main assumption made is that the repeated IOP measures in an 
individual allow us to determine his/her real IOP. In simplistic terms, the true IOP can be 
determined from the average of repeated IOP measures over time.
The models used to describe the behaviour of IOP and estimate the relevant parameters follow 
those previously reported.233 The use of linear random-effects models allows long-term prediction 
of IOP; these were used for the economic model. Different strategies for handling missing data 
can be incorporated. As the completeness of the information decreases with time, the choice 
of strategy for handling missing data impacts on the estimates of the signal and the noise. The 
most appropriate models for the transformed IOP were those based on the imputation methods 
LVCF and (incomplete) median imputation, in that order. This was because these methods are 
conservative in potentially underestimating the noise and hence leading to recommendations of 
more frequent monitoring.233
Summary of main findings
The main findings are summarised below:
  ■ Measured IOP could be incorrect (different from true IOP) by ≥ 2 mmHg at baseline 
about 30% of the time. This is consistent with repeatability coefficients of around 2 mmHg 
observed for two measurements of IOP on the same occasion using GAT as reported in 
Chapter 5.131,154,157,210
  ■ The level of IOP is relatively stable but a change ≥ 5 mmHg can be observed at 3 years in 
about 25% of participants.
  ■ The model estimates that point estimates of IOP changes may be due to noise (measurement 
error and biological variation). Based on the normal range of the noise (0.6–1.4 mmHg for a 
single measure), with two measurements (baseline and follow-up) with additive errors, and 
taking the upper level of the normal range for the error (1.4 mmHg), observed changes of the 
order of 3 mmHg could be explained as noise.
  ■ For the majority of individuals the true change in IOP is likely to be smaller than the 
measurement error plus biological variability (noise).
  ■ Assuming independence in the measurements, using the average of two measures at baseline 
increases the signal-to-noise ratio such that one would expect to be able to detect true change 
using the average of two measures at 2 years. If the average of three baseline measures of IOP 
were taken, true change might be detectable with repeat testing between 1 and 2 years. This © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
93   Health Technology Assessment 2012; Vol. 16: No. 29 DOI: 10.3310/hta16290
approach of reducing noise is based on the assumption that the measurement errors across 
the repeated IOPs are not associated (e.g. all errors going in the same direction). There were 
insufficient data to inform whether or not this assumption holds for repeat measures at the 
same session.
  ■ Individuals with higher baseline IOP (≥ 26 mmHg) are more likely to have a true change in 
IOP at around 2 years, whereas for individuals with lower IOP the model suggests that a true 
change in IOP would be unlikely within 3 years.
  ■ Participant age or observer undertaking the IOP measurement did not affect the findings for 
the main analysis. Observer was statistically associated with the variability in the treatment 
group, providing some evidence on variability associated with the person undertaking 
the tonometry.
  ■ As IOP increased fluctuations in IOP also increased. These fluctuations are likely to 
be physiological.96
  ■ As part of the internal validation of the model, the noise error term in the intervention group 
was found to be larger than that for the placebo group. This may reflect the variability of the 
treatment effect or variable participant adherence with treatment.
  ■ As part of the external validation, the model predicted the observed variability in the 
Rotterdam data.
Strengths and limitations
Our analysis focused on a single risk factor, IOP, and used statistical methods to simultaneously 
model the between- and within-subject variability over time. However, the following limitations 
are noted. First, the model estimates obtained were based on data from the placebo group of a 
single study. However, we used data from the intervention arm to provide internal validation as 
well as data from the second RCT (Rotterdam) as part of an external validation of the models. In 
both cases the behaviour of the model and the prediction of future IOP values suggest that the 
estimates were adequate.
A second limitation is that none of the models chosen appeared to capture those participants 
with a rapid clinically significant change. The ideal data set would include individuals with no 
treatment (or stable treatment) over a long follow-up period during which the IOP was measured 
regularly. However, as a high IOP triggers the clinical decision of initiating or modifying 
treatment such data are not available. Our choice of model, the LVCF model, maintaining 
higher values for those censored, minimised this problem. However, the model is likely to have 
underestimated the small proportion of individuals with a large change in IOP. To adjust for this 
we used an empirical distribution that inflates the probability of a large change (which is used as 
part of the economic analysis reported in Chapter 8).
A third limitation is the use of data from a RCT, which means that these data are likely to be 
from a well-motivated and controlled group of participants, which could explain why the long-
term IOP appears to be stable. Anecdotal evidence suggests that even within the trial there was 
operator variability, with some attenuation of IOP variation because of observers not using the 
first IOP observed but ‘calibrating’ their measurement based on previous IOP readings. This 
would mean that an extreme IOP at a particular visit might not have been taken at face value and 
multiple readings made. This would lead to an underestimation of the noise, in which case the 
signal-to-noise ratio would have been overestimated.
There are also several areas of further uncertainty. There are no clinical thresholds for IOP, and 
hence it is difficult to model the impact that noise has on clinical decisions. We have chosen a 
2 mmHg difference as a clinically significant value based on the group collective experience. 
Modifying this threshold can again have implications depending on the need for more or less 
accurate estimates of IOP. The choice of tonometer is another uncertainty not addressed in this 94 Optimal frequency of monitoring of intraocular pressure and visual fields
chapter as the models were obtained assuming GAT as the reference standard tonometer. We 
speculate that the use of other tonometers is likely to increase variability (noise). Estimates of 
these have been presented in Chapter 5 where the LoA between tonometers were explored. The 
standard current practice for IOP measurement is unclear as to whether the recording is from 
single or multiple measures and based on an average or the lowest or highest value recorded. The 
results and recommendations in this chapter assume that the measures were obtained as a single 
reading during the session.
Integration within the economic model (see Chapter 8)
The findings of this study informed the surveillance pathways compared within the economic 
modelling evaluation, namely:
1.  Measure IOP more than once at a visit and take the average.
2.  Use the signal-to-noise ratio (based on multiple measurements) to guide the frequency of 
IOP monitoring.
3.  Individuals with more extreme changes in IOP were under-represented in the standard 
modelling; however, purposive oversampling of the extremes of the estimated distribution 
using the empirical distribution of the slopes (see Appendix 9, Table 69) partially 
corrected this.
Conclusions
For the majority of individuals the true change in IOP is likely to be smaller than the 
measurement error plus biological variability (noise). Observed changes, based on a single 
measurement, of the order of 3 mmHg can be explained as noise. Reducing the noise level by half, 
by taking an average of two or three measurements, will allow an estimation of IOP with enough 
precision to make clinical decisions based on a change in IOP of 2 mmHg. This could be obtained 
by using the average of repeated measures at a single visit. However, this approach of reducing 
noise is based on the assumption that the measurement errors across the repeated IOPs are 
not associated (e.g. all errors going in the same direction). There are insufficient data to inform 
whether or not this assumption holds for repeat measures at the same session. In addition, same 
session measurements will not include diurnal variation or short-term biological fluctuations. 
Diurnal variation can be addressed by standardising IOP measurement time. Short-term 
biological fluctuations can be addressed by averaging the IOP over repeat visits, but this may not 
be feasible in current eye care services.
Using the average of two measures of IOP at baseline at a single visit increases the signal-to-noise 
ratio such that one would expect to be able to detect true change, of the order of 2 mmHg, at 
2 years. If the average of three baseline measures were taken, true change might be detectable 
with repeat testing between 1 and 2 years. These findings, together with the findings of Chapter 5, 
can be used to inform the development of a standardised algorithm for the measurement of IOP 
to reduce both measurement noise and operator variability.
Our findings are based on data from selected trial populations, and further research is required to 
validate the model in the general population of those with OHT.
Further research is required to determine the optimal interval of testing required to detect 
the onset of glaucoma. Standardisation to a single index for quantification of the visual field, 
as measured by SAP, is needed. This would enable modelling of the variability components 
of perimetry in the context of OHT to determine the optimal frequency of testing to 
detect glaucoma.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Chapter 7 
Eliciting preferences for alternative 
monitoring services using a discrete 
choice experiment
Background
In choosing an optimal monitoring service for patients with OHT it is important to take account 
of individuals’ preferences. This chapter used a discrete choice experiment (DCE) to investigate 
such preferences via a web-based online survey.
Objectives
The objectives of the DCE were:
  ■ to investigate what characteristics of a monitoring service matter to individuals, as well as the 
relative importance of these characteristics
  ■ to assess WTP for these individual characteristics as well as WTP for different configurations 
of monitoring services
  ■ to feed the WTP estimates into an economic evaluation model (presented in Chapter 8).
Developing the discrete choice experiment
Discrete choice experiments are an attribute-based measure of benefit. The technique is based on 
the premise that goods or service can be described by their characteristics (attributes). Further, 
the extent to which an individual values those goods or that service depends on the levels of these 
attributes.234,235 Participants are presented with a number of choices, each describing a series of 
attributes at different levels. The relative importance that individuals place on these attributes can 
be assessed by changing the levels of the attributes and asking participants to make their choice 
again. By including a price proxy (cost attribute) in the DCE, the monetary value of any given 
service can also be estimated. This monetary valuation, known as WTP, can be used within an 
economic evaluation as will be described in the next chapter. The process followed to develop 
the DCE is presented in Figure 58 and described in detail below. Full ethical approval for this 
substudy was obtained from the North of Scotland Research Ethics Committee in June 2009 
(REC reference number: 09/S0802/67).
Developing the attributes
The first stage of the DCE is to derive the attributes and associated levels. Although DCEs are 
a quantitative method to model preferences, qualitative methods are useful when defining 
attributes and levels (and developing the questionnaire).236 A mixed methods approach was used 
to derive attributes and levels, integrating findings from an advisory panel and a focus group with 
relevant glaucoma health outcome attributes from an existing glaucoma utility measure.496 Eliciting preferences for alternative monitoring services using a discrete choice experiment
Advisory panel
An advisory panel was convened to identify potential ‘attributes’ (characteristics influencing 
preferences for alternative monitoring services) and thus inform the framework (topic guide) for 
the planned focus group discussion with service users. Participants for the advisory panel were 
purposively selected to provide a broad UK perspective on managing OHT, but were not directly 
involved in the project. The panel included two service users [people under surveillance for OHT 
(SOH), Grampian, Scotland], one optometrist (academic optometrist, England), one non-clinical 
health service manager (ophthalmology service manager, secondary care, England), one specialist 
glaucoma nurse (secondary care, Scotland), one ophthalmologist (glaucoma specialist, England) 
and one community optometrist (Scotland). Six members of the local study team attended the 
advisory panel meeting (chief investigator, ophthalmologist, three economists and study research 
fellow). The meeting was recorded and transcribed. Minutes of the meeting with key points of 
agreement were circulated to participants following the meeting.
Discussion was driven by the participants on the desired elements of a monitoring service. Key 
themes (attributes) are summarised in Table 23.
Focus group
The findings from the advisory panel (see Table 23) were used to develop the topic guide for the 
focus group discussion with users of a service, the Grampian Glaucoma Referral and Monitoring 
Scheme Service. This service started in June 2004 and was developed to reduce unnecessary 
referrals to a hospital glaucoma clinic and to develop a community monitoring scheme for people 
at risk of developing glaucoma but not requiring treatment. Potential participants were identified 
from this scheme. Both men and women with OHT (who may or may not be undergoing 
treatment) or suspected of having OHT, of different ages and geographical locations within the 
Grampian area, were purposely sampled.
FIGURE 58  Process for determining attributes and levels for the DCE.
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Participants were approached by post with an invitation letter from the consultant 
ophthalmologist and an information leaflet explaining the purpose of the study. In total, 93 
people were invited and 11 agreed to participate in the study. Of these 11, six were able to attend 
on the suggested date for a focus group. In the event, five attended on the specified date, in 
September 2009. Summary statistics for the participants are presented in Table 24.
Pictorial cards were used to represent the most common tests for monitoring OHT (measuring 
IOP, looking at the back of the eye, measuring the field of vision and photographing the back 
of the eye) and to describe the different stages of progression of OHT and the likelihood of 
progression. This was based on a 5-year risk of conversion from OHT to glaucoma of 10%64 and 
a 0.65 treatment effect237 (i.e. treatment reduced the risk of conversion to 65% of the risk faced by 
those who were not treated) for those opportunistically detected with OHT.
Before the focus group, the topic guide and the stimulus material (pictorial cards) were piloted 
among six members of the Health Services Research Unit and Health Economics Research Unit 
at the University of Aberdeen. In general, the content of the topic guide was easily understood. 
Feedback regarding the content and format of the pictorial cards was incorporated to improve 
their value in promoting discussion among the group.
The discussion in the focus group was facilitated by the main researcher (ABP, who also acted 
as moderator), an economist (RH) and an ophthalmologist (AA) to explore participants’ views 
on how a monitoring regime could be organised. Following initial introduction, the moderator 
(ABP) explored participants’ experiences of how they were monitored and used the pictorial 
cards to introduce information about different characteristics that a monitoring service might 
have. Participants were encouraged to discuss their views and express their preferences about 
different characteristics of a monitoring programme, as well as discussing possible trading 
between attributes (i.e. how much of one attribute would they be willing to give up to get more of 
another). Throughout the discussion, the facilitators answered questions on current monitoring 
services in the UK, risk of progression of the disease and cost, as required.
TABLE 23  Summary of attributes that the advisory panel felt were important in a monitoring service
Attribute Discussion
Risk Loss of vision causing, for example, loss of the ability to drive
Trust/confidence Trust/confidence in who was seen. It was noted that patients are influenced by advice from their optometrist. Continuity of care 
would be preferable and this would contribute to building up a personal relationship and, therefore, an increase in trust
Time/cost of test Some people might be more concerned about time commitments rather than cost; however, people value their sight and may 
be willing to give their time and money to maintain their sight
Place of testing People would prefer not to have to go to a hospital for appointments because of parking problems and it would be easier if the 
location was on a bus route; however, people will go wherever they are told is best. Although location was important, overall 
confidence in a person was felt to be more important
Type of 
appointment
The merits of a fixed monitoring appointment arranged by the monitoring service rather than patient-arranged appointments 
were discussed. It was felt that a person’s availability and flexibility would be affected by whether or not they were employed
Frequency of 
appointment
The number of visits was felt to be of lesser importance than the serious consequences (e.g. visual loss) that might result if 
not seen often enough. It was noted that in England ‘low risk’ individuals are recommended to seek testing about once a year 
in the community. In Scotland the community optometrist could potentially see the patient two to three times per year with 
visual field assessment and clinical assessment (measurement of IOP) if there was concern about the results of previous tests
Length of 
appointment
Length of appointment was felt to be important. It was noted that people might prefer to see a specialist nurse if it involved a 
shorter waiting time
Type of test Type of test was felt to have an influence on the overall appointment. From a patient perspective it was noted that one might 
undergo any recommended test to avoid going blind98 Eliciting preferences for alternative monitoring services using a discrete choice experiment
The discussion was audiotaped and subsequently transcribed and analysed independently by 
two researchers (ABP, RH), using a modified framework approach.238 After initial familiarisation 
with the transcripts, the data were grouped according to common themes that reflected the main 
research questions and key issues which transpired from the discussion. These themes emerging 
are described below.
Communication between the health-care provider and service users
Most participants expressed the view that more communication was needed in the current 
monitoring scheme. They believed that this was a vital characteristic for a monitoring service to 
be effective. Examples included the information given at the point of diagnosis and an awareness 
of the consequences of not being treated. Furthermore, participants believed that lay term 
explanations about additional steps in the care pathway were needed, including the reasons 
behind any tests and an explanation of what the tests involve:
I didn’t know anything about this hyperocular hypertension and I still don’t know much 
about it either or this glaucoma thing.
(P3)
I find that with a lot of these tests the optician goes ahead and does it and doesn’t really 
explain why they’re doing it.
(P5)
Location
When discussing where participants would like to be monitored, the two locations explored were 
their local optician and the hospital. Their preferred place for monitoring was influenced mainly 
by the equipment available and the skills of the staff performing the test. However, there was 
not a clear preference for the type of health-care professional that participants would like to be 
monitored by:
I felt quite comfortable at Optician X. I felt they had the time because you’re pushed 
for time when you have anything done at the hospital. I felt comfortable, relaxed and 
explained everything as well.
(P4)
She was very professional and if she hadn’t been wearing that tag saying ‘nurse’ you 
would not know that she wasn’t a – she was a sort of pillar rather than a full top medical 
person definitely. No issues at all.
(P2)
Other factors that influenced individual preferences for location/provider were the time taken to 
attend the appointment, which varied depending on whether the person was working full-time or 
TABLE 24  Summary statistics of focus group participants
Participant Age (years) Gender Location On treatment
P1 61 Male Rural Aberdeenshire No
P2 54 Male Aberdeen city Yes
P3 67 Male Aberdeen city No
P4 59 Female Rural Aberdeenshire No
P5 65 Female Aberdeen city No© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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was retired, accessibility of the location and parking facilities. Convenience for the operator was 
also highlighted as an influential factor:
I’m quite happy to come into town. I just flash my bus pass.
(P1)
I’m willing to go just wherever it was convenient for the folk that were doing the 
examination for me.
(P3)
Continuity of care was also perceived as an important aspect of monitoring:
It would be good to see the same person.
(P5)
Health outcomes and chance of developing glaucoma
Participants felt that preserving ‘eyesight’ was very important. For example, although participants 
did not particularly like the tests for measuring IOP, or the visual field test, both being integral to 
a surveillance programme, participants would still attend for monitoring tests.
I would still have it . . . Of all the senses your eyesight is the most important one.
(P1)
If it’s going to help things, of course you would.
(P3)
Eye sight is too precious.
(P5)
The chance of developing glaucoma, particularly of losing vision, was identified as important. 
Participants perceived that risk increases when ‘people do not turn up for an eye check’, and cost 
played an important role (see Willingness-to-pay explanation):
The ordinary person, you know, who thinks they don’t need glasses or they don’t bother 
about glasses – mainly because of the cost – there is a lot of people don’t go to Optician 
Y and all that you know because you’re paying £200 for a pair of glasses so there’s a lot of 
people don’t go and that’s probably the people who end up the worst affected.
(P3)
One participant expressed concern about the apparent lack of treatment effect and questioned the 
efficacy of the treatment provided in current practice as described in the quote below:
What these figures are saying to me is that there’s not a particularly effective treatment 
to prevent advanced glaucoma . . . Yes. I’m surprised at the small difference between not 
treated and treated in advance glaucoma.
(P2)
For others, the lack of awareness of risk and its consequences if not treated was what was 
important to them and they concluded that more information at the point of diagnosis may 
have an impact on perception of risk. The participants believed that, by using pictorial cards 
representing the health risk information, people with OHT may gain a better understanding of 
the concept of risk and the consequences of monitoring:100 Eliciting preferences for alternative monitoring services using a discrete choice experiment
Just show them that (referring to the risk card). Say, ‘here’s where you are, here’s where 
you could be’.
(P2)
To fully explore the health outcome in the DCE this theme was expanded, building on our 
previous work with glaucoma patients,4 to include further attributes that reflect a patient’s 
perspective of the health impact of glaucoma. An existing utility measure, the Glaucoma Utility 
Instrument,4 was refined. This instrument was developed based on focus group studies of patients 
with existing glaucoma. The risk of developing glaucoma was redefined as three attributes (risk of 
developing: glaucoma, severe glaucoma and visual impairment). The remaining two dimensions 
in the Glaucoma Utility Instrument, describing local and systemic side effects of treatment for 
OHT and glaucoma, were combined as one attribute (unwanted effects of treatment) to capture 
the consequences of treatment within the DCE.
Summary of attributes
The final attributes for the DCE are shown in Table 25. They include four attributes of health 
outcome from the Glaucoma Utility Index and two attributes of the monitoring process 
(communication and understanding; location). When a price proxy (cost attribute) is included 
in the DCE, WTP, a monetary measure of benefit, can be calculated for changes in individual 
attributes as well as for different configurations of a monitoring programme.235,239,240 This is useful 
from a policy perspective, allowing estimation of the maximum amount of money individuals are 
willing to pay to participate in different monitoring programmes. We therefore also included a 
price proxy.
The next step was to define levels for each of these seven attributes.
Defining levels of the attributes
The levels for each attribute to be included in the DCE were informed by the focus group 
discussion, the literature, an existing economic model,241 the existing glaucoma utility measure4 
and expert opinion within the study team.
Attributes 1, 2 and 3: risk of developing glaucoma, severe glaucoma 
and visual impairment
Based on the preliminary advisory panel and focus group discussions, a description of glaucoma, 
with a definition of each disease stage, was developed. The risk of developing glaucoma was 
also illustrated. This is shown in Figure 59. The levels for the risk of developing glaucoma were 
determined using an existing economic model, tailored for individuals with OHT241 progressing 
to the different stages of glaucoma (glaucoma, severe glaucoma and visual impairment). All 
TABLE 25  Attributes for the DCE
Attribute
1 Risk of developing glaucoma
2 Risk of developing severe glaucoma
3 Risk of developing visual impairment
4 Unwanted effects of treatment
5 Communication and understanding
6 Location
7 Cost/price proxya
a  Included to enable WTP, a monetary measure of benefit, to be 
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individuals under a monitoring regime were assumed to receive treatment. Those under no 
monitoring may be opportunistically diagnosed and treated. A 5-year risk of conversion to 
glaucoma was used for untreated individuals with OHT.12 We assumed a treatment effect on risk 
of conversion, with treatment lowering the IOP for those with OHT and this reducing the risk 
of conversion to glaucoma compared with no treatment (HR 0.56, 95% CI 0.39 to 0.81). The risk 
of progression of glaucoma was also reduced by treatment237 (HR 0.65, 95% CI 0.49 to 0.87). The 
economic model estimated the proportion of individuals with OHT likely to develop glaucoma, 
severe glaucoma and visual impairment each year and cumulatively over a 10-year follow-up. We 
used 95% CIs and two mid-points between these to obtain final levels.4,237 The estimates produced 
in the economic model were reported as the number of people experiencing a particular level 
of severity over a 10-year period. Figures were developed for a hypothetical cohort of 10,000 
individuals who started in the model with OHT. The values presented to DCE participants were 
rounded to improve understanding of risk by respondents whilst still maintaining representation 
of the model estimates (see Table 26).
Because individuals are known to have problems with understanding risk,242 visual aids were 
used to help explain the concept of risk both in the focus group and subsequently in the DCE. 
Following Ancker and colleagues,243 a graphical presentation was used in the DCE (Figure 60).
Attribute 4: unwanted effects of treatment
Levels were defined from the glaucoma-specific utility measure4 and are detailed in Table 26.
Attribute 5: communication and understanding
There was some indication from the focus group that understanding the purpose of monitoring 
and feeling at ease were key components for monitoring. Therefore, following reflection on the 
findings of the focus groups and discussion within the study team four levels were developed for 
this characteristic:
  ■ made me feel at ease and made sure I understood the purpose of monitoring
  ■ made me feel at ease but did not make sure I understood the purpose of monitoring
  ■ did not make me feel at ease but made sure I understood the purpose of monitoring and
  ■ did not make me feel at ease and did not make sure I understood the purpose of monitoring.
Attribute 6: location
Defined as hospital eye clinic or local optician.
Attribute 7: cost per year (value)
To identify levels for the cost attribute a direct WTP question was included at the focus group 
stage. Here, participants were asked to consider the value that they would put on a monitoring 
service for people with raised eye pressure. Participants were presented with an example relating 
to the purchase of an article of clothing to help in understanding the concept of monetary value.
Willingness-to-pay explanation
You go to a shop and suddenly you see something that you really like, and think about 
buying it but suddenly you look at the price, say it cost £100 – too much – I don’t want 
to pay that and you go home. Then you come back 2 or 3 weeks after that and the price 
of the good has changed – say, imagine, half price, £50 – and you really like it and you 
think ‘£50, I would pay £50 for that’ and you buy it and you take it home. The economist 
will say that between £50 and £100 is the value that you put on that article.
Then, participants were asked how much they might be willing to pay for a service.102 Eliciting preferences for alternative monitoring services using a discrete choice experiment
FIGURE 59  Describing the clinical condition. Images reproduced with permission from the Belgian Glaucoma Society 
(http://www.glaucoma.be/en/index.html).
High eye pressure
This is a condition also known as
ocular hypertension, where the eye
pressure is higher than it should be.
Ocular hypertension is usually
discovered during a routine eye test.
Monitoring is needed to make sure
glaucoma is not developing and to
give treatment if necessary.
Monitoring involves measuring
pressure, usually a check of the
vision to the sides and an
assessment of the nerve at the back
of the eye with a bright light. 
No effect on vision to the sides
This is a picture showing that a person with
high eye pressure (ocular hypertension)
has normal vision and can see everything in
this busy street.
Glaucoma
Glaucoma is an eye disease where
there is damage to the nerve at the
back of the eye, leading to a
reduced vision to the sides. Once
glaucoma is diagnosed, treatment
will be required. This is usually in
the form of daily eye drops. Eye
surgery may be needed. 
Glaucoma
Some effect on the vision to the sides. Note
that in this picture, the red car on the right
and the children cannot be seen.
About 1600 out of 10,000 people
with ocular hypertension will
develop glaucoma in 10 years if
not treated. © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Visual impairment
This is an advanced stage of
glaucoma where one can still see to
read as the central vision is not
affected very much but a lot of vision
to the sides is lost.
The main problem is difficulty
getting around without assistance
because the ability to see things at
the sides is poor. 
Visual impairment 
This is a more advanced stage of your
condition, central vision remains but vision to
the sides is lost. 
Severe glaucoma
A condition where there is a marked
restriction of the vision to the sides
due to glaucoma, leading to some
difficulties with daily activities.
Driving is not allowed (if glaucoma is
severe in both eyes) because
eyesight would not meet the
required standards. 
Severe glaucoma
Following from the previous picture, there is
more loss of vision to the sides.
About 180 out of 10,000 people with
ocular hypertension will develop
severe glaucoma in 10 years if not
treated. 
About 25 out of 10,000 people with
ocular hypertension will develop
visual impairment in 10 years if not
treated.
FIGURE 60  Graphical explanation of risk of developing glaucoma, severe glaucoma and visual impairment given to 
DCE participants. 
FIGURE 59  Describing the clinical condition. Images reproduced with permission from the Belgian Glaucoma Society 
(http://www.glaucoma.be/en/index.html). (continued)
In other words:
Now In 10 years’ time…
About 25 will
develop
visual
impairment
About 1600
people will
develop
glaucoma
About 180 will
develop severe
glaucoma
Of
10,000
people
with
high eye
pressure104 Eliciting preferences for alternative monitoring services using a discrete choice experiment
Willingness-to-pay question
Now, I would like you to imagine the best monitoring programme. For some of you it 
is going to be at the hospital, being seen by an ophthalmologist, or it might be going to 
an optometrist every 6 months. Imagine the service that you really like, the service that 
you are really comfortable with. Then, obviously, the question is how much you might be 
prepared to pay for that type of service.
The monetary value of a service was a difficult concept to understand for the participants. 
Initially, participants expressed reluctance to pay for the service. However, after it was explained 
that this was an exercise to infer value, and that money is one way of looking at value, they 
engaged with the exercise.
Willingness to pay was based on previous experience with eye services or other health services 
in Scotland. Other factors considered when giving a value were a person’s own health risk 
perception, financial circumstances, family history, previous experiences (good or bad) and 
current diagnosis (all suggesting engagement with the exercise). For example:
How much is the dentist? Is the dentist about £15? The same as the dentist.
(P4)
I would have paid it. I would have paid the £40 because my £40 gave me peace of mind.
(P3)
Something happened to my mother and in the light of today and prices and things, to 
cover National Health, I think I would be prepared to pay what about £40 for an hour’s 
consultation, once a year.
(P5)
Well if you’re wanting a figure, I would be comfortable in my wallet with £50.
(P1)
I think we’re giving a kind of philosophical stun point here and the issue is not I think 
– to put a value on what you’d pay for a consultation then you need to know I guess you 
would maybe be prepared to pay a percentage of the cost of the consultation inclusive of 
everything involved, whatever that comes out to for a consultation. If it comes out to for 
a number £100 yes I would happily pay 10/20/30%, but without knowing the cost of the 
work then I can’t really put a figure on it but perhaps the question should be ‘would you 
pay or would you not pay’ and I would pay – ‘. . . because of the situation I am in I would 
pay but it would be with extreme reluctance.
(P2)
Based on this discussion participants indicated values ranging from £15 (P4) to £50 (P1), with 
intermediate values of £30 (P2) and £40 (P3, P5). Such values provide a guide for levels of the 
cost attribute. However, given the small sample size of the focus groups, the levels for the cost 
attribute were extended beyond the maximum stated within the focus group, with an upper 
range of £70.
The final set of attributes and levels are summarised in Table 26.
Determining choice sets
The six attributes with four levels and one attribute with two levels resulted in 8192 possible 
choice sets (i.e. 46 × 21). Experimental design techniques were employed to reduce the number © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 26  Summary of the monitoring attributes and levels
Attribute included in the DCE Value for each level included in the DCE
No monitoring 
alternative
Risk of developing glaucoma
Number of people out of 10,000 
developing glaucoma in 10 years
740; 960; 1190; 1410 1600
Risk of developing severe glaucoma
Number of people out of 10,000 
developing severe glaucoma in 10 years
25; 60; 100; 130 180
Risk of developing visual impairment
Number of people out of 10,000 
developing visual impairment in 10 years
2; 6; 10; 15 25
Unwanted effects of treatment None – means that you have not noticed any discomfort or difficulties
Some – means that you have noticed occasional discomfort or difficulty
Quite a lot – means that you are aware of these discomforts or difficulties 
most of the time
Severe – means that you need or think you need additional treatment to 
control one or more of these difficulties
None
Communication and understanding 
of information provided by the health 
professional
Made me feel at ease and made sure I understood the purpose of monitoring
Made me feel at ease but did not make sure I understood the purpose of 
monitoring
Did not make me feel at ease but made sure I understood the purpose of 
monitoring
Did not make me feel at ease and did not make sure I understood the 
purpose of monitoring
Not applicable
Location  Hospital eye clinic
Local optician
No testing
Cost per year (£) 15; 30; 50; 70 No cost
of choice sets to a more manageable number while still being able to infer WTP for all possible 
configurations. More specifically, SAS version 9.1.2 software244 (SAS Institute Inc., Cary, NC, 
USA) was employed to generate a main-effects D-efficient design, ensuring that uncertainty 
around parameter estimates was minimised (by minimising the determinant of the covariance 
matrix).245 This resulted in 32 choice sets.
An opt-out ‘no monitoring’ alternative was added to each of the 32 choice sets to allow 
individuals to choose the realistic option of not being monitored. The levels for the opt-out 
option were defined in consultation with experts in the field. An example of a choice set is shown 
in Figure 61. Respondents were presented with an example of a choice set before proceeding 
to the task themselves. The order of the choice questions presented for each participant was 
randomly generated.
Additional information in the questionnaire
In addition to the 32 choices derived from the experimental design, four rationality tests were 
added to test whether respondents were engaged in the experiment. The rationality tests applied 
Sen’s contraction test.246,247 Here, individuals were initially presented with a choice set involving 
three choices (monitoring service A, monitoring service B and no monitoring service). This 
choice was then repeated later in the questionnaire, with the choice set contracted to two options. 
These two options depended on what they chose initially, with the option they chose and one of 
the other options from the original three choices being presented. The individual should choose 
the same option when the choice set is contracted. The tests were included at four points within 
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34). This allowed testing of whether or not including a larger than average number of choices 
increased the cognitive burden or task complexity for respondents.248–250
If respondents ‘fail’ such tests, the question arises of what to do with them. Although deletion 
of such responses is common,240 Lancsar and Louviere251 argue that such deletion may be 
inappropriate because such responses may be valid, and random utility models are robust to 
errors made by individuals in forming and revealing preferences. Decisions on what to do with 
those who ‘failed’ were based on discussions once responses were analysed. Given that the 
rationality checks were not derived from the experimental design, the additional contracted 
questions were not included in the econometric analysis (because adding choices to the data 
matrix would compromise the statistical properties of the experimental design).
Before completing the DCE the following characteristics of the participants were collected: 
gender, age, region of UK, level of education (secondary school, college, university, none of the 
above and other), socioeconomic status (level of income per household and number of habitants) 
and experience of eye testing. Following the choices information was collected on general health, 
using the European Quality of Life-5 Dimensions (EQ-5D) (www.euroqol.org).
The full questionnaire is available from the authors.
Pre-piloting
The questionnaire was pre-piloted opportunistically among 10 members of staff from the 
University of Aberdeen. Comments on the format of the questionnaire were given in terms of 
the ordering of the different sections. One participant argued that having the ‘easier’ questions 
concerned with personal characteristics at the beginning of the questionnaire would help to 
ease respondents into the rest of the survey. Other useful comments related to the format were: 
‘useful to have an access link to the explanation of each characteristic and its levels throughout 
FIGURE 61  Example of a DCE question.
Which monitoring service would you choose? (please tick one box below) 
Monitoring service A Monitoring service BN o monitoring service 
Number of people out of 10,000
developing glaucoma in
10 years
1600 1410 740
Number of people out of 10,000
developing severe glaucoma in
10 years 
180 130 25
Number of people out of 10,000
developing visual impairment in
10 years
25 15 2
Unwanted effects of treatment Severe None None
Communication and
understanding of information
provided by the health
professional
Made me feel at ease and
made sure I understood the
purpose of monitoring 
Did not make me feel at ease
and did not make sure I 
understood the purpose
of monitoring 
Not applicable 
Place of testing No testing Local optician Hospital eye clinic
Cost per year No cost £30/year £15/year
Service AS ervice B No monitoring
(tick one box only) ✓© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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the choice section in the same screen shot’, ‘provide a hyperlink to the example choice as a guide 
for answering the choices’, ‘highlight key words to emphasise meaning and capture attention’. 
Most people agreed that pictorial representation of disease stages together with the graphical risk 
explanation made information more understandable. Changes were made to the format of the 
survey accordingly.
Sample, pilot and main data collection
Given the poor response rates from unsolicited general population surveys,252 a web-based 
online survey method was used to collect the data set, using a market research company (www.
researchnow.co.uk/). This company contacted individuals registered with it, by email, and 
invited them to complete the DCE questionnaire. A financial incentive of £2 was promised 
for completion, credited to the respondent’s personal account. Following discussions with the 
company, further modifications were made to the questionnaire to clarify meanings and to 
accommodate the online survey format. For example, respondents were given a separate icon to 
click for a reminder of definitions of attributes and levels in choices. Those invited to respond 
were aged > 18 years and living in the UK. The company’s internal protocol was used to stratify 
by age and gender. Initially the questionnaire was piloted among a group of 183 respondents and 
provisional analysis conducted. Item response rate and the estimation using choice questions 
were analysed.
A novel component of this study was using the coefficients generated from the pilot work to 
further develop the experimental design. When deriving efficient designs there is often no prior 
knowledge about the potential values. It is thus assumed that parameters are zero. We made 
this assumption in our pilot work. A recent development is to use prior information, obtained 
from pilot work, to inform the design and improve statistical efficiency.253–255 We obtained prior 
information from our pilot data to inform our final design, using SAS.256 This changed the final 
set of choices respondents were presented with. The final version of the questionnaire is available 
from the authors. A sample size of 800 individuals was targeted for the main survey, providing a 
sufficient sample size to carry out subgroup analysis.
Econometric analysis
Responses to the choices within the DCE were analysed using a clustered conditional logit 
regression model, within Stata 11.0. The equation estimated is described in Equation 13.
V = β0 + β1Risk_earlyG + β2Risk_SevereG + β3Risk_visual_impairment  
+ β4Sideeffects_some + β5Sideeffects_quitealot + β6Sideeffects_severe  
+ β7CommUnder(at_ease/not_under) + β8CommUnder(not_ease/under)  
+ β9CommUnder(not_ease/not_under) + β10Location+ β11Costperyear + ε  [Equation 13]
where utility from the monitoring service is represented by V, characterised by different 
combinations of the attribute levels (defined in Table 26), and ε is the error term (reflecting 
unobservable factors). β0 is a constant reflecting the general preference for a monitoring service. 
If positive this would indicate a general preference for a monitoring service, and if negative a 
general preference not to have such a service (everything else being equal).
Dummy variables were employed for side effects (reference = none), communication 
and understanding (reference = not feeling at ease and not understood) and location 
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value of a change from the reference category to a given level, that is, β4 indicates the marginal 
value of moving from no unwanted treatment effects to some unwanted treatment effects.
The β parameters for the continuous variables, risk and cost, indicate the marginal value of a unit 
change in these attributes, that is, for the conversion to early glaucoma risk attribute the marginal 
value of reducing the number of people who convert to early glaucoma by 1 person in 10,000 
over a 10-year time period. The parameter β11 on the cost attribute indicates the value of a £1 
change in costs per year.
Willingness to pay
Drawing on Equation 1, the WTP for a marginal change in one of the attributes of a DCE is 
estimated as235:
i
costsperyear
β
β
−





  [Equation 14]
Thus, for example, from Equation 13, –β1/β11 indicates the WTP per year to reduce the number 
of people who convert to early stage glaucoma by 1 out of 10,000 over 10 years. Similarly, –β4/β11 
indicates the WTP for a movement from no unwanted effects of treatment to some unwanted 
effects. WTP was estimated for a marginal change in all statistically significant attributes, and 
95% CIs were obtained from bootstrapping with 1000 replications.257
Following estimation of the WTP for marginal changes in individual components of a 
monitoring service, overall WTP was estimated for two illustrative monitoring programmes: A 
(plausible best case scenario for monitoring, achieving the maximum treatment effect for OHT 
and OAG individuals)4,237 and B (plausible worst case scenario for monitoring). Both, described 
in Box 7, were compared with no monitoring.
Following estimation for the aggregate model, subgroup analysis was conducted to investigate 
how preferences/WTP vary across different sections of the population. Preferences for 
monitoring are likely to vary according to age – age 50 years generally marks the onset of 
presbyopia (need for reading glasses) and is often the first experience of having a ‘sight’ test. 
However, it may be that as individuals get older they are less concerned about relatively low 
10-year risks of conversion to glaucoma, severe glaucoma and becoming visually impaired as they 
Monitoring programme A
  ■ Avoiding 860 per 10,000 individuals converting to early glaucoma in 10 years 
  ■ Avoiding 155 per 10,000 developing severe glaucoma over 10 years 
  ■ Avoiding 23 per 10,000 developing visual impairment over 10 years 
  ■ No unwanted effects of treatment
  ■ Health-care professional makes one feel at ease and ensures understanding of the purpose of tests
Monitoring programme B
  ■ Avoiding 190 per 10,000 individuals converting to early glaucoma in 10 years 
  ■ Avoiding 50 per 10,000 developing severe glaucoma over 10 years
  ■ Avoiding 10 per 10,000 developing visual impairment over 10 years 
  ■ Severe unwanted effects of treatment
  ■ Would not feel at ease or understand purpose of tests
BOX 7  Descriptions of monitoring programmes A and B© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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believe it unlikely to affect them in their lifetime. Age was therefore investigated according to 
three groups (< 50, 50–65 and 65+ years).
Results
Characteristics of respondents
A total of 814 individuals responded to the questionnaire; Table 27 shows their demographic 
characteristics. All individuals were adults, 49% were male and 50% were > 45 years old. 
The sample was roughly evenly distributed in terms of education between those completing 
secondary, college and university level. Participants from England constituted 79% of the sample 
(645); 12% were from Scotland (97), 6% from Wales (48) and 3% from Northern Ireland (24).
In terms of experience of eye tests, 618 individuals (76%) had had their eyes tested within the 
previous 3 years, whereas 81 (10%), 40 (5%) and 54 (7%) had had them tested between 3 and 
5 years previously, between 5 and 10 previously and > 10 years previously, respectively. A total of 
21 (3%) had never had an eye test.
Rationality tests
Table 28 shows the number of individuals who failed one or more of the rationality tests. Only 
three people failed all four consistency check questions. Given this, the regression analysis 
included all individuals.
Regression results
Table 29 shows the results for the conditional logit regression analysis. The positive constant 
implies a general preference for being monitored, suggesting that, everything else being equal, 
respondents would prefer to take part in a monitoring programme.
All coefficients, other than hospital setting, were significant at the 1% level, suggesting that they 
all influence preferences for monitoring.
The results show strong theoretical/face validity, with all regression coefficients having the 
expected sign and strength. For instance, participants were less likely to choose a monitoring 
programme with a higher risk of conversion to glaucoma, severe glaucoma and visual 
impairment (as indicated by the negative signs). Furthermore, the absolute size of a coefficient 
is higher the worse the attribute, that is, becoming visually impaired is worse than conversion to 
glaucoma, as indicated by the higher negative value (–0.65 compared with –0.03). Likewise, for 
unwanted effects of treatment, participants were less likely to choose a programme that would 
result in some, quite a lot or severe side effects than one with no unwanted effects, with severe 
side effects having the largest absolute level.
Given that the reference category for communication and understanding was ‘not feeling at 
ease and did not understand’, positive coefficients were expected as any movement to another 
level would be expected to be an improvement on the reference category. The results suggest 
that respondents do not differentiate between ‘made me feel at ease but did not make sure 
I understood the purpose of the tests’ and ‘did not make me feel at ease but made sure I did 
understand the purpose of the tests’ (χ2 = 0.05, p = 0.83). As expected, ‘felt at ease and understood’ 
was the most preferred level within this attribute (as indicated by the higher coefficient).
The cost attribute had the expected negative sign, suggesting that respondents prefer to pay less 
for a given monitoring service.110 Eliciting preferences for alternative monitoring services using a discrete choice experiment
Table 30 shows the WTP for individual attributes. Marginal WTP is defined as the monetary 
value of a unit change in a given attribute. This is calculated as the ratio of the attribute of 
interest divided by the negative of the coefficient on the cost attribute. So, everything else being 
equal, individuals were willing to pay £28 per year for a monitoring programme for OHT 
[0.50811/–(–0.01843)]. This positive value indicates a general preference to be monitored.
Health outcomes were defined as the number of people out of 10,000 with OHT developing 
glaucoma/severe glaucoma/visual impairment within a 10-year period. Respondents were willing 
to pay £0.03 per year for a 1 in 10,000 person reduction in the number of people converting 
TABLE 27  Main survey sample demographic characteristics
Participant characteristics n %
Total sample size 814 100
Gender, male 400 49
Age (years)
 18–24 130 16
 25–34 129 16
 35–44 152 19
 45–54 128 16
 55–64 115 14
 65+ 160 20
Education (completed level)
  Secondary school 242 30
 College 296 36
 University 258 32
 Other 18 2
UK region
 England 645 79
 Scotland 97 12
 Wales 48 6
  Northern Ireland 24 3
Household income (£)
  < £19,999 240 29
  Between £20,000 and £39,999 298 37
  Between £40,000 and £59,999 131 16
  Between £60,000 and £79,999 54 7
  ≥ £80,000 91 11
General health
  Mean EQ-5D score (SD) 814 0.82 (0.23)
TABLE 28  Failure of rationality tests
Number of fails Frequency % Cumulative percentage
0 556 68.30 68.30
1 195 23.96 92.26
2 49 6.02 98.28
3 11 1.35 99.63
4 3 0.37 100
Total 814 100© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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TABLE 29  Main survey multinomial logistic regression results (fixed effects)
Attribute Coefficient 95% CI
Alternative specific constant (reference: no monitoring) 0.508a 0.3398 to 0.6764
OHT individual’s 10-year risk of
Conversion to early glaucoma –0.001a –0.0006 to –0.0004
Progressing to severe glaucoma  –0.001a –0.0016 to –0.0007
Becoming visually impaired –0.012a –0.0159 to –0.0081
Unwanted treatment effects (reference: none)
Some –0.286a –0.3308 to –0.2406
Quite a lot –0.620a –0.6919 to –0.5476
Severe –1.094a –1.1961 to –0.9919
Communication and understanding (reference: did not feel at ease and did not understand)
Felt at ease and understood 0.861a 0.7690 to 0.9540
Felt at ease but did not understand 0.475a 0.4218 to 0.5278
Did not feel at ease but understood 0.480a 0.4172 to 0.5437
Hospital setting (reference: community) 0.025 –0.0098 to 0.0595
Cost per year –0.018a –0.0201 to –0.0167
a  Significant at the < 1% level.
Number of observations = 78,144.
Clusters (individuals) = 814.
Log-likelihood = –26,402.
Pseudo R 2 = 0.0774.
TABLE 30  Willingness to pay for DCE attributes
Attribute Marginal WTP (£) 95% CI
Alternative specific constant (reference: no monitoring) 27.57 18.93 to 35.38
Outcomes
One OHT person per 10,000 developing glaucoma within 10 years –0.03 –0.03 to –0.02
One OHT person per 10,000 developing severe glaucoma within 10 years –0.06 –0.09 to –0.03
One OHT person per 10,000 becoming visually impaired within 10 years –0.65 –0.90 to –0.44
Unwanted treatment effects (reference: none)
Some –15.50 –18.68 to –12.92
Quite a lot –33.63 –39.15 to –28.54
Severe –59.36 –68.29 to –51.50
Communication and understanding (reference: did not feel at ease and did not understand)
Felt at ease and understood 46.75 40.40 to 54.42
Felt at ease but did not understand 25.76 22.25 to 29.93
Did not feel at ease but understood 26.07 22.05 to 31.05
Hospital setting (ref: community) 1.35 –0.53 to 3.20112 Eliciting preferences for alternative monitoring services using a discrete choice experiment
to glaucoma over the next 10 years [–0.0005/–(–0.01843)]. Thus, if 860 people with OHT per 
10,000 avoided progressing to glaucoma within 10 years (as might occur when moving from no 
monitoring service to monitoring service A), the value would be £25.80 (£0.03 × 860). Similarly, 
if 155 people with OHT per 10,000 avoided progressing to severe glaucoma within 10 years 
the value would be £9.30 (£0.06 × 155), and if 23 people per 10,000 avoided becoming visually 
impaired within 10 years the value would be £14.95 (£0.65 × 23).
As expected, unwanted effects of treatment reduce the value of any monitoring service. For 
example, WTP would be reduced by £15.50 if respondents experience some unwanted effects 
of treatment [–0.28573/–(–0.01843)]; £34 if they experience quite a lot of unwanted effects 
of treatment [–0.61979/–(–0.01843)]; and £59 if they experience severe unwanted effects of 
treatment [–1.094/–(–0.01843)].
If individuals feel at ease and understood they would value the monitoring programme 
at an additional £46; experiencing one of these components would increase value by 
approximately £26.
Table 31 shows the WTP for monitoring programmes A and B. Respondents were willing to 
pay £122 per annum for programme A, that is, they valued the monitoring programme up to 
the value of £122. However, programme B was far less desirable and they would have to be 
compensated by £17 per annum to undertake programme B (as indicated by the negative WTP). 
Failure to compensate would result in a very low take-up of such a monitoring programme.
Table 32 reports WTP (and 95% CIs) for the age subgroups. The p-value for the likelihood ratio 
chi-squared (p = 0.000) indicates that we can reject the null hypothesis that the age subgroup 
models are no better than the full model. In other words, there is heterogeneity in preferences 
that can be explained by age. In terms of WTP, those aged ≥ 50 years have a stronger preference 
to be monitored, with the 50–64 years age group having the strongest preference (as indicated by 
the higher alternative specific constant). These older age groups also had the strongest preference 
against unwanted side effects. However, they have the lowest preference for becoming visually 
impaired, with the preference being lower in the 50–64 years age group than in those aged 
≥ 65 years. This may reflect an increasing fear of ill health, and therefore blindness, as you get 
older (although it does not reach the levels of the younger group, who have the strongest aversion 
to visual impairment, as expected). The 50–64 years age group also valued more highly the 
provision of communication and understanding, with preferences being consistently higher than 
for those who are > 65 years.
Discussion
We conducted a DCE to elicit preferences for alternative glaucoma monitoring programmes for 
individuals with OHT. We used a mixed methods approach to derive the attributes and levels, 
employing a project advisory group and focus group. We developed a composite measure of 
utility that took account of both patient experiences and health outcomes. Pictures were used 
to explain the impact of glaucoma on eyesight and graphs were used to explain the concept of 
risk. We pre-piloted and piloted the survey and used parameters generated from our pilot data 
to develop the statistical design for the main DCE survey. The results from the DCE support the 
advisory groups and focus groups, with all attributes included in the DCE, other than location, 
impacting on preferences. The results were theoretically valid, with all coefficients moving in 
the direction expected. Age was a predictor of preferences, with the 50+ age groups valuing 
monitoring more highly, as well as avoiding unwanted side effects and communication and 
understanding. They also had a lower aversion to the 10-year risk of becoming visually impaired 
(compared with the < 50 years age group).© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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From a methodological perspective, a novel component of our study was the method of data 
collection – the use of an internet-based company with a panel of individuals who are willing 
to respond to surveys. This was in response to the low response rates in previous DCEs, with 
studies struggling to achieve response rates > 15%. The internet offers a promising alternative 
to conventional mail surveys, offering novel ways of communicating difficult and unfamiliar 
concepts (in terms of graphics and sound); guaranteeing response rates; offering relative ease of 
data collection and reduced costs, speed of response and the tailoring of questions to individuals’ 
responses; ensuring that all questions are complete and therefore eliminating item non-response; 
and avoiding the need for manual data entry.258 However, there are a number of issues that arose 
using this method of data collection. We do not have information on the number of individuals 
who attempted but did not complete the questionnaire. Also, the approach forces a response 
even in situations in which an individual finds it difficult to make one. Concern does exist over 
the generalisability of the results to the general population as well as the effect of such survey 
methods on the preferences elicited. Although our sample of respondents matches the general 
population in terms of age and gender mix, future work should explore representativeness with 
respect to others characteristics such as attitudes. Only two studies, to the authors’ knowledge, 
have compared WTP estimates when using internet and mail surveys. Olsen,258 in a study 
concerned with preferences for protecting different types of landscape from road encroachment, 
found no significant different between the WTP values generated. Similar results were found by 
Windle and Rolfe259 when valuing future improvements in the Great Barrier Reef. This is clearly 
an important avenue for future research within health.
TABLE 31  Willingness to pay for alternative monitoring programmes
Attribute
Regression 
coefficient
Marginal WTP 
(£)
Monitoring programme A Monitoring programme B
Attribute level WTP (£) Attribute level WTP (£)
Alternative specific constant (reference: 
no monitoring)
0.508a 27.57 Yes 27.57 Yes 27.57
10-year risk of
Conversion to glaucoma of individuals 
with OHT
–0.001a –0.03 –860b 23.29c –190b 5.14c
Progressing to severe glaucoma for 
OHT individuals
–0.001a –0.06 –155b 9.71c –50b 3.13c
Becoming visually impaired for OHT 
individuals
–0.012a –0.65 –23b 15.03c –10b 6.54c
Unwanted treatment effects (reference: none)
Some –0.286a –15.50 No 0.00 No 0.00
Quite a lot –0.620a –33.63 No 0.00 No 0.00
Severe –1.094a –59.36 No 0.00 Yes –59.36
Communication and understanding (reference: did not feel at ease and did not understand)
Felt at ease and understood 0.861a 46.75 Yes 46.75 No 0.00
Felt at ease but did not understand 0.475a 25.76 No 0.00 No 0.00
Did not feel at ease but understood 0.480a 26.07 No 0.00 No 0.00
Hospital setting (reference: community) 0.025d 1.35 No 0.00 No 0.00
Cost –0.018a
Total WTP 122.35 –16.98
a  Significant at the < 1% level.
b  Compared with no monitoring.
c  Figures do not match exactly because of rounding.
d  Significant at the < 10% level.114 Eliciting preferences for alternative monitoring services using a discrete choice experiment
From a policy perspective, although all attributes are important, there is a gradient on how the 
different stakeholders can influence them. For instance, the risk of developing glaucoma will 
depend on both the effectiveness of treatment and how the patient complies with treatment 
(and the latter may depend on other factors such as the unwanted effects of treatment). The 
effectiveness of a particular treatment will not be actionable by the individual but how much the 
person complies with treatment will be.
The importance of ‘severe unwanted effects of treatment’ and ‘feeling at ease and understanding 
the purpose of monitoring’ were major drivers of preferences and both are within the decision 
domain of the health-care professional. It is likely that severe effects of treatment are already 
considered as changes in medical treatment would occur in current practice when severe side 
effects are observed. However, the findings from the focus group suggest that community 
eye services might not have sufficient time to devote to each patient, with a resulting lack of 
explanation of the purpose of monitoring. Therefore, policy-makers/decision-makers should look 
at this area as a potential target for improvement.
TABLE 32  Willingness to pay for subgroup analysis
Variable
WTP (£) (95% CI)
Full model
Age
< 50 years
Between 50 and 
64 years ≥ 65 years
Number of observations 78,144 44,160 18,624 15,360
Clusters (individuals) 814 460 194 160
Alternative specific constant 
(reference: no monitoring)
28 (19 to 35) 23 (12 to 32) 35 (17 to 51) 38 (10 to 60)
10-year risk of
Conversion to glaucoma of individuals 
with OHT
–0.03 (–0.03 to –0.02) –0.03 (–0.03 to –0.02) –0.03 (–0.04 to –0.02) –0.03 (–0.05 to –0.02)
Progressing to severe glaucoma for 
OHT individuals
–0.06 (–0.09 to –0.03) –0.07 (–0.1 to –0.03) –0.02 (–0.08 to 0.04) –0.09 (–0.17 to –0.02)
Becoming visually impaired for OHT 
individuals
–0.65 (–0.9 to –0.44) –0.88 (–1.2 to –0.61) –0.17 (–0.62 to 0.22) –0.47 (–1.24 to 0.13)
Unwanted treatment effects (reference: none)
Some –16 (–19 to –13) –13 (–16 to –10) –16 (–24 to –11) –24 (–36 to –16)
Quite a lot –34 (–39 to –29) –31 (–37 to –25) –36 (–48 to –26) –41 (–61 to –27)
Severe –59 (–68 to –51) –53 (–63 to –44) –66 (–87 to –50) –74 (–109 to –51)
Communication and understanding (reference: did not feel at ease and did not understand)
Felt at ease and understood 47 (40 to 54) 36 (30 to 45) 62 (47 to 82) 64 (45 to 93)
Felt at ease but did not understand 26 (22 to 30) 22 (18 to 27) 30 (22 to 41) 35 (24 to 51)
Did not feel at ease but understood 26 (22 to 31) 18 (14 to 24) 37 (27 to 50) 40 (27 to 61)
Hospital setting (ref: community) 1 (–1 to 3) 1 (–1 to 3) –1 (–6 to 4) 5 (–1 to 11)
LR test
LR χ2(24) 1846.23
Probability > χ2 0.000
LR, likelihood ratio.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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The setting where monitoring takes place was not a major driver of preferences. This was also 
reflected in the focus group findings. Individuals appear to be prepared to attend a visit anywhere 
as long as a skilled testing service is available. Consequently, policy-makers might have a certain 
degree of freedom when deciding where to set up a monitoring programme as long as the quality 
of the service is not compromised.
Although avoiding glaucoma and its consequences were highlighted in the advisory panel and 
focus group as important to patients, when it comes to decision-making by the public, and in 
particular making choices about how the service could be configured, the marginal WTP value of 
reducing the frequency of developing glaucoma was lower than those for the patient experience 
factors. It should be remembered that the β parameter for the frequency attributes indicates the 
marginal value of a 1 in 10,000 person change in the number of people developing glaucoma/
severe glaucoma/visual impairment, whereas for the dummy variable (unwanted treatment effects 
and communication and understanding) the β parameter indicates the marginal value of a shift 
from the reference category (i.e. from ‘not feeling at ease’ to ‘feeling at ease and understanding’). 
This is shown clearly in Table 30 where the value of a reduction of say 860 in 10,000 people 
progressing to glaucoma is £25.80. Thus, values are still relatively low.
One possible reason for this finding is that respondents had difficulties understanding risk 
levels.11 Although we used a graphical representation to explain risk, problems of understanding 
may still exit. The small risk levels for the attributes may also have contributed to the relatively 
lower values generated as it is also known that valuing small changes in risks is even more 
challenging, and that as a result values generated are often insensitive to the scale of the risk 
change.260 Future research is clearly needed.
The results may also relate to the sample. There is debate about whose (society or service users) 
values should inform the allocation of society’s scarce resources. Current guidance for decision-
making within the NHS recommends the use of society’s preferences.261 This approach has been 
previously used in a wide range of contexts.252 It is, however, possible that sampling a higher-risk 
group would have led to higher values for changes in the risks of developing glaucoma/severe 
glaucoma and visual impairment. This is clearly an important area for future research.
Whatever the interpretation of the risk attributes, our results do point to the importance of the 
process of care in the delivery of care. Although economic evaluations have tended to focus on 
health outcomes when valuing benefits from alternative interventions, there has been increased 
debate about the importance of valuing factors beyond such narrow outcome measures. Very few 
studies have looked at the value of health outcomes and process attributes within one holistic 
measure.4 In this study we attempted to do this, valuing health and patient experience attributes 
within one composite measure. de Bekker-Grob and colleagues,252 in a review of the application 
of DCEs in health, noted the absence of DCEs within an economic evaluation decision-making 
framework. Indeed, QALYs continue to be the preferred valuation method when making 
recommendations regarding provision of alternative health-care interventions by bodies such as 
NICE.261 However, the importance of patient experiences is being increasingly recognised,262,263 
and was clearly demonstrated in this study with ‘communication and understanding’ of 
the reasons for testing and an explanation of what the tests involve being a major driver of 
preferences. In the next chapter we incorporate our broader measure of value into an economic 
evaluation framework.116 Eliciting preferences for alternative monitoring services using a discrete choice experiment
Conclusions
The DCE attributes of risk of developing glaucoma, severe glaucoma or visual impairment, 
unwanted effects of treatment, and communication and understanding, but not location, have 
a statistically significant impact on individuals’ preferences. Respondents also valued positively 
the fact of being monitored, irrespective of the particular form that this monitoring might 
take. The main drivers of individuals’ preferences were the unwanted effects of treatment 
and communication by the health-care professional and an understanding of the purpose of 
monitoring. Age was a predictor of preferences, with those aged ≥ 50 years valuing monitoring 
and communication and understanding more highly than those < 50 years. Those aged ≥ 50 years 
also valued unwanted side effects of treatment more highly than those < 50 years.
Relatively low WTP values were obtained for the risk of developing glaucoma, progressing to 
severe glaucoma and visual impairment. Further research should compare these results with 
those of a DCE conducted for ocular hypertensive respondents as these individuals might have 
a better appreciation of what glaucoma is and might understand more fully the ramifications of 
visual field loss.
From the policy perspective, our study suggests that any changes to a surveillance programme for 
OHT should take into account the communication between health-care provider and patient and 
give time for the patient to understand the purpose of monitoring.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Chapter 8 
Economic evaluation
E
conomic evaluation is the comparative analysis of alternative courses of action in terms 
of both their costs and their benefits.264 Economic evaluations may take several forms: (1) 
cost-effectiveness analysis, in which costs are equated with a single natural or clinical measure 
of effectiveness; (2) cost–utility analysis, in which costs are equated against a composite measure 
that combines both quality and quantity of life; and (3) cost–benefit analysis, in which costs and 
benefits are measured in commensurate units, normally money. A further form of economic 
evaluation also exists, a cost–consequence analysis. Here, costs are equated against several 
different measures of outcomes. These outcomes may include both health and non-health effects. 
For this study, as illustrated in the results section in this chapter, we use each of these different 
approaches to explore the relative efficiency of alternative surveillance approaches.
Systematic review of economic evaluations of ocular 
hypertension surveillance programmes
We systematically searched for economic evaluations comparing the costs and outcomes of 
two or more pathways for surveillance of individuals with OHT, including situations in which 
no active or organised surveillance service is available. The search strategy can be found in 
Appendix 1. To be included, studies had to include costs (regardless of the way that these were 
estimated) and effects (regardless of the way that these were estimated). We found no economic 
evaluations that met the inclusion criteria (see Appendix 10 for details). Two cost comparisons 
were identified that compared alternative pathways to manage individuals with stable OAG. Both 
of these were performed within a RCT context, one in the UK265 and one in the Netherlands.266 
These studies evaluated alternative management schemes for people with OAG and were not 
directly relevant to policy decisions on surveillance for those with OHT. An abstract from 
conference proceedings reporting a study by van Gestel and colleagues30 was retrieved. The 
abstract reports findings from an economic evaluation in which two follow-up pathways (i.e. treat 
all individuals with OHT or do not treat them until they convert to OAG) were defined. As this 
was an abstract it was not included in our systematic review but we used this evidence to inform 
one of our model pathways. Furthermore, the model reported within the NICE guidelines1 
focuses on alternative treatments [i.e. no treatment or medical treatment with beta-blockers 
(BBs) or prostaglandin analogues (PGAs)] for individuals with OHT and does not explicitly 
compare alternative monitoring pathways. Given the paucity of the evidence base, no definite 
conclusion on the cost-effectiveness of surveillance programmes for individuals with OHT could 
be drawn. There is a need for an economic evaluation of alternative surveillance programmes. In 
the following section we report the results of an economic evaluation of five potential pathways 
for surveillance of adults with OHT.
Economic evaluation of surveillance pathways for individuals 
with ocular hypertension
The relative efficiency of pathways for surveillance was assessed using a discrete event simulation 
model. This approach provided more flexibility when modelling the sequence of events involved 
in surveillance because it does not impose restrictive assumptions about when events might 118 Economic evaluation
occur and it allows the incorporation of heterogeneity between individuals in a modelled cohort 
compared with alternative approaches commonly adopted in economic evaluations (e.g. Markov 
models). Figure 62 provides an overview of the process captured within the discrete event 
simulation model. This basic process is identical for each of the surveillance pathways compared.
The economic evaluation involved several stages, described in the methods section:
  ■ Defining the interventions compared. The method followed to define the care pathways 
together with a description of the compared pathways are provided in Developing the 
surveillance care pathways and Description of the surveillance pathways compared and outline 
of the model. Characterisation of the risk profile of the simulated cohort and surveillance 
and treatment criteria for each pathway outlines how these pathways are tailored to reflect 
differences in the underlying risks of those being monitored; and The sequence of treatment 
describes treatments for OHT and OAG.
  ■ Structuring the discrete event simulation economic model (Description of the discrete event 
simulation economic model) to capture the essential elements of the disease and the care 
provided as identified in the conceptual models that form the care pathways described in 
Developing the surveillance care pathways.
  ■ Paramaterising the model, specifically:
  – estimation of parameters describing the natural history of OHT and OAG (Estimation of 
parameters for the natural history of ocular hypertension and open-angle glaucoma)
  – estimation of parameters used to modify the natural history of OHT and 
OAG (Parameters used to modify natural history of ocular hypertension and 
open-angle glaucoma)
  – estimation of parameters used to describe the costs of surveillance and treatment 
(Parameters used to describe the costs of surveillance, diagnosis and treatment)
  – estimation of parameters used to value the health effects and other benefits of 
surveillance (Health state utilities and benefit valuations).
  ■ Calibrating the model (Model calibration and validation) to ensure that the model outputs are 
credible and informative for decision-making.
  ■ Data analysis (Developing the surveillance care pathways) describing how estimates of costs, 
effects and measures of relative efficiency were produced.
The results section presents the model calibration results, cost-effectiveness analysis and cost–
utility and cost–benefit analyses. The final section provides a summary of the key finding, the 
strengths and limitations of the analysis and key uncertainties that remain.
Methods
Developing the surveillance care pathways
The clinical care pathways for surveillance of patients diagnosed with OHT were developed by 
the Aberdeen project management group. The group included three ophthalmologists (AAB, AT 
and JB), three health economists (LV, RH and MR), a statistician (JC) and two project research 
fellows (APB and KB). Over a number of meetings the group reviewed national guidelines and 
FIGURE 62  Overview of the process captured by the economic model.
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used information from a review of economic evaluations of monitoring for OHT (Systematic 
review of economic evaluations of ocular hypertension surveillance programmes), a review of 
risk prediction tools (see Chapter 4), the optimal criteria for monitoring (see Chapters 5 and 6) 
and public preferences for monitoring (see Chapter 7) to determine the most appropriate care 
pathways to be compared in the model.
Five pathways were developed:
1.  SOH in a primary care (community) setting
2.  SOH in a hospital eye service setting
3.  ‘treat all’ pathway
4.  NICE guidelines (intensive)
5.  NICE guidelines (conservative).
Public preferences for monitoring (see Chapter 7) and the evaluation of optimal monitoring 
criteria (see Chapters 5 and 6) informed a new pathway of care defined as the SOH pathway. This 
pathway was developed for both a community eye care setting (optometry) and a hospital eye 
service setting.
In the ‘treat all’ pathway, all individuals with an IOP > 21 mmHg would be treated with a PGA 
with advice to have their IOP checked annually at their community optometrist. This pathway 
was informed by a modelling evaluation by van Gestel and colleagues,30 which suggests that this 
pathway is cost-effective in a Dutch context.
The comparator pathways were defined by the NICE guidance.1 Detailed specification of these 
pathways can be found in the next section. In brief, the NICE guidelines present a range of 
recommended monitoring intervals for patients dependent on both the initial risk stratification 
and treatment recommendation. We developed two pathways for current care from the 
NICE guidelines: ‘NICE intensive’, representing monitoring on the more intensive side of the 
guidelines’ recommended monitoring frequency (4-monthly to annually depending on initial 
risk stratification), or ‘NICE conservative’, representing the more conservative end of the 
recommended frequency of monitoring (6-monthly to biennially).
Description of the surveillance pathways compared and outline of 
the model
The SOH pathways were defined for a primary care (community) setting and a hospital eye 
service setting. In both of these pathways baseline IOP would be measured twice and a mean 
value calculated. Also, the frequency of the surveillance visits was taken to be 2 years. This 
interval was based on the work conducted to estimate the signal-to-noise ratio for measurement 
of IOP, reported in detail in Chapter 6. Other features of the pathways, such as the level of 
communication and understanding between the health-care professional and the patient or 
the formula for the estimation of the risk level that would trigger treatment, were informed by 
professional experts and public preferences for surveillance (see Chapter 7) and the comparison 
of IOP measurement agreement between alternative tonometers (see Chapter 5), respectively.
The ‘treat all’ pathway reflects a minimum level of care of people with OHT (i.e. no explicit or 
organised surveillance). In this pathway, all individuals with OHT receive treatment and these 
individuals are advised to seek, and assumed to take up, an annual IOP check-up from a provider 
based in the community (e.g. community optometrist). If there is a < 15% reduction in IOP from 
baseline (model entry) individuals are referred to secondary care.120 Economic evaluation
The NICE guidelines1 provide a broad description of the range of management options but do 
not provide a sufficiently precise definition of the management that would be provided to an 
individual with a given set of risk characteristics; such detail is required to construct a model. 
Nevertheless, using the descriptions provided within the guidelines we developed two pathways 
for current care: ‘NICE intensive’ or ‘NICE conservative’. These pathways differed in terms of 
the time intervals between surveillance visits. For instance, with a range of 6–12 months stated 
within the NICE guidelines, the ‘NICE intensive’ pathway used a 6-month interval between 
surveillance visits whereas the ‘NICE conservative’ pathway used a 12-month interval between 
visits. For both of these surveillance pathways the location of surveillance was taken to be a 
hospital setting. Treatment was recommended as detailed in the NICE guidance.
These pathways are summarised in Table 33.
Characterisation of the risk profile of the simulated cohort and 
surveillance and treatment criteria for each pathway
Table 34 gives a detailed description of the risk stratification rules and surveillance and treatment 
criteria for each pathway. Every simulated individual entering the model has confirmed OHT 
based on an IOP of > 21mmHg and no ocular comorbidity. The pathways described in the first 
two columns of Table 34 are founded on the premise that an individual’s risk of converting to 
OAG is based on a set of definable characteristics. In contrast to this the ‘treat all’ pathway, 
described in the third column of Table 34, is implicitly based on the premise that individuals, 
regardless of their underlying characteristics, face the same risk of converting to OAG.
The sequence of treatment
Within the model the initial treatment choice for each individual is defined by the individual’s 
characteristics at the time when surveillance is initiated. Although the initial treatment may 
vary between individuals, based on a judgement of their risk of conversion to OAG, a common 
sequence of treatments was defined following discussions within the project team and with 
expert clinicians. Individuals will vary according to the point at which they enter this sequence 
(Figure 63). An individual with OHT would progress through these treatments if a judgement 
is made that IOP is not controlled. IOP is considered uncontrolled if the reduction from the 
IOP level at the start of the model is < 15% of the initial IOP [e.g. if an individual’s IOP level 
at the start of the model is 26 mmHg, then an IOP level > 22 mmHg (26 – 26 × 0.15 = 22.1) after 
treatment has been initiated would be regarded as uncontrolled]. Individuals who convert to 
OAG would receive PGAs if they had previously received either no treatment or BBs. However, 
a proportion of individuals will receive surgery (trabeculectomy) if prior to conversion they had 
received treatment with PGAs or combination therapy. The sequence of treatments allows for a 
TABLE 33  Surveillance pathways compared within the model
Pathway Risk stratification Surveillance criteria Treatment 
SOH (primary care) Risk prediction algorithm (see 
Chapter 4)
NICE guidelines modified according to findings 
in SOH substudy B (see Chapters 5 and 6)
PGAs for medium- or high-risk 
individuals
SOH (hospital) Risk prediction algorithm (see 
Chapter 4) 
NICE guidelines modified according to findings 
in SOH substudy B (see Chapters 5 and 6)
PGAs for medium- or high-risk 
individuals
NICE guidelines 
(intensive)
NICE guidelines (based on age, CCT 
and IOP level)
NICE guidelines; using minimum intervals 
between surveillance visits
NICE guidelines
NICE guidelines 
(conservative)
NICE guidelines (based on age, CCT 
and IOP level)
NICE guidelines; using maximum intervals 
between surveillance visits
NICE guidelines
‘Treat all’ IOP > 21 mmHg: no further risk 
stratification
IOP surveillance only once a year PGAs for all with IOP 
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TABLE 34  Risk stratification rules and surveillance and treatment decision criteria for each pathway
The NICE pathways (intensive and 
conservative) The SOH pathways (community/hospital) ‘Treat all’ pathway
Risk
The criteria used to categorise individuals with OHT 
as low, medium or high risk of conversion to OAG 
are not explicitly stated
Used the best available risk prediction tool (see 
Chapter 4) to inform the choice of initial treatment 
of individuals
All individuals with IOP > 21 mmHg 
judged to be at high risk of conversion 
to OAG
Guidelines provide clear criteria to inform 
surveillance and treatment decisions, with 
decisions on surveillance and treatment made on 
CCT and level of IOP together with age1
Information on age, VCD ratio, IOP, CCT and a 
measure of visual field loss (PSD) combined using 
an algorithm based on the pooled OHTS-EGPS 
model64 to calculate the 5-year risk of conversion 
to OAG
No further risk stratification considered
The 5-year risk of developing OAG was grouped 
into three categories: low (< 6%), intermediate 
(6–13%) and high (> 13%)13
Surveillance
For those with untreated OHT, a full assessment is 
recommended every 6 or 24 months depending on 
risk (level of IOP or CCT – see Table 35 for details)
All those starting treatment with a PGA, and those 
changing to a new medical treatment, have two 
consecutive (same visit) IOP measurements within 
2 months of starting or changing a treatment
No active monitoring: individuals are 
advised (and assumed) to attend a 
community optometrist annually for 
measurement of IOP
For treated OHT, IOP measurement 2 months 
after initiating treatment is recommended. 
Full assessments are every 4, 6 or 12 months 
depending on risk (see Table 35 for details)
Individuals are monitored every 2 years in either 
a secondary or primary care setting for the 
‘SOH hospital’ and ‘SOH primary care’ pathways 
respectively
For the ‘SOH primary care’ pathway individuals 
would only be referred to secondary care if IOP 
was ‘off target’ or conversion to OAG being 
detected
Treatment decisions
Details of the criteria under which treatment is 
initiated are provided in Table 35
Individuals with low risk (5-year risk of conversion 
< 6%) are not treated
All individuals with IOP > 21 mmHg are 
treated with PGAs
Medical treatment is stopped when individuals 
reach 60, 65 or 80 years of age if they are taking 
BBs, PGAs or combination therapy, respectively
Individuals with intermediate or high risk (5-year 
risk of conversion ≥ 6%) are treated with a PGA
The decision to stop treatment taken only if IOP 
remains on target and progression to OAG has not 
occurred. Finally, the decision about what initial 
treatment to be given is based upon the age and 
measures of CCT and IOP as defined in Table 35
If IOP off target the sequence of treatments is as 
outlined in The sequence of treatment
If IOP off target (< 15% reduction) from 
baseline (model entry) then individuals 
are referred to an ophthalmologist in a 
secondary-care setting
Care following conversion to OAG
All surveillance and care once an individual has 
converted to OAG provided by an ophthalmologist 
in a secondary care setting
All surveillance and care once an individual has 
converted to OAG provided by an ophthalmologist 
in a secondary care setting
All surveillance and care once an 
individual has converted to OAG 
provided by an ophthalmologist in a 
secondary-care setting
PGA, prostaglandin agonist.
maximum of two trabeculectomies, but does not allow those who are not diagnosed with OAG to 
receive surgery.
A further restriction on use of treatment is that we assume that individuals can progress through 
the treatment sequence but if they are initiated on a treatment that is part way through the 
sequence then they cannot subsequently go back to a treatment earlier in the sequence. The 
possible changes in treatment for those who have uncontrolled OHT are described in Table 36. 122 Economic evaluation
Table 37 describes the possible changes in treatment for those who convert to OAG and Table 38 
outlines the possible sequence of treatments for those with OAG.
Description of the discrete event simulation economic model
As already noted a discrete event simulation model was used to compare the pathways outlined 
in Table 33. On entry each individual has a predefined risk of developing OAG. This risk is based 
on their characteristics (e.g. age, IOP, etc., as described in Estimation of parameters for the natural 
history of ocular hypertension and open-angle glaucoma) defined above and the risk prediction 
algorithm reported in detail in Chapter 4. The model then compares the consequences for an 
individual, depending on their risk characteristics, for each of the five surveillance pathways 
described in Developing the surveillance care pathways. As described in Characterisation of the 
risk profile of the simulated cohort and surveillance and treatment criteria for each pathway, these 
TABLE 35  Treatment and follow-up frequency rules for individuals with OHT developed from the NICE 
glaucoma guidelines1
Treatment allocation criteria
CCT > 590 µm 555–590 µm < 555 µm Any
Untreated IOP (mmHg) > 21 to 25 > 25 to 32 > 21 to 25 > 25 to 32 > 21 to 25 > 25 to 32 > 32
Age (years) Any Any Any Treat until 60 Treat until 65 Treat until 80 Any
Initial treatment No treatment No treatment No treatment BB PGA PGA PGA
Surveillance intervals
NICE intensive pathway
IOP only NA NA NA At 2 months At 2 months At 2 months At 2 months
Full assessmenta Every 
12 months
Every 
6 months
Every 
6 months
Every 
6 months
Every 
4 months
Every 
4 months
Every 
4 months
NICE conservative pathway
IOP only NA NA NA At 2 months At 2 months At 2 months At 2 months
Full assessmenta Every 
24 months
Every 
12 months
Every 
12 months
Every 
12 months
Every 
6 months
Every 
6 months
Every 
6 months
NA, not applicable; PGA, prostaglandin agonist.
a  Full assessment: IOP and assessment of the optic nerve head, and visual fields.
FIGURE 63  Treatment sequence assumed for the model.
No  treatment → BB → PGA → PGA  &  BB → surgery  (trabeculectomy) → 
PGA → PGA & BB → second surgery (trabeculectomy) → PGA → PGA & BB
TABLE 36  Treatment transitions for those with OHT
From
To
No treatment BB PGAs PGAs and BB
No treatment Yes Yes No No
BB Yes Yes Yes No
PGAs Yes No Yes Yes
PGAs and BB Yes No No Yes
PGA, prostaglandin agonist.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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TABLE 37  Treatment transitions for those observed to convert to OAG from OHT
From
To
BB PGA PGA and BB
Surgery 
(trabeculectomy)
No treatment No Yes No No
BB No Yes No No
PGAs No No No Yes
PGAs and BB No No No Yes
PGA, prostaglandin agonist.
TABLE 38  Treatment transitions for individuals with OAG
From
To
No treatment PGA PGA and BB
Surgery 
(trabeculectomy)
PGAs Yes Yes Yes No
PGAs and BB Yes No Yes Yes
Surgery (trabeculectomy)a Yesb Yesc No No
PGA, prostaglandin agonist.
a  Individuals can have a second surgery if the first surgery was unsuccessful and they cannot be controlled with medication therapy (e.g. PGAs 
or PGAs and BB).
b  If surgery successful.
c  If surgery not successful.
surveillance pathways differ in terms of the process of surveillance, but following a correct 
diagnosis of OAG the progression of disease and the process of care are assumed to be identical. 
Thus, the model for these elements for the five surveillance pathways compared is also identical.
In discrete event simulation models a process or system is represented as a chronological 
sequence of events. The situation of an individual being modelled changes as a result of an event 
happening. For instance, in a model for the surveillance of individuals with OHT, the event can 
be a visit to the ophthalmologist where a particular set of tests is conducted. The change that 
might occur as a result of this event would be the diagnosis (or not) of OAG at that time.
Discrete event simulation models usually have five elements:
1.  Entities: in this evaluation the entities are the individuals modelled within the discrete 
event simulation.
2.  Characteristics: a set of characteristics for those individuals, which for this model are age and 
other risk predictors for OAG. These were defined based on the OHTS-EGPS risk prediction 
algorithm presented in Chapter 4.
3.  Events: events occur at a particular point in time. The main events in this model are 
surveillance visits where the levels of defined characteristics are checked and the disease 
condition assessed. Other events include glaucoma surgery (e.g. trabeculectomy) after 
which individuals might enjoy a length of time with no progression without the need for 
further treatment.
4.  Outcomes: these include mean cost, clinical outcomes (e.g. number of individuals converted 
to OAG), mean QALYs and mean WTP (as described in Chapter 7).124 Economic evaluation
5.  Relationships: mathematical or logical relationships that link the elements noted above 
together. An example of relationships in the model would be the way that the characteristics 
of an individual would link to the outcome of converting to OAG.
The important feature of a discrete event simulation is that an individual’s pathway through the 
model can change only if an event occurs. The likelihood of these events occurring is governed by 
the characteristics of the individual (i.e. the entity) and the relationships we define for the disease 
process and hence pathways of care. As events occur at particular moments in time during the 
individual’s pathway of care, the model includes a ‘clock’ to register an event.
Figure 64 illustrates how this process is operationalised to model the sequence of events involved 
in surveillance. This figure is based on the visual representation of the model in Simul8 version 
17.0 (Simul8 Corporation, Boston, MA, USA), the software package used to construct the model.
In Figure 64 we have marked five parts of the sequence of events involved as A, B, C, D and E. 
These points represent (A) the starting point, described in modelling terminology as the work 
entry point (WEP); (B) ‘queues’, where individuals wait until a further component in the model is 
free; (C) work centres (WC), where an event happens and some action is taken (e.g. a surveillance 
visit at which IOP measurement or perhaps a full assessment will take place); (D) end points, 
from which individuals cannot move elsewhere (i.e. death); and (E) the point at which, as a 
result of the findings of surveillance tests, IOP is judged to be off target or conversion to OAG 
is observed.
At the start of the model (marked as A in Figure 64) and within the WEP, the level for the 
characteristics (age, IOP, etc.) of each individual are defined, which determines the risk of 
progression to OAG. The value for each characteristic is based on data on the distribution of 
these characteristics in the population; we used the data from the Rotterdam study,34 the details of 
which are described in Chapter 3. As described in Table 34, for each surveillance pathway a set of 
criteria are used to decide whether treatment for OHT is prescribed and, if so, which treatment. 
This is reflected in Figure 64 by allocating individuals to no treatment, BBs or PGAs at the point 
at which they wait to start regular surveillance visits, illustrated by the queues marked as points B 
in the ‘monitoring visit loop’). The queues are an important aspect of a discrete event simulation 
as they are used to capture the potentially variable length of time that might exist between events, 
which in the context of Figure 64 are the surveillance visits.
When individuals enter the monitoring visit loop they go through a succession of surveillance 
visits (these are marked with a C in Figure 64). Before each visit the model re-estimates the level 
of IOP that the individual has at that time and whether or not they have truly converted to OAG. 
During each visit, IOP and disease stage are assessed and, based on the findings of the tests, 
any change in management is made (e.g. remain with current therapy and follow-up; change of 
therapy if IOP is ‘off target’; or referral to OAG follow-up if conversion to OAG is detected). This 
is marked with an E.
Figure 65 provides a more detailed illustration of this sequence and shows the model schematic 
for an individual who is currently receiving BBs. If at a surveillance visit IOP is off target or 
conversion to OAG is detected then the individual is sent to a queue (identified by point F) where 
they await assignment to the next treatment in the sequence of treatments available to them 
(see The sequence of treatment).
If an individual converts to OAG then subsequent management will follow the NICE guidelines1 
for individuals with diagnosed OAG. The model structure describing the sequence of events 
following conversion is shown in Figure 66 and is identical for all individuals who convert to © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Q_BB
0
Q_ongoing
monitoring
0
Q_IOP only
0
Observed OAG or IOP off
target change therapy
WC_ongoing
monitoring
0
WC_IOP only
0
0
F
OAG regardless of the surveillance pathway that they were on. As described in Table 34 the 
model assumed that all surveillance and care once an individual has converted to OAG would be 
provided by an ophthalmologist in a secondary care setting.
The first stage of the treatment sequence (not shown in Figure 66) is when the ophthalmologist 
decides what treatment should be given (see Characterisation of the risk profile of the simulated 
cohort and surveillance and treatment criteria for each pathway). Within the model this occurs in 
the working centre ‘WC_ophthalmologist decision node’ (marked as G in Figure 66).
Within the model there are three possible therapeutic options: (1) medical management (PGAs 
only or in combination with BBs); (2) surgery; and (3) PGA only or in combination with BBs 
prescribed after failed surgery. Once an individual is prescribed a medical treatment, he or she 
will undergo a programme of surveillance that will continue until the individual exhausts the 
available medical treatment options (because medical treatments fail to keep IOP on target or 
the OAG continues to progress despite medical treatment and potentially escalation of medical 
treatment). This option is represented by the rectangle to the left-hand side of Figure 66.
Once medical treatment options have been exhausted then surgery will be considered as the 
second therapeutic option (represented by the rectangle in the centre of Figure 66). Surgery may 
also be ineffective at keeping IOP on target or preventing OAG progressing. In such a situation, 
individuals might return to medical therapy (e.g. PGAs only or in combination with BBs), the 
third therapeutic option. This option is represented by the rectangle on the right-hand side 
of Figure 66.
FIGURE 65  Surveillance visit loop. Q represents queues for specific surveillance visits defined as WC at which either 
IOP measurements only are taken (WC_IOP only) or there is a full assessment (WC_ongoing monitoring).© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Estimation of parameters for the natural history of ocular 
hypertension and open-angle glaucoma
In this section we describe how we define several key sets of parameters used to populate the 
model structure described in Characterisation of the risk profile of the simulated cohort and 
surveillance and treatment criteria for each pathway. The first set of parameters relates to how we 
simulated the characteristics of the individuals who enter into the model. The second and third 
sets of parameters relate to assessment of IOP and changes in OAG status. Within the model 
both IOP and OAG status are assessed as these determine changes in management. The final set 
of parameters relates to the natural history of OHT and OAG and how treatments may alter the 
natural history.
Baseline characteristics of the simulated population
As described above, the model starts with the simulation of relevant individual characteristics 
shown to be predictors of conversion to OAG (e.g. age, IOP, CCT, VCD ratio and a measure 
of visual field loss, PSD). The characteristics for each individual were drawn from probability 
distributions for these characteristics obtained from sources that were judged by the study team 
to be most appropriate for the population of interest. Table 39 provides the point estimates of 
the cohort of individuals modelled as well as information used to define the distribution of the 
characteristic values in the population. The age- and sight-related characteristic values estimated 
for each individual were drawn from probability distributions fitted to the individual data from 
the Rotterdam study. Expected mortality rates for each individual were developed from UK 
interim life tables.267
Parameters relating to the modelling of the underlying level of 
intraocular pressure
An integral part of the model was that at surveillance visits IOP would be assessed. Therefore, 
an underlying level of IOP was needed. The level of IOP for an individual at any particular time 
was obtained by using the predictions of a mixed linear regression model, derived from the 
analysis described in Chapter 6 and based on data from two RCTs, the Rotterdam study34 and the 
Moorfields study,32 with time as the dependent variable. The value of IOP at any particular time 
was given by:
IOPi = (0.26 × Tiopi + 1)1/0.26  [Equation 15]
TABLE 39  Model population: baseline characteristics
Description Mean
Type of distribution and its 
parameters Source/note
Age (years) 58.1 N(58.1,109) Rotterdam data set34 (see Chapter 3)
CCT (µm) 574.7 N(574.7,1027) Rotterdam data set34
IOP (mmHg) 4.96a  N(4.96,0.068) Rotterdam data set.34 Note: normal distribution on transformed (log) IOP –  
see Equation 15. Mean = 24.19 mmHg
PSD (dB) 1.71 N(1.708,0.11) Rotterdam data set34
VCD ratio 0.37 N(0.37,0.03) Rotterdam data set34
Mortality Various   UK interim life tables 2007–9 (males)267
a  This is the transformed IOP level.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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where IOPi is the IOP (measured in mmHg) for individual i, and Tiopi was given by:
Tiopi = α + βt  [Equation 16]
where  ∼ N(4.96,0.068), β followed an empirical distribution (see Chapter 6) and t is time, 
measured in number of days from baseline.
Parameters used to model the conversion to open-angle glaucoma
The risk of conversion to OAG was developed using the risk prediction algorithm based on the 
pooled OHTS-EGPS model, described in Chapter 4, which is available as an online calculator 
(http://ohts.wustl.edu/risk/calculator.html), which provides an estimate of the 5-year risk of 
developing OAG. The risk of conversion in any subsequent 5-year period was estimated using 
the same risk prediction tool by entering into the calculator the level for each of the individual’s 
characteristics at the start of the that 5-year period. Also included in Table 40 are details of the 
type of distribution and information used to define the shape of the distribution.
Parameters used to model progression of open-angle glaucoma
As OAG is a chronic condition with a long natural history, the model also considered what 
would happen to an individual once he or she had converted from OHT to OAG. This required 
consideration of how OAG would progress over time. OAG was defined in terms of four levels of 
severity that differed according to the degree of visual impairment (and hence patient-reported 
health status and quality of life). The levels of severity considered were mild OAG, which 
individuals were assumed to have immediately following conversion from OHT, moderate OAG, 
severe OAG and visual impairment. These levels were consistent with those used in the DCE 
reported in Chapter 7. The risks of progression into moderate and severe OAG and eventually 
visual impairment were obtained from a systematic review conducted by Burr and colleagues.268 
Burr and colleagues estimated the number of years before visual field progression to the next 
level of OAG severity for untreated OAG. Based on these estimates, the model will delay the time 
of progression to the next level of severity depending on treatment efficacy and an individual’s 
adherence to treatment. Table 41 shows the average number of years to progression as well as the 
distribution used to sample the time to progression for each individual. Also, the lower part of 
this table reports the visual field-based staging system used.
Parameters used to modify natural history of ocular hypertension 
and open-angle glaucoma
Within the model there are two sets of parameters that have the effect of modifying the natural 
history of OHT and OAG. The first set relates to how accurate the measurement of IOP is in 
determining whether or not there is a clinically important change in IOP. This set of parameters 
determines whether or not the treatment of an individual should change. The second set 
of parameters relates to the effectiveness of treatments to control IOP and slow the rate of 
conversion to and progression of OAG.
TABLE 40  Parameters for risk of conversion to OAG
Description Mean (years) Type of distribution and its parameters Source/note
5-year risk of conversion 
to OAG
Predictions from regression model on 
transformed data (see Chapter 4)
Calculated in the model based on literature 
(see Chapter 4)
Time to conversion 2.5 Uniform (0,5) Assumption130 Economic evaluation
Parameters describing the precision of the measurement of 
intraocular pressure and progression of open-angle glaucoma
Within the model it is not assumed that IOP measurement, conversion to OAG or progression 
between the different severities of OAG will be known with certainty. The data on IOP were 
based on the Rotterdam and Moorfields data sets. These data sets collected IOP measurements 
made by ophthalmologists in secondary-care settings using GAT. Measurement of IOP by an 
ophthalmologist in the secondary-care setting and using GAT is generally considered to be the 
most reliable and accurate measure, but it is not perfect (see Chapter 5). To reflect this within the 
secondary care-based surveillance visits as well as for referrals to secondary care within the ‘SOH 
primary care’ and ‘treat all’ pathways we used the error term in the regression model reported in 
Chapter 6 to estimate the uncertainty surrounding the measurement of IOP by ophthalmologists 
in a secondary-care setting.
Measurement of IOP by other staff in other settings and using other equipment might be less 
precise. To capture this further level of uncertainty for the ‘SOH primary care’ and ‘treat all’ 
pathways we used data obtained from the tonometry review reported in detail in Chapter 5 
to generate the uncertainty in the measurement of IOP when measurements were made by 
tonometers other than GAT.
With respect to the diagnosis of OAG, the assumption was made that when this was made in a 
secondary-care setting by an ophthalmologist the sensitivity and specificity were equal to 1 (i.e. 
the ophthalmologist in a secondary-care setting would always make a correct diagnosis). As 
already noted the model assumed that all surveillance and care once an individual has converted 
to OAG would be provided by an ophthalmologist in a secondary-care setting. It was therefore 
assumed that, if the individual progressed to a more severe stage of OAG, this would be identified 
by the ophthalmologist at the next visit of the individual.
Data on the ability of a non-ophthalmologist in a primary-care setting to detect conversion 
to OAG (e.g. within the ‘SOH primary care’ pathway) were taken from Azuara-Blanco and 
colleagues.269 Azuara-Blanco and colleagues estimated the sensitivity and specificity of a diagnosis 
of OAG made from tests conducted by an optometrist (Table 42).
Parameters describing the clinical effectiveness of treatments
The model allowed for the effects of treatment on the level of IOP, the risk of conversion to OAG 
and the speed of progression of OAG once an individual had converted but the rules describing 
possible sequences of treatments, as described in The sequence of treatment, were the same.
TABLE 41  Open-angle glaucoma progression
Description
Mean 
(years)
Type of distribution and its 
parameters Source/note
Time of progression from OAG conversion to 
moderate OAG 
4 N(4,2) Developed from Burr 2007.268 Untreated 
individuals. Variance based on assumption
Time of progression from moderate OAG to 
severe OAG 
9 N(9,2)
Time of progression from severe OAG to 
visual impairment
10 N(10,2)
Visual field-based OAG staging system
Mild OAG MD score (dB): –0.01 to –6.00
Moderate OAG MD score (dB): –6.01 to –12.00
Severe OAG MD score (dB): –12.01 to –20.00
Visual impairment MD score (dB): –20.01 to worse© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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The type of treatment initiated varied by screening pathway, as described in Description of the 
surveillance pathways compared and outline of the model, and treatments for OHT were assumed 
to work solely by reducing IOP. If a treatment resulted in a ≥ 15% reduction in IOP compared 
with IOP at the start of the model we assumed that IOP was on target (based on expert opinion 
and the model calibration) and no change in treatment was warranted. If the percentage 
reduction in IOP was < 15% then a change of treatment would occur in accordance with the 
decision rules set out in Characterisation of the risk profile of the simulated cohort and surveillance 
and treatment criteria for each pathway. To estimate whether treatment maintained IOP on target, 
the effect of treatment on IOP was entered into the model as percentage reduction in IOP level 
measured when the individual entered the model.
The percentage reductions in IOP for each treatment were developed from data reported in the 
NICE guidelines1 and are shown in Table 43. The studies considered by the NICE guidelines had 
similar mean IOPs (i.e. between 23.1 mmHg and 25 mmHg) as the values estimated for the 10,000 
individuals simulated in the model. However, the follow-up in the studies varied from 5 years for 
a comparison of BBs versus no treatment to 6 months for PGAs versus BBs and for combination 
therapy versus PGAs only.1
As described in The sequence of treatment, the possible sequences of treatments given to those 
who converted to OAG (see Table 37) and those for whom OAG had progressed (see Table 38) 
varied according to what previous treatment an individual had received, but the possible 
sequence of treatments was the same for each surveillance pathway (see Figure 63).
Thus, the treatment effect for those who had converted to OAG and those for whom OAG had 
progressed came from the same source, Maier and colleagues,237 for all surveillance pathways 
(Table 44). The model assumed that this treatment effect would be enjoyed only by individuals 
who adhered to the treatment regimen and whose IOP was on target. Data on adherence to 
medical treatment were sparse. Therefore, based on expert opinion we assumed that individuals 
receiving treatment while undergoing surveillance would adhere to the treatment regimen only 
75% of the time. The exception to this was the ‘treat all’ community IOP pathway in which 
everyone is prescribed PGAs and advised to have their IOP measured yearly by a community 
optometrist. For this pathway a lower rate of adherence (50%) was assumed as it was felt that 
there would not be the same level of reinforcement given to promote adherence.
Other parameter values required for the model were the proportion of individuals converting to 
OAG who will go through surgery (e.g. trabeculectomy) as well as the proportion of individuals 
TABLE 42  Measurement precision of IOP and accuracy of conversion to OAG
Description Mean value Source/note
Ophthalmologist
IOP measurement error (mmHg)a 1 Based on regression model in Chapter 6
OAG diagnosis sensitivity 1 Assumption
OAG diagnosis specificity 1 Assumption
Community optometrist/primary-care setting professional
IOP measurement error (mmHg) 0  Based on NCT (see Appendix 4, Table 61); sampled from N (0,5.76)
OAG diagnosis sensitivity 0.76 Azuara-Blanco 2007269
OAG diagnosis specificity 0.93 Azuara-Blanco 2007269
a  IOP (mmHg) will result from applying Equation 15 but using only the original regression model error term (ε ~ N(0,0.036).132 Economic evaluation
with successful surgery. These data were obtained from a Cochrane review conducted by 
Burr and colleagues.270 The surgical failure rate was assumed to be equal to the proportion of 
patients assessed to be in need of further treatment (e.g. argon laser trabeculoplasty) from the 
Collaborative Initial Glaucoma Treatment Study.271
Parameters used to describe the costs of surveillance, diagnosis 
and treatment
When surveillance was performed in a secondary-care setting (i.e. the NICE pathways and 
the SOH hospital eye service pathway, which were defined in Description of the surveillance 
pathways compared and outline of the model), we used the unit cost for an ophthalmology service 
outpatient visit from the Scotland National Statistics Information Services Division272 to cost 
a visit to measure IOP only. This cost was doubled to reflect the cost of a full assessment (i.e. 
IOP measurement together with visual field measurement and assessment of the optic nerve) 
conducted in a secondary-care setting.
For the ‘SOH primary care’ pathway the unit cost for a non-ophthalmologist full assessment 
conducted in a primary care or community setting was assumed to be that of the NHS sight 
fee.273 Likewise, we assumed that the cost of an appointment at which only an IOP measurement 
was taken would be half of that of a full assessment (this latter value was also used as the cost 
of the annual measurement of IOP by a community optometrist recommended as part of 
the ‘treat all’ pathway).
Table 45 reports the unit costs for full assessment and IOP measurement only visits.
Treatment costs
Medication costs were obtained from the British National Formulary (BNF)274 (Table 46). When 
a BB was used, we assumed one bottle of eye drops per month and took the unit cost to be that 
of non-proprietary timolol. Because of the variation in the type of PGA used we selected the 
unit costs for Xalatan® (Pharmacia) and Xalacom® (Pharmacia) to calculate the annual cost for 
TABLE 43  Treatment effect on IOP for those with OHT
Description
Mean IOP reduction 
(%)  Source/note
BBs vs no treatment 12 Developed based on weighted mean differences in NICE guidelines1
PGAs vs BBs 5 Developed based on weighted mean differences in NICE guidelines1
PGAs + BBs vs PGAs only 1.5 Developed based on weighted mean differences in NICE guidelines1
TABLE 44  Treatment parameter values for those with glaucoma
Description Mean value Source/note
Reduction in risk of progression from 
any medical treatment (HR)
  Individuals with OHT  0.56 Maier 2005237
  Individuals with OAG  0.65 Maier 2005237
Proportion of OAG individuals 
receiving surgery for OAG
8.50% Burr 2009270
Proportion of successful surgeries 88% at 1 year and 
79% at 4 years
Burr 2009.270 Note: based on expert opinion the failure rates were assumed to be 
equal to the proportions of surgical patients subsequently in need of argon laser 
trabeculoplasty© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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PGA and combination therapy. The cost for OAG surgery was obtained from NHS reference costs 
2008–9275 (e.g. HRG BZ18Z).
Health state utilities and benefit valuations
Health state utilities
The main objective of the economic evaluation was to inform decision-making in the UK. 
Current guidelines advocate the use of a quality-adjusted measure of health status utility obtained 
from the general population. Therefore, data were sought on health state valuation obtained 
using the EQ-5D valued using UK population tariffs,276 or something similar (e.g. Short Form 
questionnaire-6 Dimensions).
Previous research by members of the study team used the EQ-5D to value quality of life states 
for those with mild, moderate or severe OAG and visual impairment and these data were used 
in the model to value the time spent in these health states. The EQ-5D data obtained from 255 
OAG individuals from Leeds and Aberdeen as well as members of the International Glaucoma 
Association were used.277 As the degree of visual impairment with mild OAG is minimal, it was 
assumed that the score for those with OHT would be the same as the score for those with mild 
OAG. This value is comparable to the mean age group population EQ-5D score276 that would be 
estimated for the model-simulated cohort age group. Table 47 shows the utility weights used in 
the model.
Monetary values for cost–benefit analysis (willingness to pay)
As an alternative to estimating benefits in terms of QALYs derived from the EQ-5D scores, 
the WTP values obtained from the DCE reported in detail in Chapter 7 were used. The WTP 
estimates per unit change of a specific outcome (see Table 30 in Chapter 7) compared with a 
situation described in the DCE as ‘no surveillance’ were used as weights within the model.
A ‘no surveillance’ strategy implies that individuals could be opportunistically diagnosed 
with OAG and eventually treated. However, within the DCE (see Chapter 7) it was assumed 
that there were no unwanted effects of treatment in a ‘no surveillance’ strategy. This level of 
service was not considered a relevant option to formally compare within the economic model 
because of the absence of any form of surveillance, although it has been used as a baseline 
against which the total WTP for the other treatments was estimated and facilitated the indirect 
comparison between the pathways formally compared within the model. It was believed that 
the cost of opportunistic case finding should be close to that of the ‘treat all’ pathway as these 
two approaches assume that a minimum level of health care is provided. Therefore, we assumed 
a cost for a ‘no surveillance’ strategy equal to 80% of the cost of the ‘treat all’ pathway as an 
approximation of the costs of opportunistic case finding. Hence, in order to complete the 
TABLE 45  Costs of surveillance visits
Description Mean cost (£) Source/note
Secondary-care based
IOP measurement only 90 Information Services Division Scotland 2010 (Table R044X Speciality group costs for 
consultant – ophthalmology – outpatients)272
Full assessment 180 Information Services Division Scotland 2010 (Table R044X Speciality group costs for 
consultant – ophthalmology – outpatients)272
Primary-care based
IOP measurement only 10.35 Assumption
Full assessment 20.7 Department of Health (General Ophthalmic Services: NHS sight test fee)273134 Economic evaluation
cost–benefit analysis results, the costs of each surveillance pathway compared within the model 
were reduced by a value equal to 80% of the cost of the ‘treat all’ pathway.
The DCE included seven attributes; six of these had four levels and one had two levels (see 
Table 26 for details). Some levels defined in the DCE were merged to facilitate the incorporation 
of the DCE results into the economic evaluation model. The first situation where this occurred 
was when two levels within the unwanted treatment effects (i.e. ‘some’ and ‘quite a lot’) were 
collapsed into a single level. The rationale underpinning this was that the data obtained from 
the literature on the proportion of individuals suffering unwanted effects of treatment did not 
distinguish between ‘some’ unwanted treatment effects and ‘quite a lot’ of unwanted treatment 
effects. A second situation where this occurred was when two levels within the communication 
and understanding attribute (‘felt at ease but did not understand’ and ‘did not feel at ease but 
understood’) were collapsed into one level. This decision was made to simplify the analysis 
and also because there was little evidence to suggest that preferences for these two levels were 
different (this is illustrated by the overlap in the CIs surrounding the WTP values for these two 
levels – see Chapter 7, Table 30). Table 48 shows the marginal WTP for the considered attributes 
together with the 95% CIs. The 95% CI data were used to produce distributions around the point 
estimates of marginal WTP. It was assumed that a normal distribution would be most appropriate 
to define the variance surrounding the mean value as distributions of this form are assumed by 
the econometric methods used to analyse the DCE data.
The WTP values in Table 48 were obtained by asking how much individuals in the DCE 
survey would be willing to pay per year for a surveillance programme with alternative sets 
of characteristics. Therefore, these values are WTP amounts per year that the individuals are 
under surveillance.
To estimate the mean WTP to avoid unwanted effects of treatments for each surveillance 
pathway, the proportion of the 10,000 cohort who developed unwanted effects of treatment 
(obtained from the literature) was combined with the WTP to avoid this event. It was assumed 
TABLE 46  Costs of medical and surgical treatments
Description Mean cost (£) Source/note
BB (£ per year of 
treatment)
18.72 BNF 2011,274 based on non-proprietary timolol, 0.5%, 5 ml = £1.56. Assumed one bottle per 
month
PGAs (£ per year of 
treatment)
149.76 BNF 2011,274 based on Xalatan, 2.5 ml = £12.48. Assumed one bottle per month
PGAs + BB (£ per year of 
treatment)
171.84 BNF 2011,274 based on Xalacom, 2.5 ml = £14.32. Assumed one bottle per month
Surgery for OAG 1479 NHS reference costs 2008–9 275 (HRG BZ18Z)
TABLE 47  European Quality of Life-5 Dimensions utility weights used in the model
Description Mean score Source/note
Individuals with OHT  0.8015 Assumed equal to OAG mild individuals
Individuals with mild OAG  0.8015 Burr 2007277
Individuals with moderate OAG  0.7471 Burr 2007277
Individuals with severe OAG  0.7133 Burr 2007277
Visually impaired individuals with OAG  0.535 Burr 2007277© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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that the unwanted effects of treatment would last for the period of time between the last and the 
current surveillance visits.
We used the reference category level (‘did not feel at ease and did not understand’) for the 
communication and understanding attribute to define the level of this attribute associated with 
the NICE guidelines-based pathways. This was based on the assumption that the hospital eye 
service does not communicate well with patients (because of, for instance, lack of time given 
that they are working in excess of their capacity). Similarly, we used ‘felt at ease but did not 
understand’ or ‘did not feel at ease but understood’ to define the level of communication and 
understanding associated with the SOH and ‘treat all’ pathways. Finally, as each surveillance 
strategy took place in a predefined setting (e.g. the community or in hospital), the mean WTP for 
each pathway with respect to location of care was either the positive (+£1.05 for surveillance in 
hospital) or the negative (–£1.05 for surveillance in the community) of the mean value reported 
in Table 48 for a unit change in this attribute.
In the DCE reference case no surveillance and no treatment were assumed unless cases were 
found opportunistically. From the model the estimated number of individuals who converted to 
OAG in 20 years and the numbers who progressed to severe OAG and visual impairment were 
obtained. The differences between the model estimates and the numbers of cases in the DCE 
reference case (e.g. 3200, 360 and 50 for the numbers of individuals who converted to OAG and 
progressed to severe OAG and visual impairment, respectively) were calculated. These were 
multiplied by the cumulative WTP for the number of years under surveillance (e.g. assumed to 
be 10 years on average) to obtain the total benefits resulting from the numbers of avoided cases 
of OAG, severe OAG and visual impairment. Furthermore, for final net benefit calculations we 
assumed, as described above, that the average cost for the DCE reference case was equal to 80% 
of the cost for the ‘treat all’ pathway. This was deducted from the average cost for each pathway 
(see Table 52).
Model calibration and validation
In the development of any simulation model, care should be taken throughout the process so 
that credible and eventually useful results are produced. Parts of the development process are the 
TABLE 48  Marginal WTP for alternative surveillance programme attributes
Attribute Marginal WTP (£) 95% CI
Alternative specific constant (reference: no surveillance) 28.31 19.61 to 36.35
10-year risk of
Conversion to OAG of individuals with OHT –0.03 –0.04 to –0.03
Progressing to severe OAG for OHT individuals –0.06 –0.09 to –0.04
Becoming visually impaired for OHT individuals –0.50 –0.74 to –0.29
Unwanted treatment effects (reference: none):
Some or quite a lot –24.40 –28.61 to –21.00
Severe –60.05 –69.19 to –52.17
Communication and understanding (reference: did not feel at ease and did not understand)
Felt at ease and understood 46.42 39.95 to 53.71
Felt at ease but did not understand or did not feel at ease but understood 26.87 23.16 to 31.24
Hospital setting (reference: community) 1.05 –0.90 to 3.10136 Economic evaluation
verification, validation and eventually calibration of the model. Verification of the model refers 
to the steps taken to ensure that the model of an individual’s pathway, as well as all mathematical 
calculations that govern the journey through the model, are correct. Model validation refers to 
the actions taken to verify that the model fits with empirical data. If the model predictions do 
not appear to tally with the available empirical data, calibration is needed (i.e. change of model 
parameter values in order to correct these discrepancies).
To calibrate the model we first simulated individual characteristics for a population of 1000 
people at the point at which they enter into the model. The data produced were then presented 
to the project management group and clinical experts and interpreted alongside data from the 
literature to form a judgement as to whether they had face validity. We did this by comparing the 
model simulated values with those of the Rotterdam data set (see Table 5).
Data analysis
The model compared alternative surveillance regimes by simulating for each pathway the cost 
per individual, clinical outcomes (e.g. number of individuals converted to OAG, number of 
individuals who progressed to moderate OAG, severe OAG and visual impairment), mean 
QALYs (e.g. EQ-5D-based QALYs) and mean WTP (e.g. monetary measure of benefits) for 
10,000 individuals with OHT. A cohort of this size was chosen to enable the variation that would 
be expected between individuals to be represented in the estimates of costs and outcomes. Within 
the base-case analysis we adopted an NHS perspective and discounted costs and QALYs at the 
recommended 3.5% discount rate. WTP estimates were not discounted in the base-case analysis 
as these data implicitly included the respondents’ rates of time preference as respondents to the 
DCE were asked to consider trade-offs between short- and long-term outcomes. The model itself 
estimated costs and outcomes over a 20-year time horizon and all monetary values are expressed 
in 2009/10 prices.
From the data produced by the model for each surveillance pathway the following comparative 
results between surveillance pathways were estimated:
  ■ incremental cost per number of OAG cases avoided, and incremental cost per case of each 
level of severity of OAG avoided
  ■ incremental cost per QALY gained and
  ■ incremental net benefit.
We addressed uncertainty by conducting deterministic (e.g. one-way) sensitivity analyses. The 
following sensitivity analyses were considered.
Changes to the 5-year risk of conversion
Based on a 13-year follow-up of the participants in the OHTS study,61 the cumulative proportion 
of participants developing OAG, categorised into tertiles according to their baseline risk,64 
was < 6%, 6–13% and > 13%, respectively.13 The benefit of treatment was most evident among 
participants at a higher baseline risk. We thus defined 6% as the threshold at which to start 
treatment for the base-case analysis. We increased this threshold to 40% to explore the effects of 
treating only a very high-risk group.
Within the base case individuals would enter the model if they were diagnosed with OHT 
(defined as an IOP level > 21 mmHg). In a further sensitivity analysis, individuals would enter the 
model if their 5-year risk of conversion was equal to or above a stated threshold (e.g. from 6% up 
to 50%). The intuition behind this was that, for individuals with higher levels of risk, monitoring 
pathways could become cost-effective compared with a minimal level of care ‘treat all’ pathway or 
a no formal monitoring pathway.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Changes to the unit price of prostaglandin analogue
In the near future the patents for the PGAs will expire, which will allow the entry of 
manufacturers of generic versions of the drug to enter the market. This will drive the price of 
PGAs down, although at this stage it is unclear by how much. To address this uncertainty we ran 
the model (1) when the unit price of the PGA was 50% of the value used in the base-case analysis 
and (2) making the unit price equal to the unit price of a BB used in the base-case analysis.
Changes to the unit price of monitoring visits
Follow-up visits are potentially the main resource use within this model. Further sensitivity 
analyses were undertaken using the NHS reference costs data for 2009–10275 as a way of exploring 
alternative values for unit costs for follow-up visits. Unit costs for consultant-led and non-
consultant-led follow-up attendance were used for full assessment and IOP measurement only 
visits, respectively (code 130). Three sensitivity analyses were run using these national average 
figures. These were:
1.  using £73 and £51 for full assessment and IOP measurement only visits, respectively, as 
opposed to £180 and £90 in the base-case analysis
2.  using the lower estimated value from the IQR of £61 for full assessment and £32 for IOP 
measurement only visits
3.  using the upper estimated value from the IQR of £83 for full assessment and £68 for IOP 
measurement only visits.
It should be noted that the base-case analysis assumption of a longer time needed to perform a 
full assessment (i.e. twice that of a normal visit) was dropped for these sensitivity analyses. We 
tested this assumption by conducting an additional one-way sensitivity analysis on the unit cost 
of IOP measurement only visits. This involved maintaining the unit cost of full assessment at 
£180 (the same as for the base-case analysis) but varying the cost of IOP measurement only visits 
within the range of £51–68 per visit.
Scenario analysis
Given the base-case analysis results we actively identified specific situations in which conclusions 
might change. Therefore, we looked for those variable values that would favour monitoring, 
particularly monitoring with the ‘SOH hospital’ pathway, which appeared to have the greatest 
possibility of being cost-effective compared with a ‘treat all’ pathway in terms of average costs 
and QALYs. The values for some variables could eventually favour the ‘treat all’ pathway much 
more so than the monitoring pathways. For instance, a very much higher rate of conversion 
and progression would eventually favour a ‘treat all’ pathway; more individuals would benefit 
from the PGAs that are initially prescribed to everyone with this pathway. However, we 
identified a group of variables that unequivocally favour ‘SOH hospital’ monitoring. These were 
adherence with treatment (higher for ‘SOH hospital’, lower for ‘treat all’ compared with the 
base case), higher precision of IOP measurement with GAT, lower precision for non-GAT IOP 
measurements in the community and lower accuracy for testing for OAG in the community. 
Table 49 reports the figures used in this scenario analysis. The analysis is reported for alternative 
values of risk at which these individuals would initiate treatment within the SOH pathways.
The model was computationally too demanding (e.g. around 10 minutes for 10,000 individual 
runs). Consistency between 10,000 and 1000 individual runs was high for the base-case 
cost–utility analysis results. Therefore, all sensitivity analyses were conducted for 1000 ocular 
hypertensive individuals and reported on cost–utility analysis results only.138 Economic evaluation
Further one-way sensitivity analyses
To further explore results from the scenario analysis, further one-way sensitivity analyses were 
conducted, particularly on the adherence to treatment rates for non-monitoring and monitoring 
pathways. Starting from the base-case analysis, we conducted a threshold analysis to identify 
values for the adherence rates which could result in estimates of the incremental cost per QALY 
that society might find acceptable.
Results
Model calibration
The simulated individual characteristics for a population of 10,000 ocular hypertensive 
individuals at model entry are described in Table 50.
We consulted the project management group and clinical experts about whether or not these 
data had face validity. It was agreed that, in comparison with available data detailed in Table 5 
(the Rotterdam and Moorfields data sets), these estimates were appropriate; in Table 5 the mean 
age ranged from 56 to 64 years, while IOP ranged from 21 to 25 mmHg for those without OAG. 
Similar assessments can be drawn for CCT, VCD ratio and PSD. Finally, the predicted average 
5-year risk of conversion for the (untreated) simulated individual group was 10%.
Estimates of effectiveness and mean cost per pathway
Table 51 shows the discounted cost and effectiveness analysis results. Effectiveness of SOH 
was expressed in several different ways: the number of individuals who converted to OHT; 
the number of individuals who progressed to moderate or severe OAG; and the number who 
progressed to visual impairment. Although not a prespecified form of analysis, the presentation 
of cost and clinical effect data for each pathway is equivalent to presenting the analysis as a cost–
consequence analysis.
Of the 10,000 OHT individuals entered into each surveillance pathway, 2073 individuals 
were estimated to have converted to OAG over the 20-year time horizon of the model for the 
‘SOH hospital’ pathway, while 2060 and 2079 converted for the ‘NICE intensive’ and ‘NICE 
conservative’ pathways, respectively. For the ‘SOH primary care’ pathway 2114 individuals 
converted to OAG and for the ‘treat all’ pathway 2282 individuals converted.
In terms of progression to moderate OAG, the worst-performing pathway was the ‘treat all’ 
pathway (1708 people progressed to moderate OAG), whereas the best performing was the ‘NICE 
intensive’ pathway (1507 progressed). A total of 336 individuals in the ‘NICE intensive’ pathway 
TABLE 49  Scenario analysis: extreme plausible values
Variable Base case Scenario analysis Source
Time of progression from OAG conversion to OAG moderate 4 2 Assumption
Time of progression from OAG moderate to OAG severe 9 4.5 Assumption
Time of progression from OAG severe to visual impairment 10 5 Assumption
Test performance
Community OAG diagnosis sensitivity 0.76 0.32 Azuara-Blanco 2007269
Community OAG diagnosis specificity 0.93 0.96 Azuara-Blanco 2007269
Proportion of individuals adhering to treatment
NICE and SOH monitoring pathways 0.75 0.95
‘Treat all’ pathway 0.5 0.2© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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progressed to severe OAG. The corresponding figures were 343 for the ‘SOH hospital’, 365 for 
the ‘SOH primary care’, 349 for the ‘NICE conservative’ and 468 for the ‘treat all’ pathways. No 
individuals progressed to visual impairment under any of the pathways, primarily because of the 
relatively short (20-year) time horizon of the model and the relatively long lead time it would take 
an individual to develop disease of this level of severity (on average 9 years for progression from 
moderate to severe OAG and 10 years for progression from severe OAG to visual impairment 
respectively). The pathway with the lowest total average cost was the ‘treat all’ pathway (£3393), 
and the most costly pathway was the ‘NICE intensive’ pathway (£6862).
Incremental cost-effectiveness
Table 51 details the incremental cost-effectiveness ratios (ICERs) for the cost–consequences 
outcomes. As the data presented in this table illustrate, a judgement about which pathway is 
most cost-effective is dependent on which single measure of effectiveness (e.g. progression, cases 
of moderate or severe OAG) is believed most important as well as how much society would 
be willing to pay for that particular extra unit of effectiveness. Overall, the ‘SOH primary care’ 
pathway is dominated by the ‘SOH hospital’ pathway. Moreover, the ‘NICE conservative’ pathway 
is dominated if cases of conversion to OAG or progression to severe OAG are used as measures 
of effectiveness. The decision on which pathway to adopt depends on society’s WTP to avoid a 
case of OAG, moderate OAG or severe OAG. If society were willing to pay > £3 (and < £224) for 
an additional case of OAG avoided, then the ‘SOH hospital’ pathway should be adopted. Should 
avoidance of moderate or severe OAG be the sole measure of effectiveness relevant to a decision-
maker then the ‘SOH hospital’ pathway would be considered cost-effective should society be 
willing to pay > £3 or > £4 per additional case avoided of moderate and severe OAG, respectively. 
However, the ‘NICE intensive’ pathway might be selected if WTP were > £224, > £85 or > £415 per 
additional case avoided of OAG or moderate or severe OAG, respectively.
TABLE 50  Descriptive statistics for simulated individual characteristics at the start of the model: ocular hypertensive 
individuals (n = 10,000)
Variable
Age 
(years)
IOP at start 
(mmHg)
Untreated IOP at year 5 
(mmHg) CCT (µm)
PSD 
(dB) VCD ratio
5-year risk of 
conversion (units)
Mean (SD) 57 (9.8) 24.9 (2.4) 25.1 (5.4) 574.5 
(31.7)
1.8 
(0.3)
0.4 (0.2) 0.1 (0.1)
Median 
(IQR)
57.1 
(13.2)
24.6 (3.3) 24.6 (6.4) 574.2 
(42.3)
1.8 
(0.4)
0.4 (0.2) 0.1 (0.1)
TABLE 51  Cost-effectiveness analysis results (discounted)
Pathway
Average 
total 
cost (£)
Incremental 
cost (£)
Number of individuals ICER (£)
Converted 
to OAG
Progressed 
to moderate 
OAG
Progressed to 
severe OAG
Converted 
to OAG
Progressed 
to moderate 
OAG
Progressed to 
severe OAG
Treat all 3393 2282 1708 468    
SOH hospital 3956 562 2073 1536 343 3 3 4
SOH primary care 4696 740 2114 1545 365 Dominated Dominated Dominated
NICE conservative 5087 1131 2079 1528 349 Dominated 141 Dominated
NICE intensive 6862 1776 2060 1507 336 224 85 415
ICER, incremental cost-effectiveness ratio.
Dominated = more costly and less effective than another alternative.140 Economic evaluation
Cost–utility analysis
The advantage of cost–utility analysis over cost-effectiveness analysis is that multiple dimensions 
of clinical effectiveness can be combined into a single unitary measure, the QALY. Table 52 shows 
the cost–utility results when both costs and QALYs are discounted at 3.5%. In the cost–utility 
analysis the costs are identical to those reported in Table 51. Given the modest number of 
individuals out of the cohort of 10,000 OHT individuals who progress to any stage of OAG the 
differences in QALYs are relatively small. Both NICE pathways as well as the ‘SOH primary 
care’ pathway are dominated (are more costly and produce less QALYs) by the ‘SOH hospital’ 
pathway. The ‘SOH hospital’ pathway is more costly and provides more QALYs than the ‘treat all’ 
pathway; however, the ICER is well above the usual threshold of WTP for a QALY adopted by 
NICE (i.e. £30,000).21
Cost–benefit analysis
Table 53 shows the results of the cost–benefit analysis. As noted above a hypothetical reference 
pathway was defined (which in the DCE was called ‘no surveillance’). This reference case is 
relevant as estimates of cost and WTP derived from the DCE are relative to this reference case. 
For the hypothetical reference case 3200 individuals out of a cohort of 10,000 would develop 
OAG, while another 360 and 50 out of a cohort of 10,000 would progress to severe OAG and 
visual impairment, respectively, over a time horizon of 20 years (the time horizon used in the 
DCE – see Chapter 7). Differences between the numbers of cases within the model pathways and 
the reference case were used when calculating average total benefits.
The SOH pathways provided on average £600 more benefits than the NICE-based pathways. This 
can be explained by the added value generated by the better communication and understanding 
assumed within the SOH pathways.
The average total benefits for every pathway except the ‘SOH hospital’ pathway were less than 
the average costs. Hence, the net benefits for all of the pathways except for the ‘SOH hospital’ 
TABLE 52  Cost–utility analysis results (discounted)
Pathway
Average total  
cost (£)
Incremental  
cost (£) Average total QALYs Incremental QALYs ICER (£)
Treat all 3393 9.7866
SOH hospital 3956 562 9.7932 0.0066 85,312
SOH primary care 4696 740 9.7920 Dominated Dominated
NICE conservative 5087 391 9.7923 Dominated Dominated
NICE intensive 6862 1776 9.7931 Dominated Dominated
Dominated = more costly and less effective than another alternative.
TABLE 53  Cost–benefit analysis results (discounted)
Pathway Average total cost (£) Average total benefits (£) Average net benefit (£)
Treat all 679 564 –114
SOH hospital 1241 1693 452
SOH primary care 1981 1484 –498
NICE conservative 2372 1051 –1321
NICE intensive 4148 1099 –3049© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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pathway were negative. This indicates that compared with a ‘no surveillance pathway’ these 
surveillance pathways would not be regarded as being worthwhile. The only pathway that has 
a positive net benefit was the ‘SOH hospital’ pathway, indicating that this pathway would be 
considered worthwhile compared with the reference case. The main driver of these results is the 
very low valuation put on prevention of OAG and subsequent progression coupled with the low 
rates of OAG observed.
Sensitivity analyses
We ran a number of sensitivity analyses. For all of these analyses the model would report 
outcomes in clinical (e.g. number of cases of OAG), utility (e.g. QALYs) and monetary (e.g. 
British pounds) units; however, for the sake of simplicity we focus only on the cost–utility 
analysis results.
Table 54 reports the results for the one-way sensitivity analysis for the risk threshold at which 
the decision to initiate treatment would be made within the SOH pathways. This threshold value 
was 6% for the base-case analysis (i.e. we would treat only if the risk of converting over 5 years 
was ≥ 6%). Table 53 shows the results for the cost–utility analysis when the risk threshold that 
triggered treatment was increased to 50%. ‘Treat all’ was the pathway with the lowest mean 
cost when the risk threshold values were ≤ 10%. When the risk threshold was between 10% and 
15% the ‘SOH hospital’ pathway becomes the pathway with the lowest average cost and because 
it provides greater QALYs it dominates the ‘treat all’ pathway. However, over the range of risk 
thresholds considered none of the other pathways had an incremental cost per QALY that 
approached £30,000.21
In the base-case analysis individuals would enter the model if they had OHT (i.e. IOP 
> 21mmHg.). We ran a sensitivity analysis in which individuals would enter the model if they 
were ocular hypertensive but also if their 5-year risk of conversion was higher than a particular 
threshold (e.g. from 6% to 50%). This sensitivity analysis showed similar results to those reported 
in the base-case analysis (data not shown). In these analyses, SOH pathways dominated NICE-
based pathways but, although the SOH pathways were more effective than the ‘treat all’ pathway, 
they were also more costly and the ICERs were well above the usual threshold considered 
by NICE.21
Sensitivity analysis was also conducted on the unit price of PGAs and combination therapy (data 
not shown). As expected, as only unit price changed, no effect was observed on QALYs for any 
of the pathways. However, average costs for all pathways fell but proportionally more in those 
that used PGAs more intensively (e.g. the ‘treat all’ pathway). Therefore, none of the more costly 
pathways was associated with an incremental cost per QALY approaching £30,000.21
Further sensitivity analysis was conducted for the unit price of follow-up visits. For the base-case 
analysis it was assumed that a full assessment visit would take twice the time of a normal visit. 
This assumption was dropped for the sensitivity analysis and this partially explains the lower unit 
costs used. When using the national average costs (i.e. unit cost of £73 and £51 for full assessment 
and IOP measurement only visit, respectively) the ‘treat all’ pathway was the lowest cost pathway 
followed by the ‘SOH hospital’ pathway (Table 55). The ICER in this case was £10,857 while all 
other pathways were dominated by the ‘SOH hospital’ pathway. Using the lower value from the 
IQR from the NHS reference costs (i.e. £61 and £32 for full assessment and IOP measurement 
only visits, respectively) resulted in the ‘SOH hospital’ pathway dominating all others (data not 
shown). Finally, when using the upper value from the IQR (i.e. £83 and £68, respectively) the 
‘treat all’ pathway had the lowest average cost followed by the more effective ‘SOH hospital’ 142 Economic evaluation
TABLE 54  Treatment risk threshold: one-way sensitivity analysis
Treatment risk 
threshold Pathway
Average total cost 
(discounted) (£)
Average total QALYs 
(discounted) ICER (£)
6% Treat all 3412 9.7757
SOH hospital 3974 9.7828 78,911
SOH primary care 4555 9.7826 Dominated
NICE conservative 5156 9.7813 Dominated
NICE intensive 6879 9.7828 Dominated
8% Treat all 3412 9.7757
SOH hospital 3811 9.7813 71,704
SOH primary care 4401 9.7808 Dominated
NICE conservative 5156 9.7813 21,722,687
NICE intensive 6879 9.7828 1,175,663
10% Treat all 3412 9.7757
SOH hospital 3631 9.7812 39,701
SOH primary care 4379 9.7807 Dominated
NICE conservative 5156 9.7813 15,022,678
NICE intensive 6879 9.7828 1,175,663
15% SOH hospital 3311 9.7805
Treat all 3412 9.7757 Dominated
SOH primary care 4118 9.7802 Dominated
NICE conservative 5156 9.7813 2,213,752
NICE intensive 6879 9.7828 1,175,663
20% SOH hospital 3183 9.7805
Treat all 3412 9.7757 Dominated
SOH primary care 3956 9.7803 Dominated
NICE conservative 5156 9.7813 2,445,687
NICE intensive 6879 9.7828 1,175,663
25% SOH hospital 3158 9.7793
Treat all 3412 9.7757 Dominated
SOH primary care 3888 9.7795 3,565,397
NICE conservative 5156 9.7813 677,141
NICE intensive 6879 9.7828 1,175,663
30% SOH hospital 3122 9.7789
Treat all 3412 9.7757 Dominated
SOH primary care 3885 9.7799 753,380
NICE conservative 5156 9.7813 890,088
NICE intensive 6879 9.7828 1,175,663
35% SOH hospital 3117 9.7782
Treat all 3412 9.7757 Dominated
SOH primary care 3915 9.7795 606,993
NICE conservative 5156 9.7813 693,262
NICE intensive 6879 9.7828 1,175,663
40%  SOH hospital 3063 9.7793
Treat all 3412 9.7757 Dominated
SOH primary care 3988 9.7791 Dominated
NICE conservative 5156 9.7813 1,045,106
NICE intensive 6879 9.7828 1,175,663
50% SOH hospital 3071 9.7787
Treat all 3412 9.7757 Dominated
SOH primary care 3954 9.7797 871,101
NICE conservative 5156 9.7813 746,284
NICE intensive 6879 9.7828 1,175,663© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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pathway (ICER for ‘SOH hospital’ pathway vs ‘treat all’ pathway was £40,332 – data not shown). 
All other pathways were dominated by the ‘SOH hospital’ pathway.
One-way sensitivity analysis shows that the results were not sensitive to the unit price of full 
assessment visits but were to the unit price of IOP measurement only visits. Table 56 presents 
the cost–utility analysis results when the unit cost for full assessment visits was maintained at 
£180 as for the base-case analysis, but alternative values were used for the unit cost for hospital-
based IOP measurement only visits. The £180 cost for the full assessment visit assumed that 
the time for a full assessment was twice that needed for a normal ophthalmological follow-up 
visit. Comparison between Tables 55 and 56 show that increasing the unit cost from £73 to £180 
has a small impact on the incremental cost per QALY between the ‘SOH hospital’ and the ‘treat 
all’ pathways (i.e. it increases from £10,857 to £11,410). However, varying the unit cost for IOP 
measurement only visits has a larger impact on the results, namely, the incremental cost per 
QALY between the ‘SOH hospital’ and the ‘treat all’ pathways increases to > £30,000 when the 
unit price for an IOP measurement only visit is between £61 and £62. The incremental cost per 
QALY reaches £40,834 when the unit cost for a hospital-based IOP measurement only visit is £68.
Table 57 gives details of the scenario analysis results for alternative values of 5-year risk threshold 
at which individuals initiate treatment within the SOH pathways. As this risk threshold is used 
only within the SOH pathways, the values for mean cost and mean QALYs for the other pathways 
do not change. Furthermore, the higher the risk threshold, the lower the mean cost and QALYs 
associated with the SOH pathways. The NICE-based pathways either are dominated or have an 
incremental cost per QALY well above the £30,000 threshold.21
For the stated variable values (see Table 49) and a 6% risk threshold (i.e. base-case level) the 
‘SOH hospital’ pathway has the lowest mean cost followed by the ‘treat all’ pathway. The next 
most costly pathways are ‘SOH primary care’, ‘NICE conservative’ and ‘NICE intensive’. The ‘SOH 
hospital’ pathway would give additional QALYs at a slightly lower cost and therefore dominates 
the ‘treat all’ pathway. Moreover, at a 10% risk threshold ‘SOH primary care’ dominates the 
‘treat all’ pathway. However, even at a risk threshold of up to 50% the incremental cost per 
QALY for the comparison between the ‘SOH primary care’ and ‘SOH hospital’ pathways is well 
above £30,000.21
Tables 58 and 59 report the findings from the one-way sensitivity analysis on the adherence rate 
for the ‘treat all’ and monitoring pathways, respectively. For the base-case analysis, adherence to 
treatment rates was assumed to be 50% for the ‘treat all’ pathway and 75% for the NICE or SOH 
monitoring pathways. When adherence to treatment decreases for the ‘treat all’ pathway, the cost-
effectiveness of the ‘SOH hospital’ pathway improves. For adherence rates < 40% the incremental 
cost per QALY for the SOH pathway compared with the ‘treat all’ approaches £30,000. The 
incremental cost per QALY falls below £30,000 when the adherence rate drops towards 30%.
Similarly, when the adherence rate to treatment within the monitoring pathways rises, the cost-
effectiveness of these pathways improves because the average cost for each falls and the QALYs 
increase. At an adherence rate to treatment just below 90% the incremental cost per QALY for the 
‘SOH hospital’ pathway compared with the ‘treat all’ pathway will be approximately £30,000.
In summary, differences in adherence rates between the ‘treat all’ and the SOH pathways of 
approximately ≥ 40% will result in the SOH pathway having an incremental cost per QALY of 
≤ £30,000.21144 Economic evaluation
TABLE 55  Sensitivity analysis on costs: cost–utility analysis results (discounted)
Strategy Average total cost (£) Incremental cost (£) Average total QALYs Incremental QALYs ICER (£)
Treat all 2736 9.7757
SOH hospital 2814 77 9.7828 0.0071 10,857
NICE conservative 3120 306 9.7813 Dominated Dominated
SOH primary care 3180 60 9.7826 Dominated Dominated
NICE intensive 3861 680 9.7828 Dominated Dominated
Unit costs: full assessment visits = £73; IOP only visits = £51.
Dominated = more costly and less effective than another alternative.
TABLE 56  One-way sensitivity analysis on unit cost of IOP measurement only visits: cost–utility analysis results 
(discounted)
Unit cost of IOP 
measurement only visits (£) Strategy
Average total 
cost (£)
Incremental 
cost (£)
Average total 
QALYs
Incremental 
QALYs ICER (£)
51 Treat all 3188 9.7757
SOH hospital 3270 81 9.7828 0.0071 11,410
SOH primary care 3856 586 9.7826 Dominated Dominated
NICE conservative 4381 526 9.7813 Dominated Dominated
NICE intensive 6075 1694 9.7828 Dominated Dominated
55  Treat all 3211   9.7757    
SOH hospital 3342 131 9.7828 0.0071 18,333
SOH primary care 3927 586 9.7826 Dominated dominated
NICE conservative 4461 533 9.7813 Dominated Dominated
NICE intensive 6158 1697 9.7828 Dominated Dominated
60  Treat all 3240   9.7757    
SOH hospital 3432 192 9.7828 0.0071 26,987
SOH primary care 4017 585 9.7826 Dominated Dominated
NICE conservative 4560 543 9.7813 Dominated Dominated
NICE intensive 6261 1701 9.7828 Dominated Dominated
61 Treat all 3246 9.7757
SOH hospital 3450 205 9.7828 0.0071 28,718
SOH primary care 4035 585 9.7826 Dominated Dominated
NICE conservative 4580 545 9.7813 Dominated Dominated
NICE intensive 6281 1701 9.7828 Dominated Dominated
62  Treat all 3251   9.7757    
SOH hospital 3468 217 9.7828 0.0071 30,449
SOH primary care 4053 584 9.7826 Dominated Dominated
NICE conservative 4600 547 9.7813 Dominated Dominated
NICE intensive 6302 1702 9.7828 Dominated Dominated
65 Treat all 3269 9.7757
SOH hospital 3523 254 9.7828 0.0071 35,641
SOH primary care 4107 584 9.7826 Dominated Dominated
NICE conservative 4659 553 9.7813 Dominated Dominated
NICE intensive 6364 1704 9.7828 Dominated Dominated
68  Treat all 3286   9.7757    
SOH hospital 3577 291 9.7828 0.0071 40,834
SOH primary care 4160 584 9.7826 Dominated Dominated
NICE conservative 4719 559 9.7813 Dominated Dominated
NICE intensive 6426 1706 9.7828 Dominated Dominated© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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TABLE 57  Scenario analysis: extreme plausible values favouring monitoring
Treatment risk 
threshold Pathway
Average total cost 
(discounted) (£)
Average total QALYs 
(discounted) ICER (£)
6% SOH hospital 3556 9.7671  
Treat all 3642 9.7280 Dominated
SOH primary care 3774 9.7634 Dominated
NICE conservative 4691 9.7658 Dominated
NICE intensive 6506 9.7681 2,844,867
8% SOH hospital 3390 9.7651  
Treat all 3642 9.7280 Dominated
SOH primary care 3704 9.7659 420,454
NICE conservative 4691 9.7658 Dominated
NICE intensive 6506 9.7681 1,241,806
10% SOH hospital 3227 9.7631  
SOH primary care 3583 9.7649 207,454
Treat all 3642 9.7280 Dominated
NICE conservative 4691 9.7658 1,151,063
NICE intensive 6506 9.7681 794,299
15% SOH hospital 2924 9.7605  
SOH primary care 3293 9.7638 114,736
Treat all 3642 9.7280 Dominated
NICE conservative 4691 9.7658 678,076
NICE intensive 6506 9.7681 794,299
20% SOH hospital 2772 9.7595  
SOH primary care 3096 9.7637 77,533
Treat all 3642 9.7280 Dominated
NICE conservative 4691 9.7658 756,147
NICE intensive 6506 9.7681 794,299
25% SOH hospital 2720 9.7578  
SOH primary care 3010 9.7622 66,109
Treat all 3642 9.7280 Dominated
NICE conservative 4691 9.7658 458,465
NICE intensive 6506 9.7681 794,299
30% SOH hospital 2712 9.7569  
SOH primary care 3047 9.7608 84,955
Treat all 3642 9.7280 Dominated
NICE conservative 4691 9.7658 329,129
NICE intensive 6506 9.7681 794,299
35% SOH hospital 2669 9.7574  
SOH primary care 3104 9.7612 113,636
Treat all 3642 9.7280 Dominated
NICE conservative 4691 9.7658 344,544
NICE intensive 6506 9.7681 794,299
40% SOH hospital 2667 9.7568  
SOH primary care 3071 9.7610 97,413
Treat all 3642 9.7280 Dominated
NICE conservative 4691 9.7658 333,038
NICE intensive 6506 9.7681 794,299
50% SOH hospital 2662 9.7561
SOH primary care 3026 9.7606 81,022
Treat all 3642 9.7280 Dominated
NICE conservative 4691 9.7658 319,080
NICE intensive 6506 9.7681 794,299146 Economic evaluation
TABLE 58  One-way sensitivity analysis on the adherence rate for the non-monitoring pathway (‘treat all’)
Adherence 
rate Pathway Average total cost (discounted) (£) Average total QALYs (discounted) ICER (£)
50% Treat all 3412 9.7757  
SOH hospital 3974 9.7828 78,911
SOH primary care 4555 9.7826 Dominated
NICE conservative 5156 9.7813 Dominated
NICE intensive 6879 9.7828 Dominated
40% Treat all 3526 9.7725  
SOH hospital 3974 9.7828 43,153
SOH primary care 4555 9.7826 Dominated
NICE conservative 5156 9.7813 Dominated
NICE intensive 6879 9.7828 Dominated
30% Treat all 3635 9.7699  
SOH hospital 3974 9.7828 26,334
SOH primary care 4555 9.7826 Dominated
NICE conservative 5156 9.7813 Dominated
NICE intensive 6879 9.7828 Dominated
20% Treat all 3713 9.7670  
SOH hospital 3974 9.7828 16,455
SOH primary care 4555 9.7826 Dominated
NICE conservative 5156 9.7813 Dominated
NICE intensive 6879 9.7828 Dominated
TABLE 59  One-way sensitivity analysis on the adherence rate for the monitoring pathways
Adherence 
rate Pathway Average total cost (discounted) (£) Average total QALYs (discounted) ICER (£)
75% Treat all 3412 9.7757  
SOH hospital 3974 9.7828 78,911
SOH primary care 4555 9.7826 Dominated
NICE conservative 5156 9.7813 Dominated
NICE intensive 6879 9.7828 Dominated
80% Treat all 3412 9.7760  
SOH hospital 3886 9.7833 64,144
SOH primary care 4666 9.7829 Dominated
NICE conservative 5034 9.7832 Dominated
NICE intensive 6811 9.7845 2,504,296
90% Treat all 3412 9.7763  
SOH hospital 3715 9.7868 28,723
SOH primary care 4506 9.7865 Dominated
NICE conservative 4864 9.7863 Dominated
NICE intensive 6646 9.7879 2,678,852
95% Treat all 3412 9.7765  
SOH hospital 3635 9.7890 17,828
SOH primary care 4429 9.7887 Dominated
NICE conservative 4783 9.7878 Dominated
NICE intensive 6559 9.7897 3,739,358© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Discussion and summary
Key findings
No previous economic evaluation has reported a comparison of alternative surveillance pathways 
for surveillance of individuals with OHT from the perspective of the UK NHS. As a consequence, 
we developed an economic evaluation of alternative surveillance pathways.
The base-case cost-effectiveness analysis showed that the ‘SOH hospital’ pathway, 2-yearly 
monitoring to measure IOP and detect the onset of glaucoma (standard clinical assessment), was 
able to reduce the number of cases converting to OAG as well as avoid extra cases of progression 
to moderate and severe OAG compared with a ‘treat all’ pathway. However, the incremental 
cost per extra QALY (generated by those cases avoided) is far beyond the usual stated threshold 
of WTP for a QALY.21 For the cost–benefit analysis the ‘SOH hospital’ pathway was the only 
pathway relative to ‘no surveillance’ that had a positive net benefit. The main drivers of these 
results appeared to be the very low valuations put on avoiding disease, the low number of events 
occurring and the relatively high costs of surveillance.
Strengths and limitations
Because of a lack of existing information on relative efficiency relevant to the NHS, we developed 
an economic evaluation of alternative pathways that was based on a discrete event simulation 
model. This approach enabled the introduction of further disease and event complexities than 
those allowed by alternative modelling approaches such as decision tree models or Markov 
models. We incorporated into the economic model data obtained from rigorous systematic 
reviews268 as well as information retrieved and produced within this project, namely, we used the 
best available glaucoma risk prediction tool identified from a systematic review of alternative risk 
prediction tools (see Chapter 4) to generate the risk of conversion to OAG for OHT individuals, 
and data to inform the optimal frequency of surveillance came from the analysis of the signal-to-
noise ratio reported in Chapter 6.
A novel feature of this analysis was the conduct and comparison of different methods of 
economic evaluation. Overall, the results of the cost–utility and cost–benefit analyses are similar, 
with surveillance pathways that provide more benefits (QALYs or WTP) not being considered 
worth the extra cost. The main difference of note was that the ‘SOH hospital’ pathway is unlikely 
to be considered worthwhile when efficiency is measured in terms of incremental cost per 
QALY but may be when efficiency is measured in terms of net benefits. This is mainly because 
of the value that society places on being monitored for a particular condition as well as the 
value placed on obtaining better communication and understanding during the monitoring 
visits. It is a matter for judgement whether the cost per case of unit of clinical effectiveness 
avoided is worthwhile, but the data on clinical effects does allow policy-makers to question 
whether the methods used to weight different clinical or natural measures into QALYs or WTP 
are reasonable.
The results were sensitive to the rate of adherence to treatment assumed in the model. We 
conducted extensive searches for relevant data but could find little robust evidence. As a 
consequence, the values used within the model were based on the limited available evidence278–280 
and expert opinion. Should the rates of adherence to medical treatments differ between 
monitoring and non-monitoring pathways then it is possible that the incremental cost per QALY 
of a surveillance pathway (‘SOH hospital’) may fall to a value that society might find acceptable.261 
Further research in this area is thus warranted.
The results were also sensitive to the unit price of hospital-based IOP measurement only 
follow-up visits with an ICER for the ‘SOH hospital’ pathway compared with the ‘treat all’ 148 Economic evaluation
pathway of around £30,000 at a unit price of just over £61. This can be explained by the relatively 
high number of IOP measurement only visits within the monitoring pathways. In this economic 
model there are no restrictions to the number of subsequent times that the IOP can be measured 
as ‘off target’, and therefore the number of times that individuals could – depending on the 
pathway– return for an IOP check at 2 or 4 months. This could have led to an overestimation 
of the number of IOP visits in the model and a slight underestimation of the cost-effectiveness 
of the monitoring pathways. This could partially explain the sensitivity of the results to the unit 
cost of hospital-based IOP measurement only visits. In reality, clinicians will eventually find the 
adequate drop combination to control IOP. However, caution should be used when interpreting 
the results of this sensitivity analysis as the lower hospital-based visit unit costs might not fully 
account for the opportunity cost of the use of those resources (e.g. take into account the potential 
lack of capacity in hospital-based eye services).
The value of the different methods of surveillance in terms of their ability to prevent conversion 
to or progression of OAG is modest. This is because OAG is a chronic disease in which the 
majority of affected individuals progress slowly to stages at which vision is substantially affected. 
This slow progression together with the relatively short time horizon (20 years) considered in 
the base-case analysis resulted in no one progressing into the most severe stages of disease. 
Increasing the time horizon would allow many of those who had converted to OAG to progress 
to more severe disease (as well as allowing more people to develop OAG).
Coupled with this, the available data suggested that there was no difference in quality of life 
between individuals with OHT and those converted to OAG because in its early stages OAG is 
asymptomatic. As a consequence of this, the difference in QALYs between surveillance pathways 
is, on average, very small. Similarly, in the cost–benefit analysis, the mean WTP to avoid a single 
case of OAG was very modest (£0.03) and given the predicted low risk of developing OAG the net 
benefits of surveillance are, as a consequence, very small.
The incorporation of a DCE into an economic evaluation model is novel and there have been 
relatively few examples where this has been attempted in the past. Previous work281 attempted to 
incorporate an existing DCE into an economic model comparing alternative methods of surgery 
for inguinal hernia but as the DCE was not designed for incorporation into the economic model 
its incorporation placed restrictions on the model structure. For example, the DCE imposed a 
time horizon on the economic model that differed between attributes and was also insufficient 
to fully capture all of the differences in clinical effectiveness. A further study282 developed a DCE 
and economic model in conjunction but the model developed was a simple decision-analytic 
model. This modelling approach was appropriate to the context but is rarely appropriate to 
capture the complexity of decision problems more usually faced. In this study, the DCE has 
been explicitly designed to facilitate its incorporation into a far more complex form of model, a 
discrete event simulation, which to the best of our knowledge has never before been attempted. 
To do this represented a major challenge, and it was surprising how little respondents valued 
avoiding an extra case of OAG, severe OAG and visual impairment, especially given comments 
during initial piloting about how important avoiding OAG and its consequences were. One 
reason for this is that the respondents to the DCE were members of the general public and not 
those with OAG or OHT. It is possible that had the results of the DCE been restricted to these 
groups the valuations would have differed and hence the results of the cost–benefit analysis 
would have differed. Further research will be needed to explore this issue in more detail.
Care should be taken when interpreting the results of the cost–benefit analysis. The WTP values 
generated in Chapter 7 were derived from a DCE in which individuals were asked to choose 
between alternative arrangements compared to those as a result of the health-care status quo for 
a 10-year time horizon. We tried to adjust for this when calculating final net benefit figures for 
the alternative model pathways. The 10-year time horizon for the DCE was chosen before the © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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results of the discrete event simulation were available (and hence before predictions on rates of 
conversion and progression were estimated). This was due to the necessity of conducting the 
different elements of the project concurrently rather than consecutively.
NICE-based pathways were developed in this study as a way of representing current practice 
within the economic evaluation model. It has been argued that there is a lack of capacity within 
hospital eye services in the UK. We retrieved figures from the NHS Scotland Information 
Services Division to cost ophthalmology visits in the model. This might be an underestimation of 
the true ‘opportunity’ costs of these visits. The opportunity cost in this case would be given by the 
benefits foregone as a result of other conditions or diseases not being attended to at the hospital 
level. If there is a lack of capacity in UK hospital eye services then hospital-based pathways will 
not be feasible and only the ‘treat all’ and ‘SOH primary care’ pathways would be viable.
We used the risk prediction tool from Chapter 4 to model the underlying condition of the 
sampled individuals in the model. We used this same tool to assess the risk of conversion within 
the SOH pathways. This helps explain the better performance of the SOH pathways compared 
with the NICE-based pathways. However, this is the best available information we have to assess 
OHT individuals at risk of developing OAG.
Finally, because the discrete event simulation model was computationally demanding we could 
not run probabilistic sensitivity analyses and therefore we did not obtain the value of information 
for further research. The current analysis failed to fully capture the parameter uncertainty in our 
economic model and, as such, its results should be interpreted with caution.
Uncertainties
As with any economic evaluation there are a number of uncertainties. These can be split into 
two broad categories: structural and parameter uncertainties.283,284 The first category relates to 
uncertainties about the particular care pathway that should be modelled or about the type of 
mathematical functions that govern the relationship between different elements of the model. 
In the second category, uncertainties are related to what particular parameter values should be 
within the economic model. Outlined below are the key structural and parameter uncertainties.
Structural uncertainties
  ■ Model time horizon. The base-case analysis took a 20-year time horizon. This period of time 
might not be long enough to capture the whole effect of surveillance pathways compared 
with no surveillance. However, we chose this particular time period as we believed that 
extrapolating 5-year effectiveness data (e.g. 5-year risk of conversion to OAG) to even longer 
time horizons would be questionable. Had we chosen a longer time horizon some cases 
of visual impairment would have occurred and hence differences in QALYs would have 
potentially been captured. However, given the time it takes to develop visual impairment, 
discounting would tend to reduce the impact of differences in the number of cases of 
visual impairment.
  ■ Time to event function. In the absence of other information we opted to use a uniform 
distribution to model time to conversion, and progression to moderate OAG, severe OAG 
and visual impairment. This approach means that the number of events occurring in each 
unit of time is the same. An alternative would have been to use Kaplan–Maier curves derived 
from the data from the identified RCTs, which would have provided a cumulative conversion 
function for the 20-year period. However, such a function would not have provided 
predictions of the risk of conversion that were fully consistent with those provided by the risk 
prediction tool.
  ■ Pathways included in the model. We did not formally include a ‘do nothing’ alternative, 
although a simplified version of one was required for analytical purposes in the cost–benefit 
analysis. When developing the pathways to be compared it was believed that a ‘do nothing’ 150 Economic evaluation
pathway would not be relevant as the policy currently is to monitor individuals with OHT 
in the UK.
Parameter uncertainty
  ■ We ran one-way sensitivity analysis as well as scenario analysis. As often stated, this might 
not fully capture the joint parameter uncertainty and its effect on results.284 Probabilistic 
sensitivity analysis is often used to address this issue; however, our model proved to be 
computationally too demanding and probabilistic sensitivity analysis was not feasible. As a 
result, we could not produce cost-effectiveness acceptability curves or value of information 
analysis. This is a limitation of the present analysis.
  ■ We assumed 50% and 75% adherence rates for non-monitoring (‘treat all’) and monitoring 
(NICE or SOH) pathways, respectively. We based these figures on limited available evidence 
and expert opinion. These rates might range between 20% and 95%, depending on which 
data are judged relevant.278 The results of the cost–utility analysis were shown to be sensitive 
to variations in the rate of adherence between surveillance pathways and further research on 
this would reduce the uncertainty surrounding the results.
Conclusions
We conducted cost-effectiveness, cost–utility and cost–benefit analyses of monitoring pathways 
for individuals with OHT using a discrete event simulation model. We incorporated into this 
economic model data obtained from rigorous systematic reviews268 as well as information 
retrieved and produced within this project [e.g. best available glaucoma risk prediction tool (see 
Chapter 4) and data to inform the optimal frequency of surveillance (see Chapter 6)].
Overall, the results of the cost–utility and cost–benefit analyses are similar, with interventions 
that provide more benefits (QALYs or WTP) not being considered worth the extra cost. The main 
difference of note was that the ‘SOH hospital’ pathway is unlikely to be considered worthwhile 
when efficiency is measured in terms of incremental cost per QALY but may be when efficiency is 
measured in terms of net benefits. This is mainly because of the value that society places on being 
monitored for a particular condition as well as the value placed on the patient experience of the 
testing process during the monitoring visits, which is captured in the WTP estimates but not by 
the QALYs. The cost–utility analysis results were particularly sensitive to the rate of adherence 
to medical treatment assumed for the ‘treat all’ and the other surveillance pathways modelled as 
well as the unit price of IOP measurement only hospital visits. The ‘SOH hospital’ pathway has 
an incremental cost per QALY of < £30,000 compared with the ‘treat all’ pathway when the cost 
of return visits to hospital to measure IOP was around £60 or less. It is unlikely that either of the 
NICE strategies is cost-effective compared with the less intensive monitoring pathways developed 
in this study. The feasibility of a ‘treat all’ pathway and its acceptability by patients and providers 
have not been explored.
Any policy recommendations about the placing of a surveillance programme at a hospital 
level should take into account capacity in hospital eye services in the UK. If a hospital-based 
surveillance programme is not feasible then the modelling suggests that basing the programme in 
the community is the second best option.
Further research is required to provide new primary data to update the economic model. In 
particular, robust data are required on adherence to ocular hypotensive treatment and the impact 
of treatment on health status. The feasibility of alternative low-cost monitoring pathways should 
be explored. New technologies suitable for self-monitoring are required.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Chapter 9 
Discussion
Summary of main findings
Glaucoma is a chronic progressive optic neuropathy leading to impaired vision and blindness 
if inadequately treated. OAG is the most common form. A raised IOP is the only modifiable 
risk factor. OHT is defined as IOP of > 21 mmHg and the absence of clinical signs of glaucoma. 
Although it is important to treat early disease to reduce the costs and disability associated with 
glaucoma, only a minority of those with OHT develop glaucoma and, of these, not all are at 
risk of visual impairment in their lifetime. The challenge is therefore to identify the groups 
most at risk of developing significant glaucoma, and to determine monitoring criteria for those 
individuals who are most likely to benefit from surveillance and treatment. For monitoring 
to be worthwhile it would have to lead to early identification of the need for treatment or 
change of treatment, or development of glaucoma, and thus reduce sight loss while not causing 
unacceptable harms associated with monitoring and treatment. Furthermore, it must represent a 
good use of scarce health-care resources and also be acceptable to patients.
To guide management of patients with OHT there is a need for accurate and reliable risk 
assessment that would help predict conversion from OHT to glaucoma. We identified three 
published models predicting the risk of developing OAG for individuals with OHT.42,62–64 These 
models were derived using data from two large multicentre RCTs evaluating the efficacy of 
ocular hypotensive medication, the OHTS42 and the EGPS.14 The OHTS-EGPS means model64 
was the most robust and estimated the 5-year risk of conversion to glaucoma based on age, IOP, 
CCT, VCD ratio and PSD. The model uses the means of the right and left eyes of an individual to 
calculate eye-specific predictors and all variables can be routinely collected in clinical practice. 
The discriminatory ability of the model was good in the four populations included in our study, 
with c-indexes between 0.69 and 0.83. However, in calibration analyses, the OHTS-EGPS model 
generally overestimated the risk of OAG in all cohorts, although for the Rotterdam cohort the 
calibration slope was close to 1 (1.09, 95% CI 0.72 to 1.46), the ideal value when there is complete 
agreement between predicted and observed risks. A calculator to estimate the 5-year risk of 
developing OAG, based on the pooled OHTS–EGPS means model, is available online at http://
ohts.wustl.edu/risk/calculator.html. This can be used in conjunction with clinical assessment to 
inform patients of their glaucoma risk and to guide treatment decisions.
Once OHT is diagnosed, monitoring includes measuring IOP by tonometry (as treatment 
decisions may need to be changed according to the level of IOP) and tests to detect glaucoma. 
These include tests of visual function, commonly SAP, and an evaluation of structural changes 
in the optic nerve by clinical examination, photography and/or automated estimates of RNFL or 
optic disc neuroretinal rim loss. The clinically important changes in the test, the signal, need to 
be considered alongside the noise, which includes biological variability (over short periods) and 
measurement error (including interobserver and device variability), in successive measurements.
Several tonometers are available for the measurement of IOP. To estimate the measurement 
error between different tonometers we undertook a systematic review of published directly 
comparative studies. We compared the agreement of IOP readings between tonometers available 
in clinical practice and GAT, the commonly accepted reference standard device for measuring 152 Discussion
IOP. We identified 102 studies comparing eight candidate tonometers with GAT. The studies 
were generally poorly reported. Sizeable inter- and intraobserver variability was observed for all 
tonometers, including GAT, casting doubt on the validity of GAT as the default standard.
We explored the signal-to-noise relationship of serial measures of IOP and visual fields in a 
secondary analysis of IPD from a RCT including data on 300 participants with OHT over a 
4-year follow-up. The results were validated in a second independent trial data set. In terms 
of IOP, the average change in IOP over time for the whole group was close to zero (a decrease 
of < 1 mmHg in a 3-year period), but when it changes it can change quickly: > 5 mmHg at 
3 years in about 25% of participants. For most individuals, any true change in underlying IOP 
(‘signal’) was smaller than the estimated ‘noise’. The ‘noise’ was lower in those with high baseline 
IOP (≥ 26 mmHg). Observed changes of ≤ 3 mmHg could be explained as ‘noise’. Assuming 
independence of repeated measures, the mean of two baseline IOP readings increased the 
signal-to-noise ratio such that true change in IOP could be detected at 2 years. With three 
baseline measures, true change could be detectable between 1 and 2 years. In those with lower 
baseline IOP (< 26 mmHg), a true change in IOP would be unlikely to happen within 3 years. 
Age and observer did not affect the findings. A similar exercise was carried out regarding visual 
field tests. Serial data on visual fields, measured by SAP, were available in only one data set, and 
these were limited to sufficient data to explore only the variability of one index of visual field loss, 
the MD. The variability of the MD of repeated visual fields was explored, estimating the mean 
and variance of change at every visit. The MD fluctuated, both increasing and decreasing, with 
minimal signal detected over 4 years.
To estimate the efficiency of alternative surveillance regimes, we undertook an economic 
evaluation, which was informed by public preferences for monitoring ascertained by a survey of 
the public (n = 814) using a DCE design. The findings of the survey showed a general preference 
for being monitored if an individual had OHT. Individuals were willing to pay £28 per year for 
a monitoring service, everything else being equal. Health outcome (risk of conversion to OAG, 
progression to severe glaucoma or visual impairment) and patient experience (communication 
and understanding between patient and health-care professional and side effects of treatment), 
other than location of service (hospital or community optometrist), were significant predictors 
of preferences at the 1% level. Marginal valuations of the risk of developing glaucoma and sight 
loss over 10 years were statistically significant in the expected direction but very small. Side 
effects of treatment reduced the value of any service, with disbenefits increasing as side effects 
became more severe. Good communication with the health professional and understanding of 
the process of testing were important predictors of the value of alternative services. Preferences 
varied according to age, with those aged > 50 years being less concerned with the risk of sight 
loss (compared with those aged < 50), but more concerned about medication side effects and the 
importance of good communication and understanding of the process.
In the economic modelling component of the evaluation we used cost–consequence, cost–utility 
and cost–benefit analyses to compare the efficiency of five alternative surveillance pathways. 
Two were based on NICE guidelines, with the monitoring interval depending on initial risk 
stratification: ‘NICE intensive’ – 4-monthly to annual monitoring – and ‘NICE conservative’ – 
6-monthly to biennial monitoring; two further pathways were developed based on the findings 
of this study, differing in location (‘SOH hospital’ and ‘SOH primary care’) and with monitoring 
biennially; and a final ‘treat all’ pathway, identified in the literature, involved treatment with a 
PGA if IOP was > 21 mmHg, with IOP measured annually in community optometry and referral 
to a hospital eye service if response to treatment was inadequate (< 15% IOP reduction).
‘Treat all’ was the least costly pathway and ‘NICE intensive’ the most costly. The ‘SOH hospital’ 
pathway reduced the number of cases of conversion to glaucoma and progression compared © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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with the ‘treat all’ pathway and provided more QALYs but the ICER was considerably > £30,000. 
The ‘NICE intensive’ pathway also avoided conversion to glaucoma and progression, but NICE-
based pathways are dominated (more costly and less effective) by the ‘SOH hospital’ pathway. In 
the cost–benefit analysis, compared with a ‘no monitoring option’, ‘SOH hospital’ was the only 
pathway with a net benefit.
The results were sensitive to the risk threshold for initiating treatment. If treatment was initiated 
when the 5-year risk of developing OAG was > 10% (e.g. a 60 year old with ocular parameters 
based on means of measurements in both eyes of IOP of 27 mmHg, CCT of 560 µm, VCD ratio 
of 0.4 and PSD of 1.4 dB has a 10.3% likelihood of developing OAG in at least one eye), the ‘SOH 
hospital’ pathway was less costly and more effective than the ‘treat all’ pathway. Differences in 
treatment adherence rates between the ‘treat all’ and SOH pathways of approximately ≥ 40% led 
to the SOH pathways having an ICER of ≤ £30,000.
The results were also sensitive to the unit price of hospital-based IOP measurement only 
follow-up visits, with an ICER for the ‘SOH hospital’ pathway compared with the ‘treat all’ 
pathway of around £30,000 at a unit price of just over £61. This can be explained by the relatively 
high number of IOP measurement only visits within the monitoring strategies. This could have 
led to an overestimation of the number of IOP visits in the model and a slight underestimation 
of the cost-effectiveness of the monitoring strategies. This could partially explain the sensitivity 
of the results to the unit cost of hospital-based IOP measurement only visits. Caution should be 
taken when interpreting the results of this sensitivity analysis as the lower hospital-based visit 
unit costs might not fully account for the opportunity cost of the use of those resources (e.g. 
take into account the potential lack of capacity in hospital-based eye services). Patient self-
measurement as part of a point of care testing programme to monitor responses to initiation or 
changes in therapy could be considered but this option is limited by the reliability of the currently 
available tonometers.
In every sensitivity analysis conducted, NICE-based pathways were the most costly and were 
either dominated or had an ICER well above £30,000 per QALY.
Strengths and limitations
The strength of this study is the multidisciplinary approach including robust systematic reviews 
of the literature, analysis of existing IPD sets and consultation with patients, clinical experts and 
the public to inform the individual and ocular characteristics of a population with OHT and the 
surveillance pathways for comparison within an economic modelling evaluation framework. In 
addition to cost-effectiveness and cost–utility analyses, we report a cost–benefit analysis using 
the monetary values derived from a survey of public preferences for alternative monitoring 
programmes. Thus, the economic evaluation considered patient experience factors as well as 
health outcomes when valuing alternative monitoring programmes.
There are several limitations to the study and interpretation of the findings should be carried out 
with caution. The main limitation is the limited available data, both in the published literature 
and in primary individual-level data sets, on which our analyses were based.
The most robust risk prediction model identified from the literature was the OHTS-EGPS model. 
However, this was developed in a selected population within the context of a RCT and is not 
necessarily generalisable to the population of patients with OHT in clinical practice. Important 
prognostic factors may not have been included. Similarly, our validation data sets were selected 
populations, although we made an effort to avoid this problem by including both a trial-based 154 Discussion
and an observational setting. The definitions of glaucoma varied across data sets, and the 
observational data sets did not include all patients with OHT. Thus, the findings may not be 
generalisable. However, despite these limitations in the available data the OHTS-EGPS model 
generally discriminated well in estimating the 5-year risk of conversion to OAG. The model 
was not well calibrated in all populations. Further validation, especially using a larger sample 
including non-Caucasians, and recalibration in other patient subgroups (e.g. those with a family 
history of glaucoma) are required.
Ideally, the optimal interval for repeat testing to detect the onset of glaucoma should be informed 
by the variability in the tests (noise) and the number of tests required to detect a true change 
(signal). We aimed to explore the variability of IOP measurements and clinical measures of 
glaucoma within a signal-to-noise framework. Data were available on repeated measures of IOP, 
but no data were available to estimate the variability in measures of structural damage to the 
optic nerve and only limited data were available on repeated visual field examinations. Serial 
data on visual fields, measured by SAP, were available only in the Moorfields data set and these 
were sufficient to explore only the variability of one index of visual field loss, the MD. The MD 
represents the overall reduction in sensitivity, averaged across all test point locations in the visual 
field, compared with age-matched healthy control subjects.285 The MD, although widely used to 
monitor glaucoma,286 is not a useful measure for monitoring OHT as repeated measures of MD 
measured only noise over a 4-year period. There is no agreed summary index of visual field loss 
that constitutes definite glaucoma. The glaucoma hemifield test (GHT) has been incorporated 
into the commonly used standard automated perimeter, the Humphrey perimeter, to diagnose 
glaucoma,287 and classifies the visual field as ‘within normal limits’, ‘outside normal limits’, 
‘borderline’, ‘general loss of sensitivity’ and ‘abnormally high sensitivity’. Its performance to detect 
conversion from OHT to glaucoma is uncertain.288 The variability of the GHT in a signal-to-noise 
framework has not be explored. The Visual Field Index is a new measure289 that quantifies the 
total visual field loss as a percent rather than in decibels, but its performance in a context of 
monitoring OHT to detect early glaucoma has not been established.290
We established the measurement variability in IOP based on a rigorous systematic review and on 
a secondary analysis of serial measures of IOP by GAT from the Moorfields data set. A number of 
factors, such as CCT, are thought to influence IOP measurement, but our systematic review was 
not able to identify their impact. Primarily this was because of poor reporting of the studies not 
having the IPD to tease out any relationships for important subgroups. Similarly, we were unable 
to estimate any interobserver variability. In the IPD analysis of the Moorfields data set, variability 
in IOP measurement did not differ between observers.
Estimates of the variability between tonometers and the signal-to-noise relationship in repeated 
measures of IOP were incorporated into the economic evaluation. We found that IOP level 
remains fairly constant in subjects with OHT. True changes in IOP, within 2 years, were very 
unlikely. Thus, we used this 2-year interval to define the care pathways for the ‘SOH hospital’ 
and ‘SOH primary care’ strategies in the economic evaluation. Although IOP is not a clinically 
valid measure to detect glaucoma it is the measure on which treatment decisions are made and 
the variability in IOP is important when monitoring response to treatment. Further research 
is required to estimate the variability of visual field testing to inform the optimal monitoring 
interval for those with OHT, and to explore the role of automated imaging technologies in 
detecting conversion to glaucoma.
We developed the surveillance pathways based on input from clinical experts, methodologists, 
the literature and findings from other study objectives. These included the best risk prediction 
model, optimal frequency of testing and the survey of public preferences (the DCE). The NICE-
based pathways were considered to be current best monitoring practice. Ideally, the new care © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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pathways in the economic model should have been explored in the development and conduct of 
the DCE. This was not possible in the timeline of the project. A ‘treat all’ pathway was included 
based on emerging findings from the literature and appears to be a more efficient strategy. 
However, there are major uncertainties around the acceptability of a ‘treat all’ strategy to patients 
or heath-care providers and these were not explored in this study.
Across all pathways it was not possible to disentangle quality of life decrements as a result of 
side effects of treatment. However, our quality of life data (EQ-5D scores) were retrieved from a 
sample of treated participants, and a proportion of these had side effects. Therefore, the average 
quality of life scores used did incorporate quality of life decrements as a result of treatment 
side effects.
In the cost–utility analysis we did not compare surveillance with a ‘do nothing’ alternative as 
this was not an acceptable option given current NHS policy. The modelling took a 20-year 
time horizon, which might not be sufficient to capture the long-term benefits of surveillance. 
The economic model used (discrete event simulation approach) proved to be computationally 
demanding. Because of this we could not undertake a probabilistic sensitivity analysis. Therefore, 
the sensitivity analyses conducted may not fully capture the uncertainty surrounding parameter 
estimates. However, we believe that our deterministic sensitivity analysis reflects the key 
uncertainties in the analysis and managed to identify the main drivers of the economic model 
results (e.g. adherence rate to treatment and side effects of treatment and the costs of visits to 
secondary care to measure IOP following treatment changes when the IOP was ‘off target’). 
Although patient views were consulted when developing the DCE, the results were based on 
public preferences, which could differ from those of patients.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Chapter 10 
Conclusions
Implications for health care
The best available risk prediction model to estimate the 5-year risk of developing glaucoma is 
based on age and ocular predictors, namely IOP, CCT, VCD ratio and PSD. This risk prediction 
model is publicly available online at http://ohts.wustl.edu/risk/calculator.html and can be used to 
provide more accurate risk assessment in conjunction with clinical assessment. The model was 
developed from the characteristics of participants enrolled in RCTs and thus may not include all 
important predictors in the general population of patients with OHT.
An algorithm for the measurement of IOP using the average of repeat measurements would 
reduce measurement ‘noise’. Our findings support the clinical importance of establishing a true 
baseline IOP before initiating monitoring or treatment. Using the average of two measures 
at baseline at a single visit increases the signal-to-noise ratio such that one would expect to 
detect a true change, of the order of 2 mmHg, at 2 years. The data sets analysed did not have 
repeated measures on the same visit, thus the recommendation of reducing noise is based on 
an assumption in the model that the measurement errors across repeated readings are not 
correlated (i.e. all errors moving in the same direction). Repeated measures at the same visit will 
not incorporate diurnal or short-term biological variation. Diurnal variation can be addressed by 
standardising the time of measurement. Short-term biological variation could be addressed by 
averaging the IOP over repeat visits but this has to be balanced against the opportunity costs of 
an additional visit. IOP measurement using the NCT or Perkins tonometer is in close agreement 
with measurement using GAT in > 50% of measurements. However, the evidence suggests that 
GAT may not be the most appropriate reference standard. The same tonometer should be used 
when comparing IOP measurements in an individual. The optimal frequency of measurement of 
the visual field or the optic nerve head/RNFL to detect the onset of glaucoma remains uncertain.
For confirmed OHT there is no clear benefit from intensive monitoring. Our findings, based on 
data derived from participants in two relatively small RCTs, which may not be representative of 
the general population of patients with OHT, suggest that 2-yearly IOP monitoring of untreated 
or stable treated OHT is the recommended interval to detect true change of the order of 2 mmHg. 
The average of repeated measures of IOP at each visit reduces measurement noise. Our findings, 
based on an economic evaluation, suggest that if the costs of repeat visits to measure IOP 
following treatment initiation or change are minimised (< £60 per visit), then the surveillance 
(SOH) pathway developed in this study, based in the hospital, with 2-yearly monitoring to 
detect glaucoma, may be a cost-effective option compared with a ‘treat all’ policy with annual 
monitoring of IOP only, without clinical tests for glaucoma. Our findings may not fully account 
for the opportunity costs of the use of those resources (e.g. may not take into account the 
potential lack of capacity in hospital-based eye services). The feasibility of alternative low-cost 
monitoring pathways should be explored. Patient self-measurement as part of a point of care 
testing programme to monitor responses to initiation or changes in therapy could be considered, 
but this option is limited by the reliability of the currently available tonometers. Service 
reconfigurations should consider the patient experience, ensuring adequate time to explain the 
purpose of monitoring, and avoid treatment side effects.158 Conclusions
If services have adopted NICE guidance on monitoring OHT, then our findings suggest that 
efficiency may improve by moving to a less intensive approach. If NICE guidance has not been 
adopted, the findings of this study could be used to inform the development of an alternative 
hospital- or community-based service.
Implications for research
Further research is recommended to provide new primary data to inform on the optimal 
organisation of a surveillance programme for those identified at risk of glaucoma as a result 
of OHT:
  ■ A prospective cohort study including newly diagnosed patients with OHT with long-term 
outcomes. The purpose of the study will be to update and validate the OHT-EGPS risk 
prediction model and refine the monitoring and treatment criteria developed in this study 
in a larger sample representative of the general population of patients with OHT. Before 
commencing the study, standardisation of a summary measure of automated perimetry (and/
or RNFL analysis), with consensus on what constitutes conversion to glaucoma, is required. 
A comparison of alternative tonometers, and factors influencing IOP measurements, could 
be nested within the study. Costs and patient preferences for alternative surveillance and 
treatment programmes should be explored. The data could be used to update the economic 
model developed in this study.
  ■ The development of new technologies to meet the needs of the NHS and patients. This 
includes further development of tonometers suitable for self-monitoring.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Appendix 1 
Search strategies
Risk prediction (Chapter 4)
MEDLINE (1987 to January week 3 2011), MEDLINE In-Process & Other 
Non-Indexed Citations (28 January 2011) and EMBASE (1987 to week 4 2011)
Ovid Multifile Search – URL: https://shibboleth.ovid.com/
1.  ocular hypertension/use mesz
2.  intraocular hypertension/use emez
3.  glaucoma, open-angle/use mesz
4.  open-angle glaucoma/use emez
5.  *glaucoma/
6.  (glaucoma or poag or iop).ti.
7.  (ocular adj3 (hypertension or pressure)).ti.
8.  (intraocular adj3 (hypertension or pressure)).ti.
9.  or/1–8
10.  prediction/use emez
11.  prognosis/
12.  risk assessment/
13.  predictor variable/use emez
14.  disease progression/use mesz
15.  disease course/use emez
16.  (predict$or prognos?s or prognostic or progress$or risk).ti.
17.  or/10–16
18.  9 and 17
19.  model$.hw,tw.
20.  algorithms/
21.  algorithm$.tw.
22.  tool?.hw,tw.
23.  toolkit?.tw.
24.  calculator?.tw.
25.  or/19–24
26.  18 and 25
27.  animal/or nonhuman/
28.  human/
29.  27 not 28
30.  26 not 29
31.  limit 30 to yr=“1987 – 2011”
32.  remove duplicates from 31
Science Citation Index (1987 to 27 January 2011), BIOSIS (1987 to 
26 January 2011)
Web of Knowledge – URL: http://wok.mimas.ac.uk/
#1 TS=glaucoma180 Appendix 1
#2  TS=(ocular SAME hypertension)
#3  TS=(ocular SAME pressure)
#4  TS=(intraocular SAME hypertension)
#5  TS=(intraocular SAME pressure)
#6  #1 OR #2 OR #3 OR #4 OR #5 AND Document Type=(Article)
#7  #6 AND TI=(predict* or prognos* or progress* or risk) AND Document Type=(Article)
#8  #7 AND TS=(model* or algorithm* or tool* or calculat*) AND Document Type=(Article)
Database of Abstracts of Reviews of Effects and Health Technology 
Assessment database (January 2011)
NIHR Centre for Reviews and Dissemination – URL: www.crd.york.ac.uk/crdweb/
#1  MeSH Ocular Hypertension EXPLODE
#2 glaucoma
#3  poag OR iop
#4  “ocular pressure”
#5  “intraocular pressure”
#6  “intraocular hypertension”
#7  #1 OR #2 OR #3 OR #4 OR #5 OR #6
#8  MeSH Prognosis
#9  MeSH Disease Progression
#10 MeSH Risk Assessment
#11 predict* OR prognos* OR progress*
#12 #8 OR #9 OR #10 OR #11
#13 #7 AND #12
#14 model* OR algorithm* OR tool* OR calculat*
#15 #13 AND #14
Journal websites consulted (accessed 31 January 2011)
(model* OR tool*) and (predict* or progress*) and (glaucoma or ocular)
American Journal of Ophthalmology – URL: www.sciencedirect.com/science/journal/00029394
Archives of Ophthalmology – URL: http://archopht.ama-assn.org/
British Journal of Ophthalmology – URL: http://bjo.bmj.com/
Eye – URL: www.nature.com/eye/index.html
Graefe’s Archive for Clinical and Experimental Ophthalmology – URL: www.springerlink.com/
content/101559/
Investigative Ophthalmology and Visual Science – URL: www.iovs.org/
Journal of Glaucoma – URL: www.glaucomajournal.com
Ophthalmology – URL: www.sciencedirect.com/science/journal/0161642
Professional organisations consulted (accessed January 2011)
American Academy of Ophthalmology – URL: www.aao.org/
American Glaucoma Society – URL: www.glaucomaweb.org/
European Glaucoma Society – URL: www.eugs.org/eng/default.asp
Glaucoma Research Foundation – URL: www.glaucoma.org/
National Eye Institute – URL: www.nei.nih.gov/
Royal College of Ophthalmologists – URL: www.rcophth.ac.uk/© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Systematic review of tonometers (Chapter 5)
MEDLINE (1987 to February week 2 2010), MEDLINE In-Process & Other 
Non-Indexed Citations (8 February 2010) and EMBASE (1987 to week 5 2010) 
Ovid Multifile Search – URL: https://shibboleth.ovid.com/
1.  Tonometry, Ocular/use mesz
2.  Oculoplethysmography/use emez
3.  Ocular Hypertension/di use mesz
4.  Intraocular hypertension/di use emez
5.  (ocular adj5 (tonometer$or tonometry or tonopen$)).tw.
6.  ocular response analys$.tw.
7.  ocular hypertension/or intraocular hypertension/or intraocular pressure/or exp glaucoma/
8.  7 and (tonometer$or tonometry or tonopen$).tw.
9.  (oculoplethysmograph$or pneumotonomet$).tw.
10.  or/1–6,8–9
11.  “reproducibility of results”/use mesz
12.  reproducibility/use emez
13.  observer variation/
14.  (variation or variability).tw.
15.  (reliable or reliability).tw.
16.  (reproducible or reproducibility).tw.
17.  (agree? or agreement).tw.
18.  or/11–17
19.  10 and 18
20.  exp clinical trial/
21.  randomized controlled trial.pt.
22.  controlled clinical trial.pt.
23.  randomization/use emez
24.  randomi?ed.ab.
25.  randomly.ab.
26.  trial.ab.
27.  groups.ab.
28.  comparative study/use mesz
29.  major clinical study/use emez
30.  controlled study/use emez
31.  clinical trial/use emez
32.  (prospective$or retrospective$).tw. use mesz
33.  (compare$or compara$).tw.
34.  or/20–33
35.  19 and 34
36.  humans/
37.  35 and 36
38.  limit 37 to (english language and yr=“1987 – 2010”)
Science Citation Index (1987 to 8 February 2010) and BIOSIS (1987 to 8 February 2010)
Web of Knowledge – URL: http://wok.mimas.ac.uk/
#1  TS=((ocular OR intraocular) SAME (tonometer* or tonometry or tonopen*)) AND 
Language=(English) AND Document Type=(Article)182 Appendix 1
#2  TS=(oculoplethysmograph* or pneumotonomet*) AND Language=(English) AND 
Document Type=(Article)
#3  #1 or #2 AND Language=(English) AND Document Type=(Article)
#4  #3 AND TS =(variation or variability) AND Language=(English) AND Document 
Type=(Article)
#5  #3 AND TS=(reproducible or reproducibility) AND Language=(English) AND Document 
Type=(Article)
#6  #3 AND TS=agree* AND Language=(English) AND Document Type=(Article)
#7  #3 AND TS=(reliable or reliability) AND Language=(English) AND Document 
Type=(Article)
#8  #7 OR #6 OR #5 OR #4
#9  #8 AND TS=(random* OR trial* OR control* OR compar* OR prospective OR retrospective) 
AND Language=(English) AND Document Type=(Article)
The Cochrane Library (Issue 1 2010)
URL: www.thecochranelibrary.com/
#1  MeSH descriptor Tonometry, Ocular, this term only
#2  MeSH descriptor Ocular Hypertension, this term only with qualifier:DI
#3  MeSH descriptor Intraocular Pressure, this term only
#4  MeSH descriptor Ocular Hypertension, this term only
#5  MeSH descriptor Glaucoma explode all trees
#6  (#3 OR #4 OR #5)
#7  (tonometer* or tonometry or tonopen*)
#8  (#6 AND #7)
#9  (ocular NEAR (tonometer* or tonometry or tonopen*))
#10 (#1 OR #2 OR #8 OR #9)
#11 MeSH descriptor Reproducibility of Results, this term only
#12 MeSH descriptor Observer Variation explode all trees
#13 (variation OR variability) or (reliable OR reliability) or (reproduce OR reproducibility) or 
(agree*)
#14 (#11 OR #12 OR 13)
#15 (#10 AND #14)
Database of Abstracts of Reviews of Effects and Health Technology 
Assessment database (February 2010)
NIHR Centre for Reviews and Dissemination – URL: www.crd.york.ac.uk/crdweb/
#1  Tonometry, Ocular/
#2  Ocular Hypertension/
#3  Intraocular Pressure/
#4  Exp Glaucoma/
#5  #2 OR #3 OR #4
#6  #1 AND #5
World Health Organization International Clinical Trials Registry Platform 
(February 2010)
URL: www.who.int/ictrp/en/
Tonomet* AND ocular© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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ClinicalTrials.gov (February 2010)
URL: http://clinicaltrials.gov/ct/gui/c/r
Ocular AND (tomometer or tonometry)
Current Controlled Trials (February 2010)
URL: www.controlled-trials.com/
tonomet% AND ocular
Journal websites consulted (accessed 8 February 2010)
American Journal of Ophthalmology – URL: www.sciencedirect.com/science/journal/00029394
Archives of Ophthalmology – URL: http://archopht.ama-assn.org/
British Journal of Ophthalmology – URL: http://bjo.bmj.com/
Eye – URL: www.nature.com/eye/index.html
Graefe’s Archive for Clinical and Experimental Ophthalmology – URL: www.springerlink.com/
content/101559/
Investigative Ophthalmology and Visual Science – URL: www.iovs.org/
Journal of Glaucoma – URL: www.glaucomajournal.com
Ophthalmology – URL: www.sciencedirect.com/science/journal/0161642
Systematic review of economic evaluations (Chapter 8)
MEDLINE (1950 to October week 4 2010), MEDLINE In-Process & Other 
Non-Indexed Citations (25 October 2010) and EMBASE (1980 to week 41 2010)
Ovid Multifile search – URL: http://gateway.ovid.com
1.  intraocular hypertension/use emez
2.  exp ocular hypertension/use prmz
3.  tonometry, ocular/use prmz
4.  oculoplethysmography/use emez
5.  iop.tw.
6.  (ocular adj3 (pressure or hypertension)).tw.
7.  (intraocular adj3 (hypertension or pressure)).tw.
8.  ((applanation or contact or noncontact or dynamic or contour or rebound) adj1 tonomet$).
tw.
9.  or/1–8
10.  disease surveillance/use emez
11.  periodic medical examination/use emez
12.  exp population surveillance/use prmz
13.  (surveillance or monitor$).tw.
14.  or/10–13
15.  exp «costs and cost analysis»/use prmz
16.  exp economic evaluation/use emez
17.  economics/
18.  health economics/use emez
19.  exp economics,hospital/use prmz
20.  exp economics,medical/use prmz
21.  economics,pharmaceutical/use prmz
22.  exp budgets/
23.  exp models, economic/use prmz184 Appendix 1
24.  exp decision theory/
25.  ec.fs. use prmz
26.  monte carlo method/
27.  markov chains/
28.  exp technology assessment, biomedical/
29.  cost$.ti.
30.  (cost$adj2 (effective$or utilit$or benefit$or minimis$)).ab.
31.  economics model$.tw.
32.  (economic$or pharmacoeconomic$).tw.
33.  (price or prices or pricing).tw.
34.  (financial or finance or finances or financed).tw.
35.  (value adj2 (money or monetary)).tw.
36.  markov$.tw.
37.  monte carlo.tw.
38.  (decision$adj2 (tree? or analy$or model$)).tw.
39.  quality of life/
40.  quality adjusted life year/
41.  «Value of Life»/use prmz
42.  exp health status indicators/use prmz
43.  health status/use emez
44.  sickness impact profile/use prmz
45.  disability evaluation/use prmz
46.  disability/use emez
47.  activities of daily living/use prmz
48.  exp daily life activity/use emez
49.  cost utility analysis/use emez
50.  rating scale/
51.  questionnaires/
52.  (quality adj1 life).tw.
53.  quality adjusted life.tw.
54.  disability adjusted life.tw.
55.  (qaly? or qald? or qale? or qtime? or daly?).tw.
56.  (euroqol or euro qol or eq5d or eq 5d).tw.
57.  (hql or hqol or h qol or hrqol or hr qol).tw.
58.  (hye or hyes).tw.
59.  health$year$equivalent$.tw.
60.  (hui or hui1 or hui2 or hui3).tw.
61.  (health adj3 (utilit$or disutili$)).tw.
62.  (health adj3 (state or status)).tw.
63.  (sf36 or sf 36 or short form 36 or shortform 36).tw
64.  (sf6 or sf 6 or short form 6 or shortform 6).tw.
65.  (sf12 or sf 12 or short form 12 or shortform 12).tw.
66.  (sf16 or sf 16 or short form 16 or shortform 16).tw.
67.  (sf20 or sf 20 or short form 20 or shortform 20).tw.
68.  willingness to pay.tw.
69.  standard gamble.tw.
70.  trade off.tw.
71.  iop publishing.ab.
72.  ocular hypertension/
73.  or/15–70
74.  9 and 14 and 73© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
185   Health Technology Assessment 2012; Vol. 16: No. 29 DOI: 10.3310/hta16290
75.  74 not 71
76.  72 or 75
77.  remove duplicates from 76
Health Management Information Consortium (HMIC) (September 2010)
Ovid gateway – URL: http://gateway.ovid.com
1.  intraocular hypertension.tw.
2.  iop.tw.
3.  (ocular adj3 (pressure or hypertension)).tw.
4.  tonometry.tw.
5.  ((applanation or contact or noncontact or dynamic or contour or rebound) adj1 tonomet$).
tw.
6.  or/1–5
NHS Economic Evaluations Database (NEED) and Health Technology Assessment 
database (October 2010)
Centre for Reviews and Dissemination – URL: www.york.ac.uk/inst/crd/
#1  MeSH Ocular Hypertension EXPLODE 1
#2  ocular AND (hypertension OR pressure)
#3 iop
#4  (intraocular AND (hypertension OR pressure))
#5  (applanation OR contact OR noncontact OR dynamic OR contour OR rebound) 
AND tonomet*
#6  MeSH Population Surveillance EXPLODE 1 2 3 4
#7  surveillance OR monitor*
#8  #1 or #2 or #3 or #4
#9  #5 or #6 or #7
#10 #8 and #9© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Appendix 2 
List of excluded full-text studies
Risk prediction (Chapter 4)
Reference Reason for exclusion
Alencar LM, Bowd C, Weinreb RN, Zangwill LM, Sample PA Medeiros FA. Comparison of HRT-3 
Glaucoma Probability Score and subjective stereophotograph assessment for prediction of progression in 
glaucoma. Invest Ophthalmol Vis Sci 2008;49:1898–906
Includes not only patients with ocular 
OHT
Bengtsson B, Heijl A. Diurnal IOP fluctuation: not an independent risk factor for glaucomatous visual field 
loss in high-risk ocular hypertension. Graefes Arch Clin Exp Ophthalmol 2005;243:513–18
Conducted before 1987
Bhatt N. A 10-year follow up of ocular hypertensive patients within the Bolton Corneal Thickness Study. 
Can measured factors predict prognostic outcomes? Cont Lens Anterior Eye 2008;31:147–53
Retrospective case note review
Cohen SL, Lee PP, Herndon LW, Challa P, Overbury O, Allingham RR. Using the arteriolar Pressure 
Attenuation Index to predict ocular hypertension progression to open-angle glaucoma. Arch Ophthalmol 
2003;121:33–8
Retrospective case note review
de Voogd S, Ikram MK, Wolfs RC, Jansonius NM, Witteman JC, Hofman AI, et al. Is diabetes mellitus a 
risk factor for open-angle glaucoma? The Rotterdam Study. Ophthalmology 2006;113:1827–31
Includes not only patients with OHT
de Voogd S, Wolfs RC, Jansonius NM, Witteman JC, Hofman A, de Jong PT. Atherosclerosis, 
C-reactive protein, and risk for open-angle glaucoma: the Rotterdam Study. Invest Ophthalmol Vis Sci 
2006;47:3772–6
Includes not only patients with OHT
Diaz Aleman, VT, Fernandez-Baca Vaca G, Lozano Lopez V, Garcia Somalo M, Perera Sanz D, Gonzalez 
De La Rosa M. [Nomogram for ocular hypertension progression risk based on the ocular hypertension 
treatment study]. [Spanish]. Arch Soc Esp Oftalmol 2005;80:151–4
Assessment of model performance in 
any data set (derivation or validation) 
not available 
Doshi V. Sociodemographic, family history, and lifestyle risk factors for open-angle glaucoma and ocular 
hypertension. The Los Angeles Latino Eye Study. Ophthalmology 2008;115:639–47
Includes not only patients with OHT
Ekstrom C, Alm A. Pseudoexfoliation as a risk factor for prevalent open-angle glaucoma. Acta Ophthalmol 
2008;86:741–6
Conducted before 1987
European Glaucoma Prevention Study (EGPS) Group, Miglior S, Pfeiffer N, Torri V, Zeyen T, Cunha-Vaz J. 
Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European 
Glaucoma Prevention Study. Ophthalmology 2007;114:3–9
No prediction equation
Gordon MO. Ocular hypertension treatment study: baseline factors that predict the onset of primary 
open-angle glaucoma. Evid Based Eye Care 2003;4:16–17
Not risk prediction model development 
or validation
Griffin BA, Elliott MN, Coleman AL, Cheng EM. Incorporating mortality risk into estimates of 5-year 
glaucoma risk. Am J Ophthalmol 2009;148:925–31
Not risk prediction model development 
or validation
Heeg GP, Jansonius NM. The groningen longitudinal glaucoma study III. The predictive value of 
frequency-doubling perimetry and GDx nerve fibre analyser test results for the development of 
glaucomatous visual field loss. Eye 2009;23:1647–52
Not risk prediction model development 
or validation
Hulsman CA, Houwing-Duistermaat JJ, Van Duijn CM, Wolfs R, Borger PH, Hofman A, et al. Family score 
as an indicator of genetic risk of primary open-angle glaucoma. Arch Ophthalmol 2002;120:1726–31
Includes not only patients with OHT
Jonas JB, Martus P, Horn FK, Jünemann A, Korth M, Budde WM. Predictive factors of the optic nerve 
head for development or progression of glaucomatous visual field loss. Invest Ophthalmol Vis Sci 
2004;45:2613–18
Includes not only patients with OHT
Kang JH, Pasquale LR, Willett WC, Rosner BA, Egan KM, Faberowski N, et al. Dietary fat consumption 
and primary open-angle glaucoma. Am J Clin Nutr 2004;79:755–64
Includes not only patients with OHT
Kang JH, Willett WC, Rosner BA, Hankinson SE, Pasquale LR. Prospective study of alcohol consumption 
and the risk of primary open-angle glaucoma. Ophthalmic Epidemiol 2007;14:141–7
Includes not only patients with OHT
Kang JH, Willett WC, Rosner BA, Hankinson SE, Pasquale LR. Caffeine consumption and the risk of 
primary open-angle glaucoma: a prospective cohort study. Invest Ophthalmol Vis Sci 2008;49:1924–31
Includes not only patients with OHT
Lalezary M, Medeiros FA, Weinreb RN, Bowd C, Sample PA, Tavares IM, et al. Baseline optical coherence 
tomography predicts the development of glaucomatous change in glaucoma suspects. Am J Ophthalmol 
2006;142:576–82
Includes not only patients with OHT188 Appendix 2
Reference Reason for exclusion
Lee AJ, Rochtchina E, Wang JJ, Healey PR, Mitchell P. Open-angle glaucoma and systemic thyroid 
disease in an older population: the Blue Mountains Eye Study. Eye 2004;18:600–8
Includes not only patients with OHT
Leske MC, Wu SY, Honkanen R, Nemesure B, Schachat A, Hyman L, et al. Nine-year incidence of open-
angle glaucoma in the Barbados Eye Studies. Ophthalmology 2007;114:1058–64
Includes not only patients with OHT
Leske MC, Wu SY, Hennis A, Honkanen R, Nemesure B, BESs Study Group. Risk factors for incident 
open-angle glaucoma. The Barbados Eye Studies. Ophthalmology 2008;115:85–93
Includes not only patients with OHT
Levine RA, McManus P, Margol V. Asymmetries and visual field summaries as predictors of glaucoma in 
the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci 2006;47:3896–903
No prediction equation
Mansberger SL. A risk calculator to determine the probability of glaucoma. J Glaucoma 2004;13:345–7 Not risk prediction model development 
or validation
Medeiros FA. Frequency doubling technology perimetry abnormalities as predictors of glaucomatous 
visual field loss. Am J Ophthalmol 2004;137:863–71
Not risk prediction model development 
or validation
Medeiros FA, Weinreb RN. Estimating the risk of developing glaucoma. Open Ophthalmol J 2009;3:50–3 Not risk prediction model development 
or validation
Medeiros FA, Sample PA, Weinreb RN. Agreement between stereophotographic and confocal scanning 
laser ophthalmoscopy measurements of cup/disc ratio: effect on a predictive model for glaucoma 
development. J Glaucoma 2007;16:209–14
Not risk prediction model development 
or validation
Medeiros FA, Weinreb RN, Zangwill LM, Alencar LM, Sample PA, Vasile C, et al. Long-term intraocular 
pressure fluctuations and risk of conversion from ocular hypertension to glaucoma. Ophthalmology 
2008;115:934–40
No prediction equation
Medeiros FA, Alencar LM, Zangwill LM, Bowd C, Vizzeri G, Sample PA, et al. Detection of progressive 
retinal nerve fiber layer loss in glaucoma using scanning laser polarimetry with variable corneal 
compensation. Invest Ophthalmol Vis Sci 2009;50:1675–81
Not risk prediction model development 
or validation
Medeiros FA, Alencar LM, Zangwill LM, Sample PA, Weinreb RN. The relationship between intraocular 
pressure and progressive retinal nerve fiber layer loss in glaucoma. Am J Ophthalmol 2009;116: 
1125–33
Not risk prediction model development 
or validation
Medeiros FA, Alencar LM, Zangwill LM, Bowd C, Sample PA, Weinreb RN. Prediction of functional loss in 
glaucoma from progressive optic disc damage. Arch Ophthalmol 2009;127:1250–6
Includes not only patients with OHT
Miglior S, Torri V, Zeyen T, Pfeiffer N, Vaz JC, Adamsons I, et al. Intercurrent factors associated with the 
development of open-angle glaucoma in the European glaucoma prevention study. Am J Ophthalmol 
2007;144:266–75
No prediction equation
Nemesure B, Wu SY, Hennis A, Leske MC, Barbados Eye Studies Group. Factors related to the 4-year risk 
of high intraocular pressure: the Barbados Eye Studies. Arch Ophthalmol 2003;121:856–62
Includes not only patients with OHT
Nordmann JP. [High blood pressure-low ocular pressure: the parallels. The ophthalmologist’s point of 
view] [French]. J Fr Ophtalmol 2007;30:S14–7
Not risk prediction model development 
or validation
Pasquale LR, Kang JH, Manson JE, Willett WC, Rosner BA, Hankinson SE. Prospective study of type 2 
diabetes mellitus and risk of primary open-angle glaucoma in women. Ophthalmology 2006;113: 
1081–6
Includes not only patients with OHT
Pasquale LR, Rosner BA, Hankinson SE, Kang JH. Attributes of female reproductive aging and their 
relation to primary open-angle glaucoma: a prospective study. J Glaucoma 2007;16:598–605
Includes not only patients with OHT
Peeters AM, Webers CAB, Prins MHM, Hendrikse FM, Schouten JSAG. The clinical impact of 2 different 
strategies for initiating therapy in patients with ocular hypertension. J Glaucoma 2011;20:30–6
Not risk prediction model development 
or validation
Philippin H. Ten-year results: detection of long-term progressive optic disc changes with confocal laser 
tomography. Graefe Arch Clin Exp Ophthalmol 2006;244:460–4
Includes not only patients with OHT
Polo Llorens V, Pablo Julvez LE, Pinilla Lozano I, Larrosa Poves JM, Ruiz MO, Honrubia Lopez FM. [Short-
wavelength automated perimetry (SWAP) in patients with suspected glaucoma (II): correlation with a 
probabilistic multifactorial model of risk for developing glaucomatous damage]. [Spanish]. Arch Soc Esp 
Oftalmol 2000;75:97–102
Not risk prediction model development 
or validation
Polo V, Abecia E, Pablo LE, Pinilla I, Larrosa JM, Honrubia FM. Functional and structural measurements in 
a multifactorial glaucoma risk model. Acta Ophthalmol Scand 2001;79:10–14
Not risk prediction model development 
or validation
Rasker MTE, van den Enden A, Bakker D, Hoyng PFJ. Rate of visual field loss in progressive glaucoma. 
Arch Ophthalmol 2000;118:481–8
Not risk prediction model development 
or validation
Strouthidis NGM, Gardiner SKP, Owen VMF, Zuniga CM, Garway-Heath DFM. Predicting progression to 
glaucoma in ocular hypertensive patients. J Glaucoma 2010;19:304–9
No IOP in the model
Tezel G, Kolker AE, Kass MA, Wax MB, Gordon M, Siegmund KD. Parapapillary chorioretinal atrophy 
in patients with ocular hypertension: I. An evaluation as a predictive factor for the development of 
glaucomatous damage. Arch Ophthalmol 1997;115:1503–8
No prediction equation© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Reference Reason for exclusion
Walland M. Use of the Medmont Automated Perimeter with the Scoring Tool for Assessing Risk (STAR) II 
glaucoma risk calculator. Clin Exp Ophthalmol 2008;36:899–900
Not risk prediction model development 
or validation
Weinreb RN, Medeiros F. Risk assessment for glaucoma. Open Ophthalmol J 2009;3:30–1 Not risk prediction model development 
or validation
Weinreb RN, Friedman DS, Fechtner RD, Cioffi GA, Coleman AL, Girkin CA. Risk assessment in the 
management of patients with ocular hypertension. Am J Ophthalmol 2004;138:458–67
Not risk prediction model development 
or validation
Weinreb RN, Zangwill LM, Jain S, Becerra LM, Dirkes K, Piltz-Seymour JR, et al. Predicting the onset 
of glaucoma: the confocal scanning laser ophthalmoscopy ancillary study to the Ocular Hypertension 
Treatment Study. Ophthalmology 2010;117:1674–83
Not risk prediction model development 
or validation
Zangwill LM, Weinreb RN, Beiser JA, Berry CC, Cioffi GA, Coleman AL, et al. Baseline topographic optic 
disc measurements are associated with the development of primary open-angle glaucoma: the Confocal 
Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Arch 
Ophthalmol 2005;123:1188–97
No prediction equation
Zenker HJ. Use of multivariate analysis in evaluating the individual risk of glaucomatous visual field 
damage. Chibret Int J Ophthalmol 1989;6:38–44
Includes not only patients with OHT
Agreement and reliability of tonometers (Chapter 5)
Study details  Technology
No. of 
participants Reasons for exclusion
Losch A, Scheuerle A, Rupp V, Auffarth G, Becker M. Transpalpebral 
measurement of intraocular pressure using the TGDc-01 tonometer 
versus standard Goldmann applanation tonometry. Graefes Arch Clin Exp 
Ophthalmol 2005;243:313–16
Transpalpebral  109 Age range uncertain
Grolman B, Myers KJ, Lalle P. How reliable is the Goldmann tonometer as a 
standard? J Am Optomet Assoc 1990;61:857–62
NCT 620 eyes Age range uncertain
Babalola OE, Kehinde AV, Iloegbunam AC, Akinbinu T, Moghalu C, Onuoha 
I. A comparison of the Goldmann applanation and non-contact (Keeler 
Pulsair EasyEye) tonometers and the effect of central corneal thickness in 
indigenous African eyes. Ophthal Physiol Optics 2009;29:182–8
NCT 88 Age – included those 
< 16 years
Barreto J Jr, Babic M, Vessani RM, Susanna R Jr. Dynamic contour 
tonometry and Goldman applanation tonometry in eyes with keratoconus. 
Clinics 2006;61:511–14
DCT 12 Age – included those 
< 16 years
Brencher HL, Kohl P, Reinke AR, Yolton RL. Clinical comparison of air-puff 
and Goldmann tonometers. J Am Optomet Assoc 1991;62:395–402
NCT 227 Age – included those 
< 16 years
Danesh-Meyer HV, Niederer R, Gaskin BJ, Gamble G. Comparison of the 
Proview pressure phosphene tonometer performed by the patient and 
examiner with the Goldmann applanation tonometer. Clin Exp Ophthalmol 
2004;32:29–32
PPT 96 Age – included those 
< 16 years
Iliev ME, Goldblum D, Katsoulis K, Amstutz C, Frueh B. Comparison of 
rebound tonometry with Goldmann applanation tonometry and correlation 
with central corneal thickness. Br J Ophthalmol 2006;90:833–5
RT 55 Age – included those 
< 16 years
Kao SF, Lichter PR, Bergstrom TJ, Rowe S, Musch DC. Clinical comparison 
of the Oculab Tono-Pen to the Goldmann applanation tonometer. 
Ophthalmology 1987;94:1541–4
TonoPen 103 Age – included those 
< 16 years
Kretz G, Demailly P. X-PERT NCT advanced logic tonometer valuation. Int 
Ophthalmol 1992;16:287–90
NCT 60 Age – included those 
< 16 years
Lawson-Kopp W, DeJong A, Yudcovitch L, Williams S, Kohl P, Yolton RL. 
Clinical evaluation of the Keeler Pulsair 3000 non-contact tonometer. 
Optometry 2002;73:81–90
NCT 113 Age – included those 
< 16 years
Levy Y, Zadok D, Glovinsky Y, Krakowski D, Nemet P. Tono-Pen versus 
Goldmann tonometry after excimer laser photorefractive keratectomy. 
J Cataract Refract Surg 1999;25:486–91
TonoPen  18 Age – included those 
< 16 years
Moseley MJ, Thompson JR, Deutsch J, Misson GP, Naylor G, Tan-Yee A, 
et al. Comparison of the Keeler Pulsair 2000 non-contact tonometer with 
Goldmann applanation. Eye 1993;7:127–30
NCT 160 Age – included those 
< 16 years190 Appendix 2
Study details  Technology
No. of 
participants Reasons for exclusion
Munkwitz S, Elkarmouty A, Hoffmann EM, Pfeiffer N, Thieme H. Comparison 
of the iCare rebound tonometer and the Goldmann applanation tonometer 
over a wide IOP range. Graefes Arch Clin Exp Ophthalmol 2008;246:875–9
RT 75 Age – included those 
< 16 years
Pearce CD, Kohl P, Yolton RL. Clinical evaluation of the Keeler PULSAIR 
2000 tonometer. J Am Optomet Assoc 1992;63:106–10
NCT 190 Age – included those 
< 16 years
Poostchi A, Mitchell R, Nicholas S, Purdie G, Wells A. The iCare rebound 
tonometer: comparisons with Goldmann tonometry, and influence of central 
corneal thickness. Clin Exp Ophthalmol 2009;37:687–91
RT 100 Age – included those 
< 16 years
Recep OF, Hasiripi H, Cagil N, Sarikatipoglu H. Relation between corneal 
thickness and intraocular pressure measurement by noncontact and 
applanation tonometry. J Cataract Refract Surg 2001;27:1787–91
NCT 60 Age – included those 
< 16 years
Sandner D, Bohm A, Kostov S, Pillunat L. Measurement of the intraocular 
pressure with the ‘transpalpebral tonometer’ TGDc-01 in comparison with 
applanation tonometry. Graefes Arch Clin Exp Ophthalmol 2005;243:563–9
Transpalpebral  103 Age – included those 
< 16 years
Toker MI, Vural A, Erdogan H, Topalkara A, Arici MK. Central corneal 
thickness and Diaton transpalpebral tonometry. Graefes Arch Clin Exp 
Ophthalmol 2008;246:881–9
Transpalpebral 81 Age – included those 
< 16 years
Yan QC, He YH, Bai QH, Di Y, Wang XL. Comparison of the intraocular 
pressure value measured with Goldmann applanation tonometer and non-
contact tonometer. Int J Ophthalmol 2006;6:537–9
NCT 265 Age – included those 
< 16 years
Kniestedt C, Lin S, Choe J, Bostrom A, Nee M, Stamper RL. Clinical 
comparison of contour and applanation tonometry and their relationship to 
pachymetry. Arch Ophthalmol 2005;123:1532–7
DCT  258 Age – included those 
< 16 years
Kniestedt C, Lin S, Choe J, Nee M, Bostrom A, Sturmer J, et al. Correlation 
between intraocular pressure, central corneal thickness, stage of glaucoma, 
and demographic patient data: prospective analysis of biophysical 
parameters in tertiary glaucoma practice populations. J Glaucoma 
2006;15:91–7
DCT 406 Age – included those 
< 16 years
Paranhos A Jr, Paranhos FR, Prata JA Jr, Omi CA, Mello PA, Shields MB. 
Influence of keratometric readings on comparative intraocular pressure 
measurements with Goldmann, Tono-Pen, and noncontact tonometers. 
J Glaucoma 2000;9:219–23
TonoPen, NCT 202 Age – included those 
< 16 years
Bonomi L, Baravelli S, Cobbe C, Tomazzoli L. Evaluation of Keeler Pulsair 
non-contact tonometry: reliability and reproducibility. Graefes Arch Clin Exp 
Ophthalmol 1991;229:210–12
NCT 414 eyes Age – not reported
Denis P, Nordmann JP, Bertin V, Gayraud JM, Laroche L, Saraux H. 
Evaluation of the Tono-Pen 2 and the X-Pert noncontact tonometers in 
cataract surgery. Ophthalmologica 1993;207:155–61
NCT 45 Age – not reported
Draeger J, Rumberger E, Dauper J, Deutsch C. Microprocessor controlled 
tonometry. Eye 1989;3:738–42
NCT, TonoPen 99 Age – not reported
Fresco BB. A new tonometer – the pressure phosphene tonometer: clinical 
comparison with Goldman tonometry. Ophthalmology 1998;105:2123–6
PPT 100 Age – not reported
Geyer O, Mayron Y, Loewenstein A, Neudorfer M, Rothkoff L, Lazar M. Tono-
Pen tonometry in normal and in post-keratoplasty eyes. Br J Ophthalmol 
1992;76:538–40
TonoPen 82 Age – not reported
Hollo G, Follmann P, Pap G. A clinical evaluation of XPERT NCT (Reichert) for 
glaucoma screening by optometrists. Int Ophthalmol 1992;16:291–3
NCT 300 eyes Age – not reported
Iester M, Mermoud A, Achache F, Roy S. New Tonopen XL: comparison with 
the Goldmann tonometer. Eye 2001;15:1–8
TonoPen 104 Age – not reported
Koopmans SA, Kooijman AC, van Rij G, Eisses J, de Groot-Woltjer J. Clinical 
evaluation of two non-contact tonometers. Doc Ophthalmol 1991;78: 
259–63
NCT 33 Age – not reported
Lam AK, Lam CH, Chan R. The validity of a digital eyelid tonometer (TGDc-
01) and its comparison with Goldmann applanation tonometry – a pilot 
study. Ophthalmol Physiol Optic 2005;25:205–10
Transpalpebral  40 Age – not reported
Midelfart A, Wigers A. Clinical comparison of the ProTon and Tono-Pen 
tonometers with the Goldmann applanation tonometer. Br J Ophthalmol 
1994;78:895–8
TonoPen 53 Age – not reported© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Study details  Technology
No. of 
participants Reasons for exclusion
Mok KH, Wong CS, Lee VW. Tono-Pen tonometer and corneal thickness. Eye 
1999;13:35–7
TonoPen 48 Age – not reported
Parker VA, Herrtage J, Sarkies NJ. Clinical comparison of the Keeler 
Pulsair 3000 with Goldmann applanation tonometry. Br J Ophthalmol 
2001;85:1303–4
NCT 150 eyes Age – not reported
Schneider E, Grehn F. Intraocular pressure measurement – comparison 
of dynamic contour tonometry and Goldmann applanation tonometry. 
J Glaucoma 2006;15:2–6
DCT 100 Age – not reported
Theofylaktopoulos I, Diestelhorst M, Krieglstein GK. Self-tonometry with the 
Ocuton S versus Goldmann tonometry. Graefes Arch Clin Exp Ophthalmol 
1999;237:720–4
Ocuton S 100 Age – not reported
Verdoorn C, Deutman AF. Clinical evaluation of the Topcon CT10 tonometer. 
Int Ophthalmol 1988;12:223–5
NCT 115 Age – not reported
Frenkel RE, Hong YJ, Shin DH. Comparison of the Tono-Pen to the 
Goldmann applanation tonometer. Arch Ophthalmol 1988;106:750–3
TonoPen 142 Age – not reported
Minckler DS, Baerveldt G, Heuer DK, Quillen-Thomas B, Walonker AF, 
Weiner J. Clinical evaluation of the Oculab Tono-Pen. Am J Ophthalmol 
1987;104:168–73
TonoPen 130 Age – not reported
Wingert TA, Bassi CJ, McAlister WH, Galanis JC. Clinical evaluation of five 
portable tonometers. J Am Optom Assoc 1995;66:670–4
TonoPen, Perkins, 
NCT, Schiotz
31 Age – not reported
Armstrong TA. Evaluation of the Tono-Pen and the Pulsair tonometers. Am J 
Ophthalmol 1990;109:716–20
TonoPen, NCT 130 Age – not reported
Bhan A, Browning AC, Shah S, Hamilton R, Dave D, Dua HS. Effect 
of corneal thickness on intraocular pressure measurements with the 
pneumotonometer, Goldmann applanation tonometer, and Tono-Pen. Invest 
Ophthalmol Vis Sci 2002;43:1389–92
Ocular blood flow, 
TonoPen
94 Age – not reported
Boothe WA, Lee DA, Panek WC, Pettit TH. The Tono-Pen. A manometric and 
clinical study. Arch Ophthalmol 1988;106:1214–17
TonoPen, 
pneumotonometer
50 Age – not reported
Siganos DS, Papastergiou GI, Moedas C. Assessment of the Pascal dynamic 
contour tonometer in monitoring intraocular pressure in unoperated eyes 
and eyes after LASIK. J Cataract Refract Surg 2004;30:746–51
DCT, NCT 60 Age – not reported
Farrar SM, Miller KN, Shields MB, Stoup CM. An evaluation of the Tono-Pen 
for the measurement of diurnal intraocular pressure. Am J Ophthalmol 
1989;107:411–16
TonoPen 30 Age – not reported
Baddon AC, Osborne SF, Quah SA, Batterbury M, Wong D. Comparison of 
Luneau SA disposable and Goldmann applanation tonometer readings. Eye 
2007;21:789–92
Disposable prism 79 Comparison of disposable 
prims
Bhatnagar A, Gupta AK. Disposable devices for measuring intraocular 
pressure: a clinical study to assess their accuracy. Eye 2005;19:752–4
Disposable prism 40 Comparison of disposable 
prims
Desai SP, Sivakumar S, Fryers PT. Evaluation of a disposable prism for 
applanation tonometry. Eye 2001;15:3–82
Disposable prism 100 Comparison of disposable 
prims
Goel S, Chua C, Dong B, Butcher M, Ahfat F, Hindi SK, et al. Comparison 
between standard Goldmann applanation prism and disposable applanation 
prism in tonometry. Eye 2004;18:175–8
Disposable prism 42 Comparison of disposable 
prims
Kim P, Lertsumitkul S, Clark M, Gardner L, Macken P. Accuracy of the 
Tonosafe disposable tonometer head compared to the Goldmann tonometer 
alone. Clin Exp Ophthalmol 2004;32:364–7
Disposable prism 69 Comparison of disposable 
prims
Lotti R, Frau B, Cerruti S, Trillo C, Traverso CE. Reliability of applanation 
tonometry readings obtained with a disposable latex cap. Ophthalmologica 
1999;213:277–80
Disposable prisms  80 Comparison of disposable 
prisms
Maino AP, Uddin HJ, Tullo AB. A comparison of clinical performance 
between disposable and Goldmann tonometers. Eye 2006;20:574–8
Disposable prisms  153 Comparison of disposable 
prisms
Maldonado MJ, Rodriguez-Galietero A, Cano-Parra J, Menezo JL, Diaz-
Llopis M. Goldmann applanation tonometry using sterile disposable silicone 
tonometer shields. Ophthalmology 1996;103:815–21
Disposable prisms  60 Comparison of disposable 
prisms
Salvi SM, Sivakumar S, Sidiki SS. Use of disposable prism tonometry in 
routine clinical practice. Eye 2005;19:743–6
Disposable prisms  200 Comparison of disposable 
prisms192 Appendix 2
Study details  Technology
No. of 
participants Reasons for exclusion
Lim L, Ng TP, Tan DT. Accurate intraocular pressure measurement in contact 
lens wearers with normal pressures. CLAO J 1997;23:130–3
TonoPen 20 Contact lens wearers
Choi WJ, Kim JW, Tchah H, Jin YH, Kim YJ. Non-contact tonometry: an ideal 
method for mass screening. Korean J Ophthalmol 1990;4:30–3
NCT 76 Corneal disease
Hamilton KE, Pye DC, Kao L, Pham N, Tran AQ. The effect of corneal 
edema on dynamic contour and Goldmann tonometry. Optom Vis Sci 
2008;85:451–6
DCT  30 Corneal disease
Chew GS, Sanderson GF, Molteno AC. The pressure phosphene tonometer – 
a clinical evaluation. Eye 2005;19:683–5
PPT 100 Corneal disease
Lisle C, Ehlers N. A clinical comparison of the Xpert non-contact tonometer 
with the Goldmann applanation tonometer after penetrating keratoplasty. 
Acta Ophthalmol Scand 2000;78:211–15
NCT 42 Corneal surgery
Alfaro DV, Tran VT. A clinical comparison of the Oculab Tono-Pen with the 
Goldmann applanation tonometer in eyes filled with silicone oil. Retina 
1991;11:219–20
TonoPen 21 Eyes filled with silicone
Stodtmeister R, Kron M, Gaus W. IOP measurement and central corneal 
thickness. Br J Ophthalmol 2002;86:120–1
NA NA Letter
Leung DY, Lam DS. Clinical comparison of the Proview eye pressure 
monitor with the Goldmann applanation tonometer and the TonoPen. Arch 
Ophthalmol 2005;123:578–9
NA NA Letter (related to included 
paper)
Bayraktar S, Bayraktar Z. Central corneal thickness and intraocular pressure 
relationship in eyes with and without previous LASIK: comparison of 
Goldmann applanation tonometer with pneumatonometer. Eur J Ophthalmol 
2005;15:81–8
Pneumotonometer 234 No candidate tonometer
Abbasoglu OE, Bowman RW, Cavanagh HD, McCulley JP. Reliability of 
intraocular pressure measurements after myopic excimer photorefractive 
keratectomy. Ophthalmology 1998;105:2193–6
Ocular blood flow 21 No candidate tonometer
Dielemans I, Vingerling JR, Hofman A, Grobbee DE, de Jong PT. Reliability 
of intraocular pressure measurement with the Goldmann applanation 
tonometer in epidemiological studies. Graefes Arch Clin Exp Ophthalmol 
1994;232:141–4
GAT 62 No candidate tonometer
Duch S, Serra A, Castanera J, Abos R, Quintana M. Tonometry after laser in 
situ keratomileusis treatment. J Glaucoma 2001;10:261–5
Ocular blood flow 60 No candidate tonometer
Gardiner SK, Demirel S. Assessment of patient opinions of different 
clinical tests used in the management of glaucoma. Ophthalmology 
2008;115:2127–31
None 101 No candidate tonometer
Hallberg P, Eklund A, Bäcklund T, Lindén C. Clinical evaluation of 
applanation resonance tonometry: a comparison with Goldmann 
applanation tonometry. J Glaucoma 2007;16:88–93
Applanation 
resonance tonometry
78 No candidate tonometer
Nardi M, Bartolomei MP, Romani A, Barca L. Intraocular pressure changes 
in secondary positions of gaze in normal subjects and in restrictive ocular 
motility disorders. Graefes Arch Clin Exp Ophthalmol 1988;226:8–10
GAT 85 No candidate tonometer
Singh RP, Goldberg I, Graham SL, Sharma A, Mohsin M. Central corneal 
thickness, tonometry, and ocular dimensions in glaucoma and ocular 
hypertension. J Glaucoma 2001;10:206–10
Ocular blood flow 87 No candidate tonometer
Vaegan, RAM, Sanderson GF. Glaucoma affects steady state VEP contrast 
thresholds before psychophysics. Optom Vis Sci 2008;85:547–58
None 42 No candidate tonometer
Wang X, Shen J, McCulley JP, Bowman RW, Petroll WM, Cavanagh 
HD. Intraocular pressure measurement after hyperopic LASIK. CLAO J 
2002;28:136–9
Ocular blood flow 15 No candidate tonometer
Zadok D, Tran DB, Twa M, Carpenter M, Schanzlin DJ. Pneumotonometry 
versus Goldmann tonometry after laser in situ keratomileusis for myopia.  
J Cataract Refract Surg 1999;25:1344–8
Pneumotonometer 17 No candidate tonometer
Schmidt KG, von Ruckmann A, Pillunat LE. Topical carbonic anhydrase 
inhibition increases ocular pulse amplitude in high tension primary open 
angle glaucoma. Br J Ophthalmol 1998;82:758–62
Ocular blood flow 33 No candidate tonometer© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Study details  Technology
No. of 
participants Reasons for exclusion
Georgopoulos GT, Diestelhorst M, Fisher R, Ruokonen P, Krieglstein GK. The 
short-term effect of latanoprost on intraocular pressure and pulsatile ocular 
blood flow. Acta Ophthalmol Scand 2002;80:54–8
Ocular blood flow 24 No candidate tonometer
Wolfs RC, Klaver CC, Vingerling JR, Grobbee DE, Hofman A, de Jong PT. 
Distribution of central corneal thickness and its association with intraocular 
pressure: the Rotterdam Study. Am J Ophthalmol 1997;123:767–72
None 395 No candidate tonometer
Shah S, Chatterjee A, Mathai M, Kelly SP, Kwartz J, Henson D, et al. 
Relationship between corneal thickness and measured intraocular pressure 
in a general ophthalmology clinic. Ophthalmology 1999;106:2154–60
None 868 (eyes) No candidate tonometer
Troost R, Vogel A, Beck S, Schwenn O, Grus F, Pfeiffer N. Clinical 
comparison of two intraocular pressure measurement methods: SmartLens 
dynamic observing tonography versus Goldmann. Graefes Arch Clin Exp 
Ophthalmol 2001;239:889–92
SmartLens 80 No candidate tonometer
Munger R, Hodge WG, Mintsioulis G, Agapitos PJ, Jackson WB, Damji KF. 
Correction of intraocular pressure for changes in central corneal thickness 
following photorefractive keratectomy. Can J Ophthalmol 1998;33:159–65
None 318 No candidate tonometer
Hoffmann EM, Grus FH, Pfeiffer N. Intraocular pressure and ocular pulse 
amplitude using dynamic contour tonometry and contact lens tonometry. 
BMC Ophthalmol 2004;4:4
DCT, SmartLens 19 No candidate tonometer 
(prototype version of DCT)
Kontiola A. A new electromechanical method for measuring intraocular 
pressure. Doca Ophthalmol 1996;93:265–76
Electromechanical 
method
Pig eyes Non-human population
Erdurmus M, Totan Y, Hepsen IF, Yagci R. Comparison of dynamic contour 
tonometry and noncontact tonometry in ocular hypertension and glaucoma. 
Eye 2009;23:663–8
DCT, NCT 104 Reference tonometer not 
used
Garcia-Resua C, Gonzalez-Meijome JM, Gilino J, Yebra-Pimentel E. 
Accuracy of the new ICare rebound tonometer vs. other portable 
tonometers in healthy eyes. Optom Vis Sci 2006;83:102–7
RT, TonoPen 65 Reference tonometer not 
used
Moreno-Montanes J, Garcia N, Fernandez-Hortelano A, Garcia-Layana A. 
Rebound tonometer compared with Goldmann tonometer in normal and 
pathologic corneas. Cornea 2007;26:427–30
RT 150 Reference tonometer not 
used
Moreno-Montanes J, Maldonado MJ, Garcia N, Mendiluce L, Garcia-
Gomez PJ, Segui-Gomez M. Reproducibility and clinical relevance of the 
ocular response analyzer in nonoperated eyes: corneal biomechanical and 
tonometric implications. Invest Ophthalmol Vis Sci 2008;49:968–74
ORA 262 Reference tonometer not 
used
Kontiola A, Puska P. Measuring intraocular pressure with the Pulsair 3000 
and Rebound tonometers in elderly patients without an anesthetic. Graefes 
Arch Clin Exp Ophthalmol 2004;242:3–7
RT  131 Reference tonometer not 
used
Herdener S, Pache M, Lautebach S, Funk J. Dynamic contour tonometry 
(DCT) versus Goldmann applanation tonometry (GAT) – a comparison 
of agreement and reproducibility. Graefes Arch Clin Exp Ophthalmol 
2007;245:1027–30
DCT  23 Same study sample as in 
an included study
NA, not available.194 Appendix 2
Economic evaluations of ocular hypertension surveillance 
programmes (Chapter 8)
Reference Reason for exclusion
Althin R, Grima DT, Dhawan R, Bernard LM. Considerations in developing model-based economic evaluations of 
glaucoma treatment. J Glaucoma 2006;15:541–7
Not surveillance strategy
Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO, Ocular Hypertension Treatment Study Group (OHTS). 
Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. 
Am J Ophthalmol 2006;141:997–1008
Not surveillance strategy
Peeters A, Schouten JS, Webers CA, Prins MH, Hendrikse F, Severens JL. Cost-effectiveness of early detection and 
treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist. Eye 2008;22:354–62
Not surveillance strategy
Stewart WC, Stewart JA, Nasser QJ, Mychaskiw MA. Cost-effectiveness of treating ocular hypertension. Ophthalmology 
2008;115:94–8
Not surveillance strategy
Tuck MW, Crick RP. The cost-effectiveness of various modes of screening for primary open angle glaucoma. Ophthal 
Epidemiol 1997;4:3–17
Not surveillance strategy
Coast J, Spencer IC, Smith L, Spry PG. Comparing costs of monitoring glaucoma patients: hospital ophthalmologists 
versus community optometrists. J Health Serv Res Policy 1997;2:19–25 
Not OHT patients
Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension:  
a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States.  
J Glaucoma 1998;7:95–104
Description of costs only
Spencer IC, Spry PG, Gray SF, Baker IA, Menage MJ, Easty DL, et al. The Bristol Shared Care Glaucoma Study: study 
design. Ophthal Physiol Optics 1995;15:391–4
Model design without 
results
van Gestel A, Severens JL, Webers CA, Beckers HJ, Jansonius NM, Schouten JS. Modeling complex treatment 
strategies: construction and validation of a discrete event simulation model for glaucoma. Value Health 2010;13: 
358–67
Model design without 
results
Gottlieb LK, Schwartz B, Pauker SG. Glaucoma screening. A cost-effectiveness analysis. Surv Ophthalmol 
1983;28:206–26
Review article
Rosenbaum LJ. Management of patients with ocular hypertension: a cost-effectiveness approach from the Ocular 
Hypertension Treatment Study. Am J Ophthalmol 2007;143:191–2
Letter© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Appendix 4 
Systematic review of the agreement and 
reliability of tonometers: further analysis 
(Chapter 5)
F
ull results of the sensitivity analyses and subgroup/factor analyses as detailed in Chapter 5, 
Data analysis are given below by tonometer.
Dynamic contour tonometry
The full results of all analyses (main and sensitivity) are reported in Table 60. The impact of the 
sensitivity analyses and subgroup analyses and a summary of the factor analyses are given below.
Sensitivity analyses
The fixed-effect estimates were marginally different for the mean difference (1.7 mmHg; 95% CI 
1.6 mmHg to 1.7 mmHg) and random error (2.2 mmHg; 95% CI 2.1 mmHg to 2.2 mmHg). The 
imputed correlation value had little impact on the estimates for either random- or fixed-effect(s) 
meta-analyses. Exclusion of studies classified as low quality similarly did not have a substantial 
impact on the estimates of either the mean difference or the random error and therefore the 
LoA. Using studies in which only one eye per participant was included led to a mean difference 
of 1.9 mmHg (95% CI 1.4 mmHg to 2.5 mmHg) and a random error of 2.5 mmHg (95% CI 
2.2 mmHg to 2.7 mmHg). The sensitivity analyses, which sought to address the impact of differing 
numbers of repeated observations (SMD and adjustment for repeated measurements analyses), 
did not lead to substantially different estimates of the mean difference although, as expected, the 
latter (based on a single measurement of both GAT and DCT across studies) had a slightly larger 
random error estimate of 2.7 mmHg (95% CI 2.5 mmHg to 2.9 mmHg) versus 2.4 mmHg (95% CI 
2.1 mmHg to 2.7 mmHg). None of the sensitivity analyses had a marked impact on the observed 
heterogeneity. The impact on the LoA of these analyses is also shown in Table 60.
Clinical factor analyses
A meta-analysis investigating the impact of manufacturer was not possible as there was a sole 
manufacturer. Analyses exploring the IOP, impact of refractive surgery and examiner type were 
carried out involving 32, 21 and 18 studies, respectively. It was not clear that refractive surgery 
influenced the mean difference: 2.2 mmHg (95% CI –1.2 mmHg to 5.5 mmHg) for operative 
participants versus 2.0 mmHg (95% CI 1.6 mmHg to 2.5 mmHg) for non-operative patients. 
There was no suggestion of an impact on the mean difference of examiner type: ophthalmologist 
1.5 mmHg (95% CI 0.8 mmHg to 2.3 mmHg) versus non-ophthalmologist 1.7 mmHg (95% CI 
1.1 mmHg to 2.3 mmHg).
Two studies131,210 reported results for IOP subgroups. In the study by Johannesson and 
colleagues.210 the mean IOP difference between DCT and GAT was 2.5 mmHg for patients with 
the lowest IOP (< 16 mmHg), 1.3 mmHg for mid-range IOP and −0.8 mmHg for those with the 
highest IOP (> 23 mmHg). Punjabi and colleagues,131 however, reported very little difference 
between high- and low-IOP subgroups, with a mean IOP difference of 1.8 mmHg for patients 
in the primary open-angle glaucoma group (all of whom had IOP > 22 mmHg) and a mean IOP 204 Appendix 4
difference of 1.7 mmHg in the normal-tension glaucoma group (IOP ≤ 22 mmHg). Four further 
studies130,141,148,218 carried out similar subgroup analyses of mean IOP difference by categorising 
patients as either healthy or glaucomatous, but this is not directly equivalent to an IOP 
subgroup analysis.
A total of 26 out of the 32 DCT studies in the meta-analysis (81%) reported CCT results, of 
which 14 related the results to difference in IOP measurements between DCT and GAT. Eleven 
studies110,134,141,143,144,161,163,202,203,210,215 reported varying levels of correlation (from no correlation 
to a correlation coefficient of 0.46 in one study141) and the other three studies123,148,189 reported 
results directly relating to CCT subgroups. Martinez-de-la-Casa and colleagues189 reported 
the mean IOP difference between DCT and GAT as 5.5 mmHg for patients in the lowest CCT 
tertile (≤ 530 µm), 4.2 mmHg for mid-range CCT and 3.5 mmHg for those in the highest CCT 
tertile (> 565 µm). In the Doyle and Lachkar study,123 the mean difference was 2.6 mmHg for 
patients in the lowest CCT tertile (≤ 530 µm), 0.1 mmHg for mid-range CCT and 0.1 mmHg for 
those in the highest CCT tertile (> 580 µm). Ceruti and colleagues148 reported the mean IOP 
difference in healthy subjects as 3.7 mmHg for patients with low CCT (≤ 530 µm), 2.9 mmHg for 
mid-range CCT and 2.3 mmHg for those in the highest CCT tertile (> 560 µm). Using the same 
CCT thresholds as in their analysis of healthy patients, the Ceruti and colleagues study148 also 
reported mean differences in patients with open-angle glaucoma of 4.2, 2.3 and 0.7 mmHg and 
in patients with angle-closure glaucoma of 3.5, 2.0 and 1.3 mmHg for low, mid-range and high 
CCT, respectively.
Three DCT studies reported preoperative and postoperative results for a cohort of patients 
undergoing refractive surgery. Duba and Wirthlin186 reported a preoperative mean difference of 
1.9 mmHg and a 3-month post-laser-assisted in situ keratomileusis (LASIK) mean difference of 
4.2 mmHg. Pepose and colleagues135 reported a preoperative mean difference of 3.3 mmHg and 
a 1-week post-LASIK mean difference of 4.5 mmHg. Liu and colleagues171 reported a mean IOP 
difference prior to LASIK surgery of 1.3 mmHg compared with 5 mmHg 1 week postoperatively 
and 5.45 mmHg after 4 weeks. A further study150 found a mean difference of 2.4 mmHg in 
non-operated corneas and a mean difference of 1.5 mmHg in corneas thinned by photorefractive 
keratectomy, but these groups were independent samples and not necessarily comparable.
Non-contact tonometry
The full results of all analyses (main and sensitivity) are reported in Table 61. The impact of the 
sensitivity analyses and subgroup analyses and a summary of the factor analyses are given below.
Sensitivity analyses
The fixed-effect estimates were marginally different for the mean difference (0.1 mmHg; 95% CI 
0.0 mmHg to 0.2 mmHg) and random error (1.8 mmHg; 95% CI 1.7 mmHg to 1.8 mmHg). The 
imputed correlation value had little impact on the estimates for either random- or fixed-effect(s) 
meta-analyses. Exclusion of low-quality studies did not have a substantial impact on the estimates 
for either the mean difference or the random error. Only analysing studies in which one eye per 
participant was used led to a mean difference of 0.5 mmHg (95% CI 0.0 mmHg to 0.9 mmHg) 
and random error of 2.0 mmHg (95% CI 1.8 mmHg to 2.3 mmHg). The impact on the LoA is 
also shown in Table 61. The sensitivity analyses, which sought to address the impact of differing 
numbers of repeated observations (SMD and adjustment for repeated measurements analyses), 
did not lead to substantially different estimates of the mean difference although random error 
was substantially larger (2.6 mmHg vs 2.1 mmHg). None of the sensitivity analyses had a marked 
impact on the observed heterogeneity.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Clinical factor analyses
It was not possible to carry out a subgroup meta-analysis investigating the impact of IOP and 
CCT because of the way that the data were reported in individual studies. Analyses exploring 
the impact of refractive surgery, examiner type and manufacturer were carried out and included 
10, 11 and 24 studies, respectively. It was possible, although not clear, that receiving refractive 
surgery impacted on the mean difference; however, this was based on a small number of studies 
with operative patients. There was no suggestion of an impact on the mean difference according 
to examiner type [ophthalmologist 1.0 mmHg (95% CI 0.3 mmHg to 1.6 mmHg) and non-
ophthalmologist 0.4 mmHg (95% CI –0.5 mmHg to1.3 mmHg)] or self-tonometry –0.5 mmHg 
(–95% CI –0.9 mmHg to –0.1 mmHg). Manufacturer-based estimates of mean difference were 
broadly similar.
Two NCT studies182,196 reported results for IOP subgroups. In Van de Velde and Zeyen,182 
the mean IOP difference between NCT and GAT was 0.8 mmHg for patients with the lowest 
IOP (< 12 mmHg), 0.4 mmHg for mid-range IOP and 0.6 mmHg for those with the highest 
IOP (> 18 mmHg). Conversely, Gupta and colleagues196 reported a mean IOP difference of 
0.4 mmHg for patients with IOP of ≤ 18 mmHg and −1.7 mmHg for those with the highest IOP 
(> 18 mmHg). One study152 carried out a regression of the mean difference on the underlying IOP 
(average of NCT and GAT values), which suggested that values of –1 to 2 mmHg were plausible.
A total of 6 out of the 26 NCT studies reported CCT results, three of which reported correlation 
between CCT levels and the IOP difference between GAT and NCT. The correlation coefficient in 
the Papastergiou and colleagues study201 was 0.34, Murase and colleagues180 reported a correlation 
coefficient of 0.53 and Tonnu and colleagues152 reported a value of 0.25. However, none of the six 
studies reported results that directly related to CCT subgroups.
Three studies reported preoperative and postoperative results for a cohort of patients 
undergoing refractive surgery. Garzozi and colleagues206 reported mean differences of 0.1 mmHg 
preoperatively with 0.2 mmHg 1 year after photorefractive keratectomy, Naruse and colleagues178 
reported a preoperative mean difference of –1.6 mmHg with a 1-week post-LASIK mean 
difference of –2.2 mmHg and Cheng and colleagues176 reported a mean difference of 0.5 mmHg 
preoperatively with a 3-month post-LASIK difference of –4.5 mmHg.
Ocuton S
The full results of all analyses (main and sensitivity) are reported in Table 62. The impact of the 
sensitivity analyses and subgroup analyses and a summary of the factor analyses are given below.
Sensitivity analyses
The fixed-effect estimates (mean correlation) were marginally different for the mean difference 
(2.4 mmHg; 95% CI 1.9 mmHg to 3.0 mmHg) and random error (3.5 mmHg; 95% CI 3.1 mmHg 
to 3.9 mmHg). It was not necessary to input any correlation values. None of the studies was 
classified as low quality. Using the studies in which only one eye per participant was included 
led to a mean difference of 4.4 mmHg (95% CI 0.5 mmHg to 8.2 mmHg) and random error 
of 3.2 mmHg (95% CI 1.4 mmHg to 5.0 mmHg). The sensitivity analyses to address the 
impact of differing numbers of repeated observations (SMD only) led to a SMD of 0.6 mmHg 
(95% CI –0.2 mmHg to 1.5 mmHg) although the I2 was still very large (97%). The adjustment 
of the repeated measurements led to a marginally smaller mean difference and as anticipated a 
slightly larger random error (5.2 mmHg; 95% CI 4.3 mmHg to 6.2 mmHg). None of the sensitivity 
analyses had a marked impact on the observed heterogeneity. The impact on the LoA of these 
analyses is also shown in Table 62.210 Appendix 4
Clinical factor analyses
A subgroup meta-analysis investigating the impact of CCT, refractive surgery, examiner type 
and manufacturer was not performed either because of the way that the data were reported in 
individual studies or because there were no studies representing a particular clinical factor.
Three studies were included in IOP analysis with the suggestion of a difference in mean difference 
depending on IOP level (–0.5 mmHg vs 4.4 mmHg). No Ocuton S studies reported preoperative 
and postoperative results for a cohort of patients undergoing refractive surgery. One Ocuton S 
study reported CCT results146 but, although the CCT results were reported in relation to IOP 
measurements, it did not report results for any CCT subgroups. It was not possible to conduct 
an examiner analysis as none of the studies had an ophthalmologist examiner. All studies used a 
tonometer by the same manufacturer.
Ocular response analyser
The full results of all analyses (main and sensitivity) are reported in Table 63. The impact of the 
sensitivity analyses and subgroup analyses and a summary of the factor analyses are given below.
Sensitivity analyses
The fixed-effect estimates (mean correlation) were marginally different for the mean difference 
(1.2 mmHg; 95% CI 1.1 mmHg to 1.4 mmHg) and random error (2.7 mmHg; 95% CI 2.6 mmHg 
to 2.9 mmHg). The imputed correlation value had little impact on the estimates for either 
random- or fixed-effect(s) meta-analyses. Exclusion of the sole low-quality study184 did not 
have a substantial impact on the estimates of either the mean difference or the random error. 
Using studies in which only one eye per participant was included led to a mean difference of 
1.8 mmHg (95% CI 1.0 mmHg to 2.7 mmHg) and random error of 2.8 mmHg (95% CI 2.4 mmHg 
to 3.2 mmHg). The sensitivity analyses addressing the impact of differing numbers of repeated 
observations (SMD) led to a SMD of 0.4 mmHg (95% CI 0.3 mmHg to 0.6 mmHg) although the 
I2 was still very large (88%). The adjustment of the repeated measurements did not alter the mean 
difference estimate although, as anticipated, there was a slightly larger random effect estimate. 
None of the sensitivity analyses had a marked impact on the observed heterogeneity. The impact 
on the LoA of these analyses is also shown in Table 63.
Clinical factor analyses
A subgroup meta-analysis investigating the impact of IOP, CCT and manufacturer was not 
performed either because of the way that the data were reported in individual studies or because 
studies represented only one subgroup. Analyses exploring the impact of refractive surgery 
and examiner type were carried out involving 11 and 6 studies, respectively. Neither refractive 
surgery nor examiner type appeared to have any impact although only one study included 
ophthalmologist examiners. None of the studies used patient examiners.
No ORA studies reported results for IOP subgroups. However, Morita and colleagues130 carried 
out a subgroup analysis of mean IOP difference by categorising patients as either healthy or 
glaucomatous, but this is not equivalent to an IOP subgroup analysis. One study110 regressed the 
difference between ORA and GAT values to the underlying (average) IOP value. The estimated 
correlation was 0.41 with a slope of –0.3 (mmHg).
A total of 5 out of the 12 studies reported results for CCT with two reporting low correlation 
between CCT levels and the IOP difference between ORA and GAT. These studies were those by 
Lam and colleagues,174 with a correlation coefficient of 0.17, and Kotecha and colleagues,110 with a 
value of 0.1.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Two studies reported preoperative and postoperative results for a cohort of patients undergoing 
refractive surgery. Pepose and colleagues135 reported a preoperative mean difference of 1.6 mmHg 
and a 1-week post-LASIK mean difference of 1.1 mmHg. Kirwan and O’Keefe214 reported a pre-
LASIK mean difference of 0.7 mmHg with a 3-month postoperative mean difference of 3.5 mmHg 
and, similarly, a pre-laser-assisted subepithelial keratectomy mean difference of 0.2 mmHg with a 
3-month postoperative mean difference of 2.8 mmHg.
Perkins
The full results of all analyses (main and sensitivity) are reported in Table 64. The impact of the 
sensitivity analyses and subgroup analyses and a summary of the factor analyses are given below.
Sensitivity analyses
The fixed-effect estimates (mean correlation) were quite different for the mean difference 
(–0.4 mmHg; 95% CI –0.5 mmHg to –0.2 mmHg) because of the impact of one study.166 This 
was not the case for the random error (2.1 mmHg; 95% CI 1.3 mmHg to 2.8 mmHg), which was 
similar. The imputed correlation value had little impact on the estimates for either random- or 
fixed-effect(s) meta-analyses. None of the studies was classified as low quality. Excluding the 
one study which used data from both eyes of the same individual from the analysis did affect the 
results. However, this was driven by the unusual results of this study.166 The sensitivity analyses 
to address the impact of differing numbers of repeated observations (SMD) led to a SMD of 
0.0 mmHg (95% CI –0.1 to 0.1 mmHg) although the I2 was still very large (70%). The adjustment 
for repeated measurements was not conducted as none of the studies reported the appropriate 
data. None of the sensitivity analyses had an impact on the observed heterogeneity. The impact 
on the LoA of these analyses is also shown in Table 64.
Clinical factor analyses
No subgroup meta-analyses were performed either because of the way that the data were 
reported in individual studies or because of a lack of studies representing different groups.
None of the Perkins tonometer studies reported results for IOP subgroups, nor did any study 
report CCT results. There were also no studies that reported preoperative and postoperative 
results for a cohort of patients undergoing refractive surgery. An analysis of examiner or 
manufacturer was not carried out. General practitioners used the Perkins tonometer in the 
Jackson and colleagues study,166 which had a high mean difference and random error relative to 
the other studies.
Rebound tonometry
The full results of all analyses (main and sensitivity) are reported in Table 65. The impact of the 
sensitivity analyses and subgroup analyses and a summary of the factor analyses are given below.
Sensitivity analyses
The fixed-effect estimates (mean correlation) were marginally different for the mean difference 
(1.4 mmHg; 95% CI 1.3 mmHg to 1.5 mmHg) and random error (1.8 mmHg; 95% CI 1.8 mmHg 
to 1.9 mmHg). No imputation of the correlation value was needed. Exclusion of low-quality 
studies led to a slightly lower mean difference whereas the random error was the same. Using 
studies in which only one eye per participant was included led to a mean difference of 0.5 mmHg 
(95% CI 0.0 mmHg to 1.0 mmHg) and random error of 2.7 mmHg (95% CI 2.4 mmHg to 
3.1 mmHg). The sensitivity analyses to address the impact of differing numbers of repeated © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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observations (SMD) led to a SMD of 0.2 mmHg (95% CI 0.1 to 0. 3 mmHg). None of the 
sensitivity analysis had a marked impact on the observed heterogeneity. The impact on the LoA 
of these analyses is also shown in Table 65.
Clinical factor analyses
A subgroup meta-analysis investigating the impact of CCT, refractive surgery and manufacturer 
was not performed because of the way that the data were reported in individual studies for CCT 
and refractive surgery, and because there was only a sole manufacturer. Analyses exploring the 
IOP and examiner type were carried out involving 13 and 11 studies, respectively. The underlying 
IOP level did not appear to have an impact on mean difference or random error although the 
random error for the higher IOP group was larger. There was no clear evidence of an impact on 
the mean difference of examiner: ophthalmologist 0.8 mmHg (95% CI 0.0 mmHg to 1.5 mmHg) 
and non-ophthalmologist 1.3 mmHg (95% CI 0.5 mmHg to 2.1 mmHg). None of the studies used 
patient examiners.
Three RT studies reported results for IOP subgroups. In Sahin and colleagues,211 the mean 
IOP difference between RT and GAT was 0 mmHg for patients with IOP within the normal 
range (< 20 mmHg) and 1.9 mmHg for those with high IOP (≥ 20 mmHg). Johannesson 
and colleagues210 reported a mean difference of 2.4 mmHg for patients with the lowest IOP 
(< 16 mmHg), 2.4 mmHg for mid-range IOP and 1.3 mmHg for those with the highest IOP 
(> 23 mmHg). Pakrou and colleagues167 was the only study in the whole review to use the 
21-mmHg threshold of OHT to define subgroups. In this study, patients with IOP < 21 mmHg 
had a mean difference of 0.7 mmHg compared with –0.7 mmHg for those with high IOP.
A total of 8 of the 14 RT studies reported CCT results, five of which related CCT levels to the 
IOP difference between GAT and RT. One of these studies189 presented results relating directly to 
CCT subgroups with a mean IOP difference between RT and GAT of 0.4 mmHg for patients in 
the lowest CCT tertile (≤ 530 µm), 2.3 mmHg for mid-range CCT and 1.5 mmHg for those in the 
highest CCT tertile (> 565 µm). The other studies reported correlation between IOP difference 
and CCT, with correlation coefficients of 0.42 in Johannesson and colleagues,210 0.3 in Sahin and 
colleagues,211 0.63 in Brusini and colleagues145 and 0.47 in Nakamura and colleagues.107
No RT studies reported preoperative and postoperative results for a cohort of patients 
undergoing refractive surgery.
TonoPen
The full results of all analyses (main and sensitivity) are reported in Table 66. The impact of the 
sensitivity analyses and subgroup analyses and a summary of the factor analyses are given below.
Sensitivity analyses
The fixed effect estimates (mean correlation) were marginally different for the mean difference 
(–0.1 mmHg; 95% CI –0.2 mmHg to 0.0 mmHg) and random error (2.1 mmHg; 95% CI 
2.0 mmHg to 2.2 mmHg). The imputed correlation value had little impact on the estimates for 
either random- or fixed-effect(s) meta-analyses. Exclusion of low-quality studies did not have 
a substantial impact on the estimates for either the mean difference or the random error. Using 
studies in which only one eye per participant was included led to a mean difference of 0.3 mmHg 
(95% CI –0.7 mmHg to 1.2 mmHg) and random error of 3.0 mmHg (95% CI 2.5 mmHg to 
3.5 mmHg). The sensitivity analyses to address the impact of differing numbers of repeated 
observations (SMD) led to a SMD of 0.1 mmHg (95% CI 0.0 mmHg to 0.3 mmHg) although the I2 
was still very large (94%). The adjustment for repeated measurements led to a marginally smaller © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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mean difference and slightly larger random effect as anticipated. None of the sensitivity analysis 
had a marked impact on the observed heterogeneity. The impact on the LoA of these analyses is 
also shown in Table 66.
Clinical factor analyses
A meta-analysis investigating the impact of CCT was not performed because of the way that 
the data were reported in individual studies. Analyses exploring the IOP, refractive surgery, 
examiner type and manufacturer were carried out involving 12, 3, 10 and 12 studies, respectively. 
There was no clear evidence that underlying IOP level had an impact on either the mean 
difference or random error although there was only a single study in the higher IOP group. 
Refractive surgery did not appear to have any impact although there was only one study with 
no operative participants available. There was a suggestion of an impact on the mean difference 
according to examiner: ophthalmologist –0.8 mmHg (95% CI –1.5 mmHg to –0.2 mmHg) and 
non-ophthalmologist –0.3 mmHg (95% CI –2.5 mmHg to 1.9 mmHg). GPs used the Perkins 
tonometer in the Jackson and colleagues study,166 which had a high mean difference relative to 
the other studies. None of the studies had patients as examiners. There was no clear evidence of a 
difference in either the mean difference or the random error between manufacturers.
Results for IOP subgroups were reported in two studies. In the Kooner and colleagues study,140 
the mean IOP difference between TonoPen and GAT was 0.5 mmHg for patients with the lowest 
IOP (< 16 mmHg), −1.8 mmHg for mid-range IOP (16–30 mmHg) and −7.1 mmHg for the single 
patient with IOP > 30 mmHg. A similar pattern was observed by Horowitz and colleagues,169 
who reported a mean difference of 0.5 mmHg for patients with the lowest IOP (< 16 mmHg), 
0.1 mmHg for mid-range IOP and –2.2 mmHg for those with the highest IOP (between 20 
and 30 mmHg).
Three TonoPen studies reported CCT results, two of which reported the correlation between 
CCT levels and the difference in IOP between TonoPen and GAT. Both studies had an 
identical low correlation of 0.2.144,152 No TonoPen study reported results directly in relation to 
CCT subgroups.
Two TonoPen studies reported preoperative and postoperative results for a cohort of patients 
undergoing refractive surgery, both of which measured IOP in the central part of the cornea 
preoperatively and 1 month following photorefractive keratectomy. Schipper and colleagues188 
reported a preoperative mean difference of 0.4 mmHg with a postoperative mean difference of 
1.2 mmHg and Garzozi and colleagues206 reported a preoperative mean difference of 0.1 mmHg 
and a postoperative mean difference of 0.3 mmHg. Schipper and colleagues also reported a 
mean difference of 0.1 mmHg after 3 months, but only followed up 27 patients from the original 
cohort of 35.
Transpalpebral
The full results of all analyses (main and sensitivity) are reported in Table 67. The impact of the 
sensitivity analyses and subgroup analyses and a summary of the factor analyses are given below.
Sensitivity analyses
The fixed-effect estimates (mean correlation) were marginally different for the mean difference 
(–0.1 mmHg; 95% CI –0.3 mmHg to 0.0 mmHg) and random error (2.5 mmHg; 95% CI 
2.4 mmHg to 2.5 mmHg). The imputed correlation value had little impact on the estimates 
for either random- or fixed-effect(s) meta-analyses. Exclusion of low-quality studies did not 
have a substantial impact on the estimates of either the mean difference or the random error © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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(a slight increase in the former and a reduction in the latter). Using studies in which only one 
eye per participant was included led to a mean difference of –0.9 mmHg (95% CI –2.0 mmHg 
to 0.2 mmHg) and random error of 3.7 mmHg (95% CI 2.9 mmHg to 4.6 mmHg. The sensitivity 
analyses to address the impact of differing numbers of repeated observations (SMD) led to a 
SMD of 0.1 mmHg (95% CI –0.1 mmHg to 0.3 mmHg) although the I2 was still very large (97%). 
The adjustment of the repeated measurements led to a smaller mean difference and as anticipated 
a slightly larger random effect. None of the sensitivity analysis had a marked impact on the 
observed heterogeneity. The impact on the LoA of these analyses is also shown in Table 67.
Clinical factor analyses
A subgroup meta-analysis investigating the impact of CCT was not performed because of the 
way that the data were reported in individual studies. Analyses exploring the IOP, refractive 
surgery, examiner type and manufacturer were carried out involving 18, 12, 15 and 20 studies, 
respectively. It was not clear that underlying IOP level had an impact on mean difference. 
Refractive surgery did appear to have an impact although there were only three studies with 
operative participants. There was a suggestion of an impact on the mean difference according to 
examiner [ophthalmologist 3.6 mmHg (95% CI 1.3 mmHg to 5.9 mmHg), non-ophthalmologist 
–0.8 mmHg (95% CI –3.4 mmHg to 1.8 mmHg) and patient examiners –0.3 mmHg (95% CI 
–1.3 mmHg to 0.7 mmHg)] and also possibly on the random error. There was no evidence of a 
difference in either mean difference or random error between the two represented manufacturers.
Results for IOP subgroups were reported in two studies. Alvarez and colleagues127 reported a 
mean difference of –0.4 mmHg in patients with normal IOP and 6.2 mmHg for patients with IOP 
of ≥ 22 mmHg. In the Tai and colleagues study125 the mean IOP difference between the phosphene 
tonometer and GAT was 4.3 mmHg for patients with the lowest IOP (< 10 mmHg), 0.4 mmHg for 
patients with IOP within the normal range (10–20 mmHg), –2.7 mmHg for patients with higher 
IOP (20–30mmHg) and –6.1 mmHg for patients with severe OHT (IOP > 30 mmHg). Gunvant 
and colleagues133 carried out a similar subgroup analysis of mean IOP difference by categorising 
patients as either healthy or glaucomatous, but this is not directly equivalent to an IOP subgroup 
analysis. Only two133,138 studies reported CCT results, both of which presented results in relation 
to the IOP difference between GAT and transpalpebral tonometry. Gunvant and colleagues133 
reported a low correlation coefficient of 0.10. Neither study reported results directly relating to 
CCT subgroups.
Three studies reported preoperative and postoperative results for a cohort of patients undergoing 
refractive surgery. Naruse and colleagues178 reported a preoperative mean difference of 1.6 mmHg 
and a 1-week post-LASIK mean difference of 5 mmHg. A further two studies followed-up LASIK 
patients 3 months after surgery. Cheng and colleagues176 reported a preoperative mean difference 
of 1.3 mmHg with a postoperative mean difference of 5.5 mmHg and Shemesh and colleagues205 
reported a preoperative mean difference of 0.2 mmHg with a postoperative mean difference 
of 1.8 mmHg.222 Appendix 4
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Appendix 5 
Recordability data by tonometer (Chapter 5)
Study % recordable IOP (n/N) Comments
DCT 
Barleon 2006161 93 (197/211) 14 eyes (3/69 healthy and 11/142 glaucoma) had difficulties with DCT 
Johannesson 
2008210
99 (149/150) Four eyes of four people (19 measurements) for which not all six measurements were 
achieved. Mean quality value of measurement was also reported, which ‘implied’ mean of 
0.84 extra measurements needed. Only one eye for which a mean IOP was not reported
Martinez-de-la-
Casa 2006189
100 (146/146) No eyes were excluded because of poor or unreliable measurements
Medeiros 2007134 100 (176/176) Two patients needed a third DCT measurement because of excessive blinking
Milla 2009192 99 (99/100)  
Sullivan-Mee 
2009142
98 (62/63) Three subjects were excluded due to: reliable DCT readings could not be obtained for the 
second measurement set in one participant
NCT 
Boles 1992147 76 (68/90)  
Mackie 1996156 96 (43/45) Any notably apprehensive patients who made the examination difficult by narrowing their 
palpebral aperture during measurements were also excluded
Ogbuehi 2008194 100 (72/72) Some patients needed to have their IOP measurement repeated to get valid readings
Van de Velde 
1995182
99 (99/100) One eye with corneal oedema and unreliable NCT readings was excluded
Ocuton S 
Sacu 2004126 94 (64/68) Excluded those with corneal disease, astigmatism > 1 D, contact lens, inflammation, recent 
surgery (< 3 months)
Wells 2003170 82 (70/85) 70 patients obtained one measurement with the Ocuton S; 61 patients obtained three 
measurements; 15 were unable to obtain any measurements
ORA 
Kynigopoulos 
2008185
98 (49/50) 199/200 (99.5%) for the proportion of recordable eyes
Sullivan-Mee 
2009142
98 (62/63) Three subjects were excluded because reliable DCT readings could not be obtained for the 
second measurement set; the second set of ORA readings was lost as a result of computer 
malfunction; and one subject was post strabismus surgery (contraindication for inclusion in 
the study) 
RT 
Johannesson 
2008210
100 (150/150) One eye for which not all six measurements were achieved. Mean quality value of 
measurement was also reported, which ‘implied’ a mean of 1.64 extra measurements needed. 
No eyes for which a mean IOP was not reported
Martinez-de-la-
Casa 2005190
50 (18/36) Estimate would seem to be the average across three examiners taking a measurement on 12 
eyes. For valid measurement after two attempts it was 92% (33/36) and after three attempts 
it was 100%. A mean of 1.58 ± 0.67 attempts were needed to obtain a valid measurement 
Martinez-de-la-
Casa 2006189
100 (146/146) No eyes were excluded because of poor or unreliable measurements
Pakrou 2008167 100 (143/143) 286/292 (97.9%) eyes had no error bar with RT (i.e. optimal SD) after a maximum of three 
attempts226 Appendix 5
Study % recordable IOP (n/N) Comments
TonoPen 
Bandyopadhyay 
2002197
100 (208/208)  
Christoffersen 
1993216
90 (132/146) Reason for exclusion related to measurement for five patients (10 eyes) who were unable to 
cooperate with tonometry 
Van der Jagt 
2005207
100 (103/103)  
Transpalpebral 
Alvarez 2004127 91 (124/137) 13 subjects could not see the phosphene 
Baskaran 2006198 95 (72/76) Four patients were excluded because they could not see the phosphene ring during self-
tonometry
Brigatti 2005137 76 (55/72) Pressure phosphene could not be seen
Cheng 2005176 97 (60/62) Two patients could not appreciate the phosphene phenomenon
Herse 2005168 95 (203/213) Pressure phosphene could not be seen in 10/213 normal eyes
Lam 2004172 97 (99/102) Three patients unable to perceive phosphenes
Li 2004138 95 (86/91)  
Naruse 2005177 93 (94/101) ‘7 glaucoma patients were unable to detect the pressure phosphene and could not self-
measure their IOP with the PPT’
Rai 2005124 95 (135/142)© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Appendix 6 
Acceptability/practicality data by tonometer 
(Chapter 5)
Study Reported (Y/N)
Acceptability
Description Reported (Y/N)
Practicality 
Description
DCT 
Doyle 2005123 N   Y ‘We did not find the tonometer 
(DCT) easy to use’
Eichenbaum 2007132 Y No difficulties with the introduction of 
DCT. Ready compliance when repeat 
measurement was required
N  
Johannesson 2008210 N   Y 0.84 extra measurements per 
eye were required for DCT
Ku 2006215 Y Preference of tonometer: 36 (34%) 
prefer DCT, 15 (14%) GAT and 55 (52%) 
no preference. List of reasons given
N  
Lanza 2008143 Y ‘Patient comfort was ensured’ and 
‘pressure on the globe’ was avoided
N  
Pache 2005163 Y ‘GAT and DCT measurements were 
comparably well tolerated by the study 
participants’
N  
Salvetat 2007144 Y   Y Measurements ‘were not easy 
to perform and entailed a 
learning curve’
Vandewalle 2009184 Y No patient reported more than moderate 
discomfort with any of the procedures 
N  
NCT 
Cho 1997173 Y The subjects were asked to comment on 
each technique. ‘About 50% of subjects 
preferred NCT-2000 over the other 
tonometers’ as air puff is ‘weaker’ and 
is non-contact tonometer. The remaining 
subjects had ‘no particular comments 
on the test used’
Y The operator found that NCT-
2000 was the ‘easiest and 
fastest’ to operate
Mackie 1996156 N   Y 2, 3 and 3 minutes mean time 
for Pulsair 200, GAT and AO 
MkII, respectively
Ogbuehi 2008194 Y Eight patients (11%) (Pulsair EasyEye) 
had anxiety about the procedure and 
needed to calm down
Y IOP screening is quick with 
NCT
Ocuton S 
Marchini 2002146 Y Safety was assessed clinically, including 
complaints reported by patients. Of the 
80 subjects, 62 (78%) did not complain, 
14 (17.5%) complained of foreign 
body sensation, 4 (5%) complained of 
burning. All lasted < 20 minutes and 
were resolved without consequence
Y Participants were taught how 
to perform self-tonometry by 
practising at least three times228 Appendix 6
Study Reported (Y/N)
Acceptability
Description Reported (Y/N)
Practicality 
Description
ORA 
Vandewalle 2009184 Y No patient reported more than moderate 
discomfort with any of the procedures. 
No difference in patient preference was 
reported
N  
Perkins 
Eichenbaum 2007132 Y ‘No difficulty with acceptance’ although 
it is noted that ‘the patients were not 
new to the practice’
N  
Jackson 1995166 Y ‘All patients interviewed found 
tonometry acceptable’
Y Time (mean) to measure IOP: 
Perkins: 96 seconds; GAT: 120 
seconds.
RT 
Johannesson 2008210 N   Y 1.64 extra measurements per 
eye were required, increasing 
to 2.25 for thick CCT
Pakrou 2008167 Y RT well tolerated by patients: 2 (5%) 
preferred GAT and 28 (74%) preferred 
RT and 8 (21%) had no preference. 
Mean response score for patient 
comfort was 2.03 in favour of RT 
(p < 0.001)
Y 1.36 extra measurements per 
eye for RT. Overall ease of use 
was reported, although it was 
noted that extra attention was 
required to position Icare and 
the operator correctly and to 
take the measurements as 
quickly as possible. However, 
no apparent learning effect 
when comparing first third of 
patients to final third. Also, no 
anaesthetic required. However, 
RT cannot be used for supine 
patients
Rehnman 2008209 Y Stated that it was ‘minimally invasive for 
the patient’
Y ‘Very easy to use’
Roukonen 2007160 N   Y In general, easy to use and no 
anaesthetic required. However, 
difficulty was reported with 
the required positioning of the 
tonometer
Sahin 2007211 N   Y Noted that there is no 
requirement for anaesthetic 
and has disposable tips
van der Jagt 2005207 Y 10-point comfort scale used: mean (SD) 
8.2 (1.0)
Y ‘Easy to use and 
measurements could be 
performed in all subjects’
Vandewalle 2009184 Y No patient reported more than moderate 
discomfort with any of the procedures 
N  © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Study Reported (Y/N)
Acceptability
Description Reported (Y/N)
Practicality 
Description
TonoPen 
Bandyopadhyay 2002197 Y Patient preference: ‘which of these 
two procedures do you find more 
acceptable?’: 30 (14.8%) preferred GAT, 
64 (31.5%) preferred TonoPen, 100 
(49.3%) found them equally acceptable, 
9 (4.4%) had no preference
Y Time (mean) to measure IOP: 
TonoPen, 15 seconds (SD 4); 
GAT, 54 seconds (SD 18)
Jackson 1995166 Y ‘All patients interviewed found 
tonometry acceptable’
Y Time (mean) to measure IOP: 
TonoPen, 50 seconds; GAT,120 
seconds
Salvetat 2007144 Y ‘TonoPen offered greater patient 
comfort’ than Pascal
Y TonoPen is ‘easy to use, 
portable’
van der Jagt 2005207 Y 10-point comfort scale used: mean (SD) 
7.4 (1.3)
Y ‘Easy to use and 
measurements could be 
performed in all subjects’
Transpalpebral 
Brigatti 2005137 Y No adverse events. Data not reported 
although 0–100 scale used
N  
Gunvant 2007133 Y Analysis of covariance used to assess 
different levels of instruction/training/
experience resulting in no significant 
learning curve (p = 0.14)
Y Clinicians can benefit from 
obtaining IOP data from 
between visits if home 
tonometry is used
Lam 2004172 Y Rating scale (0–100), with the following 
definitions: 0, very great difficulty; 25, 
great difficulty; 50, some difficulty; 75, 
easy; 100, very easy to use at home. 
Results: easy to use PPT for home 
self-tonometry: 87.4 ± 16.3. Ease of 
perceiving phosphene: 78.0 ± 20.4
N Initial training lasted 1 hour. 
The patient was then asked to 
practice for another hour
Li 2004138 Y Grading: 1, very easy; 2, easy; 3, 
moderate; 4, difficult; 5, very difficult. 
Results: 70 (81%) described Proview as 
‘easy’ or ‘very easy’, 6 (7%) described it 
as ‘difficult’
N  
Morledge-Hampton 
2006136
N   Y Subjectivity of what a patient 
thinks a phosphene is makes it 
impractical for clinicians
Shemesh 2007205 Y ‘With appropriate instruction, the 
device is easy to use and causes no 
discomfort’
N  
Tai 2005125 Y 92% rate as easy to use. 0–100 scale 
with mean of 79 for willingness to use 
at home
N  
van der Jagt 2005207 Y 10-point comfort scale used: mean (SD) 
8.0 (0.9)
Y ‘Easy to use and 
measurements could be 
performed in all subjects’
N, no; Y, yes.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Appendix 7 
Reliability data by tonometer (Chapter 5)
Study
Examiner 
number/type 
Number of 
measurements  Interobserver  Intraobserver  Comments
DCT 
Doyle 
2005123
DCT: two 
ophthalmologists; 
GAT: NR 
DCT: two measurements; 
if reading ≥ 2 mmHg a 
third measurement was 
taken
GAT: 2; if ≥ 2 mmHg 
of difference a third 
measurement was taken
  GAT: 0.52 (SD) mmHg; 
DCT: 0.62 (SD) mmHg
 
Fogagnolo 
2010218
DCT: one 
experienced 
investigator per 
site; GAT: NR
DCT: measurements were 
repeated if Q > 3; this 
occurred in 8% of the 
readings and twice for 2% 
of the time
GAT: 2; if ≥ 2 mmHg 
of difference a third 
measurement was taken
DCT: ICC 0.96 (n = 350 
eyes) and test–retest 
variability was 
significant (p = 0.01, 
F = 2.86 > 2.12, 6 df)
DCT: CoV 5.0%; RC 3.24 
mmHg
 
Herdener 
2008159
DCT: one 
experienced 
ophthalmologist; 
GAT: NR 
DCT: NR; GAT: NR   DCT: short-term (same 
day) and long-term 
(2–8 days) reproducibility 
was 1.2 and 1.5 mmHg, 
respectively
GAT: short-term (same 
day) and long-term 
(2–8 days) reproducibility 
was 1.1 and 1.2 mmHg, 
respectively
Sensitivity analyses 
excluding lower-
quality DCT readings 
showed greater 
intraobserver reliability
Johannesson 
2008210
DCT: one student; 
GAT: one clinician 
DCT: 6; GAT: 6   95% CI (may be LoA) for 
RC: DCT ± 1.7 mmHg 
(n = 149); GAT 
± 1.9 mmHg (n = 150)
IOP appeared to 
decrease (aside from 
tonometer) as multiple 
measurements were 
taken
Kaufmann 
2004104
DCT: four 
examiners; GAT: 
four examiners 
DCT: 3; GAT: 3 DCT: 0.65 mmHg residual 
variance estimate
GAT: 1.10 mmHg residual 
variance estimate
DCT: 0.44 mmHg 
investigation plus 
interaction variance 
estimate
GAT: 1.28 mmHg 
investigator plus 
interaction variance 
estimate
ANOVA model with 
examiner, subject and 
examiner–subject 
interaction as factors
Kotecha 
2005155
DCT: one of two 
technicians; GAT: 
one optometrist 
DCT: 3; GAT: 2 DCT: mean difference 
of 0.2 (95% LoA –4.9 
to 5.3) mmHg. Based 
only on measurements 
2 and 3
GAT: average readings 
between clinician and 
technician was mean 
difference of 0.4 (95% 
LoA –3.5 to 4.2) mmHg
Technician: DCT: 
RC 4.2 mmHg and 
3.2 mmHg, respectively, 
for measurements 1 
and 2, and 2 and 3; 
GAT: corresponding RC 
1.6 mmHg
Clinician: DCT: RC 
3.3 mmHg and 
2.6 mmHg, respectively; 
GAT: corresponding RC 
1.7 mmHg
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Study
Examiner 
number/type 
Number of 
measurements  Interobserver  Intraobserver  Comments
Kotecha, 
2010129
DCT: one 
optometrist and 
two others (non-
ophthalmologists); 
GAT: NR 
DCT: 3; GAT: 2 DCT: –0.20 (95% 
LoA ± 2.8) mmHg 
(between observer 1 and 
observers 2 and 3)
GAT: mean difference 
of –0.80 (95% 
LoA ± 3.9) mmHg
Observer 1: DCT: 
1.8 mmHg; GAT: 
2.2 mmHg
Observers 2 and 3: 
GAT: 2.3 mmHg; DCT: 
2.0 mmHg (n = 100, 
all RC)
Only good-quality 
measurements 
accepted (DCT) – 
value 1 or 2
Pourjavan 
2007181
DCT: one 
ophthalmologist; 
GAT: one 
ophthalmologist 
DCT: 4; GAT: 2   DCT: ICC 0.78 (one 
measurement) and 
0.91 (mean of three 
measurements)
 
Roszkowska 
2009150
DCT: one 
observer; GAT: NR 
DCT: 2, GAT: 2   GAT: 0.8 mmHg, DCT: 
1.4 mmHg (coefficient 
uncertain, probably RC)
 
Sullivan-Mee 
2009142
DCT: two 
optometrists; GAT: 
two optometrists 
DCT: 2, GAT: 2 DCT: mean difference 
(SD) of 0.34 (1.16) (95% 
LoA –1.9 to 2.6) mmHg; 
CoV 6.6%; CCC 0.92 
(95% CI 0.88 to 0.96) 
(n = 60 eyes)
GAT: mean difference 
(SD) of 0.83 (1.14) (95% 
LoA –1.4 to 3.1) mmHg; 
CoV 7.8%; CCC 0.93 
(95% CI 0.90 to 0.96)
Examiner 1 (n = 30 eyes): 
DCT: mean difference 
(SD) 1.18 (1.33) (95% 
LoA –1.4 to 3.8) mmHg, 
CoV 8.0%, CCC 0.92 
(95% CI 0.86 to 0.97); 
GAT: mean difference 
(SD) 0.67 (1.54) (95% 
LoA –2.4 to 3.7) mmHg, 
CoV 11%, CCC 0.95 
(95% CI 0.91 to 0.98)
Examiner 2 (n = 30 eyes): 
DCT: mean difference 
(SD) 0.06 (1.62) (95% 
LoA –3.1 to 3.2) mmHg, 
CoV 9.3%, CCC 0.84 
(95% CI 0.75 to 0.94); 
GAT: mean difference 
(SD) 0.64 (1.45) (95% 
LoA –2.2 to 3.5) mmHg, 
CoV 10%, CCC 0.85 
(95% CI 0.75 to 0.95)
Both examiners: DCT: RC 
of 2.0; GAT: RC of 2.5
RC calculated using 
measurements on 
both eyes
NCT 
AlMubrad 
2008193
NCT: NR; GAT: NR  NCT: 4 (mean of last three 
used); GAT: 3
  NCT: within-session 
mean difference (SD) 0.1 
(1.2) and 0.2 (1.3) mmHg 
for the first two sessions, 
respectively (95% LoA 
–2.3 to 2.5 and –2.4 to 
2.8 mmHg, respectively). 
Between-session 95% 
LoA –2.6 to 3.0 mmHg
GAT: within-session 
mean difference (SD) 
0.1 (1.1) and 0.0 
(1.0) mmHg, respectively 
(95% LoA –2.2 to 2.3 
and –2.0 to 2.0 mmHg, 
respectively). Between-
session 95% LoA –2.2 
to 2.8 mmHg
Intraobserver 
repeatability within 
session taken from 
second and third 
measurements (for 
both GAT and NCT) 
and between sessions 
1 week apart. Unclear 
if a single observer 
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Study
Examiner 
number/type 
Number of 
measurements  Interobserver  Intraobserver  Comments
Hansen 
1995217
NCT: one 
examiner; GAT: 
one examiner 
NCT: 3; GAT: 3   NCT: 2.90 (Varmid), 
mean difference 0.10 
(95% LoA –4.88 to 
5.08) mmHg
GAT: 0.98 (Varmid), 
mean difference 0.36 
(95% LoA –2.76 to 
3.48) mmHg
 
Lafaut 
2007122
NCT: one 
examiner; GAT:  
one examiner 
NCT: 3; GAT: 3 NCT: within-session 
mean difference (SD) 1.2 
(0.7) mmHg
GAT: within-session 
mean difference (SD) 0.1 
(0.2) mmHg
Pertains to subgroup 
only. Similar results 
for the other 
participants were also 
reported
Lam 2004175 NCT: possibly 
a consultant 
ophthalmologist 
but paper is 
unclear, GAT: NR 
NCT: 3; GAT: 3   NCT: mean CoV (SD) 
4.5% (3.4%)
GAT: mean CoV (SD) 
3.7% (1.8%)
 
Mackie 
1996156
NCT: one 
optometrist; GAT: 
one of three 
ophthalmologists
NCT: 4; GAT: 2   NCT: SDs of 
measurements from 
individual patients range 
from 2 to 6.7 mmHg
 
Ogbuehi 
2006195
NCT: one 
examiner; 
GAT: one 
ophthalmologist 
NCT: 4 (only last three 
readings were averaged); 
GAT: 3. Readings taken in 
four sessions, two each 
for GAT and NCT
  NCT: mean difference 
(SD) between both 
sessions of 0.1 (1.3) 
(95% LoA –2.5 to 
2.7) mmHg
GAT: mean difference 
(SD) between both 
sessions of 0.2 (1.4) 
(95% LoA –2.54 to 
2.94) mmHg
 
Ogbuehi 
2008194
NCT: one 
ophthalmologist; 
GAT: one of three 
clinicians 
NCT: 3; GAT: 3   NCT: within-session RC 
(first session) 1.8 mmHg 
and (second session) 
1.7 mmHg; test–retest 
reproducibility 3.1 mmHg
GAT: 1.7 (first session) 
and 1.9 (second 
session); test–retest 
reproducibility 2.5 mmHg
 
Regine 
2006149
NCT: two 
ophthalmologists; 
GAT: NR 
NCT: 3; GAT: 3   NCT: RC 3.59 mmHg 
(right eye)
GAT: RC 3.98 mmHg 
(right eye)
Mean difference of 
1.94 mmHg
 Only 10 subjects
Tonnu 
2005152
NCT: one 
examiner; GAT: 
one examiner 
NCT: 3, GAT: 3   NCT: RC 3.2 mmHg
GAT: RC 2.2 mmHg
 234 Appendix 7
Study
Examiner 
number/type 
Number of 
measurements  Interobserver  Intraobserver  Comments
Ocuton S
Marchini 
2002146
Ocuton S: two 
operators and 
patient for self-
tonometry; GAT: 
NR
Ocuton S: 3 
measurements; if 
there was a difference 
≥ 5 mmHg between one 
and the other two, a fourth 
measurement was taken
GAT: NR
Ocuton S: first 
measurement between 
two observers 0.61 (95% 
CI 0.30 to 0.93) mmHg; 
second measurement 
between two observers 
0.41 (95% CI 0.02 to 
0.80) mmHg (both κ)
First observer: Ocuton 
S: 0.66 (95% CI 0.31 
to 1.00) mmHg; second 
observer: Ocuton S: 
0.42 (95% CI 0.06 to 
0.78) mmHg (both κ)
Self-tonometry: Ocuton 
S: mean difference (SD) 
0.6 (2.1) (95% CI LoA 
–3.6 to 4.8) mmHg
Each measurement 
was the mean of three 
consecutive readings
 
Wells 
2003170
Ocuton S: patient; 
GAT: 1 researcher 
Ocuton S: 3, GAT: NR ORA: RC 9.17 mmHg
ORA 
Ehongo 
2009183
ORA: NR; GAT: NR  ORA: 2 (8 readings); 
GAT: 2 
  ORA: before and after 
anaesthetised right eye 
were 1.44 and 1.11 
(RE) mmHg
 
Kotecha 
2006110
ORA: one 
optometrist; GAT: 
NR 
ORA: 3; GAT: 2   Appear to be intra (not 
explicitly stated). ORA: 
CoV 8.9% (n = 144)
 
Kotecha 
2010129
ORA: one 
optometrist and 
two others (non-
ophthalmologists); 
GAT: NR 
ORA: 3; GAT: 2 ORA: mean difference 
of 0.30 (95% LoA –4.2 
to 3.6) mmHg (between 
observer 1 and observers 
2 and 3)
ORA: observer 1: RC 
4.4 mmHg; observers 
2 and 3: RC 4.3 mmHg 
(n = 100 eyes)
Only good-quality 
measurements 
accepted (ORA)
Kynigopoulos 
2008185
ORA: one 
experienced 
technician; GAT: 
NR 
ORA: 4; GAT: NR   ORA: RC 2.22 mmHg; 
CoV 6.5%; ICC 0.89 
(lower 95% CI 0.82) 
(n = 49)
Sullivan-Mee 
2009142
ORA: two 
optometrists; 
GAT: NR 
ORA: 2 (8 readings); 
GAT: 2
ORA: mean difference 
(SD) of –0.04 (1.73) 
(95% LoA –3.4 to 
3.4) mmHg; CoV 9.6%; 
CCC 0.89 (95% CI 0.84 
to 0.94) (n = 60 eyes)
Examiner 1 (n = 30 eyes): 
ORA: mean difference 
(SD) 0.48 (1.66) (95% 
LoA –2.8 to 3.7) mmHg; 
CoV 9.9%; CCC 0.92 
(95% CI 0.86 to 0.98)
Examiner 2 (n = 30 eyes): 
ORA: mean difference 
(SD) 0.10 (1.75) (95% 
LoA –3.3 to 3.5) mmHg; 
CoV 10.1%; CCC 0.91 
(95% CI 0.71 to 0.96)
Both examiners: ORA: RC 
3.9; GAT: RC 2.0
RC calculated using 
measurements on 
both eyes
RT 
Abraham 
2008165
RT: two 
ophthalmologists; 
GAT: two 
ophthalmologists
RT: 6 (highest and lowest 
discarded); GAT: 2
RT: RC 2.38 mmHg Unclear if RC based 
on data for one or 
both examiners
Davies 
2006154
RT: NR; GAT: 
one of two 
optometrists 
RT: 2; GAT: 2   RT: mean difference 0.46 
(SD 2.61) (95% LoA 
± 5.11 mmHg)
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Study
Examiner 
number/type 
Number of 
measurements  Interobserver  Intraobserver  Comments
Johannesson 
2008210
RT: one student; 
GAT: one student 
RT: 6; GAT: 6   RT: ± 2.0 mmHg 
(n = 150) 95% CI (may 
be LoA) for repeatability
GAT: ± 1.9 mmHg 
(n = 150) 95% CI (may 
be LoA) for repeatability
IOP appeared to 
decrease (aside from 
tonometer) as multiple 
measurements were 
taken
Martinez-
de-la-Casa 
2005190
RT: one 
experienced 
ophthalmologist; 
GAT: NR 
RT: 3; GAT: 3 RT: CC 0.82 (range 
0.62–0.94) (n = 12 
eyes); CoV 8.9%
RT: first examiner: CC 
0.82 (range 0.62–0.94); 
second examiner: CC 
0.73 (range 0.46–0.90); 
third examiner: CC 0.87 
(range 0.72–0.96)
‘Intra-subject variation 
coefficient’: 8.9%
Only 12 observations
TonoPen 
Bafa 2001153 TonoPen: one 
examiner; GAT: 
one examiner 
TonoPen: 4; GAT: 1 TonoPen: CoV 5% to 
< 10% (n = 2); CoV < 5% 
(n = 97)
 
Horowitz 
2004169
TonoPen: two 
ophthalmologists; 
GAT: NR 
TonoPen: 2; GAT: 2    TonoPen: mean 
difference (SD) 0.74 
(1.50) (95% LoA –2.26 
to 3.74) mmHg; ICC 0.97
GAT: mean difference 
(SD) 0.13 (–1.75) 
(95% LoA –3.34 to 
3.63) mmHg; ICC 0.95
 
Tonnu 
2005152
TonoPen: one 
examiner; GAT: 
one examiner
TonoPen: 3; GAT: 3   TonoPen: 4.3 (RC) mmHg
GAT: 2.2 (RC) mmHg
Only measurement 
< 5% accepted for 
TonoPen
Transpalpebral 
Alvarez 
2004127
Transpalpebral: 
patient; GAT: one 
trained clinician 
Transpalpebral: each 
subject tried five different 
Proview devices, five 
measurements with each 
device (25 total). Up to 10 
attempts per device were 
permitted to achieve five 
successful measurements
GAT: 2 or 3 if > 2mmHg 
difference for first 2 
  Transpalpebral: within-
subject and within-
device variance was 
3.4 mmHg (620 means 
considered = means of 
each of five devices for 
each of 124 subjects) 
(18.2% of variation). RC 
of 5.11 mmHg
Five devices were all 
Proview and varied 
in a very minor way. 
Appeared to be from 
ANOVA analysis as 
variance is partitioned
Brigatti 
2005137
Transpalpebral: 
patient; GAT: one 
physician 
Transpalpebral: 3; GAT: 2 
sets of 3 readings 
  Transpalpebral: mean 
difference (SD) 1.76 
(1.76) mmHg; 0.71 
(CC) for first and third 
readings
GAT: mean difference 
(SD) 1.73 (1.42) mmHg; 
0.94 (CC)
 
Herse 
2005168
Transpalpebral: 
patient; GAT: 
one experienced 
clinician 
Transpalpebral: 3; GAT: 3   Transpalpebral: 4.21 
(RC) mmHg; mean 
difference (SD) 0.1 
(2.1) mmHg
GAT: 0.96 (RC) mmHg; 
mean difference (SD)  
0.1 (0.6) mmHg
 236 Appendix 7
Study
Examiner 
number/type 
Number of 
measurements  Interobserver  Intraobserver  Comments
Lam 2004172 Transpalpebral: 
patient; GAT: 
two of the 
investigators 
Transpalpebral: 3; GAT: 3. 
Two different visits 1 week 
apart. Patients asked to 
practice at home
  Transpalpebral: CoV 
7.3% (n = 194)
GAT: CoV 4.4% (unclear 
if intraobserver)
Median of the three 
readings was used for 
comparison among 
tonometers. Random 
order. Masked 
investigators
Morledge-
Hampton 
2006136
Transpalpebral: 
one 
ophthalmologist; 
GAT: NR 
Transpalpebral: 2; GAT: 
3. First and second 
measurements used in 
main analysis
  Transpalpebral: 0.82 
(CC) for first and second 
readings
GAT: 0.97 (CC) for first 
and second readings
May not be intraobserver 
as number of observers 
not reported
The third GAT reading 
was compared with 
the first two, which 
showed evidence of a 
tonometry effect (i.e. 
lowering of IOP)
Naruse 
2005177
Transpalpebral: 
patient; GAT: one 
ophthalmologist 
Transpalpebral: 3 (sets of 
five consecutive readings), 
GAT: 3
  Transpalpebral: mean 
difference (SD) 0.2 
(0.54) (95% LoA –0.83 
to 1.27) mmHg (n = 26); 
RC 1.07 mmHg
Second and third 
measurements 
compared
Rai 2005124 Transpalpebral: 
patient and 
technician; GAT: 
one examiner 
Transpalpebral: 3; GAT: NR   Transpalpebral: 0.83 
(CC) patient
GAT: 0.78 (CC) 
examiners
 
Troost 
2005158
Transpalpebral: 
two examiners; 
GAT: one 
examiner 
Transpalpebral: 3,; GAT: 3  Transpalpebral: mean 
difference of –1 (95% 
LoA –8 to 6) mmHg
   
ANOVA, analysis of variance; CC, correlation coefficient; df, degrees of freedom; kappa, kappa statistic; NR, not reported; Q, quality score; Varmid, 
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Appendix 8 
Using statistical models to develop 
monitoring criteria (Chapter 6)
T
his appendix describes possible models of IOP or visual field or RNFL parameter changes 
over time, taking into account both measurement error and long-term true changes.
The apparent change in measurements over time can be thought of as being made up of 
three components:
1.  a short-term variation: a combination of analytic variability and day-to-day biological 
fluctuation around a stable average
2.  the average true long-term change of the whole group and
3.  a variation in long-term true change between individuals (as would be seen with the 
theoretical average of a large number of measurements per individual).
The models that will be used in the project are extensions of the simple model of measurement 
error that assumes no trend. This simple model is described below using IOP measurement. The 
same model can be applied to visual field or RNFL measures.
Measurement error with no trend (simple model)
Let Ti be the true long-term IOP for individual i but let measurements of true IOP be imperfect. 
The measurement of IOP IOPit for patient i at time t will have a measurement error, ωit, so that for 
times t1 and t2:
IOPi1 = Ti + ωi1, IOPi2 = Ti + ωi2  [Equation 17]
or more generally:
IOPit = Ti + ωit  [Equation 18]
Assume that the true value Ti is normally distributed, N(µΤ,σT
2), and that the error ωit is also 
normally distributed: N(µ,σω
2). Also assume that Ti and ωit are independent and the error terms 
ωit for t = 1, . . . ni are independent from each other.
In this model σT
2 is the between-subject variability and σω
2 is the within-subject variability.
Differences in IOP between time points can be used to estimate the within-person variability. For 
example, using baseline and subsequent times we can compute σω
2 as:
Var(∆IOPi) = Var(IOPit) + Var(IOPi0) = 2σω
2 [ Equation 19]
Therefore, we can estimate σω
2 (SDω
2) as the square of the SD of any difference divided by 2.238 Appendix 8
Extension 1: linear model with an increasing variance
As the true IOP may change with time, the simple model needs to be extended. One approach 
is to assume that each individual has a linear increase over time but that that increase varies 
between individuals, that is, each person i has a rate of increase bi with time and this follows a 
normal distribution N(β,1
2). In this case the model becomes:
IOPit = Ti + βit + ωit  [Equation 20]
with Ti again being the true IOP measurement at baseline. Note that two special cases of this 
model are (1) Ν(0,σ1
2), with no average increase of the population but allowing individual 
changes, and (2) N(β,0), that is, everyone has the same change over time.
There are now three terms and three components for the variance: the population baseline 
variation (between subject), the individual variation in trend and the measurement error (within-
subject variability), that is:
var(IOPit) = σT2 + σ1
2t2 + σω
2  [Equation 21]
with the formula for the variance of the change from baseline equal to:
var(∆IOPit) = σ1
2t2 + 2σω
2  [Equation 22]
Extension 2: non-linear increase in variance (direct method)
Extension 1 assumes that the IOP and its SD will increase approximately linearly with time. This 
is likely to be true only for short ranges of time. An alternative is to use a separate parameter for 
each time point, that is, for each time point there is an average increase, and a distribution to 
that increase, so we have bit for each time t and these follow a normal distribution N(βt,σ1
2). The 
model now becomes:
IOPit = Ti + βit + ωit  [Equation 23]
There are three terms and three components for the variance: the population baseline variation 
(between subject), the individual variation in trend and the measurement error (within-subject 
variability), that is:
var(IOPit) = σT
2 + σ1t
2 + σω
2  [Equation 24]
With this model the formula for the variance of the change from baseline is derived as:
var(∆IOPit) = σ1t
2 + 2σω
2  [Equation 25]
Hence, we can estimate the variance in long-term true change by subtracting twice the within-
person variability, that is:
σ1t
2
 = var(∆IOPit) – 2σω
2  [Equation 26]
where σω
2 is estimated from short-term variability studies.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Appendix 9 
Optimal frequency of monitoring intraocular 
pressure and visual fields: further analysis 
(Chapter 6)
Parameter estimates obtained using the direct method
The direct method of estimation has a total of two parameters per time point, which is less useful 
for prediction as well as for the inclusion of its results into economic modelling. In this particular 
example, it has the disadvantage of estimating negative variances (meaningless) because of the 
way that the variance at different time points is calculated (noise subtracted from observed 
variance). For these reasons we focused on the three models obtained from the linear random 
effects model.240 Appendix 9
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FIGURE 67  Mean and variance of transformed IOP change score from baseline using the non-imputed data. (a) Mean 
of IOP change from baseline; (b) variance of IOP change from baseline.
FIGURE 68  Mean and variance of transformed IOP change score from baseline using the (incomplete) median 
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FIGURE 69  Mean and variance of transformed IOP change score from baseline using the LVCF imputed data. (a) Mean 
of IOP change from baseline; (b) variance of IOP change from baseline.
FIGURE 70  Missing data distribution for the placebo group, Rotterdam data set.
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TABLE 69  Empirical distribution from the established betas (β)
Slope value (b)
Probability, i.e. 
P(X ≤ x) [using 
normal F (x)]
Empirical 
probability, i.e. 
F^(x) = % betas ≤ x
–0.00075 0.0000 0
–0.00070 0.0001 0.0065
–0.00065 0.0004 0.0065
–0.00060 0.0009 0.0131
–0.00055 0.0021 0.0196
–0.00050 0.0047 0.0261
–0.00045 0.0098 0.0392
–0.00040 0.0192 0.0392
–0.00035 0.0353 0.0392
–0.00030 0.0613 0.0588
–0.00025 0.1001 0.0915
–0.00020 0.1545 0.1307
–0.00015 0.2255 0.1895
–0.00010 0.3120 0.3203
–0.00005  0.4104 0.3987
0.00000 0.5147 0.5294
0.00005 0.6181 0.6993
0.00010  0.7136 0.7516
0.00015  0.7960 0.8039
0.00020  0.8624 0.8431
0.00025  0.9122 0.8824
0.00030  0.9472 0.9150
0.00035  0.9701 0.9477
0.00040 0.9840 0.9542
0.00045 0.9920 0.9673
0.00050 0.9962 0.9804
0.00055  0.9983 0.9869
0.00060  0.9993 0.9935
0.00065 0.9997 1© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Appendix 10 
Systematic review of economic evaluations 
of surveillance strategies for ocular 
hypertension: methods and results 
(Chapter 8)
Aims
The aim was to systematically review the available evidence on the cost-effectiveness of strategies 
for monitoring individuals with OHT who are at risk of developing glaucoma and to inform 
the methodology of the proposed economic evaluation. Studies that considered the UK NHS 
perspective were of particular interest.
Methods
Search strategy for identification of published reports
Extensive sensitive electronic searches were conducted to identify reports of published and 
ongoing studies of economic evaluations of SOH. In addition, reference lists of retrieved papers 
were scrutinised to identify additional potentially relevant studies.
The databases searched were MEDLINE (1950 to October Week 4 2010), EMBASE (1980 to Week 
41 2010), MEDLINE In-Process & Other Non-Indexed Citations (25 October 2010), Health 
Management Information Consortium (1979 to October 2010), the NHS Economic Evaluations 
Database (NHS EED) (October 2010) and the HTA database for relevant evidence syntheses 
(October 2010).
Full details of the search strategies used are reproduced in Appendix 1.
Selection process
Inclusion criteria
  ■ Interventions: surveillance strategies of patients with OHT.
  ■ Study population: adults.
  ■ Study type: full economic evaluations – studies that compare the costs and outcomes of two 
or more strategies for monitoring individuals with OHT. An eligible strategy can include a 
situation in which no active or organised monitoring service is available.
  ■ Outcomes: studies had to include either costs (regardless of the way that these were 
estimated) or effects (regardless of the way that these were estimated).
Screening
Two reviewers (KB, AA-B) independently scanned titles and abstracts for inclusion of potentially 
relevant studies. Full-text copies of all potentially relevant reports were retrieved. The full-text 
reports were assessed against the inclusion criteria by two reviewers independently (AT, AA-B). 
Any disagreements were resolved by consensus or arbitration by a third party.246 Appendix 10
Results
In total, 161 papers were identified from the initial search. Of these, 11 were selected as 
potentially relevant and full-text copies were retrieved. On screening the full text of these 
retrieved studies; however, no studies were identified that fulfilled the inclusion criteria for the 
systematic review. A list of excluded full-text studies can be found in Appendix 2. A flow diagram 
of the selection process is shown in Figure 71.
FIGURE 71  Flow diagram of the selection process.
161 titles/abstracts screened 150 reports excluded 
•  148 clear from abstract/title that
    inclusion criteria were not met
•  1 abstract of this project
•  1 project description 
11 reports selected for full-text screening
11 reports excluded
•  5 not surveillance strategies
•  1 not OHT subject
•  1 description of costs – not full
    economic evaluation
•  2 model designs – no results
•  1 review article
•  1 letter (not full paper)© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Appendix 11 
Project protocol
1  Title: Optimal Surveillance Regimes for Individuals with 
Ocular Hypertension: Modelling and Economic Evaluation
Protocol version 3, 19 July 2010
2 BACKGROUND
2.1  Burden of Glaucoma
Glaucoma is a chronic progressive optic neuropathy leading to impaired vision and sometimes 
blindness if untreated. The underlying pathophysiology is an accelerated loss of retinal ganglion 
cells, compared with the normal ageing process, leading to a characteristic pattern of retinal 
nerve fibre layer atrophy and optic nerve head changes which ultimately result in visual loss. 
Open angle glaucoma (OAG) is the most common form of glaucoma, affecting about 2% of 
the population aged over 40 in the UK. In the UK glaucoma is second to age related macular 
degeneration as a main cause of blindness.1–3 
OAG is diagnosed primarily by glaucomatous optic neuropathy (characteristic changes of the 
optic disc) and a compatible visual field defect, in the presence of an open, normal appearing, 
anterior chamber angle. Early diagnosis is difficult as there is an overlap between normal and 
glaucomatous change. Progressive changes determine whether OAG is truly present. OAG is 
treated by interventions to lower the IOP. These include a variety of topical ocular hypotensive 
medications (eye drops), or laser trabeculoplasty or glaucoma drainage surgery or a combination 
of these.
2.1.1  Ocular Hypertension as a risk factor for OAG
Risk factors for developing OAG include raised IOP, greater age, non-white ethnicity (those of 
black ethnicity being a higher risk group), having a first-degree relative with OAG, myopia and 
diabetes.4 IOP is the most important risk factor and is the only one which is treatable. Ocular 
hypertension, generally defined as an IOP of ≥ 21 mmHg (2 standard deviations above the mean) 
used to be considered as a part of the definition of OAG, but population studies have consistently 
found that many people with OAG have an IOP below this level.5–9 The risk of developing OAG, 
and for worsening of existing disease, increases with increasing IOP,10–12 and those presenting 
with advanced glaucoma at diagnosis have higher IOPs.13 The population prevalence estimates for 
ocular hypertension range from 4.5% to 9.4% for those aged over 4014 with prevalence increasing 
with age.14,15 
The effectiveness of treatment in ocular hypertension has been evaluated in two large trials of 
medical treatment (Ocular Hypertension Treatment Study [OHTS]16 and the European Glaucoma 
Prevention Study [EGPS]).17 OHTS, an unmasked randomised controlled trial, involved 1637 
participants, 818 participants treated with any commercially available ocular hypotensive drugs 
(eye drops) to achieve 20% reduction from baseline IOP and an untreated control group. OHTS 
demonstrated that medical treatment to lower IOP reduced the incidence of the development of 
a glaucomatous visual field defect or glaucomatous optic neuropathy from 9.4% to 4.5% over a 248 Appendix 11
five year period in people with ocular hypertension (defined in OHTS as IOP ≥ 24 mmHg). EGPS, 
a multi-centre randomised double masked controlled trial randomised 1081 participants aged 
≥ 30 years to a topical ocular hypotensive eye drop (dorzolamide) or placebo eye drop. EGPS 
failed to detect a statistically significant difference between treatment and placebo in reducing the 
incidence of OAG. In this study, treatment reduced the IOP by 15–22% throughout the 5 years 
of the trial, and interestingly an IOP lowering effect of between 9 and 19% reduction in IOP was 
observed in the placebo group.17
Combining these data and data from eight smaller trials a Cochrane systematic review and 
meta-analysis by Vass and colleagues evaluating different topical medications against placebo 
or untreated controls showed about a 40% reduction in the incidence of glaucomatous visual 
field defects with treatment at five years (odds ratio 0.62 (95% confidence interval 0.5 to 0.8) for 
people with ocular hypertension.18
In the UK there is great variability in clinical practice regarding standards of care (follow-up 
and treatment) of ocular hypertension. Across Europe the annual direct costs associated with 
managing ocular hypertension and glaucoma are estimated, in 2003, as €455 per person for 
ocular hypertension increasing to €595 for early glaucoma rising to €969 for end stage disease.19 
These estimates are however very imprecise as they are based on retrospectively collected patient 
data from only 194 patient records collected across four countries, including three centres in 
the UK. Costs increased with increasing disease stage with the main cost driver of the total 
direct healthcare cost of glaucoma care being the cost of glaucoma medications. In the USA a 
cost–utility analysis, taking a societal perspective, using the OHTS data reported that treatment 
for individuals with an IOP ≥ 24 mmHg and a ≥ 2% annual risk of developing glaucoma treatment 
would be cost-effective if society were willing to pay $50,000 for an additional quality adjusted 
life year (QALY).20 
While it is important to treat early disease to reduce the costs and disability associated with OAG, 
only a minority of those with ocular hypertension develop OAG and of these not all are at risk 
of visual impairment in their lifetime. The challenge is therefore to identify the groups most at 
risk of developing significant OAG, and to determine effective and efficient monitoring criteria to 
identify those individuals who are most likely to benefit from treatment. 
2.1.2  Risk prediction for those with ocular hypertension
The OHTS study group identified baseline factors that predicted the development of OAG based 
on the entire OHTS sample, both treated and untreated individuals. These were older age, larger 
vertical or horizontal cup to disc ratios, higher IOP, greater pattern standard deviation of visual 
field loss and thinner corneas (central corneal thickness).21 Medeiros and colleagues22 validated 
the OHTS-derived predictive models in an independent observational cohort of 126 untreated 
subjects with ocular hypertension (Diagnostic Innovations in Glaucoma Study).23
A predictive model24 has recently been published building upon that of Medeiros and 
colleagues.22 This most recent prediction tool was developed and validated using data from 
the two largest treatment trials for ocular hypertension published to date (OHTS and EGPS). 
Briefly, the tool was developed from the observation group of the OHTS and then tested on 
the placebo group of EGPS for discrimination ability, and for systematic overestimation/
underestimation of predicted risk. A pooled prediction tool was then developed based on the 
observation group of the two studies, this allows the estimation of the five-year risk of an ocular 
hypertensive individual developing OAG. The risk tool incorporates the following criteria – age, 
IOP, central corneal thickness, vertical cup to disc ratio (a measure of glaucomatous optic © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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neuropathy) and pattern standard deviation (a measure of visual field loss). Based on this model 
the group have made freely available a quantitative risk calculator which can be accessed at 
http://ohts.wustl.edu/risk. 
Validation of models by their creators typically produce overestimates of their performance.25 We 
therefore propose to systematically identify and review existing risk prediction tools, and validate 
the performance of the most promising models (including that of OHTS/EGPT collaboration) in 
independent datasets. Validation of several models in the same data will facilitate comparison of 
predictive ability and transportability.
2.1.3  Current detection and monitoring strategies for ocular 
hypertension in the UK
In the UK, the majority of people are identified as ocular hypertension during a ‘sight’ test usually 
to obtain glasses at a community based optometrist. People aged 60 years and older, and people 
with a self reported family history of glaucoma 40 years and older, qualify for a free ‘sight test’ 
under the General Ophthalmic Services in England and in Scotland, since April 2007, all are 
eligible for a free test. The constituents of this ‘sight’ test are historic involving an examination 
of the fundus and the optometrist may elect to measure the IOP and test for a visual field defect. 
In the UK there is considerable debate about the role and optimal organisation of a monitoring 
service for those at risk of glaucoma.
In England a recent report on commissioning community eye care services has identified that 
Primary Care Trusts should commission high quality cost-effective services to offer patients 
sustainable choices close to home.26 Guidelines for the management of ocular hypertension and 
OAG by the National Institute for Health and Clinical Excellence (NICE) have been recently 
published. Further research was recommended to evaluate the clinical effectiveness and cost 
effectiveness of using different monitoring intervals to detect disease progression.28
The issue of monitoring people with ocular hypertension is not to measure changes in the level 
of IOP in response to treatment but initially: (a) to establish that ocular hypertension is truly 
present and not a measurement error; then (b) to decide whether monitoring is necessary. One 
would wish to monitor those individuals at risk of developing glaucoma (with a measurement 
of IOP, visual field loss and optic nerve assessment) and to decide not to monitor those with 
negligible risk; (c) to establish whether prophylactic treatment is advisable; and (d) to detect 
those individuals progressing to glaucoma in a timely manner.
There is currently insufficient evidence to guide clinicians with respect to the optimal inter-test 
spacing and frequency of testing necessary to identify clinically significant changes in IOP or 
the optimal frequency and spacing of testing required to detect clinically significant changes 
in the visual field or optic nerve over a relevant time period, which could be up to five years. 
There is uncertainty whether delaying treatment for those with ocular hypertension and in 
some cases missing the conversion to glaucoma is deleterious to patient reported outcome. It 
is widely accepted that monitoring should include a measure of visual function, commonly 
standard automated perimetry, and a measure of structural changes in the optic nerve and 
retinal nerve fibre layer (RNFL) to estimate RNFL loss that is characteristic of glaucoma. This 
may be by clinical examination, photography or automated estimates of RNFL loss. Commercial 
instruments such as the Heidelberg Retina Tomograph (HRT),28 the GDx, and a modified version 
GDX VCC29 are available providing quantitative structural information of the RNFL. These 
instruments are used in some centres for glaucoma detection and to monitor progression. 250 Appendix 11
3  PLANNED INVESTIGATION
3.1 Aim
To validate a predictive model to estimate the risk of developing open angle glaucoma (OAG) for 
individuals with ocular hypertension (raised intraocular pressures [IOP]), and to develop models 
to determine optimal thresholds for surveillance, and frequency for monitoring according to IOP, 
patient and clinical characteristics, taking into account NHS and societal costs, the health and 
wider benefits, as well as public preferences for process of care, health, and other outcomes.
The objectives are to:
1.  Identify and validate the most relevant prediction tool(s) for the risk of developing OAG in 
individuals with ocular hypertension;
2.  Determine thresholds for initiating surveillance; 
3.  Determine the optimal monitoring criteria (tests, frequency of monitoring, and determinants 
of progression to OAG);
4.  Develop feasible, preferable and reliable testing and monitoring regimes for people with 
ocular hypertension in a UK context; 
5.  Model the impact of different plausible surveillance regimes for monitoring ocular 
hypertension on costs, diagnostic yield, health outcomes, as well as public preferences for 
process of care, health, and other outcomes and relative efficiency; 
6.  Make recommendations for surveillance regimes for ocular hypertension; and
7.  Identify future research needs.
The research involves three linked work packages:
(A) Risk prediction: (Objective 1 and 2) Led by Deeks, Birmingham;
(B)  Monitoring criteria: (Objective 3) Led by Perera (Oxford), collaborating with Crabb/Garway 
Heath (City/MEH University);
(C) Modelling evaluation of alternative surveillance regimes (Objectives 4–7): Led by Burr, 
Aberdeen.
3.2  Research Methods
This research aims to determine effective and efficient monitoring criteria to identify those 
individuals who will most benefit from treatment as well as to identify those who may not need 
treatment or follow-up. 
The choice of monitoring tests and criteria should consider four factors:30 
1.  Clinical validity: The monitoring strategy (including test types and frequency of testing) 
should be either a measure of the clinically relevant outcome or a good predictor of the 
clinically relevant outcome;
2.  Responsiveness: The test should change promptly in response to changes in therapy;
3.  Large signal to noise ratio: The test should differentiate clinically important changes over 
time from background measurement variability (short-term biological fluctuations and 
technical measurement error);
4.  Practicality: Ideally the test should be non-invasive, cheap, and simple to do. Ideally test 
results should be immediately available and suitable for patient self-monitoring.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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Several approaches will be used across three interlinked work packages to achieve our objectives: 
expert and consumer opinions; population preferences; systematic reviews; individual patient 
data analysis (and possible meta-analysis); and decision analytic modelling.
Information from the systematic reviews will inform the clinical testing strategy in terms of 
validity and practicality, specifically looking at the reliability of a range of IOP measurement 
devices (tonometers). Goldmann applanation tonometry, a contact tonometer, is currently the 
most widely used tonometer by ophthalmologists, but if surveillance is to be considered in 
primary care, tonometers which do not touch the cornea may be more applicable. In addition 
a very thick or thin cornea can lead to measurement error in tonometry, including Goldmann 
applanation tonometry. New tonometers are available which account for the biomechanical 
properties and thickness of the cornea. In addition, non-invasive self measurement devices are in 
development and may be highly appropriate and relevant as monitoring devices. The systematic 
review (section 3.2.4 component ii) is thus an important component to determine reliable and 
acceptable tonometers for a primary care setting which might be more acceptable to service users 
than hospital based monitoring. 
It is important to note, however, that the individual patient data to be used in our analysis 
(section 3.2.2) includes IOP measured by Goldmann applanation tonometry in all datasets and 
therefore the proposed analyses of risk prediction and optimal monitoring frequency (sections 
3.2.3, and 3.2.4) will be informative about the comparative reliability of alternative tonometers. 
The proposed individual patient data analysis (section 3.2.4) will inform on the biological 
variability in IOP, and the responsiveness and the signal–noise ratio of the tests of visual function 
and optic nerve damage. This information will then be used in an economic modelling valuation, 
together with estimates of costs and benefits derived from the reviews and the preference surveys, 
to determine effective and efficient monitoring regimes for individuals with ocular hypertension.
The proposed population preference study (section 3.3.5 component i), using discrete choice 
experiment methodology, will inform us about preferences for alternative monitoring regimes, 
including preferences for where monitoring might best be placed (hospital eye service or 
community optometry, or alternative community based setting) and on the likely uptake of 
alternative ways of organising a service.
3.2.1  Systematic review strategy
Extensive electronic searches will be conducted to identify reports of published, unpublished and 
ongoing studies and will include abstracts from conference proceedings and other grey literature 
sources. The search strategies will be designed to be highly sensitive, including appropriate 
subject heading and text word terms that reflect both the clinical content and type of study 
required for each component of the research project. This will involve identification of:
  ■ studies that report on risk prediction tools (Work Package A); 
  ■ studies that report on the reliability of the selected IOP measurement techniques (Work 
Package B; Component ii);
  ■ economic evaluations of surveillance programmes for ocular hypertension (Work Package C; 
Component ii)
  ■ focussed searches to identify parameter values for the economic model (Work Package C; 
Component ii)
There will be no language restriction but searches will be restricted to 1987 onwards for the IOP 
measurement techniques (to reflect technological advances). The following databases will be 252 Appendix 11
searched for all components: Medline (1966 onwards), Medline Extra, Embase (1980 onwards), 
Biosis (1985 onwards), Science Citation Index (1981 onwards), Conference Papers Index (2005 
onwards), ISI Proceedings (2005 onwards) and ZETOC Conference Abstracts (2005 onwards). 
The Health Management Information Consortium Database (1979 onwards) and NHS Economic 
Evaluations Database (NEED) will be searched for economic literature. The Cochrane Database 
of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effectiveness (DARE), and 
HTA database will be searched for relevant systematic reviews and HTA reports and the National 
Research Register, UKCRN Portfolio Database, Current Controlled Trials and Clinical Trials for 
ongoing studies. In addition, an internet search using Copernic Agent will be undertaken and 
will include relevant professional organisations, manufacturers and conference proceedings of 
the Association for Research in Vision and Ophthalmology (ARVO) (2005–7) and the American 
Academy of Ophthalmology (AAO) (2005–7). Reference lists of all included studies will also be 
scanned for additional reports. The reviews will be undertaken in accordance with the Centre for 
Reviews and Dissemination31 and Cochrane Collaboration guidelines.32
3.2.2  Individual Patient Datasets (IPD)
Access to the following four datasets has been negotiated for this study. These include two 
randomised controlled trials (Moorfields Eye Hospital, London and Rotterdam Eye Hospital, the 
Netherlands) and two observational datasets – one hospital based (Dunfermline, Scotland) and 
one based on a community optometry led monitoring scheme (Nottingham, UK). The holders 
are applicants and collaborators on this project. A summary of the available data in these datasets 
is provided in Table 1. Specific details of each dataset are provided in the subsequent text.
Data from randomised controlled trials
Moorfields Eye Hospital (MEH) dataset  The MEH dataset comprises data from a randomised 
controlled trial (RCT) of medical treatment with betaxolol eye drops versus placebo in ocular 
hypertension.33 356 ocular hypertensives were randomised during the period 1992–1996, only 
eye per patient was included. Eligible participants included those aged > 35 years with an IOP, 
by Goldmann Applanation Tonometry, between 22 mmHg and 35 mmHg and no significant 
ocular or neurological pathology that would affect visual field performance; visual acuity of 
6/12 or better, and normal visual fields on Humphrey standard automated perimetry (SAP) 
(mean AGIS34 score two baseline fields of 0). Participants were followed up four monthly, 
with Humphrey SAP, IOP and optic disc imaging, in the study eye for a minimum of 2 years, 
see Table 1. Treatment status was noted at each visit. Conversion to glaucoma was based on 
predefined criteria, if a patient developed a defect the visual fields test was repeated within one 
month, and repeated 3–4 months later. Conversion was confirmed if the defect was present on 
three consecutive reliable field tests. Any participants reaching the conversion end point had 
TABLE 1  IPD for analysis (work package A and B)
Source Patient group Study design Measures collected Length of follow-up
Moorfields Eye 
Hospital, London
356 Ocular 
Hypertensives 
RCT of treatment with 
Betaxolol 0.5% eye drops and 
placebo
IOP, Visual fields, Optic 
Nerve imaging [2 measures], 
Central corneal thickness
5 years [10 years on 200]
Rotterdam  409 Ocular 
Hypertensives 
RCT of treatment with 
Betaxolol 0.25% eye drops, 
Timolol 0.5% and placebo
IOP, Visual fields [2 
measures], Optic Nerve 
imaging [3 measures], 
Central cornea thickness
6–10 years
Dunfermline 350 Ocular 
Hypertensives 
Registry with hospital based 
monitoring
IOP, Visual fields, Optic Nerve 
imaging
1–7 years
Nottingham 128 Ocular 
Hypertensives 
Registry with community 
based monitoring
IOP, Visual fields Optic nerve 
imaging [3 measures], 
Central corneal thickness
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IOP lowered by a topical ocular hypotensive, other than betaxolol. The treatment code remained 
unbroken until the end of the study in 1998 with 255 participants completing the study. The 
MEH data provides valuable RCT data, additionally, post trial surveillance with repeated 
measures of SAP and imaging with HRT every six months providing 10 year follow up data in 
205 individuals.
Rotterdam  The Rotterdam IPD comprises data from a placebo controlled, double-masked, 
prospective, 3 arms randomised controlled trial (placebo, Timolol 0.5% bid, betaxolol 0.25% 
bid) which was completed in August 2008. This ongoing study randomised 409 participants, 
including both eyes, with raised IOP, ≥ 22 mmHg and ≤ 32 mmHg by Goldmann Applanation 
Tonometry, and normal visual fields on Humphrey automated perimetry between November 
1997 and March 2001. Participants were deemed eligible if of white ethnic origin, and had a 
best corrected Snellen visual acuity of at least 20/40. Participants with any significant coexisting 
ocular or systemic disease or any use of ocular hypotensives in the preceding three months were 
excluded.35 The follow-up entails 6-monthly visual field analysis and imaging of the optic disc 
using scanning laser polarimetry (GDx at baseline, but follow up using a later model GDx VCC) 
in all participants, and HRT images in about 100 participants and stereo-optic disc photographs 
in 80 participants. To date, 360 participants remain in the study, 24 have converted to OAG. 
Data from observational cohorts
Nottingham  The Nottingham data set involves a cohort of 128 ocular hypertensives followed in 
a community scheme run by locally trained optometrists. Some are on treatment but most are 
not. The scheme started in 2003. Patients are reviewed once a year with visual fields, Goldman 
applanation tonometry and clinical disc examination. Treatment state is recorded at each visit. 
In addition all patients had stereo-photography taken at baseline for reference and a HRT 
performed at baseline and 5 years. Measurements on both eyes are available.
Dunfermline  The Dunfermline data set collated on an electronic patient record of all referrals 
with confirmed ocular hypertension from 2000, with data on both eyes of an estimated 350 
people with ocular hypertension accrued. Low risk cases are discharged after two visits (at one 
year), those who develop glaucoma remain under review, and those deemed as high risk of 
developing glaucoma remain under review. Humphrey SAP data are available on both eyes of all 
patients (except those unable to complete the test). 
3.2.3  Work package A: Risk prediction (objectives 1 and 2) – Lead – 
Deeks, Birmingham
This will include several components (i) systematic identification and critical appraisal of risk 
prediction tools for the progression of ocular hypertension to OAG (ii) validate models identified 
in the systematic review that predict progression to glaucoma using individual patient data 
(IPD) from identified cohorts (RCTs and observational) of people with raised IOP, assessing 
comparative predictive ability and transportability; (iii) Compare agreement with the published 
predictive models:
Component (i) Systematic Review to identify the risk prediction tools 
(Led by Burr, Aberdeen): 
  ■ Two reviewers will view the titles and abstracts of all the reports, identified by the electronic 
searches, and screen independently. A full copy of all possible or definitely relevant studies 
will be obtained and inspected by two reviewers, independently, to assess whether they meet 
the inclusion criteria. Where a difference in opinion exists, the two reviewers will consult a 
third party. Initial screening of the titles and abstracts will be undertaken in Aberdeen and in 
Birmingham independently to identify articles for retrieval.254 Appendix 11
  ■ Critical appraisal (Led by Deeks, Birmingham): The identified prediction tools will be assessed 
according to the data and methods used in their development, and the quality of validation 
studies. Key components which will be assessed are the completeness of recording baseline 
characteristics and outcomes, the use of prospective (rather than retrospective) methodology, 
and avoidance of the treatment paradox. In development studies the modelling used to 
create a predictive score will be evaluated for statistical soundness and validity, particularly 
for the determination of cut-points. In validation studies we will consider whether the 
score has been applied exactly as it was derived, and review the measures used to report 
predictive ability.
Component (ii) Validation in the two observational cohorts 
(Nottingham and Dunfermline) and the trial datasets (Rotterdam & 
Moorfields)
We will independently validate the identified model(s) in several datasets and explore if 
additional risk factors can be identified. Predictive equations will be applied to the available data 
for each individual in each dataset. Three challenges which will need to be addressed in this 
process will be (a) the non-availability of key predictive variables in some of the datasets and (b) 
in subsets of individuals within a dataset, and (c) the use of treatment to affect prognosis. For 
(b) we will consider the role of multiple imputation techniques where data are missing, whereas 
for (a) variables will be omitted from the predictive scores, for (c) we will adjust for the expected 
effect of interventions estimated from systematic reviews.
Component (iii) Comparison of predictive ability
Models will be compared both in terms of their calibration (using calibration plots) and 
discriminating ability (using ROC analysis). The results of the validation of the identified 
predictive models will be considered across the datasets obtained to judge transportability of 
models across settings.
3.2.4  Work package B: Monitoring criteria (objective 3) Lead – 
Perera (Oxford), in collaboration with Crabb/Garway Heath 
(City/MEH University)
Component (i) Exploratory analyses of the two randomised 
controlled trials
Data from the randomised controlled trials at Moorfields and Rotterdam will provide 
information to determine the optimal monitoring criteria to both ascertain ocular hypertension 
and for identifying clinically important rates of change. The basis of these rely on estimating the 
within-person variability, between-person variability, and the natural trend of IOP as well as 
variability of relevant clinical measures of glaucoma (visual field, optic disc and RNFL) within 
specified periods.
Exploratory analyses of the two trials will be carried out to determine the feasibility of combining 
their data. In case combining is not appropriate (e.g. significant differences in average long 
term effect, or period variation), the analysis will be limited to the dataset providing the most 
information. We aim to carry out two independent analyses, one focusing in individuals under 
no ocular hypotensive drugs (e.g. placebo) and a second on individuals under stable medication.
As the data arise from placebo controlled RCTs, the apparent change in IOP and visual field and 
RNFL measurements over time (after the initial response to therapy) can be thought of as made 
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1.  The average true long-term change in IOP, visual field and RNFL measures of the whole group
2.  A short-term variability: that is a combination of analytic variability and a week-to-week 
biological fluctuation around a stable average 
3.  The long-term variability: A variation in long-term true change between individuals (as would 
be seen with the theoretical average of a large number of measurements per individual).
These elements will be estimated using two different methods (a) a direct method and (b) a linear 
mixed-effects model. For a discussion of the methods used we focus only on IOP; however the 
same methods will be employed to estimate the different components of variability for visual field 
and RNFL parameters.
Direct Method of Estimation
The average change of the group can be estimated from the group average at each time point. 
Therefore, a direct method for estimating long term variability uses the variance of the differences 
between the baseline value and each subsequent time point, taking IOP as an example, this can be 
calculated as: 
(IOP at time i – IOP at baseline)2
The times i are equivalent to the different follow up times where data were recorded – 4 months 
for the Moorfields RCT and 6 months for the Rotterdam RCT – with a maximum of 10 years 
follow-up for either trial. These will be calculated only after the stable baseline which we have 
taken as the first measurement in each trial (4 or 6 months) after treatment for the medicated 
and placebo group to reduce the noise created by the initial response to therapy. The long term 
variability can be estimated by subtracting the short-term variability from the variability of 
the change. 
Two methods will be used to estimate short-term variation in IOP. First, the run-in period 
IOP used to determine eligibility to the trials will provide an estimate of short-term variability. 
Second, we will use linear extrapolation backward from the longer-term measures, to estimate the 
apparent variance at time 0. This second method will be the only one used to estimate short term 
variability for visual field and RNFL measures.
Modeled Method of Estimation
The above components will be estimated using a mixed longitudinal model. The main assumption 
of this model is that the IOP for each individual has a linear increase over time but that the rate of 
increase varies between individual (See Appendix for details).
Bland–Altman plots will be used to test if between- and within-person variability levels are 
dependent on different starting IOP levels within the 22 mmHg and 35 mmHg range. 
Modelling of true and false positive rates
Estimates obtained using the above methods will allow modelling of the number whose ‘true’ 
IOP level exceed pre-defined threshold(s). The average change in IOP per year and the estimated 
within-person variability at different times (e.g. 1, 2, and 5 years) will allow us to estimate the 
proportion whose true value would, and would not, have drifted beyond a specific level. 
In the economic model (work package C component ii) these data will be used to inform the 
estimates of progression of IOP to visual field loss over time and also provide information on our 256 Appendix 11
ability to correctly identify that such changes have actually occurred. Within the economic model 
the implication of progression of IOP to visual field loss and consequent effects on costs and 
quality of life will be modeled.
Component (ii) Systematic review to determine the reliability of 
alternative IOP measurement devices (tonometers)
Objective: To compare the reliability between alternative tonometers. 
Methods: 
  ■ Health technologies to be assessed: Contact, non-contact tonometry and self-measurement 
tonometers, including Goldmann Applanation Tonometry, Tonopen, Ocular Response 
Analyser, Dynamic Contour Tonometry, Rebound Tonometry, Transpalpebral Tonometry, 
Perkins Tonometry and Pressure Phosphene Tonometry.
  ■ Target Population: Adults aged 18 years.
  ■ Inclusion criteria: We will include studies which assess the reliability of for two or more of 
the alternative tonometers compared to the Goldmann applanation tonometer. Directly 
comparative studies reported since 1987 of people suspected of having raised IOP will be 
eligible for inclusion.
Two reviewers will view the titles and abstracts of all the reports, identified by the electronic 
searches, and screen independently. A full copy of all possible or definitely relevant studies will 
be obtained and inspected by two reviewers, independently, to assess whether they meet the 
inclusion criteria. Where a difference in opinion exists, the two reviewers will consult a third 
party. We will undertake dual data extraction onto data extraction forms developed for the 
reviews. Discrepancies will be resolved by discussion or by a third party.
We will quality assess included studies using a modified checklist based upon the one produced 
by Craig et al. and Whiting et al.36,37 We will extract and summarise any reliability measures 
reported (including but not limited to Kappa, intracorrelation coefficients and Bland–Altman 
limits of agreement approach). Where appropriate, estimates from comparable studies will be 
formally combined.
This review will inform the economic modelling with regards to the identification of ocular 
hypertension and tonometry devices for surveillance pathways.
3.2.5  Work package C: Economic modelling evaluation of alternative 
surveillance regimes (objectives 4–7)
Component (i) Determining the care pathways for the 
economic model
We plan to elicit the preference of the public using a discrete choice experiment (DCE), an 
approach we have considerable experience with and have successfully used to elicit preferences 
of patients with glaucoma for the outcomes of treatment.38 The DCE will assess the individuals’ 
preferences for a monitoring service for the detection of glaucoma within individuals with OHT. 
In particular we will assess:
  ■ willingness to pay for specific attributes of monitoring for detecting early, treatable glaucoma 
in those individuals at risk due to raised IOP and other characteristics (e.g. age, gender and 
general health)
  ■ willingness to pay for different configurations of monitoring services
  ■ probability of take-up of alternative monitoring regimes© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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  ■ Feed the estimates from above into an economic evaluation model that forms part of the 
wider project
DCEs are an attribute measure of benefit. The technique has the basic premise that any goods 
or service can be described by its characteristics (attributes) and second that the extent to which 
an individual values a good or service and therefore takes it up depends upon the levels of these 
attributes.39,40 The technique involves presenting choices to individuals that vary with respect 
to the level of the attribute. In this application the DCE will be applied to assess probability of 
take-up and the value of IOP surveillance regimes and their components identified in work 
packages A, B and component ii of work package B. 
Defining attributes and levels
To define attributes and levels for the DCE an Advisory Panel, a Focus Group and Questionnaire 
Piloting will be used.
Advisory Panel
An Advisory Panel will be convened for the main project to develop the care pathways for 
the economic model with participants not directly involved in the project. This will include 
two potential users of monitoring strategies, one optometrist, one non-clinical health service 
manager, one specialist nurse, one ophthalmologist, and one community optometrist. The 
Advisory Panel will develop the potential ‘attributes’ (factors influencing the take-up of 
alternative monitoring regimes) and plausible ‘levels’ for the DCE based on information available 
generated during the development of the application for funding for this work, the applicants and 
collaborators meeting and their own expertise.
Patient Focus Group
A Patient Focus Group will also be convened to further develop the attributes and levels. 
Potential participants will be identified through attendance to the Grampian Glaucoma Referral 
and Monitoring Scheme Service led by Mr Azuara Blanco, Consultant Ophthalmologist, 
Aberdeen Royal Infirmary which includes patients with ocular hypertension. This service started 
in June 2004 and has been developed to improve the diagnostic accuracy of glaucoma to reduce 
unnecessary referrals to the hospital glaucoma clinic and to develop a community-monitoring 
scheme for people at risk of developing glaucoma but who do not require treatment.
Initially, around 15 people will be approached; we aim to have a group of 6 to 8 people. 
Individuals will receive an invitation letter by post inviting them to take part in the focus group, 
together with an information leaflet describing the study and what is involved. If after reading the 
information sheet, individuals wish to participate, they will be asked to return the form attached 
to the invitation letter provided in a reply paid envelop or telephone the study co-ordinator 
(contact details will be provided in the invitation letter). After this, participants will be contacted 
by the interviewer to arrange the focus group meeting (date and time) and a confirmation 
letter will be sent. Participants will be encouraged to make contact with the research team for 
clarification of queries or further information. Participants will express their views on how a 
monitoring regime could be organised, including the setting where it might take place, testing 
frequency, monetary value and time spent attending for monitoring. We will use the framework 
approach to analyse the data obtained.
Determining choice sets
Following defining of the attributes and levels, experimental design techniques will be used to 
reduce the number of possible choice sets to a manageable size whilst still being able to estimate 
utility scores for any possible monitoring scenario. Experimental design techniques maximise 
some statistical measure of efficiency, usually D-efficiency. This ensures precision around the 258 Appendix 11
estimated parameters.40 The choice sets will ask individuals to choose between alternative profiles 
that vary with respect to the levels of the given attribute. These choices will reflect the criteria of 
minimal overlap, level balance and orthogonality. D-efficiency scores will be used to ensure an 
optimal set of choices are presented.41 Table 2 gives a hypothetical example of a DCE question.
Questionnaire Pre-piloting
Pre-piloting of the questionnaire will be conducted among members of the Health Services 
Research Unit. The purpose of this pre-piloting will be to test its rationality and validity.
A price proxy will be included so that willingness to pay, a monetary measure of benefit, can be 
indirectly estimated.42 It is believed that a reasonable number of attributes to be included within 
a DCE is around 6 as more than this might lead to an unmanageable number of options by the 
respondent.43 The more attributes the less likely the individual to adopt compensatory decision 
making, which is crucial when estimating marginal rates of substitution. Examples of potential 
attributes for the present experiment are: the setting where the monitoring might take place 
(e.g. hospital, community); testing frequency (e.g. 6 months, 12 months, 24 months); monetary 
value (e.g. £20, £40); time spent each year for monitoring sessions (e.g. 2 hours, 5 hours). Other 
attribute/s might arise from test characteristics (e.g. discomfort, anxiety).
Questionnaire piloting
Piloting of the questionnaire will be conducted in a sub-sample of the target populations. Pilot 
sample size will be big enough to conduct preliminary regression analysis (e.g. around 30 
responses per subgroup) for the general population survey. This will be provided by the private 
company (see below, section on surveys) as part of the commercial agreement. Piloting will 
allow the detection of potential inconsistencies (e.g. positive relations where negative ones are 
anticipated). Furthermore, we will pilot the patient survey in 5 to 10 participants from two 
observational cohorts of patients in Nottingham and Dunfermline (see details of dataset below) 
to check participants responses (e.g. how participants responded to rationality tests). 
The Surveys
We will conduct a survey among members of the general population – to elicit 
society’s preferences.
The questionnaires will include a set of DCE choices (around 16) with alternative monitoring 
schedules that vary with respect to the levels of the given attribute, questions on patients’ basic 
demographics and general health (EQ-5D).
Survey of the general population – a population preferences study
Adults over 18 years old living in the UK will be sampled from the general population. The 
survey will be conducted through an online research company: Research Now. This company 
has been conducting online research since 2001 and they provide a full service of field work 
management, data verification, quality control and conduct of the survey. The company was 
TABLE 2  Example of a DCE question: which monitoring service would you choose?
Monitoring service A Monitoring service B No monitoring C
Frequency of testing Yearly Every three months –
Time costs per year 2 hours 5 hours –
Money costs per year £20 £40 –
Place of testing Hospital eye clinic Local optician –
Which option would you choose? Service A  q Service B  q No monitoring C  q© Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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chosen on the basis of a tendering process and is a company members of the research team have 
used previously in a National Preventative Research Initiative funded project that used a Discrete 
Choice Experiment to investigate lifestyle interventions to prevent obesity.
Sample and setting
Sampling will be done from Research Now’s actively-managed online access panel. These 
panellists are recruited by email and online marketing from over 300 diverse online affiliate 
partners and targeted website advertising. Panel members actively joined the Valued Opinions 
panels by completing a registration survey (www.valuedopinions.co.uk). They are judged to have 
‘opted in’ by accepting the terms and conditions and by taking part in surveys with the option to 
unsubscribe at any time. Panel registrations are automatically checked at the time of registration 
for duplicate e-mail addresses with further checks (e.g. at the time of incentive fulfilment, 
address files are checked for duplicate addresses) for fraudulent panellists. Basic demographic 
information (e.g. age, gender, region, household demographics) is collected when signing up to 
the panel and updated at the end of every survey. An active panel member is defined as a member 
that has participated in at least one survey, or updated his/her profile data or registered to join 
the panel within the last 12 months. At April 2009, panel membership across Valued Opinions 
family country panels around the world was 2,560,262 (these are individual members and not 
household). Panel management is compliant with all relevant market research standards, local 
data protection and privacy laws. 
For this survey, sample selection will be based on the sample size needs (see section below on 
sample size). Once the sample has been selected, an e-mail invitation will be automatically 
generated to potential respondents. The invitation will contain key information for panellists to 
understand the commitment for the survey e.g. survey topic, survey length, incentive, and the 
length of time the survey will be open for. Panellists will access the survey through a unique link 
stated in the invitation e-mail. The content of the survey will be similar to the survey of patient 
based preferences study concerned with lifestyle interventions to prevent obesity, previously 
approved by the North of Scotland Research Ethics Committee 2 and will be fully piloted prior to 
field work. The invitation will also contain a link to the company’s privacy policy, an opportunity 
to unsubscribe from the panel and a link to a member of Research Now’s staff for any queries. 
Panellists are rewarded for the time they take to complete the survey through a structured 
incentive scheme. They receive a cash reward for participating in individual surveys – the amount 
is clearly stated in the invitation e-mail and related to the survey length, interest and complexity 
(range between 50p–£5). Once a panellist reward balance reaches £10, they can redeem a voucher 
which is valid at national retailers.
Each panellist will be assigned an individual ID, allowing the company to monitor panellist 
activity and distinguish between contact rate (e.g. those who were initially contacted and did/
did not complete the survey) and completion rate (e.g. those who completed the survey and did 
not drop out). The company follows UK data protection procedures. They have secure servers 
for collecting survey data. Sampling is carried out regularly with highly encrypted links to the 
database servers. All survey data will be anonymous and linked to the panel database by a unique 
ID so the panellists’ identity is always protected. 
Sample sizes
The following considerations govern the necessary sample size:
1.  Regression analysis needs a sample size sufficiently larger than the number of independent 
variables (e.g. DCE number of attributes and levels);9
2.  For each predetermined subgroup of the main sample, a sample size of 30–100 is sufficient;10260 Appendix 11
A number of factors have been identified which may influence preferences for monitoring for 
those with ocular hypertension. These are socio-economic status (high, medium and low); age 
(18–40, 41–60, > 60); and general health (3 categories according to EQ-5D scores collected 
simultaneously). The private company would sample individuals until the targeted sample 
size is obtained. A purposive quota sampling approach will be employed to identify sufficient 
participants in each of the defined subgroups. We believe that a sample size of 800 will be enough 
to conduct the analysis for the general population survey.
Analysis
Appropriate logistic regression techniques will be used to analyse the response data.40 The 
decision on which model to use is an empirical one and will depend, to certain extend, on the 
data. Following Amaya-Amaya and colleagues43 we will start with a standard multinomial logit 
model, then test that restricted assumptions of this model are met, to finally decide on the proper 
model according to this. For instance, if unobserved characteristics are present and the data 
likely to be clustered then a nested logit specification might be more appropriate. Moreover, if for 
particular attributes there is suspicion that tastes might vary considerably across members of the 
population, then a random parameters model might be adequate. We anticipate that a few model 
options will be tested and a final model chosen according to data characteristics. The theoretical 
validity (e.g. the extent to which the coefficients move in the direction one would expect) will be 
evaluated from the regression results.
The analysis described above will allow consideration of the relative importance of the individual 
characteristics of the service; as well as estimation of the probability of take-up of alternative 
monitoring regimes. The inclusion of a price proxy will allow estimation of the monetary value of 
any given service. This willingness to pay will be used within the economic evaluation modelling 
(section 3.2.5, component ii). In effect, monetary values will be attached to attributes and levels 
of surveillance processes and individual health outcomes. Furthermore, the model outputs 
will be expressed in terms of these processes and health outcomes and therefore net benefits 
(in monetary values) will be estimated for each strategy considered. The analysis will build 
upon the work conducted for a previous Health Technology Assessment by our group46 but we 
believe this approach has not been applied to the economic evaluation of surveillance regimes 
in ophthalmology. The DCE will also be developed iteratively with the economic evaluation 
model and we believe that this also has not been done before. More explicitly, the monetary 
values estimated for alternative surveillance methods from the DCE will be incorporated 
into an economic model, with the imprecision of estimates used explored using probabilistic 
sensitivity analysis. 
Component (ii) Economic modelling using the results of the 
systematic reviews and primary datasets to determine the 
effectiveness, cost-effectiveness, cost–utility and cost–benefit of 
differing surveillance regimes for people with ocular hypertension 
We will use an individual sampling model (e.g. a discrete event simulation) approach as the basis 
of the economic evaluation of the alternative surveillance regimes considered. We believe this will 
give a more refined approach than that of a Markov model when addressing questions such as the 
optimal length of time between surveillance contacts as the length of time between surveillance 
contacts becomes a model parameter rather than stipulated by the model structure. Moreover, 
the capacity of health care services to supply the some or all of the proposed strategies may be 
constrained and this approach gives high flexibility to model these issues. The model structure 
will be based on the findings of the other parts of this project including a review of previous 
economic evaluations of surveillance regimes. For example from component (ii) of work © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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package B we will obtain information on the type of test(s) used for surveillance and their signal 
to noise ratio). Similarly, from the risk prediction algorithm (work package A) we will obtain the 
risk of developing glaucoma; from the DCE we will obtain estimates of the public preferences for 
different surveillance strategies which vary strategy according to their characteristics defined in 
terms of the attributes and levels of the DCE. The results of the DCE along with discussion with 
the advisory panel (experts and consumer representatives) will be used to identify potentially 
feasibility surveillance strategies to be compared within the model.
The model will sample adults who are each defined in terms of certain characteristics (based 
upon the factors considered by the predictive models and the sub-groups considered by the 
DCE). According to these characteristics, each individual will have a risk of developing glaucoma 
(and also to subsequently develop visual impairment). These risks will be informed by the 
analyses conducted in the other elements of the research and additional focused searches to 
identify other relevant parameter values to populate other aspects of the model. The model 
will itself will describe the pathways of care that individuals may follow from following initial 
identification as ‘at risk’ to alternative testing strategies, compared with current practice 
alternatives. The model will be populated with cost data derived from consultation with NHS 
providers and the searches (section 3.2.1). Other sources of cost data would be the NHS 
Reference costs for health care interventions or unit costs for health care service staff (e.g. 
PSSRU). We will use a NHS and societal perspective for the economic analysis. In addition to 
NHS costs we will attempt to estimate the travel costs and costs due to absenteeism caused by the 
interventions and/or disease as proxy for indirect costs. Such costs will be presented separately 
from NHS costs. Benefits will be measured in three ways (i) a measure of clinical effectiveness 
(e.g. number of glaucoma cases avoided) (ii) QALYs derived from utility values derived from the 
EQ-5D responses included as part of the DCE questionnaire, a focused search of the literature 
and our existing quality of life research briefly described in Section 3.2.5(i); (ii) willingness to 
pay derived from the incorporation of the DCE results into the economic model. The economic 
model will thus be presented as (i) a cost-effectiveness analysis (CEA) (ii) a cost–utility analysis 
(CUA) and (iii) a cost–benefits analysis (CBA). Different limitations apply to each of these 
proposed economic evaluation approaches; for example, the CEA may be intuitively easier for a 
clinical audience but the narrow measure of benefit used may not capture preferences for health 
and process outcomes. In the CUA, QALYs will be used which will capture preferences for 
changes in health related outcomes and in the CBA willingness to pay estimates derived from the 
DCE will be used to capture individuals preferences for both process and health outcomes. The 
results from these three analyses will be compared to see whether consistent conclusions would 
be drawn. If conclusions are not consistent then the reasons for this inconsistency will be sought 
as this is potentially important information to present to decision makers (for example the CUA 
and CBA may imply different conclusions because of the preferences individual place on different 
way the surveillance service might organised which are captured in the willingness to pay values 
but not in the QALYs). 
Costs and benefits will be discounted at 3.5%.47 The analysis will also include probabilistic and 
deterministic sensitivity analyses will be conducted to explore the importance of key areas of 
uncertainty. These might include, for instance, the use of alternative utility values and/or unit 
costs. Structural uncertainty will also be explored if required.48
Component (iii) Identification of future research needs
A value of information analysis49 will be conducted to identify the expected value of perfect 
information over the expected lifetime of the surveillance strategies considered and the 
value of further research to identify more precise and reliable estimates of parameters of the 
economic model.262 Appendix 11
4  ETHICAL ARRANGEMENTS
Part of our proposed study involves analysing individual patient data from datasets collected for 
other purposes as described in section 3.2.2. This data will be anonymised and we will follow 
the guidance laid out in the MRC Ethics Series Personal Information in Medical Research 
and Section 60 of the Health and Social Care Act regarding use, storage and investigator 
responsibilities. We are also proposing to survey a sample of the UK population using a research 
marketing company (section 3.2.5i). The responses to this survey will be anonymous i.e. we will 
not be able to link responses to names and addresses. In addition, we will ask for the informed 
consent from the advisory panel members (section 3.2.5i) to confidentially use their panel 
discussions to inform the other study components and the results of the study. We will also seek 
NHS Research Ethics Committee advice and approval to conduct the patient survey and we will 
abide by the 1998 Data Protection Act.
5  EXPERTISE AND ADVISORY PANEL
The project will be led from the Health Services Research Unit (HSRU), the Health Economics 
Research Unit (HERU), University of Aberdeen and the Eye department NHS Grampian. The 
units have extensive experience in systematic reviews, statistical and economic modelling, 
discrete choice experiments and a track-record of research in the field of glaucoma (MR, LV, JC, 
RH, JB, and AAB). Additionally, HSRU has previous experience of conducting IPD meta-analyses 
including co-ordinating a large international collaboration involving 28 datasets (which included 
extensive economic modelling).50
Burr as Principal Investigator will be project manager ensuring that the three work packages 
are complementary and working to complementary time scales. This will involve weekly project 
management meetings in Aberdeen (Burr, Vale, Cook, Hernandez, Azuara-Blanco and the 
project research fellow) and communication with each of the work package leads by email 
and telephone.
The clinical research unit at MEH and the Vision Science Unit of City University (TGH, RW, DC, 
and AK) provide clinical and research expertise in epidemiology, Cochrane reviews, and on the 
optimal frequency and spacing of testing to detect change in people with ocular hypertension and 
glaucoma. Expertise in the statistical methods for monitoring will be provided by the Monitoring 
in Chronic Diseases group in the Department of Primary Health Care in the University of 
Oxford (PG, RP). JD is Professor of Health Statistics at the University of Birmingham and 
provides expertise in systematic reviews and predictive modelling. Other collaborators have 
agreed to provide data for the individual patient data analysis; Roshini Sanders, a Consultant 
Ophthalmologist leading the glaucoma service at, Fife Acute Hospitals Trust, Scotland; Hans 
G Lemij, MD, PhD, a glaucoma specialist at the Rotterdam Eye Hospital in Rotterdam, The 
Netherlands, with a primary interest in research and education in glaucoma imaging, structure–
function relations in glaucoma and in glaucoma shared care. The co-applicants from Nottingham 
have particular expertise in developing co-management care pathways for glaucoma monitoring 
involving optometrists both in a primary care, and hospital setting. 
The applicants and collaborators will meet at the start of the project and again in month 12, when 
the work packages A and B are complete to assist in the interpretation of the evidence from 
the systematic reviews, DCE and IPD analysis. The group will meet for a third time when the 
economic modelling is completed. © Queen’s Printer and Controller of HMSO 2012. This work was produced by Burr et al. under the terms of a commissioning contract issued by the 
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An advisory panel will be convened at the start of the project. Participants will be invited from 
local optometry practices, and the eye department at Aberdeen Royal Infirmary aiming for a 
panel of seven comprising: two potential users of a surveillance strategy, one optometrist, one 
health service manager, a specialist nurse, an ophthalmologist and a community optometrist. 
The panel will meet in month 2 to develop the pathways for the modelling, and determine the 
ranges of levels to be included in the DCE. The advisory panel will meet again in month 12 and 
will comment on and agree the proposed care pathways based on the outputs of the three work 
packages. The refined pathways will determine the structure of the final economic model. 
6  SERVICE USERS
The novel part of this application is the discrete choice experiment to determine preferences for 
the process of any potential surveillance service for those with ocular hypertension. In addition 
we will identify two potential users of a service from patients attending a monitoring scheme in 
Grampian for those with ocular hypertension. 
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